











This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
• This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
• A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
• This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
• The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
• When referring to this work, full bibliographic details including the author, title, 





A role for oestrogen in dynamic interactions between cell 





Douglas Alistair Gibson 





Medical Research Council  
Centre for Reproductive Health 
The Queen’s Medical Research Institute 
47 Little France Crescent 
Edinburgh, EH16 4TJ 
 
 
Thesis submitted to the University of Edinburgh for the Degree of 








The studies presented in this thesis were the unaided work of the author, except where 
acknowledgement is made by reference. The work describ d in this thesis has not been 









I would like to thank my supervisors Professors Philippa Saunders and Hilary Critchley for 
giving me this opportunity and for providing me with excellent support, guidance and 
encouragement throughout my PhD studies. I’m extremely grateful for the many things you 
have helped me to achieve and for making my PhD such a positive experience. I am also 
especially grateful to Philippa for recognising and encouraging my potential back when I 
first started with the unit. I would like to thank all the members of Philippa’s lab group, past 
and present, for their help, support, and friendship; it really has been the best group of people 
I’ve ever worked with. Frances has, and will continue to be, the science ‘oracle’ and I thank 
her for teaching me everything I know! Many thanks are also extended to Arantza, Audrey, 
Elaine, Erin, Jacqui and Karen for friendly advice, lls, Taqmans, immunos and everything 
else in between. 
I have had the privilege to work alongside some fantastic people. I don’t think the CRB can 
be matched for our specifically ‘reproductive’ themed humour and a rapacious capacity to 
enjoy a cheese and wine evening. Thanks to Rod Mitchell, Laura O’Hara, Afshan Dean, 
Sharon Eddie, Carol Fitzgerald, Matt Jobling, Vincet Bombail and anyone else from the 
CRB I may have forgotten. I’d also like to thank my office mates from the last 18 months, 
particularly Fiona and Karen, who have been great fun and a fantastic support. I am also 
extremely grateful for Fiona’s patient and precise reading of my Thesis. 
I would like to acknowledge the help of Dr. Forbes Howie for his assistance in setting up 
TLC and steroid assays. I would like to acknowledge th  assistance of Anna Bujarra and 
Arantza Esnal who carried out the immunohistochemistry for the candidate genes. I also 
acknowledge the assistance of Dr. Erin Greaves who performed the angiogenesis assays. I 
am grateful for the hard work of our dedicated research nurses; Catherine Murray and 
Sharon McPherson, and to the patients who consented to ake part in these studies. 
Special thanks go out to all of my family who have supported me throughout this time; 
thanks for all the dinners, love and support. I would also like to thank my gran Margaret, 
who sadly passed away during my PhD, but was always a great source of support and 
encouragement to me. 
Carly, I thank you for your endless support, love and understanding, I really couldn’t have 
done this without you, particularly thanks to the masterful balance with which you alternate 
between carrot and stick! Thanks for putting up with the mounds of papers, unsociable hours 
iii 
 





The human endometrium is a complex multicellular tissue, located within the cavity of the 
uterus. Its luminal surface is defined by a layer of epithelial cells supported on a 
multicellular stroma containing fibroblasts, glands (lined by a secretory epithelium), blood 
vessels (lined with endothelial cells) and several populations of immune cells; the latter 
includes a unique population of natural killer (uNK) cells. The endometrium undergoes 
dynamic remodelling across the menstrual cycle in response to fluctuating levels of sex 
steroids secreted by ovarian cells. The phases of the endometrial cycle include an oestrogen-
dominated proliferative phase, a progesterone-dominated secretory phase and menses 
(endometrial shedding precipitated by falling levels of progesterone). A key feature of the 
secretory phase is differentiation (decidualisation) f endometrial stromal fibroblasts (ESC) 
an event characterised by transformation of cell shape, secretion of growth factors/cytokines, 
angiogenesis/vascular remodelling and an increase in the numbers of resident immune cells. 
Decidualisation ensures an appropriate nutritional and hormonal environment exists during 
the establishment of pregnancy. Studies in mice suggest that de novo biosynthesis of 
oestrogen within the uterus may play an essential role in regulation of decidualisation but no 
data exist for human. Endometrial endothelial and uNK cells both contain oestrogen 
receptors but the impact of oestrogens on their functio  has not been explored. In the current 
studies three questions have been addressed:  
1. Is oestrogen biosynthesis a feature of human endometrial stromal cell decidualisation? 
2. What is the impact of oestrogen on uNK cell function?  
3. What role (if any) does oestrogen play in the int rplay between decidual, immune and 
vascular cells within the human endometrial stroma?  
Results obtained provide the first evidence that de novo biosynthesis of oestrogens occurs 
during decidualisation of human ESC. This was attribu ed to changes in expression patterns 
of mRNAs encoding proteins that play a critical role in regulation of oestrogen biosynthesis 
(STAR, CYP11A1, CYP19A1 [aromatase], HSD17B2 [17βHSD2] and STS [steroid 
sulphatase]). Changes in the pattern of metabolism were confirmed using thin layer 
chromatography and analysis of concentrations of oestr ne (E1) and oestradiol (E2) in 
culture media. Secretion of E1 and E2 was reduced by addition of an aromatase inhibitor. 
Data derived from studies described within this thesis also show for the first time that 
incubation of uNK cells with E2 not only enhanced cell migration but also stimulated 
secretion of factors that had a significant impact on endothelial cell angiogenesis. These 
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findings were supported by novel evidence that E2 had a significant impact on expression of 
genes associated with cell motility and angiogenesis. In addition, factors, including E1/E2, 
secreted by decidualised stromal cells, stimulated chemotaxis of uNK cells. Future 
experiments will focus on determining the identity of the angiogenic factors secreted by uNK 
cells in response to E2 and the mechanisms responsible for uNK cell movement.  
In summary, new data presented in this thesis provide evidence that local biosynthesis of 
oestrogens within the endometrial stroma may play a previously unrecognised role in 
regulating the function of uNK cells and endometrial endothelial cells in women. These 
results have implications for treatment of disorders such as infertility, heavy menstrual 
bleeding and endometriosis. 
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1. Literature review 
1.1. The endometrium and the menstrual cycle 
The human endometrium is a complex multi-cellular organ that undergoes cyclical 
remodelling in response to fluctuating levels of sex steroid hormones produced by the 
ovaries (1). The endometrium lines the uterine cavity and is surrounded by an outer layer of 
smooth muscle known as the myometrium. The endometrium has epithelial cells on its 
luminal surface with a multi-cellular stroma contaiing fibroblasts, blood vessels (lined with 
endothelial cells), a dynamic immune cell population (including uNK cells and 
macrophages) as well as glands bounded by a secretory epithelium  (2). The endometrium is 
composed of two layers; the basalis or basal layer which is adjacent to the myometrium and 
undergoes little obvious structural remodelling in response to hormones across the menstrual 
cycle, and a layer which includes the luminal epithel um known as the functionalis or 
functional layer which undergoes cyclical regeneration, proliferation and differentiation in 
response to fluctuations in ovarian hormones. Regulation of the endometrium by steroid 
hormones was investigated using primates in a seminal study reported by Good and Moyer 
in 1968 (3). In this study the investigators varied the ratios of oestrogen (E) and progesterone 
(P) in ovariectomised rhesus monkeys. They discovered that glandular maturation was 
favoured by E and stromal maturation modulated by P being favoured by ratios of P>E. 
Furthermore, glandular maturation was antagonized by high levels of P, highlighting the 
importance of controlled, balanced hormone levels in mediating both maturation and 
remodelling of the endometrium during a normal cycle. These findings correlate with the 
morphological changes and fluctuations in hormone lev ls observed in the endometrium of 
women. During their reproductive years hormones circulating in the blood of women are 
derived predominantly from the ovaries and adrenals (4). Whilst adrenal hormones are 
relatively constant the growth of ovarian follicles and formation of the corpus luteum after 
ovulation results in fluctuations in the concentrations of hormones across the menstrual cycle 
(Figure 1.1). 




Figure 1.1. Hormone levels through the menstrual cycle. In response to FSH, the dominant 
follicle enlarges concomitant with increased secretion of oestrogen. Following ovulation (day 
14), oestrogen levels rapidly decline and circulating concentrations of progesterone increase 
secreted by the newly formed corpus luteum. In the absence of pregnancy, the corpus 
luteum regresses leading to withdrawal of ovarian hormones resulting in the onset of 
menstruation.  
1.1.1. Changes in hormones levels during the menstr ual cycle 
The secretion of hormones by the ovary is controlled by endocrine feedback loops mediated 
by the hypothalamic-pituitary-ovarian axis. The hypothalamus is located in the base of the 
brain and hypothalamic neurons secrete gonadotropin releasing hormone (GnRH) which 
stimulate gonadotropes in the nearby anterior pituitary to synthesize and secrete follicle 
stimulating hormone (FSH) and luteinizing hormone (LH) into the circulation. These 
gonadotropins act via receptors expressed by cells in different ovarian compartments and 
stimulate steroidogenesis. At menses, a number of primordial follicles begin to enlarge in the 
ovary, an event stimulated by FSH. As follicles mature granulosa cells adjacent to the wall of 
the follicle begin to express the enzyme aromatase and these cells therefore develop the 
capacity to metabolise androgens secreted by adjacent th ca cells into oestrogens. Oestrogen 
increases responsiveness to FSH, eventually leading to the progression of a single, dominant 
follicle at the expense of the other follicles with the latter becoming atretic. Enlargement of 
the dominant follicle continues throughout the follicu ar phase (Figure 1.1.) concomitant 
with increased secretion of oestrogen. This rise in circulating oestrogen stimulates secretion 
of LH by the pituitary gonadotropes resulting in a rapid rise in the concentrations in the 
circulation (pre-ovulatory stage.) During the follicular phase the functional layer of the 
endometrium regenerates and cells rapidly proliferate in response to rising levels of 
oestrogen, this is particularly striking in the epithelial cells lining the glands. This phase of 
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endometrial function is known as the proliferative phase (Figure 1.2.) Circulating levels of 
oestrogen rise from around 50pg/ml to around 200-300 pg/ml prior to ovulation (5). 
Oestrogen also induces expression of the progesterone receptor in stromal cells during this 
stage of the cycle (6-8). Mid-cycle (approximately day 14), the LH surge triggers rupture of 
the dominant follicle, releasing the ovum and precipitating a rapid drop in ovarian oestrogen 
(50-100 pg/ml), accompanied by differentiation of granulosa cells resulting in formation of 
the corpus luteum (see Figure 1.1.). Cells within te corpus luteum synthesize progesterone 
resulting in a rise in the circulating concentration of progesterone (~8 ng/ml). This, together 
with biosynthesis of regulatory agents that enhance cyclic AMP (cAMP) concentrations 
results in profound changes in endometrial architectur  including differentiation of stromal 
fibroblasts and remodelling of the vasculature both of which are essential prerequisites for 
formation of a functional placenta following implant tion of a conceptus (9). The 
progesterone dominated luteal phase is usually referred to as the secretory phase of the 
menstrual cycle. 





Figure 1.2. Schematic of the morphological changes that take place in the endometrium 
during the menstrual cycle. The proliferative phase is characterised by growth of the mucosal 
layer through stromal and epithelial proliferation and angiogenesis. During the receptive 
phase spiral arterioles become prominent and the first pre-decidual changes take place in 
peri-vascular stromal cells. Pre-decidual cells are first evident around day 22 and form a 
solid sheet of decidual cells by day 27. Leukocyte numbers increase during the secretory 
phase; uNK increases are first evident on day 17. Adapted from (10). 
1.2. Histological features of endometrial tissue du ring the 
menstrual cycle 
Changes in the appearance of the tissue during cyclical remodelling of the human 
endometrium were detailed in a classic study by Noyes and colleagues who utilised 300 
endometrial biopsies that they examined histologically to provide a set of definitive criteria 
allowing dating endometrial biopsy samples (11); (Figure 1.2.) The descriptions of the 
endometrium in the following sections are based on th se published by Noyes et al (11) and 
are aligned to an archetypal 28 day cycle (see Figure 1.2.) which begins on day 0 with 
menstrual shedding, followed by regeneration and then growth during the proliferative 
phase. Transition from the proliferative to secretory phase following ovulation occurs at day 
14 (also LH day 0) and culminates in the formation of decidual cells in the late secretory 
phase leading to the onset of menses by day 28 (LH+14) in the absence of pregnancy. 
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1.2.1. The proliferative phase 
The proliferative phase of menstrual cycle involves regeneration and growth of the 
endometrium is responsive to rising concentrations f ovarian-derived oestrogen. On days 
four to seven of the cycle, the tissue is characterised by a thin luminal epithelium and 
straight, short, narrow glands, with some glands diplaying hallmarks of ‘secretory 
exhaustion’ denoted by cuboidal, ‘ragged’, inactive epithelium as a result of hormone 
withdrawal. Beneath the luminal epithelium the underlying stroma is compact and the 
fibroblasts appear to have relatively large nuclei and minimal cytoplasm. By the mid-
proliferative phase, days eight to ten, the tissue has a tall columnar epithelium, elongated, 
curving glands and a less compact stromal compartment due to water imbibition (oedema). 
The late proliferative phase lasting from days elevn to fourteen and is characterised by an 
undulating luminal epithelium, and tortuous glands with pseudostratified epithelium. The 
stroma underlying the surface epithelium is dense with little evidence of oedema. 
Throughout the proliferative phase, glandular and stromal mitoses are progressively and 
increasingly prominent consistent with proliferation in these cellular compartments in 
response to high levels of ovarian oestrogen. Glandul r diameter is significantly and 
positively correlated to peripheral oestradiol leves at this time (5). The epithelial nuclei also 
become increasingly pseudostratified which culminates in the late proliferative phase and 
declines once active secretion begins following ovulation. Oestrogen receptors (ER), notably 
ERα, are required for the uterine proliferative response to oestrogen in mice (12). 
Specifically, analysis of knockout mice suggests that oestrogen regulates stromal-epithelial 
interactions via an ERα-dependent signal originating from the stromal compartment. In 
support of this, Winuthayanon et al reported that in a uterine epithelial cell-specific ERα 
knock out mouse uterine proliferation was  normal (13). 
1.2.2. The secretory phase 
During the secretory phase, characteristic, progressiv  changes in endometrial function occur 
that are distinct from those of proliferative endometrium and are consistent with active 
secretion by the glandular epithelium and differentiation of the stromal compartment 
(decidualisation, see Section 1.4.4) both of which occur in an environment of rising 
progesterone. During the secretory phase the glandul r epithelium becomes highly secretory 
releasing factors such as glycogen into the uterine lumen which support blastocyst survival 
in the build up to implantation. The function of the luminal epithelium is altered so that it 
becomes ‘receptive’ to the blastocyst during the implantation window.  
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At day fourteen of the cycle, a surge in release of luteinising hormone by cells in the anterior 
pituitary gland triggers ovulation, leading to a drop in ovarian oestrogen and a rise in 
progesterone secreted from the newly formed corpus luteum (see Figure 1.2). While no 
appreciable histological changes occur in the endometrium immediately following ovulation, 
by day sixteen sub-nuclear vacuolation is prominent in the cells of the glandular epithelium. 
The number of cells with basal vacuoles has been shown to be negatively correlated to 
oestrogen levels but positively correlated to progesterone (5). Vacuolation initially has the 
effect of exaggerating the pseudostratified appearance of the epithelial nuclei, however, by 
the seventeenth day (LH+3), following increases in the diameter and tortuosity of glands, the 
pseudostratified appearance abates with nuclei being centrally aligned with vacuoles 
positioned basally and cytoplasm apically. By the eighteenth day (LH+4), vacuoles have 
decreased in size, as glycogen is secreted into the lum n and as a result the nuclei return to a 
more basal position; by the nineteenth day few vacuoles remain. In the absence of 
pregnancy, glandular secretion diminishes, and secretory ‘exhaustion’ is apparent by day 
twenty-four characterised by ‘ragged’ epithelium with shrunken nuclei.  
The mid-secretory phase, is characterised by changes that occur in the stroma, beginning 
with a marked increase in stromal oedema on day twenty-one (LH+7) which is maximal by 
day twenty-two (LH+8). Stromal cells appear denser at this time, characterised by relatively 
large nuclei and little cytoplasm. The spiral arteriol s become prominent on the twenty-third 
day (LH+9) due to the appearance of ‘pre-decidual’ ce ls characterised by enlarged nuclei 
and increased cytoplasm in the peri-vascular area which signifies the beginning of stromal 
differentiation. Stromal mitoses are evident as proliferation recurs and pre-decidual cells 
accumulate around arterioles. Stromal differentiation continues with the formation of sub-
epithelial pre-decidua on day twenty-five (LH+11) which forms a sheet of well-developed 
decidual-like cells by day twenty-seven (LH+13). In addition, the differentiation of stromal 
cells is accompanied by an increase in the number of l ukocytes present in the endometrium 
(see section 1.3) which is maximal by the late-secretory phase and persists in decidua in 
fertile cycles. Decidual cells persist in pregnancy and form the maternal component of the 
placenta, the decidua basalis (14). In the absence of pregnancy and consequent demise of the 
corpus luteum, the decidual endometrium regresses and is shed during menstruation (1, 15). 
In addition to remodelling of the endometrial stroma during the secretory phase, changes in 
the luminal epithelium also occur which facilitate implantation in the presence of blastocyst. 
This includes epithelial expression of leukaemia inhibitory factor (LIF) and regression of 
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pinopodes at implantation sites (16, 17). These functio al changes are detailed in section 
1.4.5. 
1.3. Leukocyte populations in the endometrium 
1.3.1. Overview 
Leukocytes are important in host defence against pathogens and can be found in blood, the 
lymphatics and in tissues and organs. In pregnancy the maternal uterine mucosa (decidua) is 
the primary site of contact between semi-allogenic foetal cells and immune-competent 
maternal cells. The production of cytokines by deciual cells and the signalling environment 
of the stroma affects the activity of endometrial leukocytes. A variety of immune cells are 
present in high concentrations in the uterus which through the action of steroids (section 1.5) 
and cytokines (section 1.7) control the sophisticated immunological regulation of 
implantation and pregnancy.  
CD45 (leukocyte common antigen) positive cells are int rspersed in the stroma of the 
endometrium and increase from 10-15% in the proliferative phase to 20-25% of all 
endometrial cells in the late secretory phase (18). The major leukocyte population in the 
endometrium is the uterine natural killer cell (uNK), however significant numbers of 
macrophages, T cells, B cells, dendritic cells and neutrophils constitute the milieu of 
immunocompetent cells in the endometrium. In the proliferative phase lymphoid aggregates 
of T and B cells are detected and in vitro CD3+ T cells isolated from proliferative phase 
endometrium are reported to have cytolytic activity (19). Following the transition from the 
proliferative to the secretory phase the numbers of uNK cells and macrophages rise. In the 
decidua of early pregnancy uNK cells are the predominant population, however, there are 
also increased numbers of T cells, as well as dendritic cells which increase to account for 
20% of decidual leukocytes (20); (see Table 1.1). 




Endometrium Cell type 
Proliferative phase Secretory phase 
Decidua early pregnancy 
Lymphocytes 
uNK cells + +++ +++++ 
T cells + + ++ 
B cells −/+ −/+ −/+ 
APC 
Macrophages + ++ + 
immature DC + + +++ 
mature DC −/+ + −/+ 
Table 1.1. Relative frequency of immunocompetent cells in uterine mucosa. Adapted from 
(20), APC= antigen presenting cell.  
1.3.2. Natural killer cells 
Natural Killer (NK) cells are lymphocytes that are part of the innate immune system and 
comprise 15% of all circulating lymphocytes (21). NK cells are effectors of antibody 
dependent cellular cytotoxicity (ADCC) mediated viaCD16 and they do not express CD3 
(21). The peripheral blood (pb) contains two main subsets of NK cell, delineated by their 
expression of two markers; CD56 and CD16. The CD56 antigen is an isoform of the human 
neural cell adhesion molecule which may mediate intractions between NK cells and their 
targets (22). CD16 is the low affinity Fcγ receptor III (FcγRIII) expressed on the surface of 
some NK cell subsets. CD16 mediates cytotoxicity and bi ds to opsonised (antibody coated) 
targets and signals through immunoreceptor tyrosine-based activation motifs (ITAMS) to 
direct ADCC (23).  
The two pbNK subsets are characterised as CD56bright CD16- (CD56bright) and CD56dim 
CD16+ (CD56dim) which are also classified as agranular and granular respectively. CD56dim 
NK cells constitute around 90% of pbNK cells while CD56bright are the minority subset only 
consisting around 10% of total pbNK and less than 1% of all lymphocytes (24). A 
phenotypically distinct population of NK cells has been identified as resident in human 
endometrium (25). Uterine NK (uNK) cells are found in the endometrium but not the 
myometrium and appear similar to the minority CD56bright pbNK population as they are 
CD56bright/CD16- (26) (Figure 1.3). However unlike CD56bright pbNK, the uNK cells are 
granular and like the majority pbNK population contai  Granzyme B and perforin (26). In 
agreement with differences in phenotype between uNK and pbNK transcriptional analysis 
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(27) has identified differences between the cell populations. Furthermore, functional capacity 
of uNK also appears to be distinct from pbNK, with uNK tending to have reduced 
cytotoxicity and increased cytokine secretion compared to pbNK subsets. 
 
Figure 1.3. Venn diagram summarising the characteristics of NK subsets. Notably, uNK are 
phenotypically distinct from either population of pbNK although they appear to share some 
features of both types. 
Activation of cytotoxicity in NK cells is thought to be a balance between activating and 
inhibitory signalling. NK cells express both activang and inhibitory receptors; of which 
three major superfamilies are expressed. Killer cell Ig-like receptors (KIR) which recognize 
human leukocyte antigen (HLA)-A, -B and -C are highly expressed in CD56dim pbNK and 
uNK but there is low expression in CD56bright pbNK (24, 28).  CD94 and NKG2 receptors are 
members of the C-type lectin superfamily and are expr ssed abundantly in uNK and 
CD56bright pbNKs but not CD56dim pbNK (24). Finally, natural cytotoxicity receptors (NCRs) 
are activating receptors expressed in all NK subsets. NCRs transduce intracellular signals 
that lead to the induction of cytoxicity. Expression f activating receptors; NKp30, NKp44, 
NKp46, 2B4, and NKG2D have been reported in both uNK and pbNK cells (24, 28). 
Interestingly, in uNK cells inhibition of cytoxicity can be mediated by the co-receptor 2B4 
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which is inhibitory in uNK cells due to the low expression of SAP (signalling lymphocyte 
activation molecule (SLAM)–associated protein) which controls cytotoxicity (29). 
1.3.2.1. Origin of uNK population 
While CD56bright cells in the peripheral blood are a minority population, uNK cells are 
present in high numbers in the endometrium and are the major leukocyte population in early 
pregnancy, constituting 70% of all leukocytes in first trimester decidua (30). The origin of 
the uNK cell population remains unresolved although it is likely a combination of trafficking 
from peripheral blood and in situ proliferation/differentiation of resident uNK 
cells/precursors which accounts for changes in tissue resident populations. In support of the 
idea that uNK cells become tissue-resident as a result of homing of pbNK to the endometrial 
tissue; there is a high degree of uNK cell homology with pbNK subsets and there is 
increased vascular permeability in the endometrium coincident with the increase in the uNK 
cell population. uNK cells also accumulate around spiral arterioles and are abundant in 
perivascular sites following decidualisation (25). There are increased numbers of circulating 
CD56bright pbNK cells in women of reproductive age compared to males, which may indicate 
hormone responsiveness and support recruitment of this subtype to the uterus as precursor to 
uNK cells (26). 
In addition, lineage committed CD34 positive progenitor cells have been identified in 
decidua and can undergo differentiation into functional CD56+CD16- NK cells in the 
presence of growth factors or co-culture with stromal cells in vitro (31). Notably, decidual 
CD34 positive progenitor cells express CD45 but not CD56; however expression of CD56 
can be induced by factors including IL-15 (31, 32). Strikingly, 40% of CD56-positive uNK 
cells from late secretory endometrium are Ki67 positive (33) consistent with proliferation of 
resident populations in response to factors in the uterine environment. Human chorionic 
gonadotrophin has also been shown to increase the proliferation of uNK which may partially 
explain increases in number of uNK cells at the time of implantation (34).  
1.3.2.2. Regulation of uNK 
The uterine environment is thought to play an important role in regulating the function of 
uNK cells. IL-15 is reported to induce proliferation and recruitment of uNK cells and this 
cytokine is produced in uterine stromal cells under th  influence of progesterone (35, 36). 
IL-15 is reported to increase CD56 expression in CD16- pbNK and induce a chemokine 
receptor repertoire similar to that of uNK (37). Chen et al reported that culture of uNK cells 
with conditioned media from stromal cells obtained at all stages of the menstrual cycle and 
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decidual stromal cells resulted in an increase in interferon gamma (IFNγ) secretion by uNK. 
The authors also reported that stromal cell conditioned media reduces uNK cytotoxicity (38). 
1.3.2.3. Function of uNK 
uNK cells appear to be important in regulating the ut rine environment and are associated 
with a number of processes in normal endometrial function and in early pregnancy. In 
contrast to pbNK cells, uNK exhibit decreased cytolytic activity and increased secretion of 
cytokines and growth factors such as IFNγ, tissue necrosis factor alpha (TNFα), transforming 
growth factor beta 1 (TGF-β1), interleukin 8 (IL-8), CXCL10 and CCL5 (39-41). Secretion 
of IL-1β, GM-CSF, IL-6, IL-8 and IFNγ increases with gestational age (reviewed in (42)).  
uNK cells have been shown to induce angiogenesis in in vitro and in vivo models (39) and 
they are reported to secrete angiogenic factors such as vascular endothelial growth factor 
(VEGF), placental growth factor (PLGF) and angiopoeitin 2 (39, 43, 44) all of which may 
contribute to regulation of formation/maturation of endometrial spiral arteries during the 
secretory phase of the cycle. In early pregnancy, during development of the placenta, uNK 
cells accumulate within the vascular wall of uterin arteries and are associated with spiral 
artery remodelling, a process which is generally complete by 12 weeks gestation (45). 
Consistent with this, angiogenic growth factor secretion is reported to be decreased at 12-14 
weeks compared to 8-10 weeks gestation (43) which suggests the functional role of uNK 
cells may be dependent on gestational age. 
It is thought that uNK cells can modulate immune cell function by secretion of cytokines. 
Indeed, a bias towards secretion of type 2 cytokines at the expense of type 1 cytokines is 
thought to be favourable in pregnancy. It is notable that uNK cells are associated with 
secretion of the type 2 cytokine IL-10 which inhibits synthesis of type 1 cytokines, however, 
they are also potent producers of the type 1 cytokine IFNγ (46). The balance in cytokine 
secretion may be influenced by availability of factors such as IL-2 or IL-15 in the local 
environment which stimulate uNK cells and consequently affect cytokine secretion. 
Dysregulation of uNK cell cytokine secretion may be important in disorders of pregnancy 
such as recurrent spontaneous miscarriage; this is associated with increased IFNγ and 
decreased secretion of IL-10 (47). In summary the presence of numbers of uNK cells are 
likely to have an impact on the cytokine profile in the endometrium which may be important 
in immunological regulation of implantation and pregnancy.  
Invasion of uterine tissues and spiral arteries by the trophoblast is an essential feature of 
placentation and successful pregnancy (48) and uNK cells may also be involved in the 
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regulation of these processes. Inadequate control of trophoblast invasion is associated with 
disorders of pregnancy such as pre-eclampsia and intra-uterine growth restriction. uNK cells 
have been reported to be in close association with invading trophoblast cells and may 
contribute to the regulation of trophoblast invasion n early pregnancy (49). Disorders of 
pregnancy such as recurrent pregnancy loss (RPL) have been associated with dysregulation 
of uNK cells but the mechanism is unclear (50). uNK numbers appear increased in RPL and 
are associated with greater prevalence of CD16+ NK cells (50, 51).   
Invading trophoblast cells lack expression of classical class I major histocompatibility 
complex (MHC) molecules such as HLA-A and -B, which are associated with increased 
susceptibility to NK cell-mediated cytotoxicity (52). Although decidual uNK cells express a 
range of receptors that could recognise invading trophoblast cells and isolated uNK cells are 
cytotoxic against the NK cell target K562 in vitro, their activity is severely reduced in 
comparison to the cytotoxicity of pbNK cells (28). Notably, trophoblast cells express HLA-
C, -E and –G which may interact with NK cell receptors and alters their cytotoxicity. Indeed, 
HLA-E and HLA-G expression protects MHC-1 negative targets from pbNK-mediated 
cytotoxicity and uNK do not appear to be cytotoxic in the presence of trophoblast antigens 
due to HLA-G expression on trophoblast cells (53). Consistent with expression of HLA-E 
and-G, trophoblast cells are not lysed by either uNK or pbNK in vitro (54, 55). 
The regulation of trophoblast invasion by uNK is probably due to cytokine secretion in 
response to stimuli provided by adjacent cells. For example, production of IFNγ and VEGF 
is increased by uNK cells in response to HLA-G (56) and thus secretion of these cytokines 
would be increased in the presence of trophoblast (HLA-G+) cells. Furthermore, human first 
trimester trophoblast cells secrete SDF-1 (CXCL12) which is chemoattractant to uNK cells 
in vitro (57) and may therefore encourage uNK and trophoblast cells to become more closely 
associated. In addition, supernatants recovered from IL-15-stimulated uNK cells increase the 
invasiveness of isolated cytotrophoblast cells (39) which may in turn be regulated by uNK 
secretion of IL-8 and CXCL10 (IP-10) in a gestation-dependent manner (39, 58, 59).  
1.3.3. Dendritic cells 
Dendritic cells (DCs) are a heterogeneous population of leukocytes that are important in 
immune tolerance and initiation of innate and adaptive immunity. DCs are specialised 
antigen presenting cells (APCs) that are involved in the initiation and modulation of immune 
responses through their ability to detect pathogen molecules and secrete cytokines (60, 61). 
There is emerging evidence that cross-talk between DCs and uNK cells could play a role in 
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the tolerance of the allogeneic foetus by the matern l immune system (49, 62). Dendritic 
cells can be plasmacytoid or myeloid in origin. Plasm cytoid DCs are involved in the 
recognition of viruses (63). Myeloid DCs are involved in the initiation of T cell response and 
are integral to the maintenance of peripheral immunity (64). Myeloid DCs can be further 
classified by their maturation state. Mature DCs are CD83+ and cells with this phenotype 
have been identified in human decidua close to endometrial glands in the basal layer (65). 
The presence of DC-SIGN+ (dendritic cell specific ICAM-3 grabbing non-integrin, CD209) 
immature DCs and DEC205+ intermediate DCs have alsobeen demonstrated in human 
decidua (66, 67). Immature DCs can also be identifid by expression of CD1a surface 
marker and low expression of CD40/CD80/CD86. In human endometrium the density of 
CD1a+ immature DCs is reported to be comparatively greater than the population of CD83+ 
mature DCs (61) which may in part be due to migration of DCs to lymphatic tissue upon 
maturation. Immature CD1a+ DCs increase in number in the basal layer in proliferative and 
menstrual phase endometrium and influx/proliferation of DCs may be hormonally regulated 
(61, 65, 66, 68). 
1.3.4. Macrophages 
The monocyte-macrophage system includes circulating monocytes, their bone marrow 
precursors, and various tissue macrophages. There ar  m ny different cell types in the 
monocyte-macrophage system and the phenotype of these c lls depends on their specific 
tissue environment (69). Despite phenotypical differences, macrophages share common 
functionality and play crucial roles in the immune r sponse through phagocytosis of 
pathogens and modulation of other immune cells through the release of cytokines which act 
in an autocrine and paracrine manner in the tissue environment to modulate inflammatory 
responses (70).  
Uterine macrophages are tissue-resident leukocytes that arise from peripheral monocytes 
following extravasation from the circulation and sub equently differentiate into tissue 
specific macrophages (71). Macrophages are present in the human endometrium and 
myometrium and their numbers are increased in the late secretory phase coincident with the 
onset of menstruation (18). Similar to uNK cells macrophages appear to express ERβ and 
GR but not PR ((72) and unpublished data.) Evidence from mouse models and in vitro 
studies suggest that macrophages are regulated by oestrogens (reviewed in (69)). For 
example, in mice ovariectomy rapidly reduces macrophage recruitment to the uterus (73). 
Evidence for direct impacts of sex steroids in regulating macrophage number within the 
human endometrium is limited however DeLoia (74) reported that administration exogenous 
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oestrogen resulted in increased abundance of uterine macrophages in cycling women 
undergoing IVF treatment. Sex steroids may also modulate the functional maturation of 
uterine macrophages by altering the cytokine milieu of the tissue environment through 
regulating ER-dependent activation in responsive cells (see section 1.7).  
Macrophages are reported to constitute 20-25% of CD45+ cells in decidua (75). In 
pregnancy decidual macrophages are thought to modulate functional processes at the feto-
maternal interface including uterine vascular remodelling (76) and immunotolerance towards 
foetal antigens (77, 78). Consistent with a role in foetal tolerance a recent study investigating 
the gene expression profile of human decidual macrophages using microarray analysis 
revealed a transcriptional profile comprising immunomodulatory and tissue remodelling 
genes as well as genes related to cell proliferation and metabolism (79). Decidual 
macrophages are also reported to interact with decidual NK cells (80), and trophoblast cells 
(81). Decidual macrophages may modulate uNK populations through the secretion of IL-15 
(82) (see section 1.3.2.2 and 1.7.5). Macrophages and DCs share common myelomonocytic 
origin and share common cellular properties and molecular markers. A subpopulation of 
CD14+ macrophages express the immature DC marker DC-SIGN suggesting there may be a 
functional overlap between these two subtypes in the decidua  (66, 83). 
1.4. Functional changes during the menstrual cycle 
1.4.1. Menstruation 
Menstruation is the shedding of the endometrial tissue. Menstruation occurs in only a few 
species; humans, some primates, the elephant shrew and some bat species (84, 85). In 
women, in the absence of pregnancy and the consequent demise of the corpus luteum, falling 
levels of oestrogen and progesterone trigger a cascade of cellular and molecular changes in 
endometrial tissue that culminates in shedding of the upper two-thirds of the endometrium 
(the functional layer) (15). Menstruation is characterised by the demise of all epithelial cells, 
with the exception of basal glandular epithelial cel s, blood vessel necrosis and haemorrhage 
and sloughing of the tissue (86). Matrix metalloproteinases (MMPs) have the ability to 
breakdown extra cellular matrix and have a crucial role in menstrual breakdown. MMP 
expression is increased as a result of hormone withdrawal prior to menstruation (87). In 
addition, transient hypoxia during menstruation stimulates transcription of genes regulated 
by hypoxia inducible factor 1 (HIF-1). HIF-1α protein is expressed in the human 
endometrium in the late secretory and menstrual phases (88). HIF-1α is a transcription factor 
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that is known to induce VEGF expression (89) which may be important in postmenstrual 
vascular repair.  
In fertile cycles, the terminal differentiation of the endometrial stroma may be considered a 
protective mechanism, as in humans implantation is aggressive and trophoblast invasion is 
extensive reaching the inner third of the myometrium (14). The dense decidual stromal layer 
that is formed as a result of progesterone mediated changes during the secretory phase act as 
a barrier that prevents excessive invasion. Consistent with this theory, menstruation does not 
occur in mammals with less aggressive implantation strategies (85). Thus, in the absence of 
pregnancy and progesterone withdrawal, the terminally differentiated stromal layer is shed in 
order to allow regeneration of the endometrium for the next cycle. Menstruation is also 
associated with leukocyte influx and is considered an inflammatory event. Increased 
infiltration of neutrophils and monocytes, as well as local increases in inflammatory 
mediators, such as prostaglandins, characterises the breakdown of the functional layer (15, 
90). In addition, vasoconstriction of the spiral arteries is triggered during menstruation 
reported to be mediated in part by prostaglandin F2α (91) which results in hypoxia and 
precedes bleeding (92). 
1.4.2. Endometrial regeneration and proliferation 
The human endometrium has a remarkable capacity for scar-free repair following 
menstruation (93). Following breakdown and shedding of the functional layer of the 
endometrium during menstruation, the endometrium heals and regenerates a new functional 
compartment from the basal layer of the endometrium which is not shed at menstruation 
(94). Re-epithelialisation begins during menses with basal epithelial cells repopulating the 
luminal surface of the endometrium (95, 96). Although endometrial repair was traditionally 
thought to be mediated by oestrogen studies in a mouse model of simulated menstruation 
have indicated that this may be an oestrogen-independent process (97) which would be 
consistent with healing occurring when oestrogen concentrations are low prior to growth of a 
new cohort of ovarian follicles. It is postulated that in humans a basal stem cell population is 
responsible for regeneration of the endometrium although investigations into their 
identification and regulation are preliminary at this time (98). Regeneration of blood vessels 
also occurs following menstruation and proliferation of endometrial endothelial cells is at a 
peak in the mid to late proliferative phase (99). Investigations in ovariectomised mice have 
revealed that exogenous administration of oestrogen stimulates proliferation of endometrial 
endothelial cells (100). In a study by Heryanto et al (100) the effect of oestrogen on 
endothelial proliferation was reported to be dose dependent and was reduced when low, but 
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not high, amounts of oestrogen were combined with progesterone. Oestrogen also stimulates 
proliferation of the glandular epithelium and stromal fibroblasts in the functional layer 
during the proliferative phase. This growth leads to an overall increase in the thickness of the 
endometrium from approximately 0.5mm to 7mm over a period of approximately 10 days 
(101).  
1.4.3. Angiogenesis in the endometrium 
Angiogenesis, the formation of new blood vessels from existing vessels, is a feature of 
pathologies including cancers (102). Functional angiogenesis is rare in normal tissues apart 
from those of the reproductive system where it is a feature of the dynamic remodelling of the 
corpus luteum of the ovary (103) and the endometrium (104). In the human uterus 
endometrial arterioles arise from arcuate arteries in the myometrium which pass into 
arterioles in the basal endometrium that directly supply the functional layer (105). 
Proliferation of endometrial endothelial cells peaks in the mid to late proliferative phase and 
then again in the secretory phase (99). In addition, endometrial arteries are transformed 
during decidualisation. The thin walled straight areries characteristic of the proliferative 
phase become increasingly tortuous during the secretory phase (106, 107), a phenotype 
which continues in early pregnancy decidua until remodelling of the vasculature occurs in 
response to trophoblast invasion (9, 104). Unusually angiogenesis in the endometrium does 
not seem to involve vasculogenesis from progenitor cells or capillary sprouting but instead 
appears to involve elongation and enlargement of existing vessels while still retaining the 
integral structure of the artery (2, 108). Many angiogenic factors have been identified in the 
endometrium any or all of which may mediate this process. These include; vascular 
endothelial growth factor A (VEGFA), VEGFC, placental growth factor (PlGF), 
Angiopoietins (Ang); Ang-1 and Ang-2, as well as the receptors to VEGF and Ang (Tie-1 
and Tie-2) (44, 104). In the human endometrium, immunohistochemistry studies have 
revealed that VEGF is expressed in both the epithelial and stromal compartments and i  vitro 
mRNA expression in primary endometrial stromal cells is enhanced by ovarian hormones 
(109). VEGF is a prime regulator of angiogenesis during decidualisation in mice (110) and 
angiopoietins act with VEGF to promote angiogenesis (111). 
Immunohistochemical experiments have revealed that expression of VEGF by stromal cells 
is highest in the mid-secretory phase (112) and intense immuno-expression of stromal VEGF 
is also reported in early pregnancy decidua (112). The pattern of immuno-expression of 
VEGF in the epithelial cells is similar however staining is absent in the late secretory phase 
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and less intense in early pregnancy (112). In the same study, VEGF protein was only 
detected in blood vessels in early pregnancy (112). VEGF mediates its effect via two 
receptors; the fms-like tyrosine kinase (Flt-1, VEGFR-1) and the kinase insert domain-
containing region (KDR: VEGFR-2). In the human endometrium, immunoexpression of 
VEGFR-1 and VEGFR-2 is detected mainly in vascular endothelial cells (113). VEGFR-1 is 
detected only in stromal and endothelial cells of early pregnancy, and is absent from stromal 
and epithelial cells in the normal menstrual cycle (112). However, VEGFR-2 is abundantly 
detected in epithelial and endothelial cells throughout the menstrual cycle, in early 
pregnancy and in secretory phase stromal cells (112). Treatment of primary human ESC in 
vitro with combined oestrogen and progesterone enhances mRNA expression of VEGFR-2 
(112). 
In addition to the angiogenic factors expressed by stromal and epithelial cells, there may also 
be a role for uNK cells in mediating angiogenesis. It is notable that uNK cells form 
aggregates around spiral arteries and glands in the la e secretory endometrium and decidua 
(25). Furthermore, cytokine secretion is an important feature of uNK function and secretion 
of angiogenic factors VEGFC, PLGF, and Ang-2 has been described (39, 44). In addition an 
increased capacity for network formation by HUVEC (Human umbilical vein endothelial 
cells) is seen following co-culture with uNK cells (39). The functional impact of uNK may 
be maturation dependent, as VEGFC secretion by uNK decreases with gestational age during 
pregnancy (43). Stromal derived factors may also influe ce uNK production of angiogenic 
factors, for example, IL-15, which is secreted by ESC, increases VEGFC secretion in uNK 
cells (44). 
Transcription of VEGFA mRNA can be regulated by oestrogen via either ERα or ERβ in 
human endometrial epithelial and stromal cells (114). Oestradiol-induced angiogenesis is 
disrupted in ERαKO mice (115) consistent with a role for oestrogen in regulating 
angiogenesis in the uterus. 
1.4.4. Decidualisation 
Decidualisation is the differentiation and proliferation of endometrial stromal cells (ESC) 
that is initiated in the mid to late secretory phase of the menstrual cycle in response to rising 
levels of progesterone. Stromal differentiation/deci ualisation is accompanied by increased 
angiogenesis and leukocyte infiltration (9) and is unique to species that undergo 
haemochorial placentation (116). Embryo implantation, placentation and establishment of 
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pregnancy are dependent on adequate decidualisation. Consequently, failure of 
decidualisation results in infertility (117, 118). 
Differentiation of the stromal compartment is initiated during the mid-secretory phase and is 
first apparent in cells surrounding the spiral arteriol s and thereafter spreads in a wave-like 
manner through the functional layer completing the pr -decidual transformation of the 
endometrium (119). Decidualisation is a characterised by the coordinated expression of a 
specific set of genes, including those encoding growth factors such as prolactin and IGF-
binding protein (IGFBP), and has as a defining feature the transformation of fibroblastic 
stromal cells into ‘epithelioid’ decidual cells an event apparent during the late secretory 
phase (119). Decidual cells are much larger than stromal fibroblasts with rounded nuclei, 
increased numbers of nucleoli, an expanded secretory apparatus, dilated rough endoplasmic 
reticulum and Golgi apparatus and prominent cytoplasmic accumulation of glycogen (120). 
Decidual cells persist in pregnancy and form the matern l component of the placenta, the 
decidua basalis (14).  
Progesterone acting through its cognate receptor the progesterone receptor (PR), a member 
of the superfamily of steroid receptors (see section 1.5), is essential for decidualisation. PR 
knockout (PRKO) mice are infertile as a result of implantation and decidualisation failure 
(121). Stromal PR expression is required for progesterone action which drives differentiation 
of stromal cells and secretion of classical decidual sation markers prolactin and IGFBP (122, 
123).  
In contrast the functional requirement of oestrogen in decidualisation is less clear. Oestrogen 
stimulates proliferation of the endometrium and oestrogen priming is required to induce 
stromal progesterone receptor expression as PR is an oestrogen regulated gene (124). 
Administration of a pure anti-oestrogen (ICI 182, 780) severely impairs decidualisation in 
wild type mice suggesting oestrogen priming is important in decidualisation (125). 
Puzzlingly, the decidualisation response is intact in both ERα and ERβ knockout mice and 
ovarian oestrogen is not essential for decidualisation (125-127). However, a recent study in 
mice suggests that de novo biosynthesis of oestrogen may also be essential during 
decidualisation (128) providing an extra dimension t  our understanding of the role of 
oestrogen. 
Throughout the secretory phase the endometrial spiral a teries proliferate becoming 
increasingly coiled and consequently blood flow rate decreases (129). In decidua, functional 
remodelling of spiral arteries occurs in early pregnancy via interaction with trophoblast cells, 
Chapter 1. Literature Review. 
19 
 
resulting in the formation of large low resistance vessels which permit adequate blood flow 
to the feto-placental vascular bed (9). Failure of this process is associated with disorders of 
pregnancy such as intra-uterine growth restriction (IUGR) and pre-eclampsia. Another 
feature concomitant with decidualisation is the recruitment of leukocytes to the uterus. The 
number of leukocytes rises from around 5% of uterine cells in the proliferative phase to 25% 
in the secretory phase. The most prominent of uterine leukocytes is the uterine natural killer 
cell (uNK) which further increases to account for 75% of total leukocytes in the decidua of 
early pregnancy. uNK cells and uterine leukocytes ar  discussed further in section 1.9. 
1.4.4.1. Regulation of decidualisation 
Primary cells isolated from human endometrium have proven to be an indispensible tool in 
understanding the regulation of decidualisation. In vitro studies using human endometrial 
stromal cells (ESCs) are commonly used as a model fr studying the molecular events which 
occur during decidualisation and are key to understanding the stromal contribution without 
compounding factors such as ovarian hormones and cellular cross-talk. ESC can be 
stimulated to decidualise in vitro by addition of progesterone, which on its own is a weak 
inducer of decidualisation, however its action can be significantly enhanced by addition of 
cyclic adenosine monophosphate (cAMP) or cAMP inducing agents such as prostaglandin 
E2 and relaxin (130). cAMP is a ubiquitous second messenger molecule that is generated 
upon ligand binding to GPCRs (G-protein coupled receptors) and initiates downstream 
phosphorylation of target molecules, including transcription factors, via the phosphokinase A 
(PKA) signalling pathway (119, 122, 123, 131).  Elevation of intracellular cAMP levels is 
required for maintenance of the decidual phenotype (132). Successful decidualisation in vitro 
parallels in vivo responses and is characterised by increased secretion of classical markers 
such as IGFBP1 (133) and characteristic changes in cellular morphology, including 
cytoplasmic aggregates of rough endoplasmic reticulum and secretory granules (130). 
Synthesized proteins secreted by decidual cells have been identified as decidualisation 
markers which are used to confirm decidualisation induced in vitro. Transcriptional analysis 
has revealed regulation of genes associated with cyokines, growth factors, nuclear 
transcription factors, and mediators of the cAMP signal transduction pathway following in
vitro decidualisation of ESC (134, 135).  
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1.4.4.2. Biosynthesis by decidual cells 
1.4.4.2.1. Prolactin 
Prolactin is a peptide hormone which regulates cell growth and differentiation and is an 
important regulator of the immune system. Prolactin (PRL) is synthesised by decidualised 
ESC and PRL production is correlated with the extent of stromal decidualisation (136). In 
non-pregnant endometrium secretion of prolactin can be detected in endometrial explants 
from the mid-secretory phase onwards coincident with emergence of pre-decidual cells 
(136). In pregnancy PRL secretion progressively increases until a peak at 20-25 weeks and 
thereafter declines towards term (137). PRL expression is regulated by progesterone. In 
women, administration of the synthetic progestin medroxyprogesterone acetate (MPA) 
increases expression of both prolactin mRNA and protein in secretory phase endometrium 
(138). Administration of the antiprogestin mifepristone (RU486) reduces concentrations of 
mRNAs encoding both PRL and the PRL receptor in ESC in vitro (139). The distal promoter 
of human PRL contains a functional oestrogen response element (ERE) and binding site for 
activating protein-1 (AP-1) suggesting oestrogen may regulate transcription of the PRL gene 
by both direct and or tethered binding (See section 1.5.4). Studies in T47D breast cancer 
cells using chromatin immunoprecipitation and gel shift assays have revealed that both ERα 
and ERβ can directly bind the ERE in the hPRL distal promoter but only ERα interacts with 
AP-1 proteins at the AP-1 site (140). Prolactin plays n important role in implantation and 
early pregnancy and prolactin receptor knock-out mice have severely compromised pre-
implantation development and implantation failure (141). uNK cells are also known to 
express the prolactin receptor (142) and thus prolactin has also been associated with immune 
regulation. 
1.4.4.2.2. IGFBP1 
The insulin like growth factor system contains several peptide growth factors (IGFs) and 
specific binding proteins (IGFBPs) that regulate thavailability of IGFs at their receptors 
(143). The IGF family has important roles in growth and apoptosis, metabolism and 
development (144). IGFBP1 levels are increased in secretory phase endometrium and 
decidua, coincident with decidualisation (145, 146). Consistent with this IGFBP is 
considered a marker of decidualisation and its synthesis is used to assess the extent of 
decidualisation during in vitro modelling (147). IGFBP regulates the availability of insulin 
like growth factors (IGFs) and may have multiple roles in endometrial development and 
implantation (143). The IGFBP-1 promoter contains 6 promoter regions shown to be 
functionally relevant in vitro including; two glucocorticoid response elements, an insulin 
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response element (IRE) and cAMP response element (144). Insulin acting at the IRE inhibits 
transcription of IGFBP-1 however both glucocorticoid and cAMP stimulate IGFBP-1 
transcription (144). The expression of mRNA encoding IGFBP-1 in ESC is reported to be 
promoted weakly by progesterone but more markedly by combined treatment with 
progesterone and epidermal growth factor (EGF) (147). Induction of IGFBP-1 promoter 
activity by progestins parallels the induction of IGFBP-1 mRNA reported in decidualised 
ESC in vitro (148) and is reported to be initially slow in the first 4-8 days but then increases 
exponentially thereafter. The apparent delay in respon iveness to progesterone is thought to 
be due to indirect action associated with induction of the transcription factor Sp3 which acts 
to suppress transcriptional repression of the distal IGFBP-1 promoter in decidualised stromal 
cells (149). Subsequent studies have also identified PR responsive sequences (PREs) in the 
IGFBP-1 promoter. PR/GR response elements have similar consensus sequences and 
functional analysis of the IGFBP-1 promoter in ESC has revealed that PR activates the 
promoter via a sequence termed the PRE1 in decidualised ESC but not undifferentiated ESC 
(150). The PR exists as two isotypes PR-A and PR-B (151). Studies have reported that ligand 
activated PR-A is a stronger transactivator of IGFBP-1 than PR-B in ESC (152) consistent 
with a role in stimulating expression of IGFBP-1. Notably, PR-A is the predominant PR 
isoform in the endometrial stroma from the midsecretory phase onwards in the endometrium 
and its expression therefore coincides with the onset of decidualisation and associated 
IGFBP secretion (153). 
1.4.4.2.3. Tissue factor 
Tissue factor (TF; also TTF3) is a cell surface glycoprotein involved in blood coagulation 
cascades that is present in leukocytes (154). TF is thought to maintain vascular haemostasis 
in the endometrium and is known to induce VEGF production (155, 156). In decidualised 
ESC expression of TF parallels that of prolactin (157) and it is thus also considered a 
decidualisation marker. TF expression is controlled by specificity protein (Sp)-1 which itself 
may interact with progesterone and/or oestrogen receptors (158). Consistent with this 
interaction, progestins increase TF mRNA and protein concentration in ESC although this is 
synergistically enhanced by co-stimulation with oestradiol, oestradiol alone does not increase 
TF transcription (159). Sp-1 mediated enhancement of TF transcription by oestradiol has not 
been described in ESC however in addition to SP-1 regulation, the TF promoter also contains 
two AP-1 sites which could be indirectly modulated by ER action, although no such 
mechanism has been reported (160). Increased producti n of TF during decidualisation is 
thought to mediate vascular haemostasis and angiogenesis during remodelling of the uterine 
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vasculature (155, 158). In vitro analysis of steroidal regulation of TF in ESC indicates that 
steroid withdrawal (i.e. simulation of menstruation) reduces TF mRNA expression which in 
vivo may permit menstrual-associated haemorrhage (161). 
1.4.5. Implantation 
Implantation involves the attachment of a competent blastocyst to the receptive uterine 
epithelium which in turn allows for physical and nutritional support by the endometrium 
(162, 163). Implantation occurs over two distinct phases; attachment and invasion. The 
conceptus moves from the oviduct to the uterus by ciliary beating (164). The breakdown of 
the zona pellucida allows ‘hatching’ of the blastocyst which is followed by apposition and 
adherence of trophoblast cells to the luminal epithlium of the receptive endometrium (163, 
165). This leads to blastocyst mediated breakdown of epithelial cells (166) and there is 
increased vascular permeability within the stroma underlying the conceptus in association 
with decidualisation (9). In women, blastocyst implantation occurs following degradation of 
surface epithelium which facilitates invasion of trophoblast cells into endometrial glandular 
and decidual compartment (167). In humans invasion i  deep with the blastocyst implanting 
interstitially; the surface epithelium is restored following implantation (163). The trophoblast 
consists of two cell lineages; the syncitium (syncitiotrophoblast) and the cytotrophoblast. 
The syncitiotrophoblast is a large multi-nucleated cell type which proliferates to produce 
more trophoblast cells, further invading the uterin tissue and forms the interface between 
maternal cells and the cytotrophoblast cells of the conceptus.  
The uterine epithelium is normally hostile to the blastocyst and is required to undergo 
transition to a receptive state in order for implantation to occur. Uterine receptivity occurs 
over a restricted period of time during each normal cycle (168). While the mechanisms and 
factors which control the duration of the receptive phase are poorly understood several 
features of epithelial transition are well described (169). In the non-receptive state the 
epithelium is repellent to the blastocyst due to long apical microvilli, thick glycocalyx and a 
high surface charge (168). Receptivity is characterised by the emergence of apical 
protrusions known as pinopodes which occlude the uterine cavity by bringing opposing 
epithelia into close apposition (170). The epithelium loses its negative charge and shortening 
of microvilli and thinning of mucin coat also occur (168). Glycoprotein unmasking at 
implantation sites correlates with increased blastocyst adhesion (171). The receptive phase 
lasts approximately 4 days in women usually falling on days 20 to 24 of a standard 28 day 
cycle (7-11 days post LH surge, Figure 1.2) (172). Following the receptive phase and in the 
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absence of implantation the uterine epithelium enters a refractory phase and implantation can 
no longer occur.  
Implantation depends on support from the ovarian sex st roid hormones oestrogen and 
progesterone. While progesterone drives priming of the uterus it is oestrogen that is essential 
for implantation. Oestrogen acting via oestrogen receptor alpha (ERα) transforms the 
progesterone primed uterus into a receptive state and the uterine oestrogen metabolite 
catecholestrogen can activate the blastocyst in a par crine manner (173). ERα knockout mice 
are infertile due to implantation failure however implantation is possible in ERβ knockout 
mice despite reduced ovarian capacity (126, 127). In mice, specific levels of oestrogen are 
the critical determinant of the window of receptivity; higher levels of oestrogen are 
associated with aberrant expression of genes normally conducive to implantation, while 
suboptimal levels do not promote progression from the pre-receptive state (174). Targeted 
ablation of the progesterone receptor (PR) in mice also results in infertility as a result of 
implantation and decidualisation failure (121).  
Release of cytokines and signalling factors by endometrial epithelial cells has been shown to 
be essential for normal implantation. In mice exposure to oestrogen increases expression of 
leukaemia inhibitory factor (LIF) in the glandular epithelium and LIF null mice cannot 
support implantation (16, 175). In humans, blastocysts express two receptors that bind LIF; 
LIF-Rβ and gp130, and LIF expression is maximal in the mid-luteal phase in glandular 
epithelium coincident with the receptive phase (176). Epidermal growth factor (EGF) 
receptor is expressed in human pre-implantation embryos and stimulation by EGF increases 
protein synthesis and blastocyst development (177, 8). TGF-β is reported to control 
trophoblast invasion and promotes angiogenesis and decidualisation (179). Other factors 
which are essential in mediating implantation are int grins, adhesion molecules which are 
constitutively expressed in uterine epithelium (163). While the expression of several integrin 
subunits has been described the subtype αvβ3 appears in both luminal and glandular 
epithelium at day 19 of the menstrual cycle and expr ssion persists through the secretory 
phase (180). Unlike in mice, mucin-1 (MUC1) is abunda t at the time of implantation in 
humans yet large molecules such as MUC1 are thought to inhibit implantation due to steric 
interference (181, 182). It is thought that in humans blastocysts may initially induce 
epithelial MUC1 expression but subsequently induce cleavage of MUC1 in epithelium 
during the adhesion stage at the implantation site (171). This paracrine interaction may 
confer a degree of selectivity such that only suitable, viable blastocysts can implant. 
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1.5. Sex steroids 
1.5.1. Overview 
Sex steroid hormones, including; oestrogens, androgens and progestagens, regulate a wide 
range of physiological functions and are essential mediators of reproductive function. Sex 
steroids alter cell function following binding to nuclear receptors that are members of a 
superfamily of ligand-activated transcription factors (http://www.nursa.org/) consisting of 
more than 48 different nuclear receptors (NR) in humans (183), including orphan receptors 
for which no natural ligand has been identified (184). These receptors can also be activated 
by alternative signalling pathways and have been report d to relocate to the membrane (185) 
or mitochondria (186).  
Oestrogens and progestagens are essential to female reproductive function but there is also 
an emerging role for androgens in regulating distinct gene networks in the endometrium 
(187). In humans two oestrogen receptors have been id ntified; ER alpha (ERα, NR3A1) and 
ER beta (ERβ, NR3A2) which are the products of two genes (ESR1 and ESR2 respectively) 
located in humans on chromosome 6q25.1 (ESR1) and 14q23.2 (ESR2) (188). Both ESR1 
and ESR2 are subject to alternative splicing (reviewed in (189)) and several isoforms have 
been identified for both ERα (ERα46 and ERα36) (190, 191) and ERβ (ERβ1-5) (192, 193). 
Progesterone receptor (PR; NR3C3) is encoded by a single gene (PGR) located on human 
chromosome 11q22 (194). PR has two main receptor isoforms PR-A and PR-B that differ by 
molecular weight due to an additional 165 N-terminal amino acids in PR-B and are the result 
of different promoters on the PGR gene (6). In addition, an N-terminal truncated PR-C 
isoform has been reported which inhibits PR-B transactivation when PR-B and PR-C 
heterodimerise (195).There is a single androgen receptor (AR, NR3C4) encoded by the AR 
gene located on the X chromosome at Xq11-12 (196).  
Oestrogens play a fundamental role in the development and normal physiological function of 
multiple tissue systems and are key regulators of fertility in both males and females (12). 
Progestins play a central role in the diverse functio s which are associated with the 
establishment and maintenance of pregnancy (197). Androgens are essential regulators of 
male fertility (198); in addition, ARs are expressed in the ovary (199) and endometrium 
(200). 
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1.5.2. Steroid receptor structure 
Nuclear steroid receptors contain a conserved arrangement of structural and functional 
domains (A to F; see Figure 1.4. and Figure 1.5). These include a regulatory N-terminal 
domain (A/B), a conserved DNA-binding domain which is composed of two zinc fingers 
(DBD, domain C), a hinge region (D) and a C-terminal domain (domain E/F) that contains 
peptides involved in ligand binding, receptor dimerisation and nuclear localization (183, 188, 
201-203). 
 
Figure 1.4. Protein structure of the two main ER isoforms; ERα and ERβ. Amino acid 
sequence and functional regions are shown. Adapted from (204). 
The sequences within the N-terminal (A/B) domains of NR3 family members are poorly 
conserved, for example, there is only 20% sequence homology between human ERα and 
ERβ. This domain is involved in protein-protein interactions and in transcriptional activation 
of target gene expression. In ERs, it contains the activation function (AF)-1 region as well as 
several phosphorylation and sumoylation sites (188, 205) that are downstream targets for 
growth factor signalling pathways. It has been claimed that the N terminal region of ERβ 
contains a repressor domain (206). In PR-A and PR-B, AF-1 is also located in the N-terminal 
functional domain (207) and in PR-B a further regulatory AF-3 region is present in the 
upstream sequence that is distinct to PR-B (208).  





Figure 1.5. Protein structure of progesterone receptor. PR-A and PR-B differ only in the N-
terminal amino acid sequence. PR-B has an additional upstream sequence (BUS; B 
upstream sequence) of 165 amino acids which is absent in PR-A. Adapted from (209). 
In these receptors, the ligand binding domain (LBD) also contains an additional 
transactivation domain known as AF-2, which is responsible for ligand-dependent activation 
of the receptor. Variations in peptide sequence altr the tertiary structure LBDs in different 
nuclear receptors and this specifies ligand specific interactions. The LBD of PR, ERα and 
ERβ , have all been crystallized and their 3D structure has been determined (210, 211). 
Distinct residues in the LBD distinguish interactions between 3-OH group present in 
oestrogen and 3-keto group present in other steroids such as progesterone and androgen and 
this confers ligand specificity for oestrogens (211). Notably, differences in the functional 
size of the ligand binding pocket as a result of shortened C-terminal sequences and 
disorientated helix 12 in ERβ isoforms such as ERβ2 and ERβ5 (212) prevents ligand 
binding. Thus ligand responsiveness to these ERβ isoforms is reported to require 
heterodimerisation with competent binding partners such as ERα or ERβ1 (212). 
1.5.3. Steroid hormone receptor co-regulatory prote ins 
Steroid hormone receptor (SHR) co-regulators are ess ntial mediators of steroid hormone 
function. The activities of SHRs are modulated by co-regulatory proteins which can enhance 
(co-activators) or inhibit (co-repressors) transcription (213). Co-activators are molecules 
which are recruited to SHRs, usually in a ligand dependent manner, and enhance SHR-
mediated transcription. Conversely, co-repressors are typically complexed with unliganded 
receptors and repress transcription. 
The first nuclear receptor co-activator was cloned in 1995, using a yeast two-hybrid system 
which identified a protein which could enhance transcriptional activity of the human PR 
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(214). Subsequently, this protein has been termed st roid receptor coactivator-1 (SRC-1); 
SRC-1 is reported to enhance transcriptional activity of ERs, PR and AR (214, 215). Notably 
targeted deletion of the SRC-1 gene in mice results in a phenotype which includes 
reproductive dysfunction characterized by impaired decidualisation response and reduced 
uterine growth in response to oestradiol in females, and reduced testis weight in males (216). 
Thus SRC-1 appears to be required for maximal response to steroid hormones in vivo and is 
therefore important in regulating reproductive function. 
Prototypical co-repressors were also identified using yeast two-hybrid screening and these 
include nuclear receptor co-repressor (NCo-R) (217) and silencing mediator of retinoic acid 
and thyroid-hormone receptors (SMRT) (218). Interestingly, protein expression of SRC-1 
(and SRC-2 and -3), and NCo-R has been reported in normal endometrium (219, 220) 
underlying the importance of these co-regulatory proteins in mediating steroid hormone 
responses in uterine function.  
The association of SHRs with co-regulatory proteins depends largely upon ligand-dependent 
changes in receptor conformation. Typically ligand binding results in dissociation of co-
repressors and recruitment of co-activators. Thereafter the sequential assembly of a multi-
protein complex permits recruitment of chromatin remodelling machinery (221, 222). In 
classical responses to ligand-dependent gene activation local acetyltransferase activity 
mediated by co-activators results in disruption of nucleosome structure and histone 
displacement leading to direct interaction of the receptor complex with DNA and 
transcription (223).  
In addition, post translational modifications may also modulate nuclear receptors, their co-
regulator complexes and consequently their target gene networks (223). Targeted enzymatic 
modifications such as; acetylation, methylation, and phosphorylation can all affect nuclear 
receptors and the function of co-regulatory proteins function and as a result alter 
transcriptional responses (224). The convergence of other signalling pathways such as 
growth factor signalling and phosphorylation pathways can mediate PTMs at nuclear 
receptor complexes adding further complexity to SHR signalling and contribute to cross-talk 
between responses (225).  
1.5.4. Oestrogen receptor dependent signalling 
The classical endogenous ligands for both ERα and ERβ are the naturally occurring 
oestrogens; oestradiol and oestrone, both of which exhibit agonist activity at ERs (226). In 
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addition, pregnancy associated oestrogens; oestriol and oestetrol, as well as the plant-derived 
phytoestrogen genistein, are also reported to have activity at ERs (227-229). The compound 
ICI 182,780 (ICI) acts as an antagonist of both ERα and ERβ. In addition to widely used ER 
subtype specific agonists including propyl-pyrazole triol (PPT; ERα-specific) and 
diarylpropionitrile (DPN; ERβ-selective), a wide variety of selective oestrogen r ceptor 
modulators (SERMs) are capable of mixed agonist andtagonist activities at ERs 
dependent on tissue context (230-232). Probably the best known of these is tamoxifen which 
acts as an antagonist in breast but has mixed agonist/antagonist activity in endometrial 
tissues associated with stimulation of cell proliferation even in postmenopausal women. 
The effects of oestrogens can be mediated through several different pathways (reviewed in 
(188, 233, 234)). Classically, ligand-activated ERs form homo- or hetero-dimers that interact 
with consensus sequences known as oestrogen respons elements (EREs) within the 
promoter regions of genes (reviewed in (188)). In addition to full EREs with palindromic 
sequences, oestrogen receptors can also bind imperfect EREs or ERE half sites leading to 
transcriptional responses (235). Interestingly, the promoter region of human PGR gene lacks 
a palindromic ERE but contains an ERE half-site andtwo Sp1 sites critical to oestrogen 
responsiveness (236). Genomic studies have also revealed that many oestrogen-responsive 
genes lack sequences in their promoters that resemble EREs (237) and such genes can be 
regulated through indirect association of ER with oer DNA binding proteins (238). For 
example, ER complexes can bind promoter regions indirectly through protein-protein 
interactions with Jun/Fos (at AP-1 response elements) and Sp-1 (at GC-rich Sp-1 motifs) or 
by interaction with the NFkappa ß pathway (239). The varied mechanisms of ER activation 
result in distinct ligand and tissue-specific transcriptional responses. Thus, ligand-activated 
ERs binding via tethered transcription factors may h ve agonist and antagonist profiles that 
differ from classical mechanisms of ER action; for example, using a luciferase reporter assay 
Paech et al reported that ERα tethered via activator protein-1 (AP-1) sites is an E2-dependent 
transcriptional activator, whereas E2 acting on ERβ at AP-1 sites did not induce transcription 
of the reporter (240). Interestingly the same authors reported that treatment with oestrogen 
antagonists such as ICI 182, 780 (Fulvestrant, Faslodex®) increased transcriptional activity 
of ERβ at AP-1 sites in contrast to the classical antagonist effects of ICI at ERE sites. In 
addition to AP-1 interaction, both ERα and ERβ can interact with the transcription factor 
Specificity protein 1 (Sp1.) ERα-Sp1 complexes can be activated by oestrogens, however, 
little transcriptional activation is reported for Sp1-ERβ complexes (241). Interestingly, the 
anti-oestrogen ICI 182, 780 which suppresses ERE-dependent transcription is reported to be 
a potent agonist of ERs when they are tethered to AP-1, SP-1 (237, 242) and STAT-5 
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transcription factors in the nucleus (243). The affinities of co-factors for ERs can also be 
subtype specific, for example, thyroid receptor-associated protein 220 (TRAP220) has 
selective affinity for ERβ (244) while the co-activator SRC-1 is more strongly recruited to 
ERβ following stimulation with the phytoestrogen genestein (245). 
Expression of ERα and ERβ in the human uterus is both temporally and spatially regulated. 
In the myometrium, concentrations of ERα mRNA are higher than those of ERβ (246). 
However, in the myometrium of post-menopausal women r lative mRNA expression is 
altered and ERβ expression predominates. During pregnancy there is also a switch to 
predominance of ERβ over ERα in term myometrium (247). These changes are likely to be 
related to differences in bioavailable oestrogens but their impacts on myometrial contractility 
are poorly understood. 
In the endometrium both ERα and ERβ proteins are expressed in multiple cell types, 
including the stromal fibroblasts and epithelial cells. However, ERβ but not ERα is 
expressed in endothelial cells that line blood vessel walls (248) and in immune cells such as 
uterine-specific natural killer (uNK) cells (249). During the normal menstrual cycle the 
pattern of expression in the functional layer of the endometrium of ERα and ERβ changes 
according to phase. In the oestrogen dominated proliferative phase, there is intense immuno-
expression of ERα in the glands and stroma (248) which decreases during the secretory 
phase following the post-ovulatory rise in progesteron  (250). The expression of ERβ 
isoforms also varies throughout the cycle. While full length ERβ1 mRNA and protein are 
consistently expressed throughout the cycle, ERβ2 is higher in the proliferative phase and is 
selectively down-regulated in the glandular epithelum during the secretory phase (250). In 
decidua of early pregnancy ERα expression is minimal and only detected in nuclei of stromal 
and epithelial cells however nuclear expression of ERβ is found in all compartments (251). 
In contrast to the dynamic changes in expression of ERs in the functional layer of the 
endometrium, immunohistochemical analysis of ERα and ERβ expression has revealed that 
ER levels are relatively unchanged in the basal layer throughout the menstrual cycle (248). 
The uterus is a major target tissue for oestrogen action and stimulation of the functional layer 
of the endometrium by ovarian oestrogen during the proliferative phase of the menstrual 
cycle drives uterine proliferation (252). ERα and ERβ are also expressed in the mouse uterus 
and studies in mice have demonstrated the importance of oestrogen signalling in mediating 
uterine proliferation. In mice, ovariectomy (ovx) removes the major source of endogenous 
oestrogens and exogenous administration of E2 stimulates a 3 to 4 fold increase in uterine 
Chapter 1. Literature Review. 
30 
 
wet weight (12). However, following disruption of ER by gene targeting or by co-
administration of the ER antagonist ICI 182, 780, the uterotropic effects of E2 observed in 
wild type mice are abolished, confirming the essential requirement for ER in driving uterine 
proliferation (12, 253). Oestrogen driven uterine proliferation has been shown to be ERα 
specific through the use of ER selective ligands (254). For example, Frasor et al reported that 
in female mice following ovx, administration of the ERα selective agonist PPT stimulates an 
increase in uterine wet weight and epithelial proliferation that is similar but less potent than 
E2 (255). However, the ERβ selective agonist DPN did not induce uterine proliferation 
(255). The authors also reported that co-administrat on of DPN and PPT reduces the increase 
in wet weight observed following treatment with PPT alone (255) suggesting a capacity for 
ERβ to modulate ERα responses in the mouse uterus. Consistent with a key role for ERα in 
uterine responsiveness, female ERα knock-out (ERαKO) mice exhibit uterine hypoplasia and 
have uterine weights that are half those of intact controls with a uterine morphology 
characterized by a sparse distribution of glands (12). Administration of E2 to ERαKO female 
mice does not induce uterine proliferation (12, 256). Interestingly, the decidual response is 
intact in ERαKO mice despite the requirement for E2 in inducing artificial decidualisation of 
wild type mice. Although the decidualisation response is retained, ERαKO female mice are 
infertile due to implantation failure (126). A uterine epithelial cell-specific ERα knock out 
mouse model has also been reported and the studies on female mice have demonstrated that 
proliferation of uterine epithelial cells is mediated by an ERα-dependent proliferative signal 
from the stroma (13). In contrast to the ERαKO mouse, the uterine weight in ERβKO mice is 
normal. However, loss of functional ERβ results in reduced epithelial cell differentiation a d 
ERβKO females are hyper-responsive to E2-stimulated uterine proliferation which is 
consistent with in vitro studies suggesting ERβ can act as a negative regulator of ERα 
mediated proliferation (256). 
1.5.5. Progesterone receptor dependent signalling 
PRs are expressed in all major physiological system, and are essential to reproductive 
function with highest concentrations of PR mRNA being detected in the uterus and ovary 
(www.nursa.org/10.1621/datasets.02001). PRs are activated by the naturally occurring 
hormone progesterone, as well synthetic agonists such as medroxyprogesterone acetate 
(MPA) (257). Progesterone action is inhibited by the PR antagonist RU486 (mifepristone) 
(258) while selective progesterone receptor modulators (SPRMs), such as J867 (Asoprisnil) 
(259), have tissue dependent mixed agonist/antagonist actions. 
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In the absence of hormone, PR is assembled in an inactive multi-protein chaperone complex 
in the cellular cytoplasm (260). Ligand interaction leads to dissociation of the chaperone 
complex, receptor dimerisation and modulation of transcription through binding to the 
regulatory regions in the promoters of target genes (261). PR can bind directly to 
progesterone response elements (PREs), consensus sequenc s within the promoter of target 
genes, to modulate transcription (262). Similar to ERs, PR can also interact with gene 
promoters via tethering to other transcription factors such as Sp1 (263), Sp3 (264) and the 
AP-1 complex (265). PR-A and PR-B are functionally unique transcriptional regulators and 
are capable of regulating distinct responses at promoter regions (266, 267). The protein 
structure of PR-A contains an AF-1 and AF-2 domain as well as an inhibitory domain (ID) 
which suppresses transcriptional activity (208, 268). Thus, PR-A acts as a repressor of 
transcription at a number of different promoters in the presence of both progesterone 
agonists and antagonists. PR-A is able to act as transdominant repressor, and is reported to 
modulate the transcriptional activity of PR-B (269) and ERα (270). In addition to the 
domains contained in PR-A, PR-B also contains a unique AF-3 domain in the ‘B upstream 
sequence’ (BUS) of the protein which neutralises the effect of the ID (208), allowing greater 
transcriptional activity (Figure 1.5) (271). As a result PR-B is the more transcriptionally 
active PR isoform. PR signalling is modified by interaction with cofactors which can 
positively or negatively modulate transcription (213, 272). The contribution of cofactors is 
dependent on their relative abundance which varies in a tissue-specific manner. PR-A and 
PR-B interact with distinct co-regulatory proteins. This is evidenced by PR-A having a 
higher affinity than PR-B for the co-repressor SMRT (273) and PR-B having a high affinity 
for co-activators such as SRC-1 and SRC-2 (273, 274).  
In the endometrium, the two PR isoforms appear to have distinct functions. PR-A acts as a 
transcriptional repressor and has a major role in the endometrium by inhibiting oestrogen-
induced proliferation. In contrast, PR-B has an activ ting role in the endometrium by acting 
as an endometrial oestrogen agonist (275). This may be important in endometrial pathologies 
such as endometrial cancers where unopposed oestrognic stimulation may lead to neoplasia 
which may in part be a result of altered PR isoform expression (276).  
PR isoforms are spatially and temporally regulated in the human endometrium during the 
menstrual cycle (153). The PR gene contains numerous cis elements and relies on 
cooperative interaction of numerous transcription factors to regulate PR gene expression 
(277). During the menstrual cycle PR gene expression is controlled by fluctuating levels of 
oestrogen and progesterone. During the proliferative phase, PR gene expression in the 
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endometrium is under control of oestrogen which induces PR synthesis (124). Regulation of 
the PR gene by oestrogen is a result of recruitment of ligand activated ERα to a region in the 
PR promoter which contains an ERE half site and two adjacent Sp1 sites (236, 277) and gel 
mobility shift assays have shown that ERα greatly enhances the interaction of the 
transcription factor Sp1 at the PR promoter (278). In female ERαKO mice, PR mRNA is 
detected at 60% of wild type levels and PR expression cannot be induced by oestrogen 
treatment, underlining the importance of ERα in mediating PR expression (279). During the 
secretory phase maximal activation of PR due to elevated circulating levels of progesterone 
results in reduced proliferation and increased differentiation of the endometrium as a result 
of negative feedback on expression of ERα (280). Evidence from primate models using an 
artificially induced menstrual cycle, has shown that progesterone down-regulates expression 
of both ERα and PR proteins (281). The importance of progesterone in mediating these 
functions in human endometrium was confirmed in a study in which administration of the 
progesterone antagonist RU486 to women in the early secretory phase prevented 
progesterone-induced down regulation of PR and ERα (282). Immunohistochemical studies 
have revealed that in human endometrium PR-A and PR-B protein are both expressed in the 
glandular epithelium and stroma in the functional layer of the endometrium during the 
proliferative phase (283). However, during the secretory phase, overall expression of PR-A 
and PR-B in the epithelium of the functional layer is decreased compared to the proliferative 
phase (283) while PR expression is retained in the basal layer (284). PR-B is detected in 
stromal cells in the functional layer until the mid-secretory phase but thereafter only PR-A is 
identified (153). Epithelial PR-B in the functional l yer is the predominant isoform in the 
mid-secretory phase but is absent from the epithelium thereafter (153). In mice, 
immunohistochemical analysis of PR expression has revealed that PR (isoform not specified 
as antibody used recognized both isoforms) is increased in the luminal epithelium and stroma 
in the pre-implantation phase and is absent from the uterine epithelium following 
implantation suggesting an active role for PR during implantation (285). Similarly, temporal 
expression of PR-B in mid-secretory human endometrial epithelium (i.e. during the 
implantation window) described previously suggests thi  isoform may be important in 
mediating implantation in human. 
In the PR knockout (PRKO) mouse both isoforms of PR are ablated and female PRKO mice 
are infertile due to numerous defects in the hypogonadal-pituitary axis, ovary and uterus 
(121). For example, in the uterus of PRKO mice, lack of PR expression leads to an 
impairment of decidualisation and implantation resulting in infertility (121). Steroid 
hormone receptor cross-talk is essential to mediating normal uterine function, thus, PRKO 
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mice have abnormal responses to ovarian stimulation and unopposed oestrogen results in 
uterine hyperplasia, inflammation and hyperproliferation consistent with loss of expression 
of PR removing the inhibitory effect of PR on expression of ERα in the uterus (286). PR 
isoform specific ablations have revealed the specific roles of PR-A and PR-B in uterine 
physiology. Notably, PR-A knockout (PRAKO) mice are infertile and retain uterine defects 
in decidualisation and implantation present in the global PRKO. PR-A is reported to be 
essential in mediating down-regulation of the epithel al glycoprotein mucin-1, which is 
essential for implantation in mice (17) and loss of this PR-A mediated transcriptional 
regulation may in part account for the implantation phenotype. However, epithelial 
proliferation following progesterone administration is retained in PRAKO mice suggesting 
PR-B may be the isoform responsible for mediating this response to progesterone (287). 
PRBKO mice are fertile suggesting PR-A is the essential isoform for uterine regulation and 
function (288). Consistent with greater importance of PR-A, in the mouse uterus the ratio of 
uterine PR-A: PR-B protein is 3:1 (289).  
1.5.6. Expression and functional significance of ot her members of the nuclear 
receptor superfamily. 
In addition to the well defined roles of oestrogen a d progesterone receptor signalling 
outlined in the previous sections, there is emerging evidence of a role for other members of 
the nuclear receptor superfamily in regulating endometrial function. 
Androgens are essential regulators of male fertility (198); in addition, ARs are expressed in 
female reproductive tissues including the ovary (199) and endometrium (200). ARs are 
activated by endogenous androgens such as testosterone and the non-aromatisable androgen 
dihydrotestosterone (DHT) which is a potent AR agonist (290). ARs are expressed in the 
endometrium throughout the menstrual cycle with peak xpression in stromal cells during 
the proliferative phase (187, 291). AR expression is increased in epithelial cells coincident 
with progesterone withdrawal (1). In Ishikawa cells, an endometrial adenocarcinoma cell 
line, AR protein expression can be induced by E or DHT but is down-regulated by MPA or 
the anti-androgen hydroxyflutamide suggesting progestagens may down-regulate AR 
expression in the endometrium (292). Consistent with a role for progestagens in mediating 
down regulation of AR, in women using a levonorgestrel-releasing intra-uterine device lower 
concentrations of AR mRNA are detected in total endometrial homogenates compared to 
normally cycling untreated women (293). In a study by Nantermet et al, administration of 
DHT increased uterine wet weight in ovariectomised rats and microarray analysis revealed 
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overlapping gene regulation with E2 (294) suggesting androgens may be important in 
regulating uterine function in humans. Genome-wide expression profiling has revealed that 
AR regulates distinct gene networks in decidualised human ESC involving cell cycle 
regulation and cytoskeletal organization (295). In addition, a recent in silico analysis 
revealed a novel androgen regulated gene network in human endometrium associated with 
regulation of apoptosis (200). 
In addition to ligand-activated NR3 subfamily members described previously the orphan 
oestrogen related receptors (NR3B1-3: ERRα, ERRβ, ERRγ) have important functional roles 
in regulating reproductive tissues (189, 201). ERRs share significant sequence homology 
with ERα and ERβ and are capable of binding EREs (296). Binding site recognition 
experiments have revealed a single consensus sequence that ERRα preferentially binds (ERR 
response element; ERRE) (297), which has an identical sequence to the consensus binding 
site of steroidogenic factor 1 (SF-1) (298). ERR monomers and the momomeric orphan 
nuclear receptor SF-1 preferentially recognise this binding half-site with high affinity (299). 
Although the ERR LBD exhibits significant amino acid sequence identity with ER LBD, 
ERRs are unable bind E2 as they lack key Cys residu involved in recognition of 
oestrogens. Although natural ligands to ERRs are yet to be identified the activity of ERRs 
can be modulated by synthetic inverse agonists suchas diethylstilbesterol (DES) and the 
ERRα specific inverse agonist XCT790 (296, 300). The LBD in ERR contains an AF-2 
domain that can interact with co-factors such as PPARγ and the co-repressor RIP140 (301). 
ERRs are capable of regulating the activity of other nuclear receptors via transcriptional 
cross-talk. For example, ERRβ can differentially impact on ERα-dependent gene expression 
(302) and androgen responsive genes can be down-regulat d by inhibition of ERRα (303). 
ERRs are expressed in the uterus. ERRα and ERRβ proteins have been localized to cell 
nuclei within the glandular epithelium, in stromal cells and in endothelial cells in human 
endometrium at all stages of the cycle (189, 304). Increased expression of ERRα is 
associated with decidualisation of human ESC in vitro and administration of the ERRα 
inverse agonist XCT790 is reported to inhibit mRNA expression of both the decidualisation 
marker IGFBP and ERRα itself (305). ERRβ is also expressed in immune cells in the human 
endometrium as evidenced by co-expression with CD45 (common leukocyte antigen) (304). 
In uNK cells, macrophages and endothelial cells in the endometrium, ERRβ is co-expressed 
with ERβ, while during the proliferative phase ERRβ is co-expressed with ERα in epithelial 
cells (304). 
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The orphan nuclear receptor chicken ovalbumin upstream promoter-transcription factor II 
(COUPTFII; NR2F2) is expressed in all major physiological systems with high 
concentrations of mRNA detected in the uterus and ovary 
(www.nursa.org/10.1621/datasets.02001). COUPTFII null mutants die before embryonic day 
10.5 due to cardiovascular defects (306) however conditi nal ablation of COUPTFII has 
revealed important roles in reproductive function. Ablation of COUPTFII in the uterus 
results in defects in implantation and decidualisation (186, 280). Progesterone achieves 
control of uterine function through stromal and epithelial cross-talk and regulation of PR 
action is also mediated via other transcription factors such as COUPTFII expressed in the 
stroma and the signalling factor Indian hedgehog (Ihh) in the epithelium. Furthermore, 
COUPTFII is reported to be essential for PR mediate down-regulation of epithelial ERα 
expression which is essential for successful implantation and decidualisation (307). Ihh is a 
progesterone target that signals downstream to COUPTFII. Conditional knockout of Ihh in 
the uterine epithelium results in attachment and decidualisation failure underlying the 
importance of these factors in mediating PR action in the uterus (308). 
1.6. Steroid metabolism and synthesis 
Steroid biosynthesis occurs in many tissues throught the body most notably in the gonads 
(ovary and testis) and the adrenals. There is emerging evidence to support a role for steroid 
biosynthesis within the normal endometrium in the regulation of fertility; expression of 
many steroidogenic enzymes has been reported in the endometrial cell types (summarised in 
Table 1.20). These observations suggest the expression of steroid metabolizing enzymes 
within tissue compartments in the endometrium can influence the bioavailability of different 
sex steroids in the local environment and thus influence the control of endometrial function 
through binding and activating steroid receptors. 




mRNA detection in human endometrium   
Stromal cells Epithelial cells 
References 
StAR + - (309) 
CYP11A1 + + (310) 
CYP19A1 Low/absent Low/absent (311-313) 
17βHSD1 + + (312) 
17βHSD2 Highest in secretory 
phase 
Highest in secretory phase, stronger 
than stromal 
(312, 314) 
17βHSD5 +/- Highest in early secretory phase (315, 316) 
3βHSD Not described Weak in proliferative phase, moderate 
in secretory phase 
(317) 
STS Reduced in late 
secretory phase 
+ (312) 
SRD5A1 +/- All phases (318, 319) 
Table 1.2. Summary of mRNAs encoding proteins involved in steroid biosynthesis within the 
normal endometrium. For abbreviations see text. 
Steroid biosynthesis involves a series of enzyme reactions that convert cholesterol into 
steroid hormones such as oestrogen and testosterone (see Figure 1.6). Steroidogenic acute 
regulatory protein (StAR) plays a significant role in steroidogenesis during the transport of 
cholesterol from the outer to the inner mitochondrial membrane facilitating conversion of 
cholesterol into pregnenelone as a result of side chain cleavage mediated by cholesterol side 
chain cleavage enzyme (P450scc, encoded by CYP11A1 gene). This represents the critical 
initial steps in steroid hormone biosynthesis (320, 321). The actions of 3β hydroxysteroid 
dehydrogenase and 17α-Hydroxylase sequentially convert pregnenelone intoandrogens (via 
intermediates) which in turn are converted to oestrgens by the aromatase enzyme complex 
(322). 17β hydroxysteroid dehydrogenases (17βHSD) control the inter-conversion of 
oestrogens and androgens (323).  




Figure 1.6. Schematic diagram illustrating the steroid metabolism pathway in the context of 
the endometrium. There is no conversion of 17α-progesterone to A4 in the human 
endometrium (red cross). EST: sulphotransferase (SULT1E1), STS: steroid sulphatase, 
SULT: sulphotransferase (SULT1A1). 
Following side chain cleavage of cholesterol to pregnenelone by P450scc, 3βHSD catalyses 
the conversion of pregnenelone to progesterone and also catalyses the conversion of 17α-
hydroxypregnenolone to 17α-hydroxyprogesterone and dihydroepiandrosterone (DHEA) to 
androstenedione (A4) (320). Western blot analysis has revealed 3βHSD protein is present in 
homogenates of total endometrial tissue (317). In addition, immunohistochemistry studies 
have revealed that in the human endometrium althoug some immuno-expression of 3βHSD 
can be detected in the glandular epithelium during the proliferative phase, expression in is 
markedly increased in the secretory phase (317).  
17α-Hydroxylase (P45017α) is a single enzyme encoded by the CYP17A1 gene which 
mediates both 17α-Hydroxylase and 17,20-lysae activities. 17α-hydroxy metabolites of 
progesterone and pregnenelone undergo cleavage by 17, 20-Lyase action to yield DHEA and 
A4, steroid precursors to oestrogens and androgens (324, 325). To date, there is no evidence 
for conversion of 17α-progesterone to A4 in the human endometrium (red coss on pathway, 
Figure 1.6). 
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Biosynthesis of oestrogen requires activities of the aromatase enzyme (also known as P450 
aromatase, P450arom) complex which contains the aromatase cytochrome P450 and the 
flavoprotein, NADPH-cytochrome P-450 reductase (326). The aromatase enzyme complex 
acts by aromatising androgen precursors into oestrogens. In humans the aromatase protein is 
encoded by a single gene (CYP19A1) and expression is regulated by tissue specific 
promoters (327). Targeted disruption of the CYP19A1 gene or inhibition of aromatase by 
inhibitors such as Letrozole (Femara®, Novartis) or Anastrozole (Arimidex®, AstraZeneca) 
reduces bioavailable oestrogen (328). The CYP19A1 gene is expressed in a number of cell 
types throughout the body with key sites being; ovarian granulosa cells, the placental 
syncitiotrophoblast and the testicular Leydig cells (328). In addition aromatase expression 
has been localised to extraglandular sites such as t e brain, skin and adipose (322), as well as 
in cancers of breast, endometrium and prostate. Intrestingly, adipose tissue is the primary 
site of oestrogen production in post menopausal women (329).  
17β hydroxysteroid dehydrogenases (17βHSD) are an important class of enzymes that 
catalyse the inter-conversion of oestrogens and androgens (see Figure 1.7) (323). Isozymes 
of 17βHSD permit conversion of sex steroids in a cellular and isotype specific manner (320). 
 
Figure 1.7. Inter-conversion of oestrogens and androgens mediated by 17βHSDs (HSD) and 
co-factors (orange boxes). Redox reactions of co-factors are indicated by coloured arrows. 
Green arrows indicates oxidation and red arrows indicate reduction. 
 
17βHSD1 catalyses the reduction of Oestrone (E1) to oestradiol (E2) and androstenedione 
(A4) to testosterone (T) (323). The proximal promoter of the human 17βHSD1 gene contains 
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AP-1, Sp-1 and Sp-3 sites (330) and transcription culd therefore be affected by steroid 
receptor interaction (see section 1.5). Expression of 17βHSD1 mRNA is low in normal 
endometrium although intense protein expression in both stromal and epithelial cells has 
been detected by immunohistochemistry (312). Concentrations of 17βHSD1 protein do not 
appear to vary during the menstrual cycle (312) although cAMP treatment increases 
17βHSD1 mRNA expression in eutopic endometrial stromal ce ls from women with 
endometriosis (313).  
17βHSD2 catalyses the oxidation of E2 to E1 and T to A4 (323).  17βHSD2 mRNA 
expression has been identified in human endometrium and concentrations are highest in the 
secretory phase of the menstrual cycle (314). Immunoexpression of 17βHSD2 is increased in 
early and mid-secretory endometrium with positive staining in glandular epithelium and 
some stromal cells (312).  Sp-1 and Sp-3 have been shown to interact with specific motifs in 
the 17βHSD2 gene promoter to cause up-regulation of 17βHSD2 gene expression in 
endometrial epithelial cell lines (331). In endometrial explants progesterone induces 
17βHSD2 expression. (312)  
Androstenedione is reduced to testosterone by 17βHSD3 in the testes and 17βHSD5 in 
peripheral tissues (332). 17βHSD5 (also known as AKR1C3 due to its aldo/keto reductase 
activity) is expressed in the endometrium throughout the menstrual cycle with highest 
concentrations of mRNA detected in the early secretory phase (315). Reports of protein 
expression have been contradictory, with expression reported to be limited to glandular and 
luminal epithelium in one study (315) while Hevir et al demonstrated immunopositive 
staining in both stromal and epithelial cells in another (316).  
SRD5A1, also referred to as 5α reductase, is an enzyme responsible for 5α reduction of 
steroids. 5α reductase has been shown to reduce testosterone to th more potent androgen 
dihydrotestosterone (DHT) in human endometrium (333) and SRD5A1 has also been shown 
to be very active in the metabolism of progesterone in the endometrium (334). Reports of 
protein expression in the endometrium have been contradictory, with expression reported by 
some to be limited to epithelial cells (318) while others have demonstrated immunopositive 
staining in both stromal and epithelial cells (319).  
Steroid sulphatase (STS) hydrolyses sulphated steroids, which circulate at significant 
concentrations but are unable to bind and activate steroid receptors, into biologically active 
steroids (335). STS primarily converts oestrone sulphate to oestrone. STS immunoexpression 
has been detected in both stromal and epithelial cells in the endometrium across the 
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menstrual cycle and intensity is reduced in the latsecretory phase (312).  Sulfotransferase 
(EST) catalyses the opposite reaction to STS, namely, su phation (inactivation) of steroids 
and EST mRNA is detected at all stages of the cycle in total endometrial extracts (312). 
Furthermore, EST mRNA concentrations are increased by progesterone in endometrial 
explant culture (312). In normal endometrium, concentrations of mRNAs for STS are higher 
than EST (336) which suggests the net effect of STSand EST would favour an increase the 
bioavailability of steroids that are capable of binding and activating steroid receptors in the 
endometrium. In addition to oestrogen forming activities, STS also has the capacity to 
hydrolyse DHEA sulphate (DHEAS) to DHEA which may also act as a precursor for the 
formation of oestrogens and androgens (337).  
1.6.1. Steroid metabolism in the endometrium 
In addition to measurement of proteins and mRNAs studies on steroid metabolism have 
revealed an extensive capacity for interconversion between androgens and oestrogens in 
human endometrial cells and tissue. A study by Collins et al (338) showed that in normal 
endometrial explants metabolism favours formation of oestrone and androstenedione over 
oestradiol and testosterone respectively  indicative of oxidative 17βHSD activity. Consistent 
with reactions that favoured oxidative 17βHSD activity, little conversion of oestrone to 
oestradiol is detected (339). Collins et al also repo ted that a small percentage of DHEA was 
transformed into A4, 5α-androstanedione and androsterone (338).  
The dynamics of oestrogen and androgen uptake in human endometrial tissue also appears to 
favour oxidative 17βHSD activity. A study by Gurpide et al (340) investiga ed the dynamics 
of sex steroid uptake in endometrial explants perfus d with media containing radioactively 
labelled sex steroids. This study revealed that not o ly were high levels of oestrogen and 
androgen were taken up into the endometrial tissue but the net uptake of E2 and T was 
higher than that of E1 and A4. Interestingly, the authors reported that most of the E1 and A4 
that perfused the endometrial tissue was released from the tissue unchanged. Conversely, 
following tissue uptake, a high proportion of E2 and T was released from the tissue 
metabolised into E1 and A4 respectively consistent with the oxidative 17βHSD activity 
reported by Collins et al (340). The fluctuating con entrations in blood perfusing the tissue 
as a result of changes in steroid production by the ovaries during the menstrual cycle may 
also influence the rate of metabolism. For example, 17βHSD oxidation of E2 to E1 was 
reported by Krishnan et al to be higher in the proliferative than secretory phase (341). 
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However, other studies have suggested that oxidative 17βHSD activity is highest in the 
secretory phase (342, 343). 
The capacity for aromatase activity in endometrial tissue fragments has been described by 
Tseng et al (344) who showed that incubation of endometrial tissue fragments with labelled 
testosterone results in formation of E1 (60-90%) and E2 (10-40%) in tissue fragments from 
proliferative phase endometrium, although the most abundant metabolites seen when the 
experiment was repeated with secretory phase endometriu  were E1S (50-80%) and E1 (10-
40%) (344). Further studies from the same laboratory have shown that progesterone 
stimulates aromatase activity in endometrial stromal cells in vitro and this can be potentiated 
by oestrogen (345). In addition, the synthetic progestin MPA has been shown to stimulate 
endometrial stromal cell aromatase activity in vitro, an effect which could be inhibited 
administration by the anti-progestin RU486 (346). However, subsequent studies have 
contradicted these findings and claimed that there is little capacity for aromatase activity in 
normal endometrial stromal cells (311).  
Testosterone is converted to its 5α-reduced metabolite 5α-DHT in human endometrial 
homogenates cultured with labelled testosterone (333). In endometrial tissue explants 
perfused with A4, the majority of A4 is metabolised by 5α reduction to androsterone and 5α-
androstanedione (347). Endometrial explants infused with DHEAS convert around 16% of 
DHEAS to DHEA, of which a further 3% is converted to A4 (348). Reduction of A4 to 
testosterone by 17βHSD activity is also detected in endometrial tissue explant cultures and 
the rate of this conversion is increased in secretory c mpared to proliferative endometrium 
(347, 348).These data suggest an extensive capacity for androgen metabolism in the human 
endometrium which has received very little attentio t  date. Interestingly, a recent study has 
shown that A4 up-regulates aromatase mRNA expression in human endometrial stromal cells 
and explants (349) underlining the importance of androgen metabolism in modulating the 
steroid microenvironment in the endometrium. 
A recent study revealed an essential requirement for aromatase activity during 
decidualisation in mice. Administration of the aromatase inhibitor letrozole to ovx, 
progesterone supplemented, pregnant mice was found to decrease neovascularisation and 
also blocked the decidualisation reaction (128). These data suggest that de novo synthesis of 
oestrogen is essential during the critical processes of implantation and decidualisation in 
mice, processes which are both known to be steroid regulated. This is consistent with the 
concept of ‘intracrinology’ first postulated by Labrie (350, 351). Labrie proposed that the 
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presence of steroid biosynthetic enzymes in tissues would allow for local conversion of 
inactive precursors and formation of active steroids thereby creating a tissue 
microenvironment in which steroids are present at levels which are different to those found 
in blood as a result of biosynthesis within the gonads and adrenal gland. Local formation of 
active steroids at high concentrations could have fr reaching consequences by increasing the 
capacity for interaction and activation of steroid receptors resulting in alterations in 
functional responses. Thus intracrinology could be particularly important in mediating 
control of endometrial function due to the complex, multi-cellular nature of the tissue. For 
example, changes in local bioavailability of oestrogens could have autocrine and/or paracrine 
impacts on several cell types due to the close juxtaposition of stromal, epithelial, endothelial 
and immune cells, all of which express ERs. Despite th  recent findings in mice, a 
requirement for local oestrogen production during deci ualisation in humans is yet to be 
elucidated. 
1.6.2. Changes in steroid metabolism detected in re productive health 
disorders.  
Aberrant expression of enzymes which mediate steroid metabolism and biosynthesis are 
features of many reproductive malignancies. 
Uterine fibroids (leiomyomas) are benign tumours that arise as a result of aberrant 
proliferation of uterine smooth muscle tissue and are a common cause of pre-menopausal 
hysterectomy (352). Increased risk of fibroid development is associated with conditions 
associated with increased exposure to oestrogens such a  obesity, nulliparity as well as breast 
and endometrial cancer (353). Tissue concentrations f oestrogens are elevated in 
leiomyomas (354) and oestrogen is thought to drive proliferation of uterine smooth muscle 
cells via an intracrine mechanism. Sumitani et al have reported that aromatase mRNA and 
protein is over-expressed in leiomyomas compared to normal myometrium (355). In 
addition, Sumitani et al have shown that in cultured smooth muscle cells isolated from 
leiomyomas aromatase expression is immunolocalised to cytoplasmic granules and following 
stimulation these cells are capable of converting A4 to E1, an effect which was reported to 
be inhibited by an aromatase inhibitor (355). In the same study, administration of A4 and T 
but not the non-aromatisable androgen DHT stimulated th  growth of cultured leiomyoma 
smooth muscle cells to the same extent as E2. The stimulatory effect of T on cell growth was 
shown to be aromatase dependent as it was abolished by co-treatment with an aromatase 
inhibitor (355).  Shozu et al reported that administration of the aromatase inhibitor Fadrozole 
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(Afema®, Novartis) reduced leiomyoma volume by 71% after 8 weeks of treatment in a 
patient case report providing in vivo evidence for the requirement of local oestrogen 
biosynthesis in the growth of uterine fibroids (356) .   
Endometrial cancer is the most common gynaecological m lignancy and unopposed 
oestrogen exposure predisposes risk of developing the disease (357). Concentrations of 
oestradiol measured in endometrial cancer tumour tissues are higher than those of disease 
free endometrium (358). Aromatase is expressed in endometrial cancer tissue and aromatase 
inhibitors have been used to treat endometrial cancer (359). Rizner et al showed that 
dysregulation of 17βHSD5 is associated with endometrial cancer with increased mRNA 
expression in malignant compared to normal endometrium (360). Yamamoto et al reported 
that both aromatase and STS activity is higher in endometrial cancer tissues preparations 
compared to normal endometrium (361). High levels of STS mRNA expression have been 
detected in Ishikawa cells (an endometrial adenocarcinoma cell line) (336) and STS activity 
has been demonstrated by thin layer chromatography in RL-95 an endometrial carcinoma 
cell line (335). These data suggest that dysregulation of steroid metabolism is a feature of the 
pathophysiology of endometrial cancer.  
Polycystic ovarian syndrome (PCOS) is an endocrine disorder affecting women of 
reproductive age and is associated with menstrual cycle disturbances, hyperandrogenism and 
infertility (362). Excess androgen production in PCOS is clinically associated with 
amenorrhea, infertility, hirsutism and acne (363). In the human ovarian follicle, androgen 
production arises from the theca cells which express; StAR, CYP11A1, CYP17A and 
3βHSD, the enzymes responsible for converting cholesterol into androgens (364-366). PCOS 
is associated with dysregulation of steroid metabolism.  Nelson et al reported that cultures of 
theca cells isolated from PCOS ovaries produce higher levels of progesterone, 17α-
hydroxyprogesterone and testosterone compared to theca cells from normal ovaries (367). In 
the same study the metabolism of progesterone, pregenolone and DHEA, all of which are 
precursors to androgens, was less in PCOS theca cells than theca cells from normal ovaries, 
which may contribute to excess androgen production due to the increased bioavailability of 
androgen precursors. A subsequent study by Nelson et al r ported that mRNA expression 
and activity of 17βHSD5, which may convert A4 to T, is similar in normal and PCOS-
derived theca cells suggesting 17βHSD5 is not responsible for the increased androgens 
observed in PCOS (368). However, the activity of 3βHSD and both 17α-hydroxylase and 
17,20-lyase activity of CYP17 are reported to be increased in PCOS theca cells (367, 368). 
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These data suggest an enhanced capacity of PCOS theca cells to convert steroid precursors 
into T as a result of altered steroid metabolism.  
Disorders of uterine bleeding may also be associated with alterations in steroid metabolism 
(369). Oestrogen is a known regulator of angiogenic factors such as VEGF (114) and in the 
endometrium steroidal regulation via receptor activtion can be altered by changing ligand 
availability. This may be mediated by 17βHSD2 which converts E2 to the less potent E1, and 
thus may reduce activation of ERs as a result of decreased local E2 (323). Expression of 
17βHSD2 is enhanced by progesterone in the secretory phase and expression decreases 
following progesterone withdrawal at menstruation or f llowing administration of an 
antiprogestin (282, 312, 314). The contraceptive levonorgestrel is a synthetic progestin 
which binds both AR and PR (370). Use of levonorgestrel-releasing intrauterine system 
(LNG-IUS) is associated with increased 17βHSD2 mRNA expression (consistent with PR 
mediated up-regulation) within the first 3 months of use which declines thereafter as a result 
of decidualisation and down-regulation of PR (293). The first three months of LNG-IUS use 
is often associated with unscheduled breakthrough bleeding and this was proposed by 
Critchley et al to be due in part to “intracellular oestrogen deficiency” as a consequence of 
increased 17βHSD2 mRNA expression, leading to vascular fragility (369). This may also be 
important in heavy menstrual bleeding (HMB), a condition which is characterised by 
excessive blood loss and is a leading indication for hysterectomy 
(http://www.nice.org.uk/nicemedia/pdf/CG44FullGuidelin .pdf.) Women with HMB appear 
to have lower VEGF levels than normal women (371). This may be a result of disrupted 
oestrogen metabolism and signalling. Treatment of HMB with LNG-IUS is highly effective 
in reducing menstrual blood loss from 3-12 months after insertion (372) possibly as a result 
of decreased 17βHSD2 expression which may in turn increase intracellular oestrogen 
stimulating production of VEGF and consequent improvement in vascular stability. 
Endometriosis is classified as an oestrogen dependent disease that is characterised by the 
survival of endometrial tissue lesions in ectopic sites outside the uterus, dysregulated steroid 
enzyme expression and an increased capacity to produce oestrogens (373-376). Increased 
expression of aromatase mRNA and protein have been d tected in the ectopic endometrium 
of women with ovarian, peritoneal and deep infiltrating endometriosis (312, 313, 375, 377). 
In stromal cells isolated from ovarian endometriosis (endometriomas), CYP19A1 gene 
expression can be induced by prostaglandin E2 (PGE2) (378) and cAMP (313) both of which 
are also known to enhance decidualisation (123). In co trast, aromatase is reported to be 
absent or barely detectable in normal endometrium and only low levels are detected in 
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eutopic endometrium of women with endometriosis (311, 379). In ovarian endometriosis, 
17βHSD1 mRNA concentrations are increased (312, 380) while expression of 17βHSD2 is 
reported to be down regulated (374, 380). High levels of STS activity have been correlated 
with severity of peritoneal endometriosis (381) and i creased SRD5A1 gene expression in 
ovarian endometriosis (316). Hevir et al reported a slight increase in 17βHSD5 mRNA 
expression between endometriotic tissue and normal endometrium (316). 
Women with congenital adrenal hyperplasia type V are deficient in 17α-Hydroxylase due to 
autosomal recessive mutation of the CYP17A1 gene. The reproductive capacity of these 
women is severely reduced due to chronically elevated serum progesterone which suppresses 
endometrial proliferation (382). 
1.6.3. Summary 
In summary, the human endometrium expresses many of the enzymes required for 
biosynthesis of sex steroids and studies have shown that human endometrium has the 
capacity for sex steroid metabolism, most likely by the oxidative activity of 17βHSD 
enzymes acting on oestrogens and androgens and 5α reductase acting on androgens and 
progesterone. The relative expression and activities of steroid metabolising enzymes can 
alter the local bioavailability steroids and thus their ability to regulate endometrial function 
through activation of steroid hormone receptors. Dysregulation of enzymes which mediate 
steroid metabolism are important features of the pathophysiology of reproductive 
malignancies. Aberrant expression of aromatase and local oestrogen biosynthesis are 
established features of uterine fibroids, endometriosis and endometrial cancer and as a result 
aromatase inhibitors have been utilised in clinical treatment of these disorders. There is 
emerging evidence from animal studies to suggest that aromatase activity may also be 
important in regulating decidualisation and neovascularisation (128) however a similar role 
in the human uterus is yet to be described.  
1.7. Cytokines in the endometrium 
Cytokines are regulatory peptides or glycoproteins with pleiotropic effects that typically alter 
tissue function in a paracrine and/or autocrine manner. Cytokines play key roles in regulation 
of reproduction with impacts on ovarian follicular development, endometrial development, 
implantation and trophoblast invasion. Cytokines are known to regulate uterine immune 
cells, including the uNK population, and their potential regulation by steroid hormones is 
detailed in the following section. 




Stromal derived factor 1, SDF-1 (CXCL12) is a proliferative and chemotactic factor for 
lymphocytes as well as endothelial cells and haematopoietic progenitor cells (383-385). 
Tsutsumi et al. showed that expression of SDF-1 in human endometrial stromal cells is 
induced by E2 but this is blocked with the addition of the ER antagonist ICI or the progestin 
MPA (386). Progesterone has also been shown to inhibit E2-mediated increases in 
expression of SDF-1 by rat uterine cells (387). Although information about the pattern of 
SDF-1 expression in the endometrium is limited, recent evidence suggests it may be present 
in the epithelium; a recent study by Laird et al described positive immunoexpression of 
CXCL12 in the endometrial epithelium which was not altered with menstrual phase (388). In 
contrast, Kitaya et al. reported positive immunoexpr ssion in decidua and intravascular 
trophoblasts but not decidual stroma or in endometrium (389). CXCL12 mRNA has also 
been reported in decidual stromal but not epithelial cells (37). CXCL12 is reported to 
increase the migration of pbNK and uNK cells (37) as well as the specific migration of 
CD16- NK cells (390). The receptor for CXCL12, CXCR4, is expressed on the surface of 
uNK cells (390) and throughout the endometrium particularly in epithelium and blood 
vessels walls but weak staining is also reported in the stroma (388). Laird et al reported that 
concentrations of mRNAs encoding CXCR4 are higher in endometrial biopsies from early 
proliferative phase compared to late proliferative and secretory phase (388). The 
CXCL12/CXCR4 signalling pathway is also reported to p sitively regulate oestrogen-
regulated gene transcription (391). Using MCF-7 breast carcinoma cells Sauve et al reported 
that treatment with SDF-1 increased ER transcriptional activity and expression of ER target 
genes including SDF-1 itself (391). 
1.7.2. Interleukin-1  
Interleukin-1 (IL-1) is a pleiotropic cytokine which exists in two isoforms; IL-1α and IL-1β, 
both of which act via a common receptor IL-1R. IL-1 is produced by many cell types 
including fibroblasts, endothelial cells, keratinocytes, smooth muscle cells as well as cells in 
the endometrium and decidua (392). In the endometrium, IL-1β mRNA concentrations are 
maximal in the late secretory phase with the protein detected in stromal cells, macrophages 
and endothelial cells (393, 394). Serum levels of IL-1 are also increased at this time (395). 
IL-1α and IL-1β both inhibit decidualisation of endometrial stromal cells in vitro (396, 397). 
For example, IL-1β inhibits the production of prolactin and IGFBP-1 when added to media 
bathing ESC stimulated to decidualise in vitro (396). Paradoxically, IL-1β mRNA 
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concentrations are reported to be increased in decidualised stromal cells which suggests IL-
1β may modulate the degree of decidualisation via an utocrine feedback mechanism in ESC 
(396). IL-1β protein is also abundant in the uterus during early pregnancy and its 
immunoexpression is detected in syncitiotrophoblast, cytotrophoblast, decidual stromal cells 
and activated macrophages which may indicate a role in establishment of pregnancy (398). 
Indeed, secretion of IL-1β by cultured cytotrophoblast cells is reported to be directly 
proportional to their invasiveness possibly by modulating increases in matrix 
metalloproteinase activity in trophoblast cells (399).  
IL-1β may also regulate immune populations in the uterus, in addition to expression in 
macrophages, IL-1 is reported to stimulate uNK cells to increase secretion of GM-CSF in 
vitro (400). Okada et al have demonstrated that IL-1β inhibits progesterone mediated IL-15 
secretion by endometrial stromal cells in vitro during decidualisation (401) which could have 
an impact on uNK cell populations in vivo as IL-15 is essential for uNK migration and 
proliferation (401). IL-1β also increases secretion of monocyte chemoattractant protein-1 
(MCP-1) by first trimester decidual stromal cells which may also influence the recruitment 
of macrophages to the uterus (402). In addition, IL-1 increases endometrial stromal cell 
expression of IL-8, which is an important mediator f angiogenesis and leukocyte 
chemotaxis (403). Low levels of E2 are reported to ecrease amounts of IL-1β detected in 
whole blood (404), whereas pharmacological doses of E2 (10-6M) are reported to increase 
IL-1 secretion by peripheral blood mononuclear cells (405). E2 has also been shown to 
increase secretion of IL-1β by rat macrophages (406). Furthermore, oestradiol inhibits IL-1β 
mediated responses in uterine epithelial cells through down-regulation of IL-1R type 1 (407). 
In summary, regulation of IL-1β by sex steroid hormones could have important impacts on 
the control of reproductive processes which could directly influence decidualisation and 
indirectly modulate immune populations by altering the cytokine milieu.  
1.7.3. Interleukin-8 
Interleukin-8 (IL-8) has a functional role in promoting both angiogenesis and in chemotaxis 
of leukocytes; particularly neutrophils (408, 409). It acts via the surface membrane receptors 
CXCR1 and CXCR2. IL-8 is expressed in perivascular cells in late secretory phase 
endometrium (410) and its mRNA is reported to be highest in tissue extracts prepared from 
late-secretory and mid-proliferative phase endometrium (411). IL-8 is reported to increase 
proliferation of endometrial stromal cells (412) and production of IL-8 in endometrial 
epithelial and stromal cells is induced by IL-1α and TNFα (403). Progesterone enhances the 
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IL-1 mediated increase in concentrations of IL-8 mRNA in ESC (403), however 
progesterone treatment alone is reported to reduce IL-8 secretion in endometrial explants 
(413). IL-8 secretion by uNK cells is reported to increase the invasiveness of extra-villous 
trophoblast cells treated with uNK conditioned supernatants in an in vitro model; an effect 
which could be partially abrogated by addition of an IL-8 neutralising antibody to the uNK 
supernatant (59). Interestingly, treatment of ESC with leukocyte conditioned media is 
reported to up regulate IL-8 gene expression (414). 
1.7.4. Interkeukin-11 
Interkeukin-11 is a pleiotrophic cytokine which acts on a range of different cells and tissues 
including haematopoietic cells, the nervous system and gastrointestinal tract (415). IL-11 
signals via a heterodimeric receptor complex comprising the signalling component gp130 
and the IL-11 receptor α chain (IL-11Rα) (416). In the human endometrium, IL-11 and IL-
11Rα are expressed in all cell types and immunoexpression of IL-11 is reported to be highest 
in decidualised stroma cells in secretory phase (417, 8). In addition, in situ hybridization 
studies have revealed that gp130 is detected througout the cycle restricted to the luminal 
and glandular epithelium of the human endometrium (16). Targeted mutation of IL-11Rα in 
mice results in infertility due to impaired decidualis tion during blastocyst implantation 
(118). Expression of IL-11 and IL-11Rα also enhances progesterone mediated 
decidualisation of human endometrial stromal cells (419), and neutralisation of IL-11 by an 
anti-human IL-11 antibody inhibits the secretion of IGFBP and prolactin during in vitro 
decidualisation (419). Furthermore, IL-11 is also increased following cAMP-induced 
decidualisation and is enhanced by relaxin and prostaglandin E2 via a cAMP/PKA-
dependent signalling (420). IL-11 is considered essential to differentiation of the 
endometrium and is one of few factors identified as being essential for implantation. Altered 
expression of IL-11 is also a feature of pathophysiologies, for example, loss of IL-11 
expression in glandular epithelium is a feature of infertility associated with endometriosis 
(421). Studies in mouse models suggest IL-11 may also influence immune populations and 
notably IL11Rα null mice uNK cells are virtually absent from implantation sites (422). 
However, the impact of IL-11 on uNK populations in human endometrium is unknown. 
1.7.5. Interleukin-15 
Interleukin-15 (IL-15) is a cytokine which can regulate both proliferation and activation of 
NK cells (423). Okada et al (424) reported that IL-15 protein is secreted by endometrial 
stromal cells in vitro following treatment with progesterone. In the same study the authors 
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also reported that progesterone induces IL-15 mRNA expression in a dose-dependent 
manner. Progesterone combined with oestradiol also increased IL-15 mRNA expression 
however treatment with E2 alone did not (424). In addition, expression of mRNAs encoding 
IL-15 are reported to be induced by cAMP, PGE2 and IFNγ in endometrial stromal cells in
vitro (35) suggesting a complex interplay of signals. Verma et al demonstrated that IL-15 
induces proliferation of isolated uNK cells (423) while in an in vitro migration assay IL-15 
enhanced recruitment of CD16- pbNK cells (425). IL-15 may be important in decidualisation 
as IL-15 mRNA and protein expression is reported to be increased during the secretory phase 
of the menstrual cycle and in first trimester decidua where it is prominent in perivascular 
sites surrounding spiral arterioles (36, 426). Evidence from studies in mouse models suggests 
IL-15 is important in immune cell recruitment and endometrial remodelling in response to 
implantation and decidualisation. For example, IL-15 is reported to be essential for uNK 
homing to implantation sites in mice (427) and IL-15 null mice are NK-cell deficient, 
additionally, these IL15 deficient mice have decidual abnormalities with arterial pathologies 
(428, 429). In humans, bone marrow derived CD34+ progenitor cells can be differentiated 
into CD56+ NK cells following in vitro culture with IL-15 (32). IL-15 is also reported to 
increase CD56 expression in CD16- pbNK and induce a chemokine receptor repertoire 
similar to uNK (37) underlying the importance of this cytokine in uNK function. In addition, 
IL-15 is reported to enhance in vitro expansion of regulatory T cells (Tregs), which are 
enriched in decidua, a response which was synergistically increased when administered in 
combination with IL-2 (430, 431).  
1.7.6. Interleukin-18 
The expression of the interleukin-18 (IL-18) system; comprising IL-18, IL-18 binding 
protein (IL18-BP) and IL-18 receptor (IL-18R) has been reported in human endometrium 
(432). IL-18 is structurally similar to IL-1 cytokines and requires cleavage by IL-1 
converting enzyme (also known as caspase-1) to generat  a biologically active form (433). 
IL-18BP is the natural inhibitor of IL-18 which neutralizes IL-18 effector functions (434). 
IL-18 has pro-inflammatory properties and induces production of IL-1β, TNFα, chemokines 
and prostaglandins (435). Expression of mRNAs encodi g IL-18, IL-18BP and IL-18R has 
been reported in total RNA extracted from endometrial issue however expression did not 
vary across the menstrual cycle in this study (432). In isolated endometrial cell cultures, 
Western blot analysis revealed that IL-18 protein is present in cultured endometrial epithelial 
cells but not stromal cells (432). Interestingly, in the same study, IL-18BP was detected in 
cell isolated from both cellular compartments (432). IL-18 appears to be steroid regulated in 
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humans as mRNA expression of IL-18 and IL-18BP are decreased following addition of 
exogenous ovarian hormones in women undergoing steroid substituted cycles as part of IVF 
embryo transfer protocols (436). Ledee et al (436) reported a comparison of mid luteal 
biopsies from natural cycles compared to mid luteal biopsies from the same patient following 
a steroid substituted cycle, i.e. 14 days exogenous estradiol, followed by combined 
oestradiol and progesterone from days 14 to 21 withbiopsy on day 21. The comparison of 
date matched endometrial tissue from a natural cycle and a steroid substituted cycle revealed 
that treatment with exogenous steroids significantly reduced the expression of mRNAs 
encoding IL-18 and IL-18BP (436) suggesting supraphysiological levels of oestrogen and 
progesterone may down-regulate IL-18 and IL-18BP mRNA expression in vivo. In a study 
comparing secretory phase biopsies from women who failed to become pregnant after 
repeated IVF cycles with secretory phase biopsies from fertile controls, the numbers of 
CD56bright cells were significantly greater in infertile women and these differences were 
significantly and positively correlated with IL-15 and IL-18 mRNA expression levels, (437). 
These data suggest that steroid concentrations and cytokine expression may be important in 
regulating uNK cells in successful reproductive function.  
1.7.7. Interferon gamma  
Interferon γ (IFNγ) is expressed in many cell types and is a potent stimulator of cytokine 
secretion by endometrial stromal cells (438). Immunohistochemistry studies in the human 
endometrium have revealed that secreted IFNγ protein is detected throughout the stroma and 
is concentrated beneath luminal epithelium and adjacent to glandular epithelium that is 
proximal to the lumen (439). In the same study the authors reported that detection of IFNγ 
did not vary with menstrual cycle phase or between pre-menopausal and post menopausal 
samples of endometrium suggesting that IFNγ secretion is not affected by fluctuations in 
ovarian hormone concentrations. T cells are reported to secrete IFNγ (440). In human 
endometrium, lymphoid aggregates, which predominantly contain T cells, were initially 
thought to be a likely source of IFNγ in the endometrium (439, 441, 442). However, 
immunohistochemistry co-expression studies have demonstrated no dual positive staining of 
IFNγ positive cells in the human endometrium with antigens to T, macrophage or NK cell 
markers and the authors concluded that IFNγ positive cells in the endometrial stroma were 
likely to be polymorphonuclear cells based on nuclear morphology and surface marker 
staining (439). However, uNK cells isolated from deci ua express mRNAs encoding IFNγ 
and secreted IFNγ is detected in cell culture supernatants from this cell type (40) calling into 
question the data from immunostaining.  In NK-defici nt mice, spiral artery remodelling is 
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impaired; however administration of IFNγ was able to rescue this phenotype (443) consistent 
with a role for NK-derived IFNγ in regulating spiral arteries in this species. In addition, IFNγ 
directly regulates gene expression in human uterine microvascular endothelial cells (444) 
and also reported to directly decrease the proliferation of human endometrial epithelial cells 
in vitro (445). NK-derived IFNγ may also mediate maturation of dendritic cells in the human 
endometrium (62) and IFNγ from decidual uNK cells is reported to inhibit migration of 
cytotrophoblast cells in vitro (446). In activated murine spleen cells as well as cultured T-cell 
line transiently transfected with oestrogen receptor reatment with E2 increases 
concentrations of IFNγ mRNA consistent with transcriptional regulation ofthe gene 
promoter (447). In addition, studies in mice with disrupted ERα and ERβ genes have 
revealed that ERα but not ERβ is required for enhanced E2 mediated Th1 cell 
responsiveness, which includes secretion of IFNγ (448). 
1.7.8. Monocyte chemotactic protein-1/CCL2 
Monocyte chemotactic protein-1 (MCP-1; CCL2) is β cytokine which is a potent 
chemoattractant and activator of immune cells including monocytes, macrophages, T cells, 
basophils, mast cells and NK cells (449). In vitro incubation of human cells has revealed that 
MCP-1 is secreted by endothelial cells, fibroblasts, monocytes and lymphocytes (450, 451). 
In the human endometrium, immunopositive staining for MCP-1 is detected in epithelial and 
endothelial cells but not stromal cells (452). Cultures of human uterine epithelial cells are 
reported to secrete MCP-1 and epithelial cell conditioned media has been shown to increase 
the chemotaxis of monocytes (453). Immunohistochemistry studies have demonstrated 
intense staining of MCP-1 in perivascular areas in human endometrium and decidua which in 
vivo may enhance chemotaxis of immune cells to the endometrium by stimulating 
extravasation of leukocytes at these sites (454). Expression of MCP-1 is reported to be 
inhibited by sex steroids in cultures of endometrial stromal cells in vitro with treatment with 
E2 inhibiting expression of MCP-1 mRNA and protein (455). Progesterone also decreases 
MCP-1 mRNA and protein in cultured ESC but to a lesser extent than E2 (455). In mice 
genetically ablated for CCR2, the MCP-1 receptor, the number and distribution of uNK cells 
in pregnancy were similar to those observed in wild-type mice suggesting MCP-1 is 
dispensable for the migration and distribution of uNK at least during murine pregnancy 
(456). 
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1.7.9. Macrophage inhibitory protein-1 β/CCL4 
Macrophage inhibitory protein-1β (MIP1β; CCL4) protein and mRNA have both been 
detected in the human endometrium throughout the menstrual cycle with expression being 
highest during the secretory phase (457). Consistent with increased expression in the 
secretory phase, CCL4 mRNA is reported to be induce by progesterone in cultured 
endometrial stromal cells (457). However, in cultures of endometrial tissue slices, E2 is 
reported to have no impact on concentrations CCL4 mRNA (458). CCL4 is reported to be 
chemoattractant to CD16- pbNK cells (459) and FACS analysis has demonstrated that  
human CD56+CD16- pbNK cells express CCR5, the CCL4 receptor (460). Using an in vitro 
migration assay and a neutralization assay with specific blocking antibodies, Kitaya et al 
(425) reported that  CCL4, CXCL9 and CXCL10 from secretory phase endometrium 
selectively recruited CD16- pbNK cells. Ablation ofCCR5 does not appear to have an 
impact on the number and distribution of uNK cells in mice (456). However, a recent gene 
array study on human endometrial tissue identified CCL4 as being up-regulated during the 
period of endometrial receptivity and early pregnancy (461). CCL4 may therefore have 
importance in the establishment of pregnancy in human, possibly by regulating the numbers 
of uNK cells at the implantation site by enhancing selective recruitment of CD16- pbNK 
cells to the uterus. 
1.8. General conclusions and aims of the study 
The endometrium is a multi-cellular tissue that is the source of a variety of signalling 
molecules including steroid hormones, cytokines and growth factors which act in an 
intracrine, autocrine or paracrine manner to regulate reproductive processes. In the 
endometrium implantation, decidualisation, immune cell trafficking and remodelling of the 
feto-maternal interface during pregnancy are orchestrated by the action of these signalling 
factors. A variety of immune cells are present in high concentrations in the uterus but the 
predominant uNK cell is known to be a major contributor to local control of the uterine 
environment and is believed to play an essential role in the successful establishment and 
maintenance of pregnancy.  
The human endometrium expresses many of the enzymes required for biosynthesis and 
metabolism of sex steroids. There is emerging evidence to suggest that aromatase activity 
may be important in normal uterine function and a recent study in mice suggested that de 
novo biosynthesis of oestrogen within the uterus may plaan essential role in regulation of 
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decidualisation and neovascularisation (128), however a similar role in the human uterus is 
yet to be described. The regulation of expression of steroidogenic enzymes in the 
endometrium is likely to be important in controlling the local bioavailability of sex steroid 
hormones which can in turn activate steroid hormone receptors and mediate control of 
endometrial function. The functional changes that occur in the endometrium during 
decidualisation including angiogenesis and leukocyte recruitment are essential to 
implantation and establishment of pregnancy but their control is poorly understood. Cytokine 
expression and secretion by different cell types in the endometrium may be influenced by the 
concentrations of sex steroid hormones. Cytokines produced within endometrial tissue may 
act on multiple cell types and may influence the recruitment/differentiation of immune cell 
populations, such as uNK cells, and in the formation and function of the vascular 
compartment. Endometrial endothelial and uNK cells both contain the oestrogen receptor 
beta isoforms but the impact of oestrogens on their function has not been explored. We 
hypothesize that decidualisation of the endometrium results in an altered local steroid 
environment characterised by secretion of high concentrations of oestrogens which 
consequently influence the dynamic interactions of cell populations within the endometrium. 
In the current studies three questions have been addressed:  
1. Is oestrogen biosynthesis a feature of human endometrial stromal cell decidualisation?  
2. What is the impact of oestrogen on uNK cell function?  
3. What role (if any) does oestrogen play in the int rplay between decidual, immune and 
vascular cells within the human endometrial stroma?  
The present study utilised primary human endometrial stromal cells, immortalised 
endometrial stromal cells (SHT 290) and uNK cells isolated from primary human first 
trimester decidua. Following in vitro decidualisation the expression of mRNAs encoding 
enzymes important in steroid synthesis and metabolism was assessed using Taqman Q-RT-
PCR in ESC. Secretion of the decidualisation marker IGBFP-1 and the presence of 
oestrogens in culture supernatants was determined by ELISA and the enzyme activity of 
undecidualised and decidualised SHT 290 cells was as essed using thin layer 
chromatography. Isolated uNK cells were treated with or without oestradiol for 2 hours and 
differential gene expression assessed using Taqman Q-RT-PCR. Migration and chemotaxis 
of uNK cells was assessed in response to E2 and deci ual conditioned media respectively. 
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Human endometrial endothelial cells were cultured with conditioned media from uNK cells 
treated with or without oestradiol for 24 hours and network forming capacity was measured. 
New data presented in this thesis provide evidence that local biosynthesis of oestrogens 
within the endometrial stroma may play a previously unrecognised role in regulating the 
function of uNK cells and endometrial endothelial cells in women. These results have 
implications for treatment of disorders such as infertility, heavy menstrual bleeding and 
endometriosis.




2. Materials and Methods 
2.1. Chemicals, ligands and inhibitors 
Unless otherwise specified all chemicals and standard laboratory reagents were obtained 
from Sigma (Sigma-Aldrich Company Ltd, Dorset, UK). 
2.1.1. Steroid hormones 
17β-Oestradiol (E2, C18H24O2) is a natural oestrogenic ligand. E2 (Sigma, Cat. No. E-8875) 
was reconstituted in dimethyl sulfoxide (DMSO) to a stock concentration of 10-2M from 
which a range of dilutions in phosphate buffered saline (PBS) were made and stored at -
20oC. E2 was most commonly used at a final concentration of 10-8M.  
Progesterone (P4, C21H30O2) is the major naturally occurring human progestagen. P4 (Sigma, 
Cat. No. P-0130) was reconstituted in DMSO to a stock concentration of 10-2M from which a 
range of dilutions in PBS were made and stored at -20oC. P4 was used at a final 
concentration of 10-6M to induce decidualisation.  
Testosterone (T, C19H28O2) was reconstituted in ethanol to a stock concentration of 10
-2M 
from which a range of dilutions in PBS were made and stored at -20oC. T (Sigma, Cat. No. 
T-1500) was used at a final concentration of 10-8M.  
2.1.2. Cyclic AMP 
8-Bromoadenosine 3’,5’-cyclic monophosphate (cAMP) (Sigma, Cat. No. B5386) was 
reconstituted at 100 mg/ml in H2O and stored at -20
oC. A final concentration of 0.1 mg/ml 
was used to induce decidualisation. 
2.1.3. Selective Inhibitors 
Anastrozole (Arimidex®, AstraZeneca) is an aromatase inhibitor (462). Anastrozole was 
reconstituted in DMSO and diluted in PBS to be used at a final concentration of 10-6M and 
10-5M. Stocks were stored at -20oC.  
ICI 182 780 (C32H47F5O3S) is a pure oestrogen receptor antagonist (Faslodex®, 
AstraZeneca). This antagonist has been shown to block the activity of both ERα and ERß 
(463). In the studies presented in this thesis ICI 182 780 (Tocris, Cat. No. 1047) was 
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reconstituted to a concentration of 10-2M in DMSO and diluted in PBS to be used at a final 
concentration of 10-5M and 10-6M. Stocks were stored at -20oC. 
STX64 (C14H15NO5S) is an irreversible inhibitor of steroid sulphatase (464). STX64 (Sigma 
S1950) was reconstituted in DMSO at a concentration of 5mg/ml and diluted in PBS to be 
used at final concentration of 0.5µg/ml. Stocks were stored at -20oC. 
2.2. Patients and Samples  
2.2.1. Tissue collection 
Human endometrial tissue specimens (n=27) were obtained from women undergoing surgery 
for non-malignant gynaecological conditions. Biopsies were collected with an endometrial 
suction curette and processed as described in section 2.2.2 and 2.3.1. All patients were of 
reproductive age, had regular menstrual cycles between 25-35 days and had not received 
exogenous hormones or used an intrauterine contracep ive device in the three months prior to 
surgery. After collection histological staging was performed on fixed tissue sections stained 
with haematoxylin and eosin by an expert histologist and peripheral hormone levels were 
evaluated as previously reported (250). Endometrial samples from which stromal cells were 
isolated were determined to be in the proliferative phase based on the patient history at the 
time of collection and histological staging. 
Decidual samples (n=117) were obtained from women undergoing surgical termination of 
pregnancy procedure (STOP) at 8-12 weeks gestation (dated from woman’s reported last 
menstrual period). All women had an ultrasound scan to confirm viability of pregnancy and 
gestational age. All material from suction curettage was collected and decidual tissue was 
identified and separated from specimens using sterile forceps and washed in sterile saline 
prior to tissue processing.  
Local ethical committee approval was granted and written informed patient consent was 
obtained prior to tissue collection by a dedicated r search nurse. (Ethical approval held by 
Professor H.O.D. Critchley; LREC/05/51104/12 and LREC/10/51402/59.) 
2.2.2. Tissue processing 
Tissue samples were divided equally and placed in the following; neutral buffered formalin 
(NBF) for subsequent processing into paraffin wax (see section 2.12.1), RNAlater (samples 
stored at -80oC) or PBS for isolation of cell populations (see section 2.3).  Tissues placed in 
PBS were either stored at 4oC overnight or processed immediately. 
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2.3. Cell Separation 
2.3.1. Isolation of primary human endometrial strom al cells 
Endometrial tissue samples were washed in PBS and mi ced into 1mm3 fragments using 
surgical blades. The tissue was digested in collagen s  type IV (1 mg/ml; Sigma, C5138) 
and DNAse (0.1 mg/ml; Sigma, DN25) for 80 minutes at 37oC. Repeated passage through an 
18 gauge needle was used to aid tissue dispersion. Tissue was suspended in 10ml of RPMI 
1640 medium (Sigma, Cat. No. R0883) and cells pelleted by centrifugation (115 x g, 3 
minutes). The cells were resuspended in 10mls of RPMI 1640 media (Sigma) supplemented 
with 10% foetal calf serum (Invitrogen, Cat. No. 10082-147), 1% Penicillin/Streptomycin 
(Sigma, Cat. No. P-4333) and 5µg/ml gentamycin (Sigma). The suspension was sequentially 
passed through 70 µm (BD Falcon, 352350) and 40 µm (BD Falcon 352340) cell strainers in 
order to separate stromal cells from glands.  The human endometrial stromal cells were 
subsequently maintained in vitro under conditions described in section 2.4.1. 
2.3.2. Isolation of lymphocytes 
Total decidual tissue was minced into 1mm3 fragments using surgical blades and residual 
blood clots were removed. The tissue was digested ov rnight at room temperature under 
agitation in 20mls of RPMI media (RPMI (phenol free), NEAA 5mls, 20% FCS, 5mls 
Pen/Strep, HEPES (50µL) and Na Pyruvate 0.01mM with1ml of collagenase type IV (2 
mg/ml; Sigma) and 125µL of DNAse (0.1 mg/ml; Sigma, DN25). After digestion, a further 
30mls of media was added and the mixture left for 5 minutes to allow for sedimentation. The 
supernatant was sequentially passed through 70µm and 40µm cell strainers.  The filtrate was 
then plated on a large Petri dish for 1 hour to allw for separation of adherent cells. 
The cell suspension was then collected in 50ml Falcon tube and centrifuged at 870 x g for 5 
minutes. The resulting cell pellet was resuspended in 15ml of PBS supplemented with 2% 
FCS and 0.1% NaN3.  The cell suspension was carefully overlaid on to 15 ml of Histopaque 
1077 (Sigma, Cat. No. 10771) ensuring the two layers did not mix and then centrifuged at 
1094 x g for 20 minutes with no brake and at the slowest acceleration speed. Cells at the 
interface (lymphocytes) were collected and washed in 20 ml PBS. The cell suspension was 
then centrifuged at 870 x g for 5 minutes. The resulting pellet was resuspended in 10 ml PBS 
for cell counting using a FastRead™ cell counter (ImmuneSystems, UK).  
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2.3.3. Isolation of Uterine natural killer cells 
Uterine natural killer (uNK) cells were isolated with CD3 negative selection and CD56 
positive selection using the appropriate antibody-coated magnetic microbeads and the 
MACS® system (Miltenyi Biotech, Germany). 
Cells were depleted by negative selection using magnetic separation to remove CD3+ cells. 
The lymphocytes were counted and the suspension centrifuged for 5 minutes at 870 x g. The 
cell pellet was then resuspended in 80µL of MACS buffer per 107 total cells. 20µL of CD3 
microbeads (Miltenyi, 130-050-101) were added per 107 cells and the mixture was incubated 
on ice for 20 minutes. An LD column (Miltenyi, 130-042-901), for cell depletion, was placed 
in the magnetic field of MACS separator. The column and pre-separation filter were primed 
by passing two 1ml volumes of MACS buffer. The cell suspension was then added to the 
column followed by two 1ml washes of MACS buffer. The total effluent that contained the 
unlabelled cells (CD3-) was collected and used for CD56 positive selection. The cells were 
counted and the suspension centrifuged for 5 minutes at 870 x g. The cell pellet was 
subsequently resuspended in 80µL of MACS buffer per 107 total cells and 20µL of CD56 
microbeads (Miltenyi, 130-050-401) were added per 107 cells. The mixture was incubated on 
ice for 20 minutes. LS column (130-042-401), for cell s lection, was placed in the magnetic 
field of MACS separator. The column was primed by passing three 1ml washes MACS 
buffer. The cell suspension was added to the column followed by 3mls wash of MACS 
buffer. The column was removed from the magnetic field and placed in a suitable collection 
tube. Magnetically labelled cells (CD56+) were flushed from the column by addition of five 
1ml washes of MACS buffer into a fresh tube. The resulting cell suspension was CD56+, 
CD3- and was immunophenotyped as uNK cells using flow cytometry. 
2.4. Cell Culture 
2.4.1. Primary human endometrial stromal cells 
Primary human endometrial stromal cells (hESC) were isolated from biopsies of healthy 
endometrium as detailed in section 2.3.1. Cells were s eded in 6 well plates at a density of 
2x105 cells per well. Cells were maintained for a maximum of 4 passages and cultured in 
RPMI 1640 media (Sigma, Cat. No. R0883) supplemented with 10% heat-inactivated foetal 
calf serum (FCS; Invitrogen, Cat. No. 10082-147), 10mL/L Penicillin/Streptomycin (10,000 
units penicllin and 10mg Streptomycin per ml solutin, Sigma, Cat. No. P-4333), 2mM L-
glutamine (Sigma, Cat. No. G-7513), and 2.5µg/ml fungizone (Invitrogen, Cat. No. 15290-
018). These cells were transferred to phenol red-fre RPMI 1640 medium (Sigma, Cat. No. 
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R7509) containing 10% charcoal-stripped FCS (CSFCS, section 2.4.4) and otherwise 
supplemented as detailed above for 48 hours prior to use in experimental assays. Prior to 
decidualisation hESCs were transferred to serum depleted media (as above but 2% CSFCS).  
Cells were maintained at 37oC under 5% CO2 in air. 
2.4.2. Immortalised human endometrial stromal cells  
The human TERT- immortalised stromal cell line, SHT 290, was obtained from Dr. David 
Kaufman, Department of Pathology and Laboratory Medicine, University of North Carolina 
at Chapel Hill, NC, USA. This cell line is derived from a patient with normal endometrium 
and has been immortalised by expressing a transduced human telomerase reverse 
transcriptase (TERT). This cell line was originally reported to retain steroid hormone 
receptor expression and responsiveness as well as the capacity to decidualise (465). In the 
current study maintenance of a phenotype similar to that of primary hESC was confirmed 
(see Chapter 3). 
SHT 290 cells were maintained in RPMI 1640 media (Sgma, Cat. No. R0883) supplemented 
with 10% heat-inactivated foetal calf serum (Invitrogen, Cat. No. 10082-147), 10mL/L 
Penicillin/Streptomycin (Sigma, Cat. No. P-4333), 2mM L-glutamine (Sigma, Cat. No. G-
7513), and 2.5µg/ml fungizone (Invitrogen, Cat. No. 15290-018). These cells were 
transferred to phenol red-free RPMI 1640 medium (Sigma, Cat. No. R7509)  containing 10% 
charcoal-stripped FCS (CSFCS, section 2.4.4) and otherwise supplemented as detailed above 
for 48 hours prior to use in experimental assays. Cells were seeded in 6 well plates at a 
density of 2x105 cells per well for experimental assays. Prior to deci ualisation SHT 290 
cells were transferred to serum depleted media (as above but 2% CSFCS).  Cells were 
maintained at 37oC under 5% CO2 in air. 
2.4.3. Primary human uterine natural killer (uNK) c ells 
Isolated uNK cells were cultured at a density of 1x106 cells per ml in phenol red-free RPMI 
1640 medium (Sigma, Cat. No. R7509) supplemented with 10% CSFCS, 10mL/L 
Penicillin/Streptomycin (Sigma, Cat. No. P-4333), 2mM L-glutamine (Sigma, Cat. No. G-
7513), and 2.5µg/ml fungizone (Invitrogen, Cat. No. 15290-018). Cells were maintained in 
vitro for a maximum of 24 hours at 37oC under 5% CO2 in air. 
2.4.4. Charcoal stripping of serum 
Charcoal-stripped FCS (CSFCS) was prepared by heat inac ivating serum at 57oC for 30 
minutes, followed by mixing with activated charcoal (Sigma, C3345) overnight on a stirrer at 
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4oC. Excess charcoal was removed by centrifugation and supernatant was then passed 
through 0.2 µm filters, aliquoted and stored at -20oC. 
2.5. Chemotaxis assay 
The chemotaxis of uNK cells was assessed using Ibidi µ-Slide Chemotaxis3D chamber slides 
(Ibidi, 80326, supplied by Thistle Scientific, Uddingston, UK). Isolated uNK cells were 
suspended in a collagen matrix and response to different chemotaxis stimuli was measured 
using time lapse microscopy and recorded using Axiovert 200 Inverted Fluorescent 
Microscope from Zeiss.  
 
 
Figure 2.1. Schematic diagram of cells in 3D matrix subject to chemotaxis gradient (+/-). 
Cells were viewed using inverted microscope (http://www.ibidi.com). 
Isolated uNK cells were suspended in RPMI 1640 phenol red free media (R7589, Sigma) 
supplemented with 10% charcoal stripped foetal calf serum, 200mM L-Glutamin and 10ml/L 
Penicillin/Streptomycin at a density of 3x109 cells/ml. A 1.6 mg/ml collagen gel was 
prepared from 5 mg/ml bovine collagen type I (A10644-01, GIBCO, supplied by Invitrogen, 
Paisley UK), 10x MEM (M-0275, Sigma) and 7.5% NaHCO3 (S8761, Sigma) and mixed 
carefully with the uNK cell suspension avoiding air bubbles during mixing. The collagen gel 
cell suspension was then filled into the middle chamber of the µ-Slide and placed in an 
incubator (37oC, 5% CO2) for 30 minutes to allow for gelation of the collagen matrix. Three 
chambers were seeded and two controls set up; -/- containing chemoattractant free media in 
both reservoirs and +/+ containing chemoattractant media in both reservoirs to account for 
influence of random migration (chemokinesis.) Finally  chamber with chemoattractant-free 
media in one reservoir and chemoattractant containig media in the other (+/-) was prepared 
thereby forming a chemotaxis gradient across the chamber (Figure 2.1). Chemoattractant-
free media was conditioned media recovered from undecidualised endometrial stromal cells 
(stromal conditioned media). Chemoattractant media was media recovered from decidualised 
stromal cells (decidual conditioned media). 
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Cells were imaged every 5 minutes for 4 hours using Axiovert 200 Inverted Fluorescent 
Microscope from Zeiss and image stacks analysed using ImageJ (NIH.gov) and the manual 
tracking plug-in (http://rsbweb.nih.gov/ij/plugins/track/track.html). The movement of cells 
was tracked and recorded and measurements were quantified using Ibidi Chemotaxis and 
Migration Tool 2.0 software. The analysis software p ovided output values for a number of 
criteria, detailed in Figure 2.2. Briefly, the average end point of all cells (centre of mass) is 
an estimation of the overall migration of the cell population. The centre of mass is a single 
point and the coordinates of the centre of mass can be either positive or negative depending 
on the direction of the cell movement. The length of the centre of mass is the direct distance 
between the point of origin and the centre of mass coordinates. The centre of mass is a strong 
parameter for evaluating chemotaxis. Other measurements of cell movement include the 
accumulated distance, i.e. the total distance a cell has moved irrespective of direction, the 
Euclidean distance (direct distance between point of origin and end point) and velocity of 
cells. 




Figure 2.2. Definitions in trajectory plots. “i" is the index of different single cells. 
(http://www.ibidi.com) 
2.6. Migration assay 
Migration of uNK cells was assessed using a modifie transwell migration assay. Isolated 
uNK cells were suspended in culture media; RPMI 1640 phenol red free media (R7589, 
Sigma) supplemented with 10% CSFCS, 1% Penicillin/Streptomycin (Sigma, Cat. No. P-
4333), 1% L-glutamine (Sigma, Cat. No. G-7513), and0.5% fungizone (Invitrogen, Cat. No. 
15290-018), at a density of 1x106 cells/ml. Cells were treated with vehicle control, 10-8M E2, 
10-6M ICI or combination of E2 and ICI for 1 hour prior to assay. Following treatment, cells 
were pelleted and resuspended in culture media prior to the migration assay. A 1.6mg/ml 
collagen gel was prepared from 5mg/ml bovine collagen I (GIBCO/Invitrogen, A10644-01), 
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10x MEM (Sigma, M-0275) and 7.5% NaHCO3 (Sigma, S8761) and 200µL of the gel was 
pipetted onto the bottom of the well in a 24 well plate and placed in the incubator (37oC, 5% 
CO2) for 30 minutes to allow for gelation of the collagen matrix. The collagen gel was 
considered a neutral surface that would allow adherence of uNK cells without acting as a 
chemoattractant and was prepared as described immediately prior to migration assay. In the 
same well, 800µL of serum free RPMI 1640 phenol red free media wasadded over the top of 
the collagen matrix. Cell culture inserts with 5µm membrane pore (Costar/Corning, 3421, 
NY, USA) were then placed into the well into which 200µL of uNK suspension was added. 
Cells were treated in duplicate. Cells were left in the incubator to migrate for 1 hour. 
Following migration cell culture inserts were removed and cells in the lower chamber were 
counted. Migrated cells were counted by imaging 8 random fields using Axiovert 200 
Inverted Fluorescent Microscope (Zeiss) and the mean number of migrated cells was 
calculated for each treatment.  
2.7. Angiogenesis assay 
Isolated uNK cells were cultured at a density of 1x106 cells per/ml for cell treatment in 
phenol red-free RPMI 1640 medium (Sigma, Cat. No. R7509) supplemented with 10% 
CSFCS, 1% Penicillin/Streptomycin (Sigma, Cat. No. P-4333), 1% L-glutamine (Sigma, Cat. 
No. G-7513), and 0.5% fungizone (Invitrogen, Cat. No 15290-018). Cells were cultured for 
24 hours at 37oC under 5% CO2 in air. Cells were treated with 10
-8M E2, 10-6M ICI or 
combination of E2 and ICI for 24 hours. Following treatment, cells were pelleted and the 
supernatant, uNK conditioned media (CM), was stored at -80oC until assay. uNK cell CM 
was thawed immediately prior to assay and warmed to 37oC. 
Telomerase immortalised human endometrial endothelial cells (HEEC, Gift from Dr. 
Graciela Krikun, Department of Obstetrics, Gynecology and Reproductive Science, Yale 
University, New Haven, CT, USA) (466) were plated at a density of 25,000 per transwell 
insert (inserted into 24 well plates) which had been coated with growth factor reduced 
matrigel (BD Biosciences, Oxford, UK) and allowed to solidify prior to cell plating. uNK 
cell CM was added to the bottom chambers and cells incubated overnight at 37ºC with 5% 
CO2.  Each treatment was set up in duplicate. After 16 hours incubation HEECs were fixed 
with ice cold methanol for 20 minutes and then stained with hematoxylin. The formation of 
networks was visualised using Axiovert 200 Inverted Fluorescent Microscope (Carl Zeiss, 
UK). Three fields of vision were captured at 5x magnification for each well. Network 
formation was quantified using ImageJ (NIH.gov) and verified by counting branch points. 
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2.8. RNA extraction 
Extraction of RNA from cell monolayers extracts was performed using RNAeasy® mini kit 
(Qiagen, Crawley, UK). Biological samples were collected in lysis buffer and homogenized 
using QIAshredder® spin columns (Qiagen, Crawley, UK). Ethanol was added to lysate to 
provide appropriate binding conditions, and the sample was then applied to an RNeasy® 
mini spin column. Total RNA bound to the membrane ad contaminants were washed away 
through a series of wash steps. On column DNAse digstion was performed to remove 
contaminating DNA using a Qiagen RNase-Free DNase kit (Cat. No.79254, Qiagen, 
Crawley, UK). RNA was then eluted in 30µL RNAse-free water. 
2.8.1. RNA quantification using Nanodrop® 
The total concentration of RNA was determined by measuring the absorbance of eluted RNA 
samples using a Nanodrop® ND-1000 Spectrophotometer (Nanodrop Technologies, 
Wilmington, DE, USA). RNA samples were then standardised to concentration of 100ng/µL.  
2.9. Preparation of cDNA using SuperScript® VILO™ 
synthesis kit. 
Reverse transcription of RNA to form a single stand of complementary DNA (cDNA) was 
carried out using the SuperScript VILO cDNA synthesis kit (InVitrogen, Paisley, UK) 
according to the manufacturer’s instructions. Briefly, each reaction (final volume 20µL) 
contained a final concentration of 1x VILO reaction mix, 0.125x Superscript enzyme mix 
and 100ng of RNA. Samples were incubated under the following conditions: 25oC for 
10minutes, 42oC for 60 minutes, 85oC for 5minutes in a thermal cycler (MJ Research PTC-
200 Thermo Cycler, BC-MJPC200). 
2.10. Quantitative-Real Time-PCR (Taqman® Method) 
Concentrations of mRNAs in samples under test were d t rmined by reverse transcription 
followed by quantitative-real time polymersase chain reaction (qRT-PCR) performed using 
an ABI machine and the Taqman® Method. 
2.10.1. Preparation of Taqman reaction mix using th e Universal Probe 
Library™  
Quantitative Real Time Taqman® PCR is an automated, high throughput variation of 
conventional PCR. The Taqman® method employs the use of fluorogenic probes from the 
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Universal Probe Library™ (Roche, West Sussex, UK) to enable quantification of DNA 
content based on a measure of fluorescence detection af er each PCR cycle. The Taqman® 
reaction mix was prepared using the Universal Probe Li rary™ (UPL). 
The UPL is a set of 165 short hydrolysis probes (8-9 nucleotides in length) that are labelled 
with fluorescein (FAM) at the 5’ end and a dark quencher dye at their 3’end.  
These short probes are based on locked nucleic acids (LNAs) as they have a ‘locked’ ribose 
ring with a methylene bridge where the 2’-O atom is connected to the 4’-C atom. LNAs have 
the ability to bind to their target sequences despit  their short length as they contain the six 
common nucleobases (T, C, G, A, U, mC) that appear in RNA and DNA. The resultant 
specificity of these short LNA-probes facilitates di tinction between transcripts by using a 
probe that can only bind to a specific transcript based on the primer pairs used. Primers were 
designed using the Roche online ‘probe finder’ assay design method at https://www.roche-
appliedscience.com/sis/rtpcr/upl/ (see section 2.15). 
2.10.2. Quantitative real time Taqman® PCR 
Taqman relies on two principles; fluorescence resonance energy transfer (FRET) and 
5’nuclease activity of the Taq polymerase. Taqman probes consist of a fluorophore 
covalently attached to 5’- end of the oligonucleotide probe (6-carboxyfluorescein, FAM) and 
a quencher at the 3’-end. Taqman probes amplify DNA regions to specific set of primers. 
During each PCR cycle the Taq polymerase extends the primer and the probe is cleaved and 
degraded. Fluorescence emission occurs upon cleavag of the probe as degradation breaks 
proximity and relieves the quencher affect on the fluorophore. Thus, fluorescence detected is 
directly proportional to fluorophore release and hence the amount of DNA in the PCR.  
Each reaction was prepared using the qPCR Supermix with Premixed ROX kit (11795-01K; 
Invitrogen), conducted in duplicate and plated in a96-well MicroAmp Fast Optical reaction 
plate (Applied Biosystems). Real time PCR amplification was performed using the Applied 
Biosystems® 7900HT Fast Real-Time PCR System using the reaction mix detailed in Table 
2.10. The Taqman® reaction contained passive referenc  ROX, internal control gene 18s 
(VIC-conjugated) and gene of interest (FAM-conjugated). 




Reagent Final Concentration Vol./15µL reaction (µL) 
2x Express Supermix 1x 7.5 
Forward Primer 20µM 200nM 0.15 
Reverse Primer 20µM 200nM 0.15 
Probe 10µM 100nM 0.15 
18S (10nM primer, 40nM probe) 0.1125 
H20  5.4375 
cDNA  1.5 
Table 2.1. Reaction mixtures for Taqman analysis 
2.10.3. Analysis of computational output 
Fluorescence was detected by ABI7900 sequence detection system and processed as an 
amplification plot. The threshold cycle (Ct) value is the point on the exponential curve at 
which the level of fluorescence reached is considere  statistically greater than background 
levels. The Ct value is directly proportional to the amount of PCR product formed and a 
change of one-fold Ct value represents a two-fold change in the initial cDNA concentration. 
Analysis was performed by comparative ∆∆Ct method where fold change is relative to a 
reference sample such as an untreated control as well as an internal control. The reporter was 
standardised to an internal control (18s ribosomal RNA) to correct for fluctuations between 
samples ∆Ct = FAM Ct – 18S VIC Ct. This value was then expressed as change relative to 
reference sample ∆∆Ct = ∆Ct sample – ∆Ct reference sample. Fold change was then 
calculated using the equation 2-∆∆Ct. 
2.10.4. Primer/probe Validation 
To validate use of the primer/probe mix, log ng mRNA values were plotted against the 
average of the Ct values. 
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Standard curve ER α primers












Figure 2.3. Validation of gene of interest primer/probe usage relative to 18S primer/probe 
control mix. 18s, R2=0.996, 99.5% efficiency, ERα R2=0.96, 99.5% efficiency 
2.10.5. RT2 PCR profiler arrays 
The RT2 profiler PCR arrays (SABiosciences, Frederick, MD, USA) are designed to analyse 
a panel of genes related to a specific biological function. This platform combines the 
performance of real time PCR with the multi gene profiling capabilities of a microarray. 
Each array contains a panel of 96 primer sets for a set of 84 functionally focussed genes, 
together with five housekeeping genes and three RNA and PCR quality controls. 
RNA samples from uNK cells were retrotranscribed using RT2 single strand cDNA synthesis 
kit. Samples from 3 sets of treated uNK cells were analysed for differential gene expression 
following E2 treatment. RNA samples were converted to first strand cDNA using the RT2 
first strand kit (SABiosciences, Frederick, MD, USA). Briefly, 300ng/ml RNA was mixed 
with 1x genomic DNA elimination mixture and made upto final volume of 10µL with 
nuclease-free H2O per sample. SYBR green dye binds with all types of double stranded 
DNA, therefore complete removal of genomic DNA is es ntial for accurate expression data. 
The contents were mixed and briefly centrifuged before being incubated at 42oC for 5 
minutes, then cooled on ice for at least 1 minute. The RT cocktail was prepared as follows 
for each reaction: 




RT Cocktail x1 rxn x6 rxn 
BC3 (5x RT Buffer 3) 4µL 24µL 
P2 (Primer & External control Mix) 1µL 6µL 
RE3 (RT Enzyme Mix 3) 2µL 12µL 
H2O 3µL 18µL 
Final Volume 10µL 60µL 
Table 2.2. RT cocktail mixture for cDNA synthesis 
10µL of RT cocktail was added to each treated RNA sample and mixed by pipette. The 
samples were then incubated for 15 minutes at 42oC and the reaction was then stopped by 
heating to 92oC for 5 minutes. 20µL of cDNA synthesis mix was diluted by addition of 91
µL of H2O and samples held on ice or stored at -20
oC until RT PCR was performed. Frozen 
samples were thawed on ice immediately prior to use. Th  RT PCR reaction mixture was as 
follows: 
Reagent Volume 
2X SABiosciences RT2 qPCR Master Mix 1350µL 
Diluted first strand cDNA synthesis reaction 102µL 
H2O 1248µL 
Total Volume 2700µL 
Table 2.3. RT PCR reaction mixture for each 96 well array plate. 
25µL of the experimental mixture was added to each well of the 96 well array plate using a 
multi-channel pipette to minimise intra-well variability. Following addition of samples, 
plates were sealed and held on ice until use. Prior to RT PCR plates were centrifuged for 1 
minute at room temperature 1000g to remove bubbles. R al time PCR amplification was 
performed using the Applied Biosystems® 7900HT Fast Real-Time PCR System PCR using 
RT2 Real-Timer SyBR Green/ROX PCR Mix kit according to manufacturer’s instructions. 
Using an ABI 7900HT the following two-step cycling program was set up: 




Cycles Duration Temperature 
1 10 minutes 95oC 
15 seconds 95oC 40 
1 minute 60oC 
Table 2.4. Thermal cycling program for PCR amplification. 
SABiosciences RT2 SYBR Green Master Mix utilises Hot-start Taq DNA polymerase, which 
prevents polymerase activity before heat activation and thereby reducing amplification of 
non-specific PCR products. SYBR green fluorescence was detected and recorded during the 
annealing step in each cycle and the threshold Ct for each well was calculated. As an 
additional quality control, a melt curve program was run after every cycling program for 
each array plate. A first derivative dissociation curve for each well was recorded and 
checked for single peaks at temperatures greater than 80oC. Wells which did not meet these 
criteria were excluded from analysis. 
PCR array data analysis was performed using the SABiosciences web portal 
(http://www.SABiosciences.com/pcrarrayanalysis.php). Data analysis was performed using 
the ∆∆Ct method (Section 2.10.3). 
2.11. Enzyme-linked Immunosorbant Assay 
Enzyme-linked immunosorbent assay (ELISA) is method used to detect and quantify target 
proteins in biological samples. In the present studies two forms of ELISA were utilized. 
2.11.1. Two-site sandwich ELISA. 
Using a ‘sandwich’ ELISA the target antigen, usually  soluble protein, is quantified using 
matched antibody pairs (Figure 2.4).  
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Figure 2.4. Schematic diagram of general protocol for sandwich ELISA. 1. Plate is coated 
with capture antibody and sample (analyte) is added. 2. Any antigen present (pink) binds the 
capture antibody. The biotinylated detection antibody then binds antigen-capture antibody 
complexes. 3. Streptavidin-HRP binds any biotinylated detection antibody present. 4. 
3,3’,5,5’-Tetramethylbenzidine (TMB) substrate is added and converted to signal by HRP-
linked antibody complexes. Reaction is stopped by the addition of H2SO4 which results in a 
colour change from blue to yellow. The colour signal produced is proportional to the amount 
of antigen present in the sample.  
The ELISA methodology was used for detection of human insulin-like Growth Factor 
Binding Protein 1 (IGFBP-1) in cell culture (reagents from DuoSet ELISA development kit, 
R&D Systems, Minneapolis, MN, USA). Cell growth media was collected following in vitro 
treatment of cells and stored at -80°C to preserve p otein integrity and thawed immediately 
prior to the assay.  
2.11.1.1.1. Protocol 
Clear, flat-bottomed 96-well microplates (Corning/Costar) were coated with 100µL/well of 
capture antibody diluted to working concentration of 4.0µg/ml in PBS. Plates were incubated 
overnight at 4oC on a rocker. After incubation, capture antibody solution was aspirated and 
each well washed 3 times with wash buffer (0.05% Tween20 in PBS). Complete removal of 
liquid and bubbles from wells was achieved by blotting plates against paper towel at each 
wash step which ensured good assay performance. Aftr washing, plates were blocked by 
adding 300µL of blocking buffer (5% Tween20 in PBS) to each well and incubated for a 
minimum of 1 hour at room temperature to prevent non-specific binding and reduce 
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background response.  The aspiration/wash step was then repeated and 100µL of sample or 
standards were added to each well. Standards were mad from recombinant human IGFBP-1 
reconstituted in reagent diluent (5% Tween20 in PBS) to produce a high standard of 
2000pg/ml from which two-fold serial dilutions were made to produce a seven point standard 
curve. Samples and standards were incubated overnight at 4oC on a rocker. Free, specific 
protein in the samples spontaneously bound to the capture antibody coated to the base of the 
wells in the plate. The aspiration/wash step was repeated prior to addition of a biotinylated 
detection antibody, diluted in reagent diluent with 2% heat inactivated normal goat serum to 
a working concentration of 400ng/ml (100µL/well). Plates were covered and incubated for 
two hours at room temperature, after which the plate was washed as described previously. 
The plate was then incubated with 100µL per well of Streptavidin-HRP solution (1:200 in 
PBS) for 20 minutes in the dark at room temperature. Following a final wash step 100µL of 
3,3’,5,5’-Tetramethylbenzidine (TMB) substrate was added to each well and incubated for 
20 minutes in the dark at room temperature. TMB forms a blue product in the presence of 
peroxidase enzymes. The colour reaction was stopped by addition of 50µL/well of 2N 
H2SO4. The addition of sulfuric acid changed the TMB yellow. Optical density of each well 
was measured immediately using a microplate reader set to 450nm with wavelength 
correction set to 540nm. This subtraction corrects for optical imperfections in the plate and 
thus produces more accurate readings. The delta absorbance was recorded as final values and 
concentrations were then calculated from the standard values. 
2.11.1.1.2. Standard curve 
Standards were assayed in duplicate and average responses were plotted as a standard curve 
with concentration along the x-axis and mean absorbance on the Y-axis. Data was linearised 
by plotting log concentration against log optical density. A best fit line was determined by 
regression analysis using GraphPad Prism and used to calculate concentrations of the 
unknown samples.  A standard curve was generated for each set of samples assayed. 
2.11.2. Competitive ELISA 
In competitive ELISA unlabelled antigen present in samples, standards and controls compete 
for binding with enzyme-labelled antigen (conjugate) for a limited number of target antibody 
binding sites in the microwells of the assay plate. Conjugated antigen will bind to the target 
antibody wherever binding sites are not occupied by unlabelled antigen. Washing removes 
unbound materials. Wherever conjugated antigen is bound enzyme substrate reacts with the 
conjugate (enzyme-labelled antigen) to produce a colour reaction. Thus, in competitive 
ELISA the intensity of colour formed is inversely pro ortional to the concentration of 
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antigen in the sample. The enzymatic reaction is terminated by addition of stopping solution 
and optical density of each well measured using a spectrophotometer.  
2.11.2.1. Oestradiol ELISA 
To determine the amount of oestradiol in culture supernatants a competitive ELISA was 
performed using oestradiol-6-HRP conjugate (in house preparation) and oestradiol 6 
antibody (Fitzgerald Industries International, Concrd, MA, USA.)  
Immuno 96 MicroWell™ Solid Plates (NUNC, supplied by Scientific Laboratory Supplies, 
Nottingham, UK) were coated with 100µL/well of 1:200 DARS (Donkey anti rabbit serum) 
in coating buffer (100mM Bicarbonate solution) and i cubated overnight in at 4oC on a 
rocker. After incubation, coating solution was aspirated and each well washed 3 times with 
wash buffer (0.05% Tween20 in PBS). Complete removal f liquid and bubbles from wells 
was achieved by blotting plates against paper towel at ach wash step which ensured good 
assay performance. After washing, plates were blocked by adding 300µL of blocking buffer 
(1% Gelatin in PBS) to each well and incubated for a minimum of 1 hour at room 
temperature to prevent non-specific binding and reduc  background response.  Plates were 
washed a further three times and 100µL of standards/unknowns added to the plate. 50µl of 
oestradiol-6-HRP conjugate 1:40,000 in PGBS (0.1M Phosphate Gelatin Buffered Saline, pH 
7.4) and 50µl of antibody at dilution of 1:150,000 in PGBS was dded and incubated for 3 
hours at room temperature or overnight at 4oC. Solutions were aspirated and plates washed 
four times.  This followed by addition of 100ul of TMB substrate solution to each well and 
incubation in the dark for 20 minutes. The colour reaction was stopped by addition of 
50µL/well of 2N H2SO4. Optical density of each well was measured immediat ly using a 
microplate reader set to 450nm with wavelength correction set to 540nm. This subtraction 
corrects for optical imperfections in the plate and thus produces more accurate readings. The 
delta absorbance was recorded as final values and co centrations were then calculated from 
the standard values. 
2.11.2.2. Oestrone ELISA 
Oestrone in cell culture supernatants was detected using Estrone ELISA kit (BioVendor, 
Czech Republic) and quantified against calibrator sandard set. Briefly, 50µL of samples, 
controls and calibrators were added into corresponding wells of a rabbit anti-estrone 
antibody coated microwell plate. This was followed by addition of 100µL of conjugate 
solution containing Estrone-biotin and avidin-horse adish peroxidase (at a concentration of 
1:100 diluted in assay buffer) to each well and incubation for 1 hour on a plate shaker. After 
incubation, sample and conjugate solution mix was aspir ted form the plate and each well 
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washed 3 times with wash buffer. Complete removal of liquid and bubbles from wells was 
achieved by blotting plates against paper towel at each wash step to ensure good assay 
performance. The colour reaction was initiated by addition of 150µL of TMB substrate to 
each well, followed by incubation on plate shaker for 10-15 minutes. The colour reaction 
was stopped by addition of 50µL/well of stopping soluti n (1M H2SO4). Optical density of 
each well was measured immediately using a microplate reader set to 450nm with 
wavelength correction set to 540nm. This subtraction c rrects for optical imperfections in the 
plate and thus produces more accurate readings. The delta absorbance was recorded as final 
values and concentrations were then calculated from the calibrator standard values. 
2.12. Immunohistochemistry 
Immunohistochemistry is the localisation of specific proteins of interest (antigens) in tissue 
sections through the binding of labelled antibodies to mall, unique regions (epitopes) of the 
antigen under investigation. Antigen-antibody interactions can be visualised by secondary 
interaction with a marker such as a fluorescent dye or an enzyme complex which reacts with 
a chromogen substrate. Immunohistochemistry makes it possible to visualise tissue 
localisation and distribution of a specific antigen within a cell or tissue. 
Immunohistochemistry was conducted on human endometrial and decidual tissue sections in 
accordance with standard lab protocols to establish the presence and localisation of proteins 
of interest. 
2.12.1. Tissue processing 
Tissues were collected and fixed in 4% neutral buffered formalin (NBF) overnight before 
being transferred to 70% ethanol prior to being embdded in paraffin wax according to 
standard methods by the histology team at the MRC Human Reproductive Sciences Unit, 
Edinburgh. Wax-embedded tissue blocks were cooled on ice to ensure rigidity of the wax 
and ease of sectioning. 5µm sections were cut using a microtome (Leica RM2135, Germany) 
and mounted onto coated glass slides (VWR, Poole, UK) and dried overnight in an incubator 
at 55oC to ensure complete adhesion to the slide.  
2.12.2. Dewaxing 
To ensure optimal antibody interaction with the tissue complete removal of wax was carried 
out. Tissue sections were dewaxed in xylene (two 5 minute washes) and rehydrated at 20 
second intervals through graded alcohol before being washed in water.  
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2.12.3. Antigen Retrieval 
Antigen retrieval was performed by pressure cooking in 0.05M Glycine/EDTA buffer (pH 8) 
or 0.01M citrate buffer (pH 6) for 5 minutes at full pressure and then allowed to stand for 20 
minutes. This ensures any ‘masking’ of epitopes dueto formation of cross linkages is 
disrupted and allows greater binding of the antibody to the tissue antigen. Glycine/EDTA 
buffer was considered a more suitable buffer for endometrial tissue as it gave cleaner and 
stronger staining. 
2.12.4. Blocking to promote specific signal amplifi cation 
To reduce non-specific antibody binding and to promote specific signal amplification the 
following blocking stages were utilised. 
2.12.5. Methanol peroxidase block 
To prevent endogenous peroxidases in the tissue section reacting with chromogen substrate 
endogenous peroxidase activity was blocked by washing slides in 3% (v/v) hydrogen 
peroxide in methanol for 30 minutes at room temperature. Following the block slides were 
washed in tap water and then Tris-buffered saline (TBS; 0.05M Tris-HCL, pH 7.4, 0.85% 
NaCl) for two 5 minute washes. 
2.12.6. Serum block  
To prevent non-specific binding of the secondary antibody serum from the species in which 
the secondary antibody was raised was diluted 1:4 in TBS solution containing 5% bovine 
serum albumin (BSA) was added to the slides and incubated for 30 minutes at room 
temperature. 
2.12.7. Avidin-Biotin block 
The use of biotinylated secondary antibodies in the immunohistochemistry process relies 
upon the strong affinity of avidin and streptavidin for biotin. To avoid avidin-peroxidase 
complexes binding to endogenous biotin in the tissue an avidin biotin blocking kit was used 
(Vector Laboratories, Peterborough, UK). Sections were incubated with avidin-D for 15 
minutes, followed by two 5 minute washes in TBS andthen biotin for 15 minutes, followed 
by a further two 5 minute washes. 
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2.12.8. Primary antibodies 
Primary antibodies were diluted in blocking serum at an appropriate dilution and added to 
the slides which were incubated in a humidified chamber and overnight at 4 o C. Optimal 
dilutions were obtained for each antibody outlined in Table 2.5. Negative controls were 






DAB dilution Fluorescence 
Dilution 
Sigma Aldrich ACTR3 Mouse 1:50 N/A 
Gift from Prof. Evan Simpson, 
Prince Henry’s Institute, 
Clayton, Australia. 
Aromatase Rabbit N/A 1:250 
Thermo Scientific CD10 Mouse 1:200 N/A 
Zymed CD56 Mouse 1:400 1:2500 
R&D CXCR4 Mouse 1:500 1:80 
Vector ERα Mouse 1:200 1:1000 
Serotec ERβ Mouse 1:200 1:1000 
Ab frontier PTMA Mouse 1:500 N/A 
Bioquote SOD2 Rabbit 1:200 1:400 
Table 2.5. Primary antibodies and dilutions used in immunohistochemistry studies. 
2.12.9. Secondary Antibodies 
Following two 5 minute washes in TBS, appropriate biotinylated secondary antibody in 
blocking serum were added to the slides and incubated for 30 minutes at room temperature in 
a humidified environment. 
2.12.10. Antigen Detection 
2.12.10.1. DAB immunohistochemistry 
Following 2 further washes in TBS, streptavidin-HRP (horseradish peroxidase) diluted 
1:1000 in TBS was applied for 30 minutes at room tep rature. A final TBS wash preceded 
antibody localisation determined by liquid DAB substrate chromogen system (DAKO, High 
Wycombe, UK). The chromogenic substrate 3,3’-diaminobenzidine (DAB) was oxidised by 
any antigen bound antibody HRP complexes resulting in the development of brown deposit 
at antigen sites (positive staining). DAB development was monitored microscopically and 
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the reaction was stopped by washing in water. Slides w re counterstained in Harris’ 
haematoxylin (causes cell nuclei to turn blue) followed by washes in acid alcohol (10 
seconds) and Scotts tap water (30 seconds.) Slides were then rehydrated through graded 
alcohols, washed in H20 and finally immersed in xylene before being mounted with 
coverslips in pertex glue (Cell Path, Hemel Hempstead, UK). 
2.12.10.2. Tyramide signal amplification fluorescence immunohistochemistry 
Immunofluorescent immunohistochemistry using tyramide signal amplification (TSA) 
enables the identification of multiple antigens in the same tissue section and detection of 
colocalised target antigens. Under ideal conditions the primary antibodies utilised in TSA are 
from distinct species and the fluorescent detection dyes have discernable excitation/emission 
spectra with minimal overlap. Fluorescent immunohistochemistry utilised phosphate 
buffered saline (PBS) as wash buffer in place of TBS. The slides were protected from 
photobleaching by covering in foil.  
Following antigen retrieval and hydrogen peroxide block (as described above) the slides 
were washed in water and then twice in PBS for 5 minutes. The slides were serum blocked 
for 30 minutes at room temperature before incubation overnight with primary antibody 
diluted at appropriate dilution (see Table 2.5) Following washes in PBS, slides were 
incubated with a species appropriate peroxidase-conjugated (with attached FAB fragments) 
secondary antibody for 30 min at room temperature. Slides were washed in PBS and 
incubated for 10 min with TSA kit (PerkinElmer, Mass chusetts, USA) using Tyramide-
cyanine 3 diluted 1:50 in substrate. The red fluorophore (cyanine 3) was usually used for the 
first primary antibodies as the green fluorophore (fluoroscein) was more prone to 
photobleaching and diminished signal when used first. After washing in PBS the slides were 
microwaved in boiling 0.01M citrate buffer for 2.5 minutes and then allowed to stand for a 
further 30 minutes to block cross-reactivity. The slides were then blocked in NGS/PBS/BSA 
and incubated overnight with the second primary antibody. Incubations with appropriate 
secondary antibody and TSA kit were performed as described above. The green fluorophore 
(fluorescein) was used for the second primary antibody. Following washes in PBS the slides 
were counterstained with DAPI diluted 1:1000 in PBS and mounted with coverslips in 
permafluor (Immunotech, Marseille, France). 
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2.12.11. Image analysis 
DAB positive sections were imaged using PROVIS micros ope (Olympus Optical, London 
UK) with an attached Canon DS126131 camera. Fluorescent images were examined using 
Zeiss LSM 510 Meta-Confocal microscope (Carl Zeiss, Hertfordshire, UK). 
2.13. Flow Cytometry 
Flow cytometry allows simultaneous analysis of multiple parameters of individual cells 
within a heterogeneous cell mixture. Cell suspensions are passed through the laser beam of a 
flow cytometer one cell at a time by a fluidics system which uses hydrodynamic focussing to 
ensure single cell detection. As each cell is passed through the laser the refraction pattern of 
the light is recorded by an electronic detection device. The light scatter created by cells 
passing through the laser provides information about the cell. Forward scatter (FSC) is 
roughly proportional to the volume/size of the cell. The internal complexity of cells such as 
shape of the nucleus and granularity of cells can be discerned from side scatter (SSC). 
Incubation with fluorescence-conjugated antibodies can be used to further describe the cell 
population by the detection of emission spectra of cells as they pass through the laser. Flow 
cytometry was used to describe and identify uNK cells from tissue extractions by 
immunophenotyping and viability testing using flow cytometry (see Section 4.4.2). 
2.13.1. Preparation of samples.  
Following isolation of uNK cells from human decidual tissues (see section 2.3.3) cells were 
suspended in FACS buffer (PBS, containing 1% FCS and 0.1% NaN3) at a concentration of 
500,000 cells per ml. 
2.13.2. Conjugated antibody staining 
Cell suspensions were stained with antibodies conjugated to fluorescein isothiocyanate 
(FITC) or phycoerythrin (PE) in order to immunophenotype cell populations. These 
fluorescent conjugates were chosen as their emission spectra do not overlap and therefore 
dual detection could be carried out. Single stains were set up to define the parameters for 
scanning the samples (see Table 2.60) together with unstained samples and isotype controls. 
Single and double stained samples were utilised to fully describe the sample cell population. 
Cell suspensions were centrifuged for 2 minutes at to pellet cells which were consequently 
resuspended in 100µL of FACS buffer. Conjugated antibodies at an approriate dilution 
were then added and cells incubated in the dark for 30 minutes. Following incubation cells 
were washed by adding 1ml of FACS buffer and centrifuged for 2 minutes at 1080 x g. The 
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cell pellet was resuspended in 1ml of FACS buffer centrifuged again. Finally the cell pellet 
was resuspended in 500µL of FACS buffer for scanning. Cells were placed on ice and 
protected from light until scanning was completed. 
Antibody Conjugate Ig Species Manufacturer Product code Dilution 
CD3 RPE IgG2a Mouse AbD Serotec MCA2184PE 1:50 
Isotype 
control 
RPE IgG2a Mouse AbD Serotec MCA929PE 1:50 





RPE IgG1κ Mouse BD 
Pharmingen 
555749 1:50 
CD56 FITC IgG1κ Mouse Abcam Ab48521 1:20 
Isotype 
control 
FITC IgG1κ Mouse Abcam Ab18435 1:20 
Table 2.6. Conjugated antibodies and isotype controls used in flow cytometry studies. 
2.13.3. Propidium Iodide staining 
To assess cell viability the capacity for cells to incorporate the fluorescent DNA-binding 
probe propidium iodide (PI) was measured. Non-viable cell membrane proteins become 
porous and they can readily incorporate PI. The degree of positive PI staining directly 
correlated to the proportion of non-viable cells. Viable cells are intact and do not incorporate 
the PI, thus the proportion of dye excluded cells gives an approximation of the percentage 
viability. PI (Sigma, 81845) was added to the cell suspension, incubated for 5 minutes in the 
dark and fluorescence measured using flow cytometer. 
2.13.4. BD FACScan cytometry 
Sample cell suspensions were measured using Becton Dickinson FACScan™ automated 
flow cytometer (Becton Dickinson, Oxford, UK). The FACScan™ system analyses cells as 
they pass through a focused laser beam one cell at a time in a moving fluid stream and at a 
rate of up to 2000 events per second. The FACScan™ system consists of a fixed 488nm 
Argon laser and three-colour detection capabilities. Samples were assessed at high flow rate 
(60µL/min of sample through flow cell). Five parameters a e available which describe the 
characteristics of cells in the sample suspension; f rward scatter (FSC) which gives an 
indication of cell size/volume, side scatter (SSC) which gives an indication of cell 
granularity/internal complexity and fluorescence measurements; FL-1, FL-2 and FL-3 for 
measuring the extent of positive staining in cells by fluorochrome-conjugated antibodies. 
Measurements of FSC and SSC were recorded as well as FL-1 for detection of fluorescein 
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isothiocyanate (FITC)-conjugated antibodies and FL-2 for phycoerythrin (PE)-conjugated 
antibodies and propidium iodide (PI). 
2.13.5. FACS analysis 
FACS samples were analysed using FlowJo (Tree Star Inc, OR, USA)  
2.14. Thin Layer Chromatography (TLC) 
Thin Layer chromatography is a method for separating a mixture of compounds based on 
their size and polarity. In the method employed, metabolised derivatives of tritiated steroids 
were measured along with the parent compound to give an indication of steroid metabolism 
in stromal cells. Stromal cells were cultured with media containing ‘cold’ steroid (10-8 M 
final concentration) as well as ‘hot’ steroid, whic was the same steroid but labelled with 
tritium sufficient to give 100,000 counts per ml, and incubated for various time periods. 
Following incubation for the appropriate amount of time, cell culture media was aspirated 
and mixed with 9ml dichloromethane (CH2Cl2) in a conical bottomed glass vial. The media 
and solvent were vortexed and allowed to stand for a minimum of two hours to allow steroid 
to dissolve into the solvent phase. The vials were then centrifuged at 868 x g for 15 minutes 
to ensure clear separation of the aqueous (cell culture media) and solvent (dichloromethane) 
layers. The upper aqueous layer was then discarded using suction pump at radioactive sink. 
The solvent layer was then dried using a sample drier under nitrogen gas on a heat block set 
to 40oC.  The chromatography tank was prepared by adding 150ml of running solvent 
(Chloroform/ethanol; 92/8%) and allowed to equilibrate for 1 hour before use. Dried samples 
were reconstituted in 100µL spotting mix, which contai ed ‘cold’ steroid mix and 
dichloromethane. The Aluminium Silica coated TLC plate (Alugram, SIL G/UV254, 
Macherey Nagel, Germany) was prepared by marking an origin line 20mm from the bottom 
of the plate on which samples were spotted at even intervals. Sample spotting involved 
careful dropping of sample onto the plate allowing drying between each additional spot of 
the sample and keeping the spot area as small as possible. This allowed the sample to be 
concentrated onto a small area which would be distinct from other samples on the plate. 
Following spotting of samples the plate was placed in the chromatography tank for 
approximately 1hour 30 minutes or until the solvent front reached the end of plate. Finally 
the plate was removed and allowed to dry in the fume hood before being placed on TLC 
scanner to record plate readings. Distribution of radioactivity on TLC plates was evaluated 
by radiometric scanning (Bioscan system 200 image scanner, Bioscan, Washington, DC, 
USA) and recorded using WinScan software, Lablogic software. 
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2.15. Tritiated water assay 
Aromatase activity was determined using the tritiated water release method (467) using 3H-
androstenedione as the substrate ([1β-3H]-androstenedione, Perkin Elmer Life Science, 
Boston; specific activity 23.5 Ci/mmol). In the method employed, the extent of substrate 
aromatisation was quantified by measuring the amount f tritiated water released. As a 
consequence of 3H-androstenedione aromatization, the tritium tracer is released in the form 
of tritiated water (3HOH). Released 3HOH is isolated following solvent extraction of steroids 
which removes any remaining 3H-androstenedione and thus leaves only 3HOH as the only 
detectable tracer in the sample. The relative quantity of 3HOH is measured using a beta 
counter and this is then quantitated against referenc  blanks/controls to determine the 
specific activity of aromatase in samples. 
Cells were incubated with 150pmol/ml androstenedione (A4) substrate (30pmol ‘Hot’ A4 i.e. 
3H-androstenedione and 120pmol ‘Cold’ A4) at 37°C for 2hrs. Following incubation, cells 
were incubated on ice for 10 minutes and then medium was removed and 1ml of 30% 
trichloroacetic acid (TCA) was added to the media. Cells were then washed twice in PBS 
and stored at -20oC until protein concentration was determined by Lowry method (468).  
4ml of Chloroform (CHCl3) was added to samples, which were vortexed and incubated 
overnight on a shaker to extract steroids. Samples were centrifuged at 1811 x g for 5 minutes 
and 1 ml of the upper (aqueous) phase transferred to a new glass vial. To this 2ml of 
charcoal/dextran solution (Charcoal dextran, Sigma C6241; 5%:0.5% v/w in H2O) was added 
and the sample was vortexed thoroughly. The samples were then centrifuged at 1811 x g for 
30 minutes. 1 ml of supernatant was then transferred to scintillation vials containing 10 mls 
of scintillation fluid (ProSafe FC, Meridian Biotech, Epsom, Surrey, UK), the samples were 
counted with a beta counter (Packard Tri-carb 2100TH, liquid scintillation analyzer) and the 
specific activity calculated. 




Gene name Forward Primer Reverse Primer UPL 
probe 
number 
Homo sapiens adrenomedullin (ADM) gcctgcccagacccttat gtagcgcttgactcggatg 57 
Homo sapiens aldo-keto reductase family 1, member C3 (3-alpha 
hydroxysteroid dehydrogenase, type II) (AKR1C3) 
tgggttccgccatatagatt tcgatgaaaagtggaccaaa 68 
Homo sapiens androgen receptor (AR) gccttgctctctagcctcaa gtcgtccacgtgtaagttgc 14 
Homo sapiens angiopoietin 2 (ANGPT2) tgcaaatgttcacaa tgctaa aagttggaaggaccacatgc 75 
Homo sapiens angiopoietin 4 (ANGPT4) caagctgaccgacat gag atctgggcatccattcttga 17 
Homo sapiens ARPS actin-related protein 3 homolog (yeast) (ACTR3) tggtgtcactcatgtcattcc atatctcgtcctgcgattgg 41 
Homo sapiens caveolin 2 (CAV2) ggctcaactcgcatctcaa cgtatttgctgatttcaaagagg 46 
Homo sapiens chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 
1) (CXCL12) 
ttgacccgaagctaaagtgg ccctctcacatcttgaacctct 80 
Homo sapiens coagulation factor III (thromboplastin, tissue factor) (F3) ggagaaaggggaattcagaga gggagttctcct ccagctc 51 
Homo sapiens CXCR4 (stromal cell derived factor 1 receptor) ttaagcgcctggtgactgtt gcccatttcctcggtgtag 47 
Homo sapiens cytochrome P450, family 11, subfamily A, polypeptide 1 
(CYP11A1), nuclear gene encoding mitochondrial protein, transcript variant 1, 
mRNA 
ccagacctgttccgtctgtt gaagttctgggtgtatatgtcagc 85 
Homo sapiens estrogen receptor 1 (ESR1) ttactgaccaac tggcaga atcatggagggtcaaatcca 24 
Homo sapiens estrogen receptor 2 (ER beta) (ESR2)  gctcctgtcccacgtcag tgggcattcagcatctcc 62 
Homo sapiens glycoprotein hormones, alpha polypeptid  (CGA) tgctgtgtagctaaatcatataacagg tcaagacagcacttgtaaaaca 59 
Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 (HSD17B2) cctggaggcttcctaacaaa gtcctggccgtagtcttcc  10 
Homo sapiens insulin-like growth binding protein 1 (IGFBP1) aatggattttatcacagcagacag ggtagacgcaccagcagagt 58 
Homo sapiens interleukin 15 (IL15) cagatagccagcccatacaag ggctatggcaaggggttt 46 
Homo sapiens interleukin 15 receptor, alpha (IL15RA) acaacccccagtctcaaatg tgccgtcgttactgtggag 37 
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Homo sapiens IQ motif containing GTPase activating protein 1 (IQGAP1) ctagaaacaccagccaccagt tcacggatagcacgtctctg 38 
Homo sapiens peripheral myelin protein 22 (PMP22) ttctcatcatcaccaaacgaa gctgaagatgatcgacaggat 49 
Homo sapiens progesterone receptor (PGR) tttaagagggc atggaagg cggattttatcaacgat 11 
Homo sapiens prolactin (PRL) aaaggatcgccatggaaag gcacaggagcaggtttgac 18 
Homo sapiens prothymosin, alpha (gene sequence 28) (PTMA) cgaaatcaccaccaaggact ctccccattttcctcattctc 34 
Homo sapiens Rho-associated protein kinase (ROCK) acatttgactggaaataaaga gctcgagttgcagggttaga 88 
Homo sapiens steroid sulfatase (microsomal), isozyme S (STS) cggaagtaatgggatctataaagg aacgaaggatgcctggaac 12 
Homo sapiens steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-
steroid delta 4-dehydrogenase alpha 1) (SRD5A1) 
catgttcctcgtccactacg aacataatcgccattgtacacg 59 
Homo sapiens steroidogenic acute regulatory protein (STAR), nuclear gene 
encoding mitochondrial protein, transcript variant 1 
ggcatccttagcaaccaaga actttgtccccattgtcctg 11 
Homo sapiens superoxide dismutase 2, mitochondrial (SOD2) ctggacaaacctcagcccta tgatggcttccagcaactc 22 
Homo sapiens vascular endothelial growth factor A (VEGFA) tgcccgctgctgtctaat tctccgctctgagcaagg 1 
Table 2.7. Table of oligonucleotide sequences used in RT-PCR analysis. 
 
 






3. The steroid microenvironment generated by 
decidualisation of endometrial stromal cells. 
3.1. Introduction 
The endometrium is a dynamic tissue which undergoes cyclical regeneration and 
remodelling in response to ovarian sex steroids. Decidualisation is the differentiation and 
proliferation of endometrial stromal cells (ESC) initiated in the mid to late secretory phase of 
the menstrual cycle in response to rising levels of progesterone and is accompanied by 
angiogenesis and leukocyte infiltration (9). In women decidualisation occurs independent of 
the presence of a conceptus. Decidualisation of stromal cells provides an appropriate 
nutritional and hormonal environment that is essential during the establishment of 
pregnancy. The uterine preparation for pregnancy requi s concerted control of receptivity, 
implantation and decidualisation. Indispensable to the synchronous control of these 
processes are the ovarian steroid hormones oestrogen and progesterone. 
Decidualisation occurs in an environment of rising progesterone during the secretory phase 
of the menstrual cycle (1). Stromal differentiation begins in cells surrounding the spiral 
arterioles approximately 8 days following the luteiniz ng hormone surge (LH+8) and spreads 
in a wave-like manner through the uterus (2, 119). Decidualisation is a continuum which 
features coordinated expression of decidual specific genes, secretion of growth factors such 
as prolactin and IGF-binding protein (IGFBP) and culminating in the transformation of 
fibroblastic stromal cells into ‘epithelioid’ decidual cells in the late secretory phase (119). 
Decidual cells persist in pregnancy and form the matern l component of the placenta, the 
decidua basalis (14). In the absence of pregnancy ad consequent demise of the corpus 
luteum, circulating progesterone levels fall and the decidual endometrium regresses and is 
shed during menstruation (1, 15). 
Progesterone acting through its cognate receptor (PR) is essential for decidualisation. PR 
knockout (PRKO) mice are infertile as a result of implantation and decidualisation failure 
(121). Stromal PR expression is required for progesterone action which drives differentiation 
of stromal cells and secretion of classical decidual sation markers prolactin and IGFBP (122, 
123).  





In contrast, the functional requirement of oestrogen in decidualisation is less clear. 
Oestrogen drives proliferation of the endometrium and oestrogen priming is required to 
induce stromal progesterone receptor expression. Administration of the anti-oestrogen ICI 
182780 severely impairs decidualisation in wild type mice suggesting oestrogen may be 
important in decidualisation (125). Despite this the decidualisation response is intact in both 
ERα and ERβ knockout mice and ovarian oestrogen is not essential for decidualisation (125-
127).  
Steroid biosynthesis occurs in many tissues throught the body most notably in the gonads; 
ovary and testis, and adrenals and involves a series of enzyme reactions that convert 
cholesterol into steroid hormones such as oestrogen and testosterone (see Figure 3.1). The 
activity of steroidogenic acute regulatory protein (StAR) and cholesterol side chain cleavage 
enzyme (encoded by CYP11A1 gene) mediate the critical initial steps in steroid hormone 
biosynthesis (320, 321) (See section 1.6 and Figure 3.1).  
 
 
Figure 3.1. Schematic diagram illustrating the steroid biosynthesis pathway from cholesterol 
to formation of androgens (blue section) and oestrogens (pink section). The steroid enzymes 
which were studied in ESC (white boxes) are shown in the context of steroid metabolism in 
the human endometrium.  
 





The critical step in biosynthesis of oestrogens involves the activity of the aromatase enzyme 
complex which acts by aromatising androgen precursors t  oestrogens (328). In humans 
aromatase is encoded by a single gene (CYP19A1) and expression is regulated by tissue 
specific promoters (327). 17β hydroxysteroid dehydrogenases (17βHSD) are an important 
class of enzymes that catalyse the inter-conversion of oestrogens and androgens [13]. 
Isozymes of 17βHSD permit conversion of sex steroids in a cellular and isotype specific 
manner (320). Additionally, steroid sulphatase (STS) hydrolyses sulphated steroids, which 
are abundant in the circulation but are inactive at steroid receptors, into biologically active 
steroids (335) and may be an additional source of bioavailable oestrogens. The endometrium 
is known to express a wide range of enzymes responsible for the metabolism and conversion 
of steroids (See Figure 3.1, Table 3.1). 
Expression in Endometrium  
Stromal Epithelial 
References 
StAR + - (309) 
CYP11A1 + + (310) 
CYP19A1 Not detected Not detected (311-313) 
17βHSD1 + + (312) 
17βHSD2 Highest in secretory 
phase 
Highest in secretory phase, stronger 
than stromal 
(312, 314) 
17βHSD5 +/- Highest in early secretory phase (315, 316) 
3βHSD Not described Weak in proliferative phase, moderate 
in secretory phase 
(317) 
STS Reduced in late 
secretory phase 
+ (312) 
SRD5A1 +/- All phases (318, 319) 
Table 3.1. Summary of mRNAs encoding proteins involved in steroid biosynthesis within the 
normal endometrium. See text for abbreviations. 
Studies on steroid metabolism in human endometrial tissue explants have revealed a high 
capacity for inter-conversion between androstenedione and testosterone as well as oestrone 
and oestradiol. In normal endometrium the reaction favours formation of oestrone and 
androstenedione over oestradiol and testosterone respectively (338). Steroidogenic enzymes 
also appear to be under cyclical control in the endometrium. 17βHSD2 mRNA expression 
has been identified in human endometrium and expression is highest in the secretory phase 
of the menstrual cycle (314). 17βHSD5 (also known as AKR1C3 due to its aldo/keto 
reductase activity) is expressed in the endometrium throughout the menstrual cycle with 
highest mRNA detection in the early secretory phase (315). STS immunoexpression has been 
detected in both stromal and epithelial cells in the endometrium across the menstrual cycle 
and is reduced in the late secretory phase (312).  Levels of 17βHSD1 do not appear to vary 





over the menstrual cycle (312). Endometrial expression of enzymes with oestrogen forming 
capacity such as 17βHSD1, 17βHSD2 and STS has been reported (Table 3.1). 
The role of aromatase in normal endometrium is poorly understood. Initial reports (345, 346, 
469) described aromatase activity in ESC and epithelial glands from normal endometrium. 
However subsequent studies have failed to describe CYP19A1 mRNA expression in normal 
endometrium (311, 375). Little is known about the potential for the endometrium to 
synthesise steroid hormones and this tissue has clas i ally been thought of as a steroid target 
and site of steroid metabolism but not biosynthesis (312, 338).  
Endometriosis is a chronic gynaecological disorder that is characterised by the presence of 
uterine endometrial tissue at ectopic sites outside of the normal location (373). 
Endometriosis is an oestrogen dependent disease that is associated with aberrant expression 
of steroidogenic enzymes (376). Increased expression of aromatase is reported in ectopic 
endometrium of women with endometriosis and decreased expression of 17βHSD2 is 
reported in endometriomas (313, 374, 375). Since endometriosis is an oestrogen-dependent 
disease aberrant expression of aromatase is considered to be critical in its pathophysiology. 
Thus, aromatase inhibitors have been used in the treatment of endometriosis as a means of 
impairing oestrogen formation (462). Stromal cells from endometriotic lesions also have 
reduced decidualisation capacity n vitro and dysregulation of steroidogenic enzymes in 
response to decidualising stimuli is also reported (313, 470).  
In addition to the pivotal role of ovarian progesterone (1, 121) in regulating decidualisation a 
recent study in mice suggests that de novo biosynthesis of oestrogen may also be essential 
during decidualisation (128). In mice local aromatase ctivity is essential to decidualisation 
and establishment of pregnancy, however to date ther  are no data from other species. We 
hypothesise that local biosynthesis of oestrogen occurs during decidualisation in women and 
that non-pathological changes in steroidogenic enzymes may be a feature of differentiation 
of stromal cells as part of the functional changes in the uterine environment required for 
establishment of pregnancy. This chapter describes preliminary investigations into the role of 
oestrogen biosynthesis and metabolism during i  vitro decidualisation of endometrial 
stromal cells. 
3.2. Aims of the Chapter 
1. To determine whether decidualisation of human endometrial stromal cells is 
associated with changes in local steroid metabolism. 





2. To determine the impact of inhibitors of steroidogenic enzymes on decidualisation 
and steroid biosynthesis. 
3.3. Methods 
3.3.1. Primary human endometrial stromal cells 
Primary human endometrial stromal cells (hESC) were isolated from biopsies (n=27) of 
healthy endometrium as detailed in section 2.3. Cells were seeded in 6 well plates at a 
density of 2x105 cells per well. hESC were maintained in RPMI 1640 media (Sigma, Cat. 
No. R0883) supplemented with 10% heat-inactivated foetal calf serum (FCS; Invitrogen, 
Cat. No. 10082-147), 10mL/L Penicillin/Streptomycin (10,000 units penicillin and 10mg 
Streptomycin per ml solution, Sigma, Cat. No. P-4333), 2mM L-glutamine (Sigma, Cat. No. 
G-7513), and 2.5µg/ml fungizone (Invitrogen, Cat. No. 15290-018) fora maximum of 4 
passages. Cells were transferred to phenol red-free RPMI 1640 medium (Sigma, Cat. No. 
R7509)  containing 10% charcoal-stripped FCS (CSFCS) and otherwise supplemented as 
detailed above for 48 hours prior to use in experimntal assays. Prior to decidualisation 
hESC cells were transferred to serum depleted media (as above but 2% CSFCS) for 24 
hours.  Cells were maintained at 37oC under 5% CO2 in air. Table 3.2-3.5 detail the treatment 
regimens utilised. Treatments were completed in duplicate and each experiment repeated 3-8 
times with hESC isolated from separate endometrial biopsies. 
Treatment name Treatment Final concentration Incubation period 
Control DMSO Equivalent 10-6M 6, 8 days 
8-Br-cAMP  0.1 mg/ml DEC 
Progesterone 10-6M 
6, 8 days 
Table 3.2. Experimental regimen for experiments 3.4.1, 3.4.2, 3.4.3, 3.4.4 and 3.4.7. 
Treatment name Treatment Final concentration Incubation period 
Control DMSO Equivalent 10-6M 1, 2, 4, 8 days 
cAMP 8-Br-cAMP 0.1 mg/ml 1, 2, 4, 8 days 
8-Br-cAMP  0.1 mg/ml cAMP + P4 
Progesterone 10-6M 
1, 2, 4, 8 days 
Table 3.3. Experimental regimen for experiments 3.4.5 and 3.4.8. 






Treatment name Treatment Final concentration Incubation period 
Control + Vehicle DMSO Equivalent 10-5M 8 days 
Control + 1µM AI anastrozole (AI) 1µM AI 8 days 
Control + 10µM AI anastrozole (AI) 10µM AI 8 days 
8-Br-cAMP  0.1 mg/ml 
Progesterone 10-6M 
DEC + Vehicle 
DMSO equivalent 10-5M 
8 days 
8-Br-cAMP  0.1 mg/ml 
Progesterone 10-6M 
DEC + 1µM AI 
Anastrozole (AI) 1µM 
8 days 
8-Br-cAMP  0.1 mg/ml 
Progesterone 10-6M 
DEC + 10µM AI 
Anastrozole (AI) 10µM 
8 days 
Table 3.4. Experimental regimen for experiment 3.4.9. 
Treatment name Treatment Final concentration Incubation period 
8-Br-cAMP 0.1 mg/ml DEC 
Progesterone 10-6M 
1, 2, 4, 8 days 
8-Br-cAMP 0.1 mg/ml 
Progesterone 10-6M 
DEC + STX 
STX64 5µg/ml 
1, 2, 4, 8 days 
Table 3.5. Experimental regimen for experiment 3.4.10. 
3.3.2. Immortalised human endometrial stromal cells  (SHT290) 
The human TERT- immortalised stromal cell line, SHT 290 (Gift from Dr. David Kaufman, 
Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel 
Hill, NC, USA.), was maintained under the same culture conditions as hESC (see section 
2.4.22.4.2) however unlike hESC, SHT 290 cells could be maintained for multiple passages. 
SHT 290 cells were seeded in 6 well plates at a density of 2x105 cells per well for 
experimental assays. Prior to decidualisation SHT 290 cells were transferred to serum 
depleted media Tables 3.6-3.8 detail the treatment r gimens utilised. Treatments were 
completed in duplicate and each experiment repeated 3 imes. 
Treatment name Treatment Final concentration Incubation period 
Control DMSO Equivalent 10-6M 8 days 
8-Br-cAMP  0.1 mg/ml DEC 
Progesterone 10-6M 
8 days 
Table 3.6. Experimental regimen for experiment 3.4.1. 






Treatment name Treatment Final concentration Incubation period 
Control DMSO Equivalent 10-6M 6 days 
8-Br-cAMP  0.1 mg/ml DEC 
Progesterone 10-6M 
6 days 
Table 3.7. Experimental regimen for experiment 3.4.6. 
Treatment Final concentration Incubation period 
oestrone + 3H-oestrone 10-8M 2, 4, 8, 16, 24 h 
oestradiol + 3H-oestradiol 10-8M 2, 4, 8, 16, 24 h 
testosterone + 3H-testosterone 10-8M 2, 4, 8, 16, 24 h 
androstenedione + 3H-androstenedione 10-8M 2, 4, 8, 16, 24 h 
Table 3.8. Experimental regimen for experiment 3.4.6. Cells were treated as in table 3.7 
followed by time course shown. 
3.3.3. Immunohistochemistry 
Immunohistochemistry was conducted on human endometrial tissue sections to establish the 
presence and localization of CD10 (stromal cell marker). Tissues were collected and fixed in 
4% NBF and embedded in paraffin wax. 5µm sections were cut and mounted onto coated 
glass slides (VWR, Poole, UK). Antigen retrieval was performed using 0.05M 
Glycine/EDTA buffer (pH 8) followed by methanol peroxidase block, serum block, and 
avidin-biotin block. Primary antibody to CD10 was diluted 1:200 in blocking serum (normal 
goat serum, TBS, BSA), added to sections and incubated overnight. Slides were incubated 
with goat anti-mouse biotinylated secondary antibody followed by streptavidin-HRP before 
final antibody detection using 3,3’-diaminobenzidine (DAB). Slides were counterstained in 
Harris’ haematoxylin. DAB positive sections were imaged using PROVIS micros ope 
(Olympus Optical, London UK) with an attached Canon DS126131 camera. 
3.3.4. Immunocytochemistry 
Isolated stromal cells (SHT290 and hESC) were grown n chamber slides (Ref no: 354102, 
BD Biosciences, Belgium) at an initial seeding density of 1x104 cells/ml and 
immunodetection of CD10 and aromatase was determined using immunocytochemistry. 
Following culture, cells were fixed in ice-cold methanol and endogenous peroxidase blocked 
in 0.15% H2O2 in methanol for 30 minutes. Following washes in PBS, cells were 
permeablised by incubation in 0.2% IGEPAL, 1% BSA, 10% NGS in PBS for 20 minutes 
followed by serum block for 30 minutes. Thereafter c lls were incubated overnight at 4oC 
with primary antibody. Antigen detection was performed as described in section 2.12. 





3.3.5. RNA extraction 
Extraction of RNA from cell monolayers was performed using RNAeasy® mini kit (Qiagen, 
Crawley, UK) as described in section 2.8. Samples wre collected in 350µl of lysis buffer per 
well of 6-well plate and homogenized using QIAshredd r® spin columns (Qiagen, Crawley, 
UK).  
3.3.6. Preparation of cDNA using SuperScript® VILO™  synthesis kit. 
Reverse transcription of RNA to form a single stand of complementary DNA (cDNA) was 
carried out using the SuperScript VILO cDNA synthesis kit (InVitrogen) as described in 
section 2.9. Samples were incubated under the following conditions: 25oC for 10 minutes, 42 
oC for 60 minutes, 85 oC for 5 minutes in a thermal cycler. 
3.3.7. Quantitative-Real Time-PCR (Taqman® Method) 
Concentrations of mRNAs in samples was determined by reverse transcription followed by 
quantitative-real time polymersase chain reaction performed in an ABI machine using the 
Taqman® Method (Section 2.10). 
Each reaction was prepared using the qPCR Supermix with premixed ROX kit (11795-01K; 
Invitrogen) and conducted in duplicate and plated in a 96-well MicroAmp Fast Optical 
reaction plate (Applied Biosystems). Real time PCR amplification was performed using the 
Applied Biosystems® 7900HT Fast Real-Time PCR System using reaction mix described in 
section 2.10.2 under the following cycling conditions: 95oC for 10 minutes, followed by 40 
cycles of 95 oC for 15 seconds and 60 oC for 1 minute. 
 
3.3.8. Human insulin-like Growth Factor Binding Pro tein 1 enzyme-linked 
immunosorbent assay (ELISA) 
The concentration of human Insulin-like Growth Factor Binding Protein 1 (IGFBP) protein 
in cell culture supernatants was determined by two-site sandwich ELISA as described in 
section 2.11. 
The ELISA was performed using reagents from IGFBP1 DuoSet ELISA development kit 
(R&D Systems, Minneapolis, MN, USA). Cell growth medium was collected following in 
vitro treatment of cells (sections 3.3.1 and 3.3.2) and stored at -80°C to preserve protein 
integrity and thawed immediately prior to the assay. Optical density of each well was 





measured immediately using a microplate reader set to 450nm with wavelength correction 
set to 540nm. Concentration of IGFBP1 in cell culture supernatants was calculated from the 
standard curve. Data was linearised by plotting log c ncentration against log optical density 
and unknowns determined by regression analysis using GraphPad Prism (GraphPad Prism 
version 5.04 for Windows, GraphPad Software, La Jolla California USA, 
www.graphpad.com).  
3.3.9. Oestrone ELISA 
Oestrone in cell culture supernatants was detected using an Estrone ELISA kit (BioVendor, 
Czech Republic) and quantified against a calibrator s andard set as described in section 
2.11.2.2. Optical density of each well was measured immediately using a microplate reader 
set to 450nm with wavelength correction set to 540nm. The delta absorbance was recorded 
as final values and concentrations were then calculated from the standard values. Unknowns 
were determined by non-linear regression analysis uing GraphPad Prism (GraphPad Prism 
version 5.04 for Windows, GraphPad Software, La Jolla California USA, 









Androstenedione, Cholesterol, Corticosterone, Cortis l, Cortisone, 
DHEAS, Diethylstilbesterone, Estriol, Estradiol-Sulfate, Progesterone, 
17-OH Progesterone, Testosterone. 
0.1 
Table 3.9. Specificity of oestrone ELISA kit as described in manufacturers instructions. The 
detection limit was 10 pg/ml 
3.3.10. Oestradiol ELISA 
Oestradiol in cell culture supernatants was detected by competitive ELISA using oestradiol-
6-HRP conjugate (in house preparation) and oestradiol-6 antibody (#20R-ER005, Fitzgerald 
Industries International, Concord, MA, USA) as described in section 2.11.2.1.   
Immuno 96 MicroWell™ Solid Plates (NUNC, Roskilde, Denmark) were coated with 
100µL/well of 1:200 DARS (Donkey anti rabbit serum) in coating buffer (100mM 
Bicarbonate solution, pH 9.6) and incubated overnight at 4oC on a rocker. After incubation 





coating solution was aspirated and each well washed 3 times with wash buffer (0.05% 
Tween20 in PBS). After washing, plates were blocked by adding 300µL of blocking buffer 
(1% Gelatin (Sigma, G9382, Dorset, UK) in PBS) to each well and incubated for a minimum 
of 1 hour at room temperature. Plates were washed a further three times and 100µL of 
standards/unknowns added to plate. 50 µL of oestradiol-6-HRP conjugate 1:40,000 in PGBS 
and 50 µL of oestradiol 6 antibody at dilution of 1:150,000 in PGBS was added and 
incubated for 3 hours at room temperature or overnight at 4oC. Solutions were aspirated and 
plates washed four times.  100ul of TMB substrate solution was added to each well and 
incubated in the dark for 20 minutes. The colour reaction was stopped by addition of 
50µL/well of 2N H2SO4. Optical density of each well was measured immediat ly using a 
microplate reader set to 450nm with wavelength correction set to 540nm. The delta 
absorbance was recorded as final values and concentratio s were then calculated from the 
standard values. Unknowns were determined by non-linear regression analysis using 
GraphPad Prism (GraphPad Prism version 5.04 for Windows, GraphPad Software, La Jolla 
California USA, www.graphpad.com). The specificity of the oestradiol-6 antibody is 









Table 3.10. Specificity of oestradiol-6 antibody as described in manufacturers instructions. 
The detection limit of E2 ELISA was 10 pg/ml. 
3.3.11. Thin Layer Chromatography (TLC) 
SHT 290 cells were cultured with medium containing unlabelled steroid (10-8 M final 
concentration) as well as tritium-labelled steroid, sufficient to give 100,000 counts per ml, 
and incubated for 2, 4, 8, 16 or 24 hours. Following incubation for the appropriate amount of 
time, cell culture media were aspirated and mixed with 9 ml dichloromethane (CH2Cl2) in a 
conical-bottomed glass vial. The media and solvent were vortexed and allowed to stand for a 
minimum of two hours to allow steroid to dissolve into the solvent phase. The vials were 
then centrifuged at 868 x g for 15 minutes to ensure clear separation of the aqueous (cell 
culture media) and solvent (dichloromethane) layers. The upper aqueous layer was then 
discarded by suction pump aspiration at a designated r dioactive sink. The solvent layer was 





then dried using a sample drier under nitrogen gas on a heat block set to 40oC.  The 
chromatography tank was prepared by adding 150ml of running solvent 
(Chloroform/ethanol; 92%/8%) and allowed to equilibrate for 1hr before use. Dried samples 
were reconstituted in 100µL spotting mix, which contai ed unlabelled steroid mix and 
dichloromethane. Samples were spotted onto an Alumini  Silica coated TLC plate 
(Alugram, SIL G/UV254, Macherey Nagel, Germany) which was placed in the 
chromatography tank for approximately 90 minutes or until the solvent front reached the end 
of the plate. Finally the plate was removed and allowed to dry in the fume hood before being 
placed on TLC scanner to record plate readings (see Figure 3.20 and Figure 3.3). 
Distribution of radioactivity on TLC plates was evalu ted by radiometric scanning (Bioscan 
system 200 image scanner, Bioscan, Washington, DC, USA) and recorded using WinScan 
software, Lablogic software. 


































Figure 3.2. Oestrogen TLC standards. 3H-Oestrone (E1) and 3H-Oestradiol (E2) tracers give 
Rf values of ~120 and ~95 respectively. The retention factor (Rf) values (X axis) give a 
measure of the distance the spotted analyte has travelled along the plate which directly 
correlates to the physical properties of the analyte such as polarity. Arbitrary counts (Y axis) 
are the measured radioactivity of the tracer which is greatest where the analyte is most 
concentrated on the plate i.e. the point on the plate to which the analyte has travelled. Under 
consistent assay conditions analytes are detected at the same positions on the TLC plate 
and can be identified based on the Rf values of standards. 
 






























Figure 3.3. Androgen TLC standards. 3H-testosterone (T) and 3H-androstenedione (A4) 
tracers give Rf values of ~112 and ~145 respectively. The retention factor (Rf) values (X 
axis) give a measure of the distance the spotted analyte has travelled along the plate which 
directly correlates to the physical properties of the analyte such as polarity. Arbitrary counts 
(Y axis) are the measured radioactivity of the tracer which is greatest where the analyte is 
most concentrated on the plate i.e. the point on the plate to which the analyte has travelled. 
Under consistent assay conditions analytes are detected at the same positions on the TLC 
plate and can be identified based on the Rf values of standards. 
3.3.12. Tritiated water assay 
To determine aromatase activity in hESC a tritiated water assay was performed (see section 
2.15). hESCs were cultured in 6 well plates as described previously (section 2.4). 
Decidualised cells were cultured in decidualising media (cAMP and P4, see section 3.3.1) 
for up to 6 days prior to assay. Prior to assay all cells were transferred to serum-depleted 
phenol red-free medium. 
Cells were incubated with 150pmol/ml androstenedione (A4) substrate (30pmol ‘Hot’ A4 i.e. 
3H-A4 and 120pmol ‘Cold’ A4) at 37°C for 2hrs. Following incubation, cells were incubated 
on ice for 10 minutes and then medium was removed and 1ml of 30% trichloroacetic acid 
was added to the media.  





4ml of Chloroform (CHCl3) was added to the samples, which were vortexed and incubated 
overnight on a shaker to extract steroids. Samples were centrifuged at 1811 x g for 5 minutes 
and 1 ml of the upper phase transferred to a new glass vial. To this, 2ml of charcoal/dextran 
solution (5%:0.5% v/w in H2O, Charcoal dextran; Sigma C6241) was added and samples 
were vortexed thoroughly. The samples were then centrifuged at 1811 x g for 30 minutes. 1 
ml of supernatant was then transferred to scintillation vials containing 10 mls of scintillation 
fluid and finally the activity of samples was measured using a beta counter. 
3.3.13. Statistical Analysis 
Statistical analysis was performed using GraphPad Prism (GraphPad Prism version 5.04 for 
Windows, GraphPad Software, La Jolla California USA, www.graphpad.com). The criterion 
for significance for all tests was set at p<0.05. 
3.4. Results 
3.4.1. Primary human ESC and immortalised SHT290 ce lls are both CD10-
positive and exhibit characteristic responses to de cidualising stimuli.  
Expression of CD10 was investigated in order to confirm that isolated human endometrial 
stromal cells (hESC) and SHT290 cells were phenotypically identical to endometrial stromal 
cells. CD10 is normally expressed in endometrial stromal cells (471, 472) (see Figure 3.4 A, 
B) and its expression distinguishes stromal cells from glandular epithelial cells. When 
immunocytochemistry was performed on primary hESC and SHT290 cells using chamber 
slides, intense positive cytoplasmic staining was ob erved in both cell types (Figure 3.4, D, E 
and G, H respectively).  
To confirm that both primary hESC and SHT290 retained the capacity to differentiate cells 
were treated according to standard protocol utilizing cAMP and progesterone (132, 305, 473) 
for 8 days. Decidualisation was assessed by measuring the expression of mRNAs encoding 
the classical decidualisation marker IGFBP-1. Secretion of IFGBP-1 protein was detected by 
ELISA. After 8 days, consistent with the expected rsponse to cAMP and progesterone, the 
morphology of both cell types was changed from a classical elongated fibroblast into cells 
with an ‘epithelial’ appearance (Figure 3.5, A and B). Consistent with the observed change 
in cellular morphology, expression of IGFBP-1 mRNA was significantly up-regulated in 
decidualised ESC compared to non-decidualised ESC (p<0.0001, n=4) (Figure 3.5, C). 
IGFBP-1 protein secretion paralleled mRNA expression changes and was increased in 





decidualised ESC (p<0.0001, n=4) (Figure 3.5, D). The response of SHT290 was similar to 
isolated primary ESC (Figure 3.5, E and F) confirming they represented a suitable model 
system (465). 
 
Figure 3.4. Immunodetection of CD10 in endometrial tissue sections and on isolated primary 
endometrial stromal cells and SHT cells. On sections of normal endometrium (A, B) 
immunoexpression of CD10 was intense (indicated by brown staining) in stromal fibroblasts 
(s) but epithelial cells were immunonegative and no staining was detected on the luminal 
surface (not shown) or the lining of the glands (g). Primary ESC (D, E) and immortalised 
SHT290 (G, H) both expressed CD10 confirming stromal phenotype. Negative controls were 
conducted in the absence of primary antibody for endometrium, stromal fibroblasts, and 
SHT290 (C, F, and I respectively).  
 
 









































































































Figure 3.5. Incubation of primary ESC induces a characteristic response according to a 
classical decidualisation protocol of 8 days treatment with 8-bromo cyclic adenosine 
monophosphate (cAMP) and progesterone (P4) in serum-depleted media. Changes in cell 
morphology observed in ESC upon decidualisation (A,B). Stromal cells change from 
elongated fibroblast morphology to more rounded epithelial phenotype. Expression of IGFBP 
mRNA (C) and secretion of IGFBP protein (D) in control (Ctrl) and decidualised (DEC) 
endometrial stromal cells (n=4, **** p<0.0001, ** p<0.01). Expression of IGFBP mRNA (E) 
and protein (F) was similarly upregulated in SHT cells (n=3, * p<0.05, ** p<0.01, veh control= 
vehicle control.) Statistical analysis was performed using an unpaired t-test.  
 





3.4.2. Human endometrial stromal cells express sex steroid receptors and 
their expression is altered in response to decidual isation. 
To address whether changes in the local steroid environment could have a functional impact 
on decidualised and non-decidualised ESC expression of sex steroid receptors mRNAs was 
measured (Figure 3.6). The two key receptor isoforms of the oestrogen receptor, oestrogen 
receptor α (ERα) and oestrogen receptor β (ERβ) as well as androgen receptor (AR) and 
progesterone receptor (PR) are all expressed in the stromal compartment of the endometrium 
throughout the menstrual cycle (250, 291, 474). Expression of mRNAs encoding for sex 
steroid receptors were detected in both undecidualised and decidualised ESC.  Expression of 
ERα (P<0.001, n=4), AR (P<0.01, n=4) and PR (P<0.001, n=4) mRNA was decreased in 
decidualised ESC. Expression of ERβ mRNA was increased in decidualised ESC (P<0.01, 
n=4). 































































































Figure 3.6. Expression of sex steroid receptors; oestrogen receptor alpha (ERα), oestrogen 
receptor beta (ERβ), androgen receptor (AR) and progesterone receptor (PR) in primary 
ESC (ctrl) and in ESC exposed to decidualising media for 8 days (DEC). Expression of ERβ 
mRNA was increased in DEC cells whereas expression of ERα, AR and PR mRNA was 
decreased relative to control primary ESC. Expression of  ERα (A), ERβ (B), AR (C) and PR 
(D) mRNA in non-decidualised and decidualised stromal cells as determined by Taqman 
qRTPCR (n=4 ** p<0.01; *** p<0.001). Statistical analysis was performed using an unpaired 
t-test. 
3.4.3. Decidualisation of ESC results in altered ex pression of mRNAs 
encoding enzymes associated with steroid metabolism . 
To assess whether decidualisation of stromal cells might be associated with changes in 
intracellular steroid metabolism the concentrations f mRNAs encoding key metabolising 
enzymes in primary ESC and cells decidualised in vitro (8 days treatment regime) were 





investigated. To assess whether cells could support de novo steroid synthesis expression of 
steroidogenic acute regulatory protein (StAR) and cholesterol side-chain cleavage enzyme 
(CYP11A1) were both measured.  
StAR regulates cholesterol transport within mitochondria a key rate-limiting step in steroid 
biosynthesis and although expression of StAR mRNA was decreased in decidualised ESC 
(Figure 3.7 A, p<0.01, n=4) it was still detectable. CYP11A1 catalyses the first step in 
steroid hormone production by converting cholesterol to pregnenelone. Expression of 
CYP11A1 mRNA was not significantly different (p=0.2106) between decidualised and non-
decidualised ESC (Figure 3.7 B).  
Biosynthesis of oestrogen requires aromatase (encodd by CYP19A1 gene) which acts by 
aromatising androgen precursors to oestrogens. Expression of CYP19A1 mRNA was 
increased in response to decidualisation (Figure 3.8 A, p<0.01, n=4) however a large number 
of cycles were required to detect this transcript (Ct>35).  17β hydroxysteroid dehydrogenase 
1 (HSD1) catalyses the conversion of oestrone to oestradiol. Expression of 17βHSD1 mRNA 
was detected in both decidualised and non-decidualised ESC but no significant difference in 
expression was observed (Figure 3.8 B, p=0.4632, n=4).  17βHSD2 catalyses the conversion 
of oestradiol to oestrone and testosterone to androstenedione (323). Expression of 17βHSD2 
mRNA was significantly higher in decidualised ESC than non-decidualised ESC with a 
striking 30-fold change in expression (Figure 3.8 C, p<0.01, n=4). 17βHSD5 catalyses the 
conversion of androstenedione to testosterone. Decidualisation did not significantly change 
the expression of 17βHSD5 (Figure 3.8 D, n=4). 
Steroid sulphatase (STS) converts oestrone sulphate to o strone. STS mRNA expression was 
highly and significantly up-regulated in decidualised ESC (Figure 3.9 A, p<0.05, n=4). The 
potential for conversion of androgens was also investigated by measuring of expression of 
5α reductase (SRD5A1) mRNA. SRD5A1 is responsible for c nverting testosterone to 
dihydrotestosterone and expression of 5αR was significantly increased in decidualised ESC 
(Figure 3.9 B, p<0.001, n=4).  





























































Figure 3.7. The expression of mRNAs encoding enzymes responsible for de novo synthesis 
of steroids were measured following decidualisation. CYP11A1 mRNA expression was not 
significantly changed although there was a trend toward increased expression following 
decidualisation. StAR mRNA expression was decreased after 8 days. Expression of 
steroidogenic enzymes in primary human ESC following 8 days in vitro decidualisation. A 
StAR, n=4 ** p<0.01. B CYP11A1, n=4, n/s (not significant), p=0.2106. Cells were treated 
with control (DMSO) or decidualising media (DEC) for 8 days in serum-depleted phenol red-
free medium. Statistical analysis was performed using an unpaired t-test. 
 


























































































































Figure 3.8. The expression of mRNAs encoding enzymes responsible for conversion of 
androgens to estrogens (CYP19A1) and interconversion of androgens and oestrogens 
(17βHSD1, 17βHSD2 and 17βHSD5) were assessed. Following decidualisation, expression 
of mRNAs encoding CYP19A1 and 17βHSD2 were both significantly increased but 
17βHSD1 and 17βHSD5 mRNAs remained unchanged. Expression of steroidogenic 
enzymes in primary human ESC following 8 days in vitro decidualisation. A CYP19A1 
(aromatase); B 17β hydroxysteroid dehydrogenase (HSD) 1; C 17βHSD2; D 17βHSD5 (n=4, 
** p<0.01, n/s not significant). Expression of mRNA determined by Taqman qRTPCR. Cells 
were treated with control (DMSO) or decidualising media (DEC) for 8 days in serum-depleted 
phenol red-free medium. Statistical analysis was performed using an unpaired t-test. 
 
 

































































Figure 3.9. Expression of mRNAs encoding enzymes responsible for conversion of 
sulphated oestrogens (STS) or androgens (SRD5A1) were both increased by 
decidualisation. Expression of steroidogenic enzymes in primary human ESC following 8 
days in vitro decidualisation. A STS; B SRD5A1 (n=4 * P<0.05; *** p<0.001). Expression of 
mRNA was determined by Taqman qRTPCR. Cells were treated with control (DMSO) or 
decidualising media (DEC) for 8 days in serum-depleted phenol red-free medium. Statistical 
analysis was performed using an unpaired t-test. 
3.4.4. Decidualised hESC express aromatase protein 
To assess whether decidualisation might be associated with increased expression of 
aromatase protein in primary hESC, the expression of ar matase was investigated using 
immunocytochemistry. In agreement with previously described mRNA expression data 
(section 3.4.3), aromatase was readily detected by immunocytochemistry in decidualised 
hESC (Figure 3.10, A) but absent in undecidualised hESC (Figure 3.10, B). In decidualised 
hESC, characteristic staining for aromatase was detected; positive punctate cytoplasmic 
staining was observed which was absent in the negativ  control. Antibody specificity was 
confirmed using positive control placental tissue sections in which aromatase staining was 
localized to the syncytiotrophoblast (Figure 3.10, C). 






Figure 3.10. Immunodetection of aromatase in placental tissue sections and on isolated 
primary endometrial stromal cells. Positive cytoplasmic staining for aromatase (green 
staining) was detected in isolated decidualised human endometrial stromal cells (A), 
however this was absent in undecidualised ESC (B). On sections of placenta (C) aromatase 
(green staining) was detected in the syncytiotrophoblast which was absent in the negative 
control (B). Nuclear counterstain DAPI (blue staining). Scale bar 50 µm. 
3.4.5. Expression of mRNAs encoding enzymes associa ted with biosynthesis 
and conversion of sex steroids exhibit time-depende nt changes in gene 
expression in response to decidualisation. 
To explore whether changes in steroid metabolism as a result of decidualisation were 
dynamic, an additional study was undertaken using cells exposed to either cAMP alone or 
cAMP plus progesterone for 1 to 8 days. In this experiment the concentration of StAR 
mRNA in response to treatment was found to be time dependent with a significant increase 
compared to controls at 1 and 2 days (Figure 3.11 A, p<0.001, n=4) a result that contrasted 
with that of CYP11A1 mRNA which was only significantly increased at 8 days in those cells 
incubated with both cAMP and P4 (Figure 3.11 B, p<0.01, n=4) compared with controls. 





Expression of 17βHSD2 mRNA showed a time dependent increase that was significant at 8 
days in cells treated with cAMP alone (P<0.05) or cAMP and P4 (P<0.001) with a non-
significant trend after 4 days of treatment (Figure 3.11 C). Expression of STS mRNA was 
only increased after 8 days of incubation and in agreement with results for 17βHSD2 mRNA 
this was true of cells incubated with either cAMP alone or cAMP in combination with P4 
(Figure 3.11 D, p<0.001, n=4). 

























































































































































































































































































Figure 3.11. Time-dependent changes in expression of mRNAs encoding enzymes 
responsible for de novo steroid biosynthesis (StAR and CYP11A1) as well as enzymes that 
facilitate interconversion of androgens and oestrogens (17βHSD2), and conversion of 
sulphated oestrogens (STS). Concentrations of StAR mRNA was significantly increased at 
early time points (1 and 2 days) but returned to normal thereafter. Conversely CYP11A1 
mRNA was only significantly increased at 8 days. 17βHSD2 and STS mRNAs were both 
highly and significantly expressed at 8 days but not at earlier time points. Expression of 
enzymes associated with biosynthesis of sex steroids throughout in vitro decidualisation 
determined by Taqman qRTPCR. A Steroidogenic acute regulatory protein (StAR); B 
CYP11A1; C 17β HSD2; D steroid sulfatase (STS) (n=4 * P<0.05; ** p<0.01; *** p<0.001). 
Cells were treated with control (DMSO), cyclic adenosine monophosphate (cAMP) or cAMP 
plus progesterone (P4) for 1, 2, 4 or 8 days in serum-depleted phenol red-free media. 
Statistical analysis was performed using a Two-way ANOVA. 
 





3.4.6. Analysis by thin layer chromatography reveal s dynamic changes in 
steroid metabolism associated with decidualisation.  
To compare the functional activity of steroid enzymes in ESC with their decidualised 
counterparts, metabolism of tritiated steroid hormones was assessed using thin layer 
chromatography (TLC). These studies were conducted using the SHT290 cell model. The 
activity of the 17βHSD2 enzyme was quantified by determining the metabolism of 3H-
oestradiol or 3H-testosterone to oestrone (E1) and androstenedione (A4) respectively.  
In control (non-decidualised) SHT cells greatest conversion of 3H-oestradiol occurred within 
the first 2 hours and there was 100% conversion to E1 after 16 hours (Figure 3.12 G). The 
metabolism of 3H-oestradiol was comparatively reduced in decidualised SHT cells. 
Percentage conversion of 3H-oestradiol tended to be less in decidualised SHT cells and was 
significantly reduced in decidualised SHT cells compared to normal SHT cells after 8 hours 
(Figure 3.15 A, n=4, p<0.05). Rate of conversion, determined by calculating the proportion 
of 3H-oestradiol metabolised per minute, was also consistently lower in decidualised SHT 
cells and was significantly reduced at 2 hours (Figure 3.16 A, n=4, p<0.01).  
A similar pattern was observed for metabolism of 3H-testosterone in normal and decidualised 
SHT cells (Figure 3.13). Percentage conversion of 3H-testosterone tended to be lower in 
decidualised SHT cells (Figure 3.15 B). Rate of conversion was also consistently lower in 
decidualised SHT cells and was significantly reduce at 2 hours (Figure 3.16 B, n=4, 
p<0.05). 
Overall the rate of metabolism, as determined by percentage conversion of substrate 
(nmoles) over time in minutes, appeared to be reduc in decidualised SHT cells compared 
to control SHT cells and was significantly lower after 2 hours for both E2 and T (Figure 3.16  
A and B). 
The activity of 17βHSD1 was be investigated by addition of 3H-oestrone to cells however no 
metabolism was observed in either decidualised or control (non-decidualised) SHT cells 
(Figure 3.14 A, B). Similarly no apparent 17βHSD5 activity (metabolism of 3H-
androstenedione) was detected in either control (non-decidualised) or decidualised SHT cells 
(Figure 3.14 C, D). Aromatase activity could not be assessed using TLC. 











































































































































Figure 3.12. Metabolism of 3H-oestradiol (E2) to oestrone (E1) is less rapid in decidualised 
cells. Metabolism of 3H-E2 was measured after 2, 4, 8, 16 and 24 hours in undecidualised 
(A, C, E, G, and I) and decidualised stromal cells (B, D, F, H, and J). The proportion of E2 
(first peak) converted to E1 (second peak) increases over time and is fully converted by 16 
hours in undecidualised cells (G). The rate of conversion is slower in decidualised cells 
(Figure 1.12A) and E2 is not fully converted by 24 hours (J). Cells were treated with control 
or decidualising media for 6 days and then metabolism of 3H-E2 was measured by TLC. 
Chromatographs shown representative of 1 of 3 replicates of assay. 
 

















































































































































































Figure 3.13. Metabolism of 3H- testosterone (T) to androstenedione (A4) is less rapid in 
decidualised cells. Metabolism of 3H-T was measured after 2, 4, 8, 16 and 24 hours in 
undecidualised (A, C, E, G, and I) and decidualised cells (B, D, F, H, and J). The proportion 
of T (first peak) converted to A4 (second peak) increases over time and is 75% after 24 
hours in undecidualised cells (I). The rate of conversion is slower in decidualised cells and 
less T is converted at each time point compared to undecidualised cells (Figure 1.12B). Cells 
were treated with control or decidualising media for 6 days and then metabolism of 3H-T was 
measured by TLC. Chromatographs shown are representative of 1 of 3 replicates of assay. 
 










































































Figure 3.14. Metabolism of 3H-estrone (E1) and 3H- androstenedione (A4) was not detected 
in control or decidualised cells. Metabolism of 3H-E1 and 3H-A4 was measured after 2, 4, 8, 
16 (not shown) and 24 hours. No metabolism of 3H-E1 or 3H-A4 was detected in 
undecidualised (A, C) or decidualised (B, D) cells after 24 hours. Cells were treated as 
described in Figure 1.9.  
 














































Figure 3.15. Summary of average percentage conversion of 3H-E2 to E1 (A) and 3H-T to A4 
(B) in control and decidualised cells. The proportion of each metabolite was expressed as a 
percentage of the total metabolite detected. The amount of converted steroid, either E1 or 
A4, gives an indication of the degree of metabolism of the original labelled steroid; 3H-E2 or 
3H-T. The proportion of converted steroid at each time point in control and decidualised cells 
is shown. At all time points metabolism appears reduced in decidualised cells and 












































































Figure 3.16. Rate of conversion of 3H-E2 to E1 (A) and 3H-T to A4 (B) in control and 
decidualised cells. The rate of conversion was calculated by expressing the proportion of 
converted steroid over time. The rate of conversion appears fastest at early time points and 
tends to be suppressed in decidualised cells. At two hours rate of conversion of E2 (n=4, ** 
p<0.01, Two-way ANOVA) and T (n=4, * p<0.05, Two-way ANOVA) is significantly lower in 
decidualised cells. At all time points metabolism appears reduced in decidualised cells. 





3.4.7. Decidualisation of hESC results in increased  aromatase activity. 
To assess whether the increased expression of aromatase protein and mRNA as a result of 
decidualisation might be associated with an increase in aromatase enzyme activity in hESC, 
a tritiated water assay was utilised.  
In undecidualised hESC, stimulation for 24 hours with cAMP and P4 (decidualisation 
stimulus) resulted in a significant increase in aromatase activity (Figure 3.17 A, p<0.001). 
Furthermore, in hESC which had been decidualised prior to the assay, stimulation with 
cAMP and P4 also resulted in a significant increase in aromatase activity (Figure 3.17 B, 
p<0.001). Basal aromatase activity was significantly higher in decidualised cells (Figure 3.17 
C, p<0.001) and the stimulatory effect of cAMP and progesterone was enhanced in cells 
which were pre-decidualised (Figure 3.17 D, p<0.001). 
 


































































































































Figure 3.17. Decidualisation induces aromatase activity in human endometrial stromal cells. 
Stimulation with cAMP and progesterone for 24 hours significantly increased aromatase 
activity in undecidualised (undec, A) and decidualised (dec, B) stromal cells. Basal 
aromatase activity was significantly higher in decidualised cells (C) and the stimulatory effect 
of cAMP and progesterone was greater in cells which were pre-decidualised 
(D).unstim=unstimulated, undec=undecidualised, dec=decidualised. *** p<0.001; n=3-5 
replicates. Statistical analysis was performed using an unpaired t-test and one-way ANOVA. 
 
3.4.8. Oestrogen secretion by hESC is increased by decidualisation. 
To investigate whether changes in expression of genes implicated in steroid biosynthesis 
resulted in secretion of oestrone (E1) or oestradiol (E2), concentrations in the cell culture 
supernatants were determined by ELISA. At all time points examined (days 1-8) the 





concentration of E1 was significantly higher (Figure 3.18 A; p<0.0001, n=4) in media 
recovered from ESC incubated with cAMP and P4 than in those remaining in control media 
or media with the addition of cAMP. A time-dependent increase in concentration of E2 was 
detected in media of cells treated with cAMP and P4 and it was significantly higher than that 
of control or cAMP treated cells at all time points up to and including day 8 (Figure 3.18 B; 
p<0.001, n=4). In media recovered from cells incubated with cAMP and P4, concentrations 
of E1 are significantly higher than those of E2 at 1 (p<0.0001, n=4), 2 (p<0.0001, n=4), and 
4 days (p<0.001, n=4) but there is no significant difference between the concentrations of E1 
and E2 at 8 days (Figure 3.19). To compare the response to treatment at different time points 
concentrations of IFGBP1 protein were measured in the same samples. In contrast to the 
results obtained in the steroid ELISAs a superficial increase in IGFBP protein product was 
detected in response to incubation with cAMP alone as well as cAMP and P4. Secretion of 
IGFBP1 was highest at 8 days when it was the same in cAMP treated samples as those with 
the addition of P4 (Figure 3.18 C; p<0.001, n=4). 















**** **** **** **** DMSO
cAMP
cAMP+P4














































Figure 3.18. Incubation of hESC cells with cAMP and P4 resulted in secretion of E1 and E2. 
Treatment with cAMP alone was sufficient to stimulate IGFBP secretion but treatment with 
both cAMP and progesterone (P4) was required for secretion of E1 and E2. Cells were 
treated for 1, 2, 4, or 8 days with vehicle (DMSO), cAMP alone or cAMP in combination with 
P4. Concentrations of E1 (A), E2 (B), or IGFBP protein (C) was determined by ELISA (n=4, 
** p<0.01; *** p<0.001, Two-way ANOVA).  
 

























Figure 3.19. Incubation of ESC with cAMP plus P4 was associated with biosynthesis of E1 
and a time-dependent increase in secretion of E2. E1 concentrations were significantly 
higher than those of E2 on days 1, 2, and 4. The concentrations of E1 and E2 approached 
equality after 8 days. Ratio of E1:E2 is shown in white boxes for each time point. Cells were 
treated for 1, 2, 4, or 8 days with cAMP in combination with P4. Concentrations of E1 and E2 
were determined by ELISA (n=4, Two-way ANOVA,  *** p<0.001; **** p<0.0001). 
3.4.9. The impact of aromatase inhibition on decidu alisation. 
The aromatase enzyme plays a crucial role in the conversion of androgens to oestrogens. The 
studies presented above have demonstrated that decidualised human ESC exhibit a capacity 
to synthesise and secrete both E1 and E2 consistent with de novo steroid biosynthesis and 
aromatase enzyme activity. To determine whether arom tase activity was essential for 
biosynthesis of E1 and E2 studies were undertaken usi g two concentrations of the 
aromatase inhibitor anastrozole (Arimidex®, AstraZeneca ZD1033). The aromatase inhibitor 
anastrozole was administered to non-decidualised an decidualised ESC. Addition of 
anastrozole did not have a significant impact  on secretion of IGFBP by ESC incubated with 
cAMP and P4 for 8 days with only a minor reduction when co-incubated with the higher 
concentration of anastrozole (10µM) (Figure 3.20).  
Incubation of hESC with 10µM anastrozole significantly reduced E1 biosynthesis in 
decidualised stromal cells (Figure 3.21; p<0.01, n=4); although E1 was not significantly 
reduced when cells were co-incubated with 1µM Anastrozole the mean concentration of E1 
was 30% lower than that of the vehicle control. Biosynthesis of E2 was significantly reduced 
when cells treated with cAMP and P4 were co-incubated with anastrozole. Notably addition 
of 1µM anastrozole reduced E2 production by approximately 10% (Figure 3.22, p<0.05, 





n=3) but the impact was more marked in the presence of 10µM anastrozole (Figure 3.22, 




























































Figure 3.20. Incubation of cells with the aromatase inhibitor anastrozole did not have a 
significant impact on secretion of IGFBP. The impact of anastrozole (AI) on IGFBP 
production was assessed by decidualising cells (DEC) for 8 days in the presence of vehicle, 
1µM AI or 10µM AI. Undecidualised cells were subject to the same treatment regimen to 
serve as a control. IGFBP was not detected in any of the control samples. Treatment with 
10µM AI resulted in a slight non significant decrease in IGFBP secretion in decidualised cells 
(p=0.1368, n=4, DEC Veh vs Dec 10µM AI, T test). Secretion of IGFBP protein was 
determined by ELISA. Percentage reduction of mean DEC control value shown in white.  
 



























































Figure 3.21. Inhibition of aromatase significantly reduced secretion of oestrone (E1) by 
decidualised stromal cells (DEC). The impact of the aromatase inhibitor anastrozole (AI) on 
E1 production was assessed by decidualising cells for 8 days in the presence of vehicle, 
1µM AI or 10µM AI. Undecidualised cells were subject to the same treatment regimen to 
serve as a control. E1 was not detected in any of the control samples. n=4, ** p<0.01, One-
way ANOVA. Percentage reduction of mean DEC control value shown in white. 
 
 


























































Figure 3.22. Inhibition of aromatase significantly reduced oestradiol (E2) secretion by 
decidualised stromal cells. The impact of the aromatase inhibitor anastrozole on E2 
production was assessed by decidualising cells for 8 days in the presence of vehicle, 1uM 
anastrozole (AI) and 10uM AI. Undecidualised cells were subject to the same treatment 
regimen to serve as a control. E2 was not detected in any of the control samples. n=3, * 
p<0.05, *** p<0.001, One-way ANOVA. Percentage reduction of mean DEC control value 
shown in white. 
3.4.10. Inhibition of steroid sulphatase has a sign ificant impact on 
decidualisation. 
Steroid sulphatase (STS) catalyzes conversion of oestrone sulphate (E1S) to E1. To 
investigate whether the activity of STS might contribute biosynthesis and secretion of E1 
ESC were incubated with the STS inhibitor STX64. During decidualisation expression of 
STS mRNA was increased after 8 days (see section 3.4.3). Unexpectedly, secretion of 
IGFBP by decidualised ESC was reduced in cells incubated with STX64 for 1 to 4 days; by 
day 8, IGFBP secretion had recovered to control levels possibly due to incomplete inhibition 
of STS activity (Figure 3.23; p<0.05, n=4). Following the same treatment paradigm the 
effect of STX64 on oestrogen biosynthesis was also investigated. STS inhibition did not 
have a significant impact on the production of E2 (not shown) however concentrations of E1 





in culture media were significantly reduced at 2 days (Figure 3.24; p<0.05, n=4) with a non-
significant trend on days 1 and 4. 
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Figure 3.23. Secretion of IGFBP by decidualised stromal cells was reduced by incubation of 
cells with the steroid sulfatase inhibitor STX64. Steroid sulfatase (STS) is the enzyme 
responsible for the conversion E1S to E1. IGFBP secretion was significantly decreased in 
decidualised stromal cells treated with STX64 at 1 and 4 days tended to be decreased at 2 
days. The impact of the STS inhibitor STX64 on IGFBP production over time was assessed 
by decidualising cells for 1, 2, 4, and 8 days +/- STX64. IGFBP secretion was determined by 
ELISA. n=3, * p<0.05, unpaired T-test. 





















Figure 3.24. Secretion of oestrone by decidualised stromal cells is reduced following 
inhibition of steroid sulfatase by STX64. STS is differentially expressed over time during 
decidualisation. Conversion of E1S to E1 may contribute to levels of secreted oestrogen as a 
result of decidualisation. E1 secretion was tended to be decreased in decidualised stromal 
cells treated with STX64 at early time points and was significantly decreased at 2 days. The 
impact of the STS inhibitor STX64 on E1 production over time was assessed by 
decidualising cells for 1, 2, 4, and 8 days +/- STX64. E1 secretion was determined by ELISA. 
n=3, * p<0.05, unpaired T-test. 
3.5. Discussion 
The current study sought to determine whether local biosynthesis of oestrogen occurs during 
decidualisation in women by investigating oestrogen biosynthesis and metabolism using an 
in vitro model of decidualisation. 
In the studies presented herein we report novel evidence that supports a role for local 
biosynthesis of oestrogen during decidualisation (see Figure 3.25). We have shown that in 
vitro decidualisation of primary endometrial stromal cells is associated with time-dependent 
changes in expression of genes encoding proteins important in steroid biosynthesis including 
transient up-regulation of StAR and CYP11A1 as well as increased expression of aromatase 
mRNA and protein. We detected a change in enzyme activity in decidualised cells which 
appeared to result in reduced 17βHSD2 activity and an increase in aromatase activity. 
Secretion of both E1 and E2 by primary ESC was confirmed using ELISA, with increasing 
production of E2 associated with progressive decidual sation of cells. Secretion of E1 and E2 
was partially ameliorated by inhibitors of aromatase and STS. There was also evidence to 





suggest that treatment of cells with STX64 (an STS inhibitor) resulted in reduced 
biosynthesis of E1 as well as secretion of the decidual sation marker protein IGFBP1. 
3.5.1. Evidence for biosynthesis of oestrogens 
Principal to the biosynthesis of oestrogen is the enzyme complex aromatase. Aromatase 
(encoded by CYP19A1 gene) acts by aromatising androgen precursors to oestrogens and is 
required for biosynthesis of oestrogen. Bulun et al reported that aromatase mRNA expression 
could not be detected in endometrium from normal women (311) however expression is 
reported to be increased in endometriosis (lesions and eutopic endometrium) and endometrial 
cancer (312, 376, 475).  
In the current study, decidualisation of ESC for 8 days resulted in doubling in expression of 
CYP19A1 mRNA while CYP19A1 mRNA was barely detectable in undecidualised ESC 
consistent with previous reports (311). Generally, CYP19A1 transcripts were detected at a 
very low copy number (Ct>35) however there was a consistent, significant difference in 
expression after 8 days decidualisation treatment compared to control. Interestingly, high 
levels of 17βHSD1 protein expression have been reported in the endometrium despite low 
reported levels of mRNA expression (312). Consistent with this, protein expression analysis 
revealed that aromatase protein was detected in decidualised hESC that was absent in 
undecidualised hESC. Furthermore, utilisation of a tritiated water assay revealed that 
decidualisation was associated with an increase in aromatase enzyme activity. In addition to 
increased aromatase mRNA and protein expression as well as the increased aromatase 
activity described in our study, we consequently detect d high levels of secreted oestrogens 
in matched supernatants from ESC. Furthermore, secretion of oestrogens could be 
significantly diminished following treatment with the selective aromatase inhibitor 
anastrozole (see later). Taken together these results ggest the presence of functional 
aromatase in decidualised ESC.  
In stromal cells from women with endometriosis (eutopic endometrial stromal cells from 
women with endometriosis) and stromal cells derived from ovarian endometriomas, 
CYP19A1 expression can be induced by prostaglandin E2 (PGE2) (378) and cAMP (313, 
378) both of which have been implicated in enhancing the process of decidualisation (123). 
In humans, aromatase expression is regulated by tissue specific promoters (327) and 
aromatase expression stimulated by cAMP and PGE2 in endometriosis appears to be via 
promoter II (378). Further analysis of the factors which promote aromatase expression in 





decidualising ESC may help to elucidate the transcriptional mechanisms governing 
expression of CYP19A1 in decidualised ESC.  
The interconversion of E1 and E2 is mediated via 17β hydroxysteroid dehydrogenases 
(17βHSD), an important class of enzymes that control interconversion of androgens and 
oestrogens (Figure 3.1) [13]. 17βHSD2 catalyses the oxidation of E2 to E1 and T to A4 
(323).  Expression of 17βHSD2 mRNA and protein has previously been described n human 
endometrium with expression being highest in the secretory phase (314) associated with 
positive immunoexpression in glandular epithelium and some stromal cells (312).  Sp-1 and 
Sp-3 have been shown to interact with specific motifs in the HSD17B2 gene promoter 
resulting in up-regulation in expression of HSD17B2 gene in endometrial epithelial cell lines 
(331). In endometrial explants progesterone induces 17βHSD2 expression (312). In the 
current investigation we report that incubation of ESC with cAMP and P4 had a striking and 
highly significant impact on expression of 17βHSD2 gene expression, while treatment of 
cells with cAMP alone also induced a significant increase in mRNA concentrations 
suggesting changes in expression as a result of PKA-dependent signaling (313). Thus 
decidualising stimuli are sufficient to increase mRNA expression of 17βHSD2 which would 
suggest metabolism may be directed toward the formation of E1 and A4 in response to 
decidualisation.  
Interestingly, expression of 17βHSD isotypes which catalyze the formation of E2 andT i.e. 
the opposite reaction to 17βHSD2, were unchanged following decidualisation of ESC. 
Expression of 17βHSD1 mRNA is low in normal endometrium although prominent protein 
expression in both stromal and epithelial cells has been described by immunohistochemistry 
(312). Levels of 17βHSD1 mRNA do not appear to vary over the menstrual cyc e (312) but 
cAMP treatment is reported to increase concentrations f 17βHSD1 mRNA expression in 
eutopic endometrial stromal cells from women with endometriosis (313). The proximal 
promoter of the human 17βHSD1 gene contains AP-1, Sp-1 and Sp-3 sites (330) and 
transcription could therefore be affected by steroid receptor activation. In the current study 
expression of 17βHSD1 mRNA was identical in non-decidualised and decidualised stromal 
cells consistent with observations across the menstrual cycle. Thus stimulation with cAMP 
or the presence of steroids in culture media did not have an impact on 17βHSD1 mRNA 
expression.  
A4 is reduced to T by 17βHSD3 in the testes and 17βHSD5 in peripheral tissues (332). 
17βHSD5 is expressed in the endometrium throughout the menstrual cycle with highest 





mRNA detection in the early secretory phase. Dysregulation of 17βHSD5 has been reported 
to occur in endometrial cancers with increased expression in malignant tissue compared to 
normal endometrium (360). In the current study, consistent with the expression of 17βHSD1, 
17βHSD5 mRNA expression was identical in non-decidualised and decidualised stromal 
cells.  
An additional source of oestrogens could be from the action of steroid sulphatase (STS). STS 
hydrolyses sulphated steroids, which are abundant in the circulation but are inactive at 
steroid receptors, into biologically active steroids (335). STS primarily converts oestrone 
sulphate (E1S) to oestrone (E1) which may be a potential source of oestrogen production in 
the endometrium. STS immunoexpression has been detected in both stromal and epithelial 
cells in the endometrium across the menstrual cycle and is reduced in stromal compared to 
epithelial cells in the late secretory phase (312).  In normal endometrium mRNA expression 
of STS is higher than sulfotransferase, the enzyme which catalyzes sulphation of steroids, the 
opposite reaction to STS (336). In the present study, STS mRNA expression was 
significantly and highly increased by either cAMP alone or in combination with P4 at 8 days. 
Expression of sulfotransferase mRNA could not be det ct d (data not shown). In addition to 
oestrogen forming activities, STS also has the capacity to hydrolyse dihydroepiandrosterone 
sulphate (DHEAS) to dihydroepiandrosterone (DHEA) which in turn could also be a 
potential route to oestrogen and androgen formation during decidualisation (337) (see Figure 
3.10). The metabolism of androgens could also impact on biosynthesis of oestrogens, since 
androgens are the substrate for aromatase. SRD5A1, also known as 5α reductase, is an 
enzyme responsible for 5α reduction of steroids. 5α reductase has been shown to reduce 
testosterone to the more potent androgen dihydrotestost rone (DHT) in human endometrium 
(333). Reports of protein expression in the endometrium have been conflicting, with 
expression reported by some to be limited to epithelial cells (318) while others have 
demonstrated immunostaining in both stromal and epith lial cells in normal endometrium 
(319). Increased SRD5A1 mRNA expression is associated with ovarian endometriosis (316). 
In the studies reported in this chapter, SRD5A1 mRNA expression was increased in 
endometrial stromal cells treated with cAMP and to a greater extent following treatment with 
both cAMP and progesterone after 8 days of treatment. While enzyme activity was not 
measured using TLC, increased expression may affect th  availability of bioactive androgens 
and consequently oestrogens. 
To assess whether cells could support de novo steroid biosynthesis, the expression of 
steroidogenic acute regulatory protein (StAR) and cholesterol side-chain cleavage enzyme 





(CYP11A1) were both measured and were found to be regulated in a time dependent manner 
in decidualised ESC. StAR mRNA expression was increased at early time points suggesting 
an acute response to decidualisation stimulus which would facilitate the delivery of 
cholesterol to the inner mitochondrial membrane for c nversion by the constitutively active 
CYP11A1 (321). StAR is reported to be expressed in stromal but not epithelial cells in the 
endometrium and its expression can be increased by prostaglandin E2 (PGE2). Increased 
expression in endometriotic stromal cells has also been reported (309) and cAMP treatment 
is reported to increase StAR mRNA expression in endometrial stromal cells (313). In the 
current study significant increases in StAR and CYP11A1 mRNA expression were observed 
only with combined treatment of progesterone and cAMP, however, the trend was 
reproduced in cells treated with cAMP alone to a lesser extent suggesting progesterone may 
enhance previously reported cAMP responses. 
 
 
Figure 3.25. Summary of changes in steroid biosynthesis in decidualised ESC. Increased 
concentrations of mRNAs encoding STS, 17βHSD2, CYP19A1 and SRD5A1 (5α reductase) 
were detected in decidualised ESC (yellow boxes) which may result in an increase in the 
formation of oestrogens, in particular oestrone. 
In the current experiment changes observed in mRNAs encoding proteins involved in steroid 
biosynthesis in response to a decidualising stimulus appeared to favour formation of 
oestrogens as mRNAs encoding both aromatase and STS were up regulated (Figure 3.8 and 
3.9). In addition, decidualisation resulted in increase in aromatase activity and aromatase 
protein was detected in decidualised hESC (Figure 3.10 and 3.17). Furthermore, 
interconversion of androgens and oestrogens appeared likely to favour oxidative activity as 
there was a striking increase in expression of 17βHSD2 but no change in expression of 





17βHSD1 or 17βHSD5. This was confirmed using TLC wherein conversion of E2 to E1 and 
T to A4 was demonstrated but not the reverse reactions. These results are consistent with a 
study by Collins et al which showed that in normal endometrium metabolism favours 
formation of E1 and A4 over E2 and T respectively (338). The same study showed that 
DHEA could be metabolized to androstenedione, 5α-androstanedione and androsterone in 
human endometrium albeit in small quantities (338). The capacity for endometrial 
conversion of DHEA adds weight to the potential for hydrolysis of DHEAS by STS action to 
contribute to the formation of androgens and oestrogens. The dynamics of oestrogen and 
androgen uptake by human endometrium also appears to favour oxidative 17βHSD activity. 
For example, a study by Gurpide et al. revealed a high level of oestrogen and androgen 
uptake in perfused endometrium with net uptake of E2 and T being higher than that of E1 
and A4. Following steroid uptake by endometrial tissue E1 and A4 was released 
unmetabolised from the tissue whereas a high proporti n of E2 and T was released 
metabolized to E1 and A4 respectively, consistent with oxidative 17βHSD activity (340).  
In the data presented, despite the striking increase in 17βHSD2 mRNA detected in the 
decidualised cells, 17βHSD2 enzyme activity appeared decreased compared to 
undecidualised ESC when measured by TLC. Conversion of E2 by decidualised ESC was 
significantly decreased after 8 hours as compared to that observed in parallel experiments 
using non decidualised cells. The rate of conversion was significantly lower for both E2 and 
testosterone in decidualised cells after 2 hours. This apparent contradiction to the mRNA 
expression changes observed may be due to changes i the metabolic demands of the 
decidualising tissue that may favour other reactions which could not be detected by TLC, 
such as aromatase activity, or may simply indicate that mRNA changes do not accurately 
reflect activity of the enzyme. It is also conceivable that this effect may be an artifact of the 
assay resulting from increased unlabelled substrate h t is produced from decidualised cells 
making the metabolism appear slowed as proportionally less labeled substrate is converted. 
Differentiation of stromal cells could also result in changes in availability of cofactors such 
as NAD and NADP which would also have an impact on reaction rates and which 
metabolism reactions are favoured. 
Consistent with changes in concentrations of mRNA encoding steroidogenic enzymes and 
altered metabolism as detected by TLC, E1 and E2 were readily detected in media recovered 
from decidualised ESC. Oestrogens were not detected in undecidualised ESC nor were they 
detected in cells treated with cAMP alone. Consistent with this, aromatase protein was only 
detected in decidualised ESC. Interestingly while concentrations of E2 increased in a time-





dependent manner the total concentration of E1 was the same at all time points which may 
be indicative of higher 17βHSD2 activity and contribution from STS. While the evidence 
presented above would be consistent with de novo biosynthesis of E1 and E2, it is 
conceivable that the amounts of E1 and E2 detected in the culture media may also reflect 
metabolism of progesterone as E1 and E2 were only detected in media recovered from cells 
in which progesterone was part of the treatment. Previous studies have reported no evidence 
for 17α-hydoxylase activity in progesterone metabolism in the endometrium, and that 
metabolism of progesterone is predominantly via 5α reduction (334) which would not be 
consistent with metabolism directed to oestrogen formation. This may however explain the 
increased mRNA levels of SRD5A1 observed in this study. If the oestrogens detected where 
solely metabolites of progesterone then the amounts detected would likely be proportional to 
the amount of progesterone added and thus total oestrog n amount would be roughly 
equivalent at each time point. This was not the cas. Furthermore there is anecdotal evidence 
to suggest oestrogens may be detected from cells tran ferred to control media after treatment 
(i.e. without progesterone) as E2 was detected up to two days following decidualisation in 
treated cells transferred to control media (n=1, data not shown). To clarify the contribution, 
if any, of progesterone metabolism to the amount of oestrogen produced the levels of 
progesterone should be assayed throughout the time course as well as metabolism 
investigated by TLC. 
3.5.2. The impact of inhibitors 
Treatment with the aromatase inhibitor anastrozole significantly reduced both the amount of 
E2 (27% reduction) and E1 (51% reduction) detectable in culture media. Aromatase 
inhibitors have been used in the treatment of endometriosis and in the first reported use of 
this therapy by Takayama, anastrozole reduced circulating E2 levels by 50% (462) while the 
aromatase inhibitor letrozole is reported to completely inhibit uterine oestrogen production in 
ovariectomised mice (128). Furthermore, in a recent study by Das et al (476), the 
concentration of letrozole utilized to inhibit aromatase activity in mouse uterine stromal cells 
was between 20 and 50 µM, concentrations which were much greater then those used in the 
present study. It is conceivable that letrozole may be a more effective aromatase inhibitor 
than anastrozole and its use in this model, perhaps at higher concentrations than those used 
in this study, may deliver more complete inhibition f oestrogen production, consistent with 
responses observed in the mouse.  





STS activity can be inhibited by the non-steroidal inhibitor STX64 (667 COUMATE) (381, 
464). In the current study, STX64 had no effect on E2 production suggesting that STS action 
does directly impact E2 formation. There is little evidence from either mRNA expression or 
TLC to suggest that there is conversion of E1 to E2 in endometrial stromal cells, which may 
explain why STS inhibition had no effect on E2 production as any hydrolysed E1S would not 
be further converted from E1 to E2. STX64 tended to reduce E1 formation but only after 1 
and 2 days treatment. Thus, STS may contribute to the high levels of E1 observed but only at 
early time points. Paradoxically, STS mRNA was signif cantly and highly up regulated at 8 
days but inhibition of STS had no effect on either E1 or E2 production at this time point. 
This may suggest a role for STS in ongoing function of the decidua or may simply indicate 
that inhibition was insufficient when expression is so highly increased. We detected high 
levels of E1 at all time points but found that the ratio of E1 to E2 was roughly equivalent by 
8 days. As E2 levels increase the levels of E1 remain at a similar level which does not 
suggest that E2 synthesis is from 17βHSD reduction of E1 or are at least not to the detrim nt 
of E1 levels. This would be consistent with the lack of 17βHSD1 enzyme activity determined 
by TLC reported herein.  
3.5.3. The role of the local steroid environment 
The current studies have demonstrated that human endometrial stromal cells express sex 
steroid receptors and their expression is altered in response to decidualisation. These 
observed changes in steroid receptor expression are consistent with those reported in the 
literature in secretory phase endometrial stromal ce ls (291, 477, 478) indicating 
recapitulation of the in vivo response in the endometrium. Changes in steroid receptor 
expression may be mediated by steroid receptor cross-talk, for example, PR controls the 
down-regulation of epithelial ERα via COUPTFII which is essential for successful 
implantation and decidualisation in mice (280, 479). In addition, increased expression of 
ERβ in the stromal compartment is likely to be important s changes in the ERα: ERβ ratio 
can impact transcriptional responses to oestrogen by the formation of heterodimers (480). 
We reported that as a result of local steroid biosynthesis, high concentrations of secreted 
oestrogens were detected in supernatants from decidualised stromal cells which exceed peak 
circulating levels (300pg/ml in proliferative phase (481)) and are likely to mediate 
significant effects in the local environment during decidualisation. It is also conceivable that 
there may be significant quantities of androgens, as precursors to oestrogen formation, 
present in the stromal environment as a result of increased local steroid biosynthesis. This 





may be particularly relevant as androgen receptor has been shown to regulate distinct 
processes such as cytoskeletal organization and cell cycle regulation in the decidualising 
endometrium (295) and a recent i  silico analysis revealed a novel androgen regulated gene 
network in human endometrium associated with regulation of apoptosis (200). 
A significant degree of steroid receptor regulation s likely to mediate decidualisation of 
endometrial stromal cells via altered receptor exprssion and in addition to control by 
ovarian hormones may be influenced by locally produce  sex steroids.  
In the present study a definitive impact of inhibition of steroid biosynthesis on 
decidualisation could not be observed. Inhibition of aromatase and STS appears to reduce 
IGFBP secretion in decidualising cells however this was not sufficient to completely 
ameliorate secretion or reverse decidual phenotype. However, IGFBP was significantly 
decreased by STX64 at 1 and 4 days and tended to bedecr ased at 2 days. This trend in 
decreased IGFBP secretion at early time points following STS inhibition is associated with 
modest decreases in E1 at similar time points. To our knowledge this is the first evidence of 
inhibition of decidualisation markers by steroid enzyme inhibitors in human endometrial 
stromal cells and may indicate an importance for E1 during decidualisation.  
In a mouse model the aromatase inhibitor letrozole was shown to block the stromal 
differentiation process (128) highlighting that aromatase is essential in decidualisation in 
mice. In our study inhibition of aromatase or STS did not completely block steroid synthesis 
however a more complete depletion of E1 and E2 synthesis may yield a more significant 
decrease in IGFBP. Inhibition of both aromatase and STS at all time points may have a more 
pronounced impact on decidualisation and may help to elaborate the specific roles of E1 and 
E2 during decidualisation of human endometrial stromal cells.  
Despite inhibition of aromatase and STS not having a large impact on decidualisation, the 
presence of such high levels of oestrogens during decidualisation suggests a high capacity 
for modifying the uterine environment. Oestrogen is known to be essential in implantation 
and decidualisation in mice and is the critical determinant of the window of uterine 
receptivity. In addition, down regulation of ERα is essential for successful implantation (126, 
174). Several other factors which may be important in mediating decidualisation have been 
identified as a result of studies in mice. Targeted knockout of LIF (175), HOXA10 (482), 
COX2 (483) and IL-11R (118) all result in decidualis tion defects. Interestingly many of 
these factors are under transcriptional control by oestrogen. However, expression of these 
factors was found to be normal in ERαKO mice (126) suggesting oestrogen acting via ERα 





does not regulate these factors during decidualisation in mice. Despite this, it is conceivable 
that increased local oestrogen may influence expression of these factors during 
decidualisation in human. 
While implantation triggers decidualisation in mice, in humans decidualisation occurs in the 
absence of conceptus and thus implantation. However in f tile cycles the uterine preparation 
for pregnancy requires synchronous control of receptivity, implantation and decidualisation. 
Impaired decidualisation leads to disruption of embryo-maternal interactions in sporadic and 
recurrent pregnancy loss highlighting the necessity for coordinated control of implantation 
and decidualisation in the human (484). However the mechanisms which control these 
processes are poorly understood in humans. In this study we have shown that local 
biosynthesis of oestrogen is a feature of in vitro decidualisation of ESC and that partial 
inhibition of oestrogen biosynthesis may inhibit deci ualisation. It is unknown whether local 
oestrogen biosynthesis may affect implantation or whether it is essential to decidualisation in 
humans. However locally produced oestrogen is likely to influence the implantation site and 
process of decidualisation which may involve modulation of angiogenesis and leukocyte 
recruitment (Discussed in chapter 5). 
3.5.4. Summary 
In the current study decidualisation of ESC resulted in altered expression of steroid 
metabolizing enzymes, expression of aromatase mRNA and protein as well as transient up-
regulation of StAR and CYP11A1, enzymes responsible for de novo biosynthesis of steroids. 
Changes in expression in steroidogenic enzymes were accompanied by high levels of E1 and 
E2 detected in cell culture supernatants from decidual sed cells consistent with oestrogen 
biosynthesis. There was an accompanying change in enzyme activity in decidualised cells 
which resulted in increased aromatase activity and ppeared to result in reduced 17βHSD2 
activity, which was in contrast to the observed mRNA changes. Oestrogen production could 
be partially ameliorated by inhibitors of aromatase nd STS. Inhibition of E1 formation via 
STS reduced the expression of the decidualisation marker IGFBP1 suggesting an importance 
for local oestrogen in decidualisation. The production of E1 exceeded that of E2. Consistent 
with this aromatase inhibition had a greater impact on E1 production suggesting aromatase 
mediated conversion from androstenedione to E1 is the more prominent reaction in 
decidualised ESC.  
Aromatase expression and oestrogen biosynthesis has previously been associated with 
disease states of the endometrium such as endometrisis and endometrial cancer. However, 





herein is described expression of aromatase and oestrog n biosynthesis as a result of 
decidualisation of ESC, a model of normal endometrial function. Interestingly, while we 
report no change in 17βHSD1 expression and increased expression of 17βHSD2 as a result 
of decidualisation, in endometriosis the expression pattern is reversed i.e. there is increased 
17βHSD1 and decreased 17βHSD2 expression. Thus if decidualised ESC share the capacity 
for oestrogen biosynthesis with endometriotic cells, their distinction appears to be in the 
expression of 17βHSD isotypes and thus capacity to form different oestrogens. 
The results described herein provide a novel description of the regulation of oestrogen 
biosynthesis and metabolism during in vitro decidualisation of endometrial stromal cells. 
While further elaboration of the impact of inhibitors is required to elucidate the full impact 
of locally produced oestrogens during decidualisation, this novel and important description 
of the steroid microenvironment generated by decidual sation can provide a framework from 
which comparative dysregulation in disease paradigms can be measured. This work 
highlights, for the first time, the concept of the endometrium as a steroidogenic tissue in a 
non-diseased state. 





Chapter 4  
4. The impact of oestrogen receptor-dependent signa lling on 
gene expression in uNK cells.  
4.1. Introduction 
Human endometrium contains several leukocyte populations, the composition of which 
changes during the menstrual cycle, and in pregnancy. Approximately 30% of cells in the 
stromal compartment in late secretory phase non-pregnant endometrium are natural killer 
cells (25) (uNKs) that are phenotypically and functionally distinct from the main population 
of peripheral blood NK cells (pbNKs) (24, 27). The number of uNK cells rises to account for 
75% of all leukocytes in first trimester decidua (75) . 
4.1.1. Natural killer immune cell populations 
Natural Killer (NK) cells are lymphocytes that are part of the innate immune system and 
comprise 15% of all circulating lymphocytes (21). NK cells are effectors of antibody 
dependent cellular cytotoxicity via CD16 and they do not express CD3. The peripheral blood 
(pb) contains two main subsets of NK cell, usually c assified according to their expression of 
the surface markers CD56 (also known as NCAM) and CD16, as CD56bright CD16- or 
CD56dim CD16+ also classified as agranular and granular respectively. The CD56dim 
population constitute around 90% of pbNK cells while CD56bright cells are in the minority 
representing ~10% of total pbNK and <1% of all lymphocytes (24).  
A phenotypically distinct population of NK cells has been identified as resident in human 
endometrium (25). These so called uterine NK (uNK) cells are found in the endometrium but 
not the myometrium and appear similar to the minority CD56bright pbNK population as they 
are CD56bright/CD16- (26). However unlike CD56bright pbNK, the uNK cells are granular and 
like the majority pbNK population contain Granzyme B and perforin (26). In agreement with 
differences in phenotype between uNK and pbNK (Figure 4.1) transcriptional analysis (27) 
has identified differences between the cell populations. Notably, compared to pbNK, uNK 
exhibit decreased cytolytic activity and increased cretion of cytokines and growth factors 
such as interferon gamma (IFNγ), tissue necrosis factor alpha (TNFα), transforming growth 
factor beta 1 (TGF-β1), interleukin 8 (IL-8), CXCL10 and CCL5 (39-41) and they are 
reported to secrete angiogenic cytokines such as vascular endothelial growth factor (VEGF), 
placental growth factor (PLGF) and angiopoeitin 2 (39, 43, 44). 
























Figure 4.1. Venn diagram summarising the characteristics of NK subsets. Notably, uNK are 
phenotypically distinct from either population of pbNK although they appear to share some 
features of both types (27, 39, 75).  
 
4.1.2. Origin and function of uNK 
uNK cells are abundant in the uterus. While CD56bright cells in the peripheral blood are a 
minority population, uNK cells are abundant in the endometrium and are the major leukocyte 
population in early pregnancy, constituting 70% of all leukocytes in first trimester decidua 
(30). However uNK cell numbers appear to regress as pregnancy progresses suggesting their 
role may be most significant during early pregnancy. It has been reported that uNK cells play 
an important role in having functional significance in many processes during early 
pregnancy including immune tolerance at the feto-matern l interface, regulation of 
trophoblast invasion, spiral artery remodelling and angiogenesis (reviewed in (41)). The 
interaction between uNK cells and invading trophoblast cells is reported to influence 
placentation and the establishment of pregnancy in humans (485, 486). Maternal-immune 
interactions are essential to optimal reproductive success and thus defects in this interaction 
are associated with disorders of pregnancy (41). The origin of the uNK cell population 
remains unresolved. Two main theories abide; trafficking from peripheral blood or in situ 





proliferation/differentiation of resident uNK cells/precursors. Evidence supporting both 
theories exists.  
Precursor uNK cells may be trafficked from the periheral blood and proliferate and 
differentiate in situ. In support of the idea that uNK result from homing of pbNK to 
endometrial tissue, there is a high degree of uNK homology with pbNK subsets and there is 
increased vascular permeability coincident with theincrease in the uNK cell population. 
uNK cells also accumulate around spiral arterioles and are abundant in perivascular sites 
following decidualisation (25). There are increased numbers of circulating CD56bright NK 
cells in women of reproductive age compared to males suggesting this subtype may be 
recruited to the uterus as precursor to uNK cells (26). 
In addition, lineage committed CD34+ progenitor cells have been identified in decidua and 
can undergo differentiation into functional CD56+CD16- NK cells in the presence of growth 
factors or co-culture with stromal cells (31). Decidual CD34+ progenitor cells express CD45 
but notably, not CD56; however expression of CD56 is induced with differentiation by 
factors including IL-15 (31, 32) consistent with differentiation within the decidual uterine 
environment. 
uNK cells are present in small numbers in proliferative and early secretory endometrium but 
are increased in late secretory endometrium and decidua. Stromal conditioned media from 
secretory phase endometrium and decidua increases proliferation of uNK cells. Strikingly, 
40% of CD56-positive uNK cells from late secretory endometrium are Ki67 positive (33) 
consistent with proliferation of resident uNK cells in response to factors in the uterine 
environment. Notably, human chorionic gonadotrophin ( CG) has been shown to increase 
the proliferation of uNK cells which may partially explain increases in the number of uNK 
cells at the time of implantation (34).  
4.1.3. Regulation of uNK cells 
The regulation of uNK cells by sex steroid hormones is poorly understood. Premenarche and 
postmenopause uNK cell numbers are sparse suggesting steroid regulation. Leukocytes 
constitute 5% of uterine cells in the proliferative phase but increase to 25% of total cells in 
the late secretory phase (25, 487). The number of uNK cells changes under the influence of 
ovarian hormones with low numbers during the proliferative phase of the menstrual cycle but 
a pronounced increase during the secretory phase following the post-ovulatory rise in 
progesterone and coincident with decidualisation of the uterine stroma. uNK cells do not 
express progesterone receptor (PR) or oestrogen recptor (ER) α, but do express ERβ and 





glucocorticoid receptor (GR) (249). Thus any influenc  of progesterone would be indirect 
and the influence of oestrogen could only be via ERβ-dependent receptor signalling. The 
uterine environment is thought to play an important role in regulating the function of uNK 
cells. Interleukin-15 (IL-15) is a cytokine which can regulate both proliferation and 
activation of NK cells (423). Okada et al reported that IL-15 protein is secreted by 
endometrial stromal cells in vitro following treatment with progesterone. Verma et al 
demonstrated that IL-15 induces proliferation of islated uNK cells (423) while in an i vitro 
migration assay IL-15 enhanced recruitment of CD16- pbNK cells (425).  IL-15 can also 
increase CD56 expression in CD16- pbNK and induce a chemokine receptor repertoire 
similar to that of uNK (37). Chen et al reported that culture of uNK cells with conditioned 
media from endometrial stromal cells isolated from different stages of the menstrual cycle 
and first trimester decidua influenced uNK cell function (38). The authors reported that 
stromal cell conditioned media from secretory phase and first trimester decidua significantly 
induced proliferation of uNK cells (38). Conditioned stromal cell media also increased 
interferon-γ (IFNγ) secretion by uNK cells irrespective of menstrual cycle phase. In addition 
NK cytotoxicity was reduced by stromal conditioned but this effect was not specific to 
endometrial phase (38).  
These findings indicate that the uterine environment may play a critical role in determining 
the functional characteristics that distinguish uNK cells form peripheral blood counterparts. 
There is accumulating evidence for an indirect roleof progesterone on uNK but the role of 
oestrogen is less clear.  
4.1.4. Evidence that oestrogen may influence functi on of uNK cells 
Deloia et al. reported that treatment of peri-menopausal women with oral oestrogen 
increased total uterine leukocytes detected by immunohistochemistry in endometrial 
biopsies. The authors reported a significant increase in uNK cells and macrophages detected 
in the endometrium while T cell numbers were unaffected by oestrogen treatment (74). 
Following ovarian stimulation during in vitro fertilization (IVF) treatment, 
supraphysiological levels or sex steroids, including oestrogen, are detected in the circulation. 
Lukassen et al reported that as a result of this treatment, higher leukocyte levels were 
detected in the endometrium of treated women and a shift towards increased CD56bright to 
CD56dim NK cells was observed in the endometrium while T cell numbers were unaffected 
(488). This effect was specific to the uterus as the authors reported no change in peripheral 
blood NK populations (488). In ovariectomised women o strogen and progesterone are both 





required for the presence of uNK cells in the endoemetrium, consistent with absence 
premenarche and postmenopause (489). Mouse NK cellsare recruited to the pre-
implantation uterus via oestrogen and progesterone signaling, an effect which is reversed by 
antagonism of oestrogen and progesterone receptor (490). Oestradiol increases NK cell 
number and decreases cytoxicity in mouse pbNK cells(491).   
Oestrogen induces protein inhibitor 9, a granzyme B inhibitor in YT cells, a human NK cell 
line (492, 493), which may be a mechanism by which uNK cells retain granularity but lack 
cytotoxic activity in the endometrium. The CD16 promoter contains several ERE sites and 
several Sp1 consensus sequences (494) and control of expression and in turn cytoxicity could 
be in part controlled by oestrogen via CD16. Kitaya et al. demonstrated that neither 
progesterone nor oestradiol affected proliferation or cytotoxicity of uNKs isolated from 
decidua, or secretory and proliferative endometrium (495). In the same study, in vitro 
treatment of uNK cells isolated from secretory phase endometrium and first trimester 
decidua with IL-15, oestradiol or progesterone did not affect secretion of IFNγ or tissue 
necrosis factor α (TNFα) detected by ELISA (495).  
An indirect role of for oestrogen may also be important in uNK function. uNK cells express 
high levels of CXCR3 and CXCR4 (389). Oestrogen induces CXCL10 and CXCL11 
expression in the endometrium, cytokines which interact with CXCR3 and may activate NK 
cell migration (458). CXCL10 protein is increased in secretory phase endometrial explants 
the time at which uNK numbers are increased (458). Oestradiol induces SDF-1 production in 
endometrial stromal cells (386) which may further mediate migration of uNK via CXCR4 
expression. 
4.1.5. Summary 
The function of uNK cells is affected by both the endometrial environment and the 
circulating levels of sex steroids which are important in mediating proliferation and/or 
differentiation of uNK precursors in the endometrium. Oestrogen seems to be involved in 
trafficking of NK cells to the uterus and conferring uNK phenotype however the direct 
functional impact of oestrogen on uNK cells is unresolved. 
The studies presented in Chapter 3 documenting biosynthesis of oestrogens by endometrial 
stromal cells as well as previous studies from our laboratory documenting expression of ERβ 
in this cell type (249) formed the backdrop to studies described in this chapter exploring the 
impact of oestrogens on gene expression/function of human uNK cells. 






1. To isolate and culture pure and viable populations f uNK cells and confirm ER 
expression. 
2. To investigate changes in gene expression in isolated uNK cells following in vitro 
treatment with oestradiol. 
4.3. Methods  
4.3.1. Tissue 
Decidual samples were obtained from women requesting urgical termination of pregnancy 
(STOP) between 8-12 weeks gestation. All women had an ultrasound scan to confirm 
viability of pregnancy and gestational age. All material from suction curettage was collected 
and decidual tissue was identified and separated from specimens using sterile forceps and 
washed in sterile saline prior to tissue processing. Local ethical committee approval was 
granted and written informed patient consent was obtained prior to tissue collection by a 
dedicated research nurse. (Ethical approval held by Professor H.O.D. Critchley; 
LREC/05/51104/12 and LREC/10/51402/59.) 
4.3.2. Isolation of lymphocytes 
Decidual cell preparations were prepared by an adapte  standard protocol (26, 27). Briefly, 
total decidual tissue (n=22, see section 2.30) was minced into 1mm3 fragments using surgical 
blades and residual blood clots were removed. The tissue was digested overnight at room 
temperature under agitation in 20 ml of RPMI media (RPMI (phenol free), NEAA 5mls, 
20% CSFCS, 5mls Pen/Strep, HEPES (50ul) and Na Pyruvate 0.01mM with 1ml of 
collagenase type IV (2 mg/ml; Sigma) and 125 µl of DNAse (0.1 mg/ml; Sigma). After 
digestion a further 30mls of media were added and the mixture left for 5 minutes to allow for 
sedimentation. The supernatant was sequentially passed through 70 µm and 40 µm cell 
strainers.  The filtrate was then plated on a large Petri dish for 1 hour to allow for separation 
of adherent cells. 
The cell suspension was collected in a 50 ml falcon tube and centrifuged at 870 x g for 5 
min. The resulting cell pellet was resuspended in 15 ml PBS supplemented with 2% FCS and 
0.1% NaN3. The cell suspension was carefully overlaid on to 15 ml of Histopaque 1077 
(Sigma, Cat. No. 10771) ensuring the two layers did not mix and then centrifuged at 1094 x 
g for 20 minutes with no brake at the slowest acceleration speed. Cells at the interface 
(lymphocytes) were collected and washed in 20 ml PBS and centrifuged at 870 x g for 5 min. 
The resulting pellet was then resuspended in 10 ml PBS for cell counting.  





4.3.3. Purification of uterine natural killer cells  
Uterine natural killer (uNK) cells were isolated with CD3 negative selection and CD56 
positive selection using the appropriate antibody-coated magnetic microbeads and the 
MACS system (Miltenyi Biotech, Germany) in a protocol adapted from Vassiliadou and 
Bulmer (496). 
Cells were depleted by negative selection using magnetic separation to remove CD3+ cells 
and thus deplete any T or NKT cells (a subset of T cells which are CD3+CD56+) in the cell 
suspension. The lymphocytes were counted and the suspension centrifuged for 5 minutes at 
870 x g. The cell pellet was then resuspended in MACS buffer plus 20 µL of CD3 coated 
microbeads (Miltenyi, 130-050-101) per 107 cells and the mixture was incubated on ice for 
20 minutes. An LD column (Miltenyi, 130-042-901), for cell depletion, was placed in the 
magnetic field of MACS separator. The column and pre-separation filter were primed by 
passing 2 x 1ml of MACS buffer. The cell suspension was then added to the column 
followed by 2x 1ml washes of MACS buffer. The total effluent which contained the 
unlabelled cells (CD3-) was collected and used for CD56 positive selection of uNK cells. 
The cells were counted using a FastRead™ cell counter (ImmuneSystems, UK) and the cell 
pellet was then resuspended in MACS buffer plus 20µL of CD56 microbeads (Miltenyi, 130-
050-401) per 107 cells. The mixture was incubated on ice for 20 minutes. LS column 
(Miltenyi, 130-042-401), for cell selection, was placed in the magnetic field of MACS 
separator. The column was primed by passing 3 x 1ml of MACS buffer. The cell suspension 
was added to the column followed by 3ml wash of MACS buffer. The column was removed 
from the magnetic field and placed in a suitable colle tion tube. Magnetically labelled cells 
(CD56+) were flushed from the column by addition of 5 x 1ml of MACS buffer into a fresh 
tube. The resulting cell suspension was CD56+, CD3- and was immunophenotyped as uNK 
cells using flow cytometry (see section 4.3.5.) 
4.3.4. uNK culture conditions 
Isolated uNK cells were cultured at a density of 1x106 cells per/ml for cell treatment in 
phenol red-free RPMI 1640 medium (Sigma, Cat. No. R7509) supplemented with 10% 
CSFCS, 1% Penicillin/Streptomycin (Sigma, Cat. No. P-4333), 1% L-glutamine (Sigma, Cat. 
No. G-7513), and 0.5% fungizone (Invitrogen, Cat. No 15290-018). Cells were cultured up 
to a maximum of 24 hours at 37oC under 5% CO2 in air. Cultured uNK were incubated either 
with vehicle control (DMSO), 10-8M E2, 10-6M ICI or combined E2 and ICI for 2 or 24 
hours.  






 Research number Tissue number Lab number GESTATION 
Sample 1 7762 554 CD1040D <8 wks 
Sample 2 7644 385 CD774D 8 wks 1 day 
Sample 3 7633 380 CD763D 8 wks 4 days 
Sample 4 5721 703 CT1205D 8 wks 6 days 
Sample 5* 5696 446 CD480D 9 wks 
Sample 6* 7648 387 CD778D 9 wks 2 days 
Sample 7* 5650 417 CD722D 9 wks 5 days 
Sample 8* 7663 397 CD731D 9 wks 6 days 
Sample 9* 7721 545 CD999D 9 wks 6 days 
Sample 10* 7640 383 CD770D 10 wks 1 day 
Sample 11 6415 524 CD713D 10 wks 5 days 
Sample 12 6418 527 CD716D 10 wks 5 days 
Sample 13 7688 537 CD966D 10 wks 5 days 
Sample 14 6413 523 CD798D 11 wks 2 days 
Sample 15 7647 386 CD777D 11 wks 2 days 
Sample 16 7642 384 CD772D 11 wks 2 days 
Sample 17 6417 526 CD715D 11 wks 5 days 
Sample 18 7652 390 CD782D 11 wks 5 days 
Sample 19 5667 440 CD451D 10 wks 0 days 
Sample 20 5669 441 CD453D 10 wks 1 days 
Sample 21 7697 540 CD975D 10 wks 2 days 
Sample 22 7701 542 CD979D 11 wks 2 days 
Table 4.1. Decidual samples from which uNK where isolated for treatment. Gestation in 
weeks (wks) and days based on ultrasound scan and date of last menstrual period recorded 
by a research nurse. Samples which were clustered for analysis in section 4.4.7 are 
indicated by *, samples 19-22 were those used in section 4.4.8. 
4.3.5. Flow Cytometry 
The immune-phenotype of isolated uNK cells was confirmed using flow cytometry. Briefly, 
uNK cells isolated from human decidual tissues were suspended in FACS buffer (PBS, 
containing 1% FCS and 0.1% NaN3) at a concentration of 5x10
5 cells/ml. Cell suspensions 
were stained with antibodies conjugated to fluorescein isothiocyanate (FITC) (CD56) or 





phycoerythrin (PE) (CD3 or CD16). Single stains were used to define the parameters for 
scanning the samples together with unstained samples and isotype controls. Single and 
double stained samples were utilised to fully describe the sample cell population. Cell pellets 
were resuspended in 100 µl of FACS buffer and incubated with conjugated antibodies for 30 
minutes in the dark. Following incubation cells were washed by adding 1 ml of FACS buffer 
and then resuspended in 500ul of FACS buffer for scanning. Labelled cells were placed on 
ice and protected from light until scanning was completed. 
4.3.6. Propidium Iodide staining 
To assess cell viability the capacity for cells to incorporate the fluorescent DNA-binding 
probe propidium iodide (PI) was measured. Non-viable cell membrane proteins become 
porous and they can readily incorporate PI. Viable cells are intact and do not incorporate the 
PI, thus the proportion of dye excluded cells gives an approximation of the percentage 
viability. PI was added to the cell suspension, incubated for 5 minutes in the dark and 
fluorescence measured using flow cytometer. 
Flow cytometry was performed using a Becton Dickinson FACScan flow cytometer (Bectin 
Dickinson, Oxford, UK). Forward scatter, side scatter and fluorescence measurements were 
recorded and analysed using FlowJo software (Tree Star Inc, OR, USA). 
4.3.7. Immunohistochemistry 
Immunohistochemistry was conducted on human decidual tissue sections in accordance with 
standard laboratory protocols to establish the presence and localisation of proteins of interest 
(Full details see section 2.9). Decidual tissue was collected and fixed in 4% NBF and 
embedded in paraffin wax. 5µm sections were cut and mounted onto coated glass sides 
(VWR, Poole, UK). Antigen retrieval was performed using 0.05M Glycine/EDTA buffer 
(pH 8) followed by a methanol peroxidise block, serum block, and avidin-biotin block. 
Primary antibodies were diluted in blocking serum (normal serum, TBS, BSA), added to 
tissue sections and incubated overnight. Primary antibody dilutions are detailed in 0. Slides 
were incubated with appropriate biotinylated secondary antibody followed by incubation 
with streptavidin-HRP before final antibody detection using 3,3’-diaminobenzidine (DAB). 
Slides were counterstained in Harris’ haematoxylin. DAB positive sections were imaged 
using a PROVIS microscope (Olympus Optical, London UK) with an attached Canon 
DS126131 camera. DAB detection immunohistochemistry was also preformed on cytospins 





of isolated uNK cells. 2x105 cells were applied to glass slides using centrifugal force and 
presence of CD56 was detected. 
Immunofluorescent immunohistochemistry using Tyramide signal amplification (TSA) 
enables the identification of multiple antigens in the same tissue section and detection of 
colocalised target antigens and was used to identify co-expression of the uNK marker CD56 
with other proteins of interest. 
Following antigen retrieval and hydrogen peroxide block, slides were washed in water and 
then twice in PBS. The slides were serum blocked for 30 min at room temperature before 
incubation overnight with primary antibody diluted at appropriate dilution (see Table 4.2) 
Following washes in PBS, slides were incubated with appropriate peroxidase (with attached 
FAB fragments) secondary antibody for 30 min at room temperature. Slides were washed in 
PBS and incubated for 10 min with TSA kit (PerkinElmer, Massachusetts, USA) using 
Tyramide-cyanine 3 diluted 1:50 in substrate. The red fluorophore (cyanine 3) was usually 
used for the first primary antibodies as the green fluorophore (fluoroscein) was more prone 
to photobleaching and diminished signal when used first. After washing in PBS the slides 
were microwaved in boiling 0.01M citrate buffer for 2.5 min and then allowed to stand for a 
further 30 min to block cross-reactivity. The slides were then blocked and incubated 
overnight with the second primary antibody. Incubations with appropriate secondary 
antibody and TSA kit were performed as described above. The green fluorophore 
(fluorescein) was used for the second primary antibody. Following washes in PBS the slides 
were counterstained with DAPI diluted 1:1000 in PBS and mounted with coverslips in 
permafluor (Immunotech, Marseille, France). Fluorescent images were examined using a 
Zeiss LSM 510 Meta-Confocal microscope (Carl Zeiss, Hertfordshire, UK). 






Source Primary antibody Species raised DAB dilution Fluorescence Dilution 
Zymed CD56 Mouse 1:400 1:2500 
Bioquote SOD2 Rabbit 1:200 1:400 
Sigma Aldrich ACTR3 Mouse 1:50 N/A 
Ab frontier PTMA Mouse 1:500 N/A 
R&D CXCR4 Mouse 1:500 1:80 
Vector ERα Mouse 1:200 1:1000 
Serotec ERβ Mouse 1:200 1:1000 
Table 4.2. Primary antibodies and dilutions used in immunohistochemistry studies. 
4.3.8. Cytospins 
Suspensions of isolated uNK cells were adhered to glass slides using a Shandon cytospin 2. 
Following isolation of uNK, 2x106 cells/ml were suspended in PBS and 100 µL of cell 
suspension added to each slide. Slides were spun at 24.2 x g for 3 minutes and then allowed 
to air dry for 20 minutes at room temperature. Cells were fixed in 90% acetone/10% 
methanol for 20 minutes and then air dried for a further 10 minutes. Immuno-detection of 
CD56 protein (diluted 1:50) was performed on cells immediately following fixation. 
Endogenous peroxidase activity was blocked by incubating slides in 0.15% H2O2 in 
methanol for 30 minutes at room temperature. Following TBS washes cells were serum 
blocked for 30 minutes at room temperature. Thereafter protocol was identical to 4.3.7. 
4.3.9. RNA extraction and Taqman Q-RT PCR 
Extraction of RNA from cell extracts was performed using RNAeasy® mini kit (Qiagen, 
Crawley, UK). Biological samples were collected in 350µl of lysis buffer per well of 6-well 
plate and homogenized using QIAshredder® spin columns (Qiagen, Crawley, UK). On 
column DNAse digestion was performed to remove contaminating DNA. RNA was eluted in 
30µl RNAse-free water and quanitified using a Nanodrop® ND-1000 Spectrophotometer 
(Nanodrop Technologies, Wilmington, DE, USA). RNA samples were standardised to 
concentration of 100ng/µl prior to cDNA preparation. Reverse transcription of RNA to form 
a single stand of complementary DNA (cDNA) was carried out using the SuperScript VILO 
cDNA synthesis kit (InVitrogen) according to the manufacturer’s instructions. Briefly, each 
reaction (final volume 20µl) contained a final concentration of 1x VILO reaction mix, 
0.125x Superscript enzyme mix and 100ng of RNA. Samples were incubated under the 





following conditions: 25oC for 10 minutes, 42 oC for 60 minutes, 85 oC for 5 minutes in a 
thermal cycler. Concentrations of mRNAs in samples were determined by reverse 
transcription followed by quantitative-real time polymersase chain reaction performed in an 
ABI machine using the Taqman® Method (Section 2.3). Each reaction was prepared using 
the qPCR Supermix with premixed ROX kit (11795-01K; Invitrogen) and conducted in 
duplicate and plated in a 96-well MicroAmp Fast Optical reaction plate (Applied 
Biosystems). Real time PCR amplification was performed using the Applied Biosystems® 
7900HT Fast Real-Time PCR System using reaction mix described in Table 4.3. 
 
Reagent Final Concentration Vol./15µl reaction (µl) 
2x Express Supermix 1x 7.5 
Forward Primer 20µM 200nM  0.15 
Reverse Primer 20µM 200nM  0.15 
Probe 10µM 100nM  0.15 
18S primer/probe mix 10nM primer, 40nM probe 0.1125 
H20  5.4375 
cDNA  1.5 
Table 4.3. Reaction mixture for Taqman analysis. 








Forward Primer Reverse Primer UPL 
probe 
number 
ACTR3 Nm_005721 tggtgtcactcatgtcattcc Atatctcgtcctgcgattg 41 




CXCL12 Nm_000609 ttgacccgaagctaaagtgg Ccctctcacatcttgaacctct 80 
CXCR4 NM_003467 ttaagcgcctggtgactgtt Gcccatttcctcggtgtag 47 
ESR1 Nm_000125 ttactgaccaacctggcaga Atcatggagggtcaaatcca 24 
ESR2 Nm_001437 gctcctgtcccacgtcag Tgggcattcagcatctcc 62 
IL15RA NM_002189 acaacccccagtctcaaatg Tgccgtcgttactgtggag 37 
IL15RA NM_000585 cagatagccagcccatacaag Ggctatggcaaggggttt 46 
IQGAP1 Nm_003870 ctagaaacaccagccaccagt Tcacggatagcacgtctctg 38 
PMP22 Nm_153321 ttctcatcatcaccaaacgaa gctgaagatgatcgacaggat 49 
PTMA Nm_001099
285 
cgaaatcaccaccaaggact Ctccccattttcctcattctc 34 
ROCK NM_005406 Acatttgactggaaataaaga Gctcgagttgcagggttaga  
SOD2 Nm_001024
465 
ctggacaaacctcagcccta Tgatggcttccagcaactc 22 
TTF3 Nm_001993 ggagaaaggggaattcagaga Gggagttctccttccagct 51 
Table 4.4. Table of oligonucleotide sequences used in RT-PCR analysis. 







Metacore (http://www.genego.com/metacore.php) is an integrated knowledge database of 
manually curated human protein-protein, protein-DNA and protein-compound interactions 
used in pathway analysis of gene lists. Bioinformatic nalysis was used to analyse the 
shortest path interactions with ERβ and candidate genes were carried out using Metacore. 
4.3.11. Statistical Analysis 
Statistical analysis was performed using GraphPad Prism (GraphPad Prism version 5.04 for 
Windows, GraphPad Software, La Jolla California USA, www.graphpad.com). The criterion 
for significance for all tests was set at p<0.05. 






4.4.1. Uterine natural killer (uNK) cells are prese nt in large numbers in human 
decidua. 
To document numbers of uNK cells in tissue samples of decidua used for cell isolation, 
sections were immuno-stained with anti-CD56 (Figure 4.2). Consistent with previous 
findings (25, 249) CD56 positive cells were abundant within the decidual stroma with some 
being closely adjacent to blood vessels (Figure 4.2, B). Qualitative assessment of uNK 




Figure 4.2. Immunolocalisation of CD56 to sections of human first trimester decidua from 8 
weeks gestation (A, B) and 10 weeks gestation (D, E). Note CD56+ cells (arrowheads) were 
abundant, distributed throughout the stromal compartment and often found adjacent to blood 
vessels (circled). Negative controls were conducted in the absence of primary antibody (C 
and F). Scalebar equivalent to 50µm. 
In agreement with findings from non-pregnant endometrium (249) double fluorescent 
immunohistochemistry revealed co-localisation of the CD56 surface marker with nuclear 
staining for ERβ but not ERα (Figure 4.3). Notably both ER subtypes could be detect d in 
the stromal cells in decidua. In the tissue environme t as well as in isolated cell populations 
uNK are ERβ positive and ERα negative. The absence of ERα suggests any direct impacts of 
oestrogens present within the local environment will be mediated by ERβ-dependent changes 
in gene expression. 







Figure 4.3. Decidual uNK cells are immunopositive for ERβ but not ERα. 
Immunohistochemistry shows co-localisation of ERβ but not ERα expression with CD56. In 
human first trimester decidua expression of CD56 (red staining) colocalised with ERβ 
expression (green staining, white arrows, left panel). ERα expression could be detected in 
stromal cells but not in CD56 positive uNK cells (white arrows, right panel). 
 
4.4.2. uNK cells isolated from decidual tissue usin g MACS have high purity 
and viability. 
To provide enough cells for experiments uNK cells were isolated from first trimester decidua 
using the quadro MACS system and the phenotype of the isolated cells investigated using 
flow cytometry. This analysis revealed a population that was highly enriched for CD56+ 
cells (Figure 4.4 C, ungated population >94%). Double staining of cells with CD56 and 
either CD3 or CD16 confirmed that the isolated cell population expressed the uNK 
phenotype with expression CD56+ CD3- CD16dim (Figure 4.6). Positive staining was 
validated using isotype matched Ig-conjugated controls and was found to be antibody 
specific (Figure 4.5).  
The viability of isolated uNK cells was tested using the propidium iodide assay (497) to 
confirm overall viability following isolation and to further determine viability following 
incubation for 2 and 24 hours. Viability was routinely found to be greater than 94% in the 
ungated cell population (Figure 4.7, A and C). Following incubation for two hours viability 
was >91% (Figure 4.7, B and D) and interestingly >79% after 24 hours despite no growth 





factors or cytokines being added to supplement the incubation media (Figure 4.8). This was 
important in order to distinguish changes in gene expr ssion as being mediated by the 
oestrogen treatment and not by supplemental factors. 
 
 
Figure 4.4. Purified uNK cells were CD56 positive, CD3 negative and CD16 negative. 
Forward scatter and side scatter values for the cell population (A) as well as unstained 
fluorescence levels are shown (B). Isolated cells were incubated with conjugated fluorescent 
antibodies and fluorescence intensity detected using BD FACScan. The whole ungated 
population was measured and >94% of the cells were CD56 positive (C).Greater than 99% 
of uNK were CD16 (D) and CD3 (E) negative.  
 






Figure 4.5. Isotype controls confirm specific antibody expression. Ig-matched fluorescence 
conjugated controls were incubated with the isolated cells. Positive CD56 fluorescence was 
confirmed to be antibody specific (A, B) demonstrated by increased fluorescence intensity 
following CD56 staining (black) that is distinct from the Ig-matched control (blue). There was 
no difference in fluorescence intensity between unstained (grey dots), antibody stained 
(black dots) and Ig-matched fluorescent conjugated controls (blue dots) for either CD3 (C) or 
CD16 (D) confirming lack of expression. 
 






Figure 4.6. Double staining confirms uNK phenotype, CD56+ CD3- CD16 dim. Isolated cells 
were incubated with two conjugated fluorescent antibody pairs; either CD56-FITC and CD3-
PE or CD56-FITC and CD16-PE.  The whole ungated population was measured and >93% 
of the cells were CD56 positive, CD3 negative (A) and >94% of the cells were CD56 positive, 
CD16 negative (B). 
 
 






Figure 4.7. Isolated cells are highly viable and remain so following 2 hours incubation. 
Isolated uNK cells were tested for viability by propidium iodide staining (positive staining 
shown in blue). At 0 hours (following isolation) the cell population was routinely found to be 
>94% viable (A, C). Following 2 hours incubation cells retain viability and ungated population 
was >91% propidium iodide negative (B, D). 
 






Figure 4.8. Isolated cells are viable following 24 hours incubation. Isolated uNK cells were 
tested for viability by propidium iodide staining. Following 24 hours incubation cells retain 
viability and ungated population was >79% propidium iodide negative. 
4.4.3. Purified decidual uNK cells have a phenotype  identical to that of cells in 
vivo. 
Cytospins of uNK cells purified as above were stained using the same CD56 antibody as had 
been used on tissue sections and intense immuno-positive taining was detectable in the 
majority of cells consistent with enrichment of a CD56+ population (Figure 4.9). 






Figure 4.9. Immunolocalisation of CD56 to uNK on cytospins. Cytospins of isolated uNK cells 
express intense CD56 staining further confirming the phenotype of the isolated cell 
population and the validity of CD56 immunoexpression as a marker of uNK cells. Insert: 
negative control incubated in the absence of primary antibody. 
 
To confirm that purified CD56+ uNK cells retained expression of oestrogen receptors 
qRTPCR was conducted on RNA isolated from 13 samples of uNK cells (Figure 4.10). 
Concentrations of mRNAs were compared to those in an Ishikawa cell positive control 
sample (endometrial epithelial adenocarcinoma cell line) as studies within the laboratory (F. 
Collins unpublished) have demonstrated that the ratio of ERα:ERβ is 1:1 in this cell type. All 
samples of uNK contained higher concentrations of ERβ mRNA than the control Ishikawa 
cells whereas ERα mRNA was low/undetectable.  






















































Figure 4.10. Expression of mRNAs encoding oestrogen receptor alpha (ERα) and oestrogen 
receptor beta (ERβ) in purified decidual uNK cells. Expression of ERβ mRNA (A) is greatly 
increased compared to Ishikawa (ISH) control RNA. ERα mRNA expression (B) was 









4.4.4. Changes in gene expression in uNK cells in response to oestradiol 
In an experiment undertaken within the laboratory before the start of the current study uNK 
cells purified from decidua (8-9 weeks, n=4) were incubated +/- E2 for 2h (Saunders, King, 
Marshall, unpublished). RNA was extracted and hybridized to Illumina’s Sentrix Human-6 
v2 Expression Bead Chips at the Finnish DNA Microaray Centre (Turku, Finland). 
Hybridization was detected with 1µg/ml Cyanine3-streptavidine. Chips were scanned with
Illumina Bead Array Reader (Factor=1, PMT=521, Filter=100%) and the numerical results 
were extracted with Bead Studio v3.2.6. Following the array bioinformatics was undertaken 
by the Finnish DNA Microarray Centre based on the following criteria: p<0.005, fold change 
(FC) ≥1.5, and logFC≥0.58, 28 transcripts encoded by known genes were idntified. In the 
present study, nine of these were chosen for validation (Table 4.5).  
 






Gene Symbol Gene name Source Reference_ID P value FC 
CAV2 Caveolin 2 NM_001233.3 0.003325216 -1.65 
SOD2 Superoxide dismutase NM_001024465.1 0.004461885 -1.63 
PMP22 Peripheral myelin 
promoter 22 
NM_153321.1 0.003370981 -1.58 
TTF3 Tissue Factor NM_001993.2 0.004341158 -1.52 
IQGAP IQ motif containing 
GTPase activating-like 
protein 1 
NM_003870 0.003721 1.32 
ROCK Rho associated coiled-coil 
containing protein kinase 1 
NM_005406 0.001398 1.45 
ACTR3 Actin related protein 3 NM_005721.3 0.000371033 1.50 
CGA glycoprotein hormones, 
alpha polypeptide 
NM_000735.2 0.000637427 2.24 
PTMA Prothymosin alpha NM_001099285.1 0.000484506 2.26 
Table 4.5. Candidate oestrogen-regulated genes identified by array analysis of uNK cells 
treated with E2 for 2 hours. 
4.4.5. Bioinformatic analysis of interactions betwe en candidate genes and 
oestrogen receptors. 
Metacore (http://www.genego.com/metacore.php) is an integrated knowledge database of 
manually curated human protein-protein, protein-DNA and protein-compound interactions 
used in pathway analysis of gene lists. Bioinformatic nalysis of interactions between the 
putative E2-regulated genes revealed potential interac ions between ERβ suggesting that 
whilst regulation of some (PTMA, CAV2) might be altered by direct ERE mediated protein 
interaction, others (TTF3, SOD2, ROCK1) may be regulated through indirect gene activation 
via the involvement of ERβ tethered to other transcription factors such as Sp1 (Figure 4.11). 






Figure 4.11. Pathway analysis of shortest path interactions with ERβ (ESR2) and candidate genes using Metacore. Interactions between the gene list 
were expanded to show the shortest path between them. This analysis revealed potential for both direct interaction and involvement of other 
transcriptional pathways. 





4.4.6. Immunodetection of putative E2 regulated gen es in human decidual 
tissue. 
In order to investigate protein expression of candidate genes human first trimester decidual 
tissue sections were stained for CD56 and to antibodies for selected candidate genes. Co-
localisation of the uNK cell marker CD56 was observed with SOD2 (Figure 4.12 G). 
Interestingly, positive immunodetection of SOD2, ACTR3 and PTMA could be also detected 
in the stromal cells suggesting oestrogens within te local environment might also have an 
impact on expression of these genes in other cell types.  












Figure 4.12. Immunolocalisation of selected candidate genes in sections of human first 
trimester decidua. Positive immunoexpression of SOD2 (A), ACTR3 (C), PTMA (E) could be 
detected throughout the stromal compartment. Immunohistochemistry shows co-localisation 
(white arrow, G) of SOD2 (green staining, G) with CD56 (red staining, G). Negative controls 
were conducted in the absence of primary antibody (B, D and F). Scalebar equivalent to 
50µm. 
↑ 





4.4.7. Expression of candidate genes in uNK cells t reated +/- E2 is highly 
variable. 
To confirm and extend the results from the array, concentrations of mRNAs encoded by 9 
putative E2-regulated genes were measured in a further set of samples (Figure 4.13, n=18 +/- 
E2 for 2 hours). Changes in gene expression in response to E2 treatment varied between 
samples and whilst changes in mRNA concentrations in ome samples were in agreement 
with the array findings others were not (Table 4.5). For greater consistency with the samples 
used for the original array analyses, all of which were matched for gestational age to 8 
weeks, a subset of the samples which were from gestations between of 9 to10 weeks (n=6) 
were grouped together (Figure 4.14). This resulted in more consistency in results with the 
putatively down-regulated genes showed most agreement with prior findings (Figure 4.15). 
In this set expression of Caveolin 2 (CAV2) was signif cantly decreased (P<0.01, n=6, 0, A) 
in agreement with the -1.65 fold change documented in the array data. Tissue factor (TTF3) 
was also significantly decreased (P<0.05, n=6, Figure 4.15, D) in agreement with the -1.52 
fold change predicted by the array. Superoxide dismutase 2 (SOD2) mRNA expression 
appeared unchanged by E2 treatment, while peripheral myelin protein 22 (PMP22) tended to 
be decreased by E2 treatment (p=0.0537, n=6, Figure 4.15, B and C respectively). Putatively 
up-regulated genes showed less agreement with previous findings and response to E2 was 
more variable (Figure 4.16). Expression of mRNAs encoding ACTR3 (p=0.2538), PTMA 
(p=0.3028) and ROCK (p=0.1035) tended to be slightly increased with oestrogen treatment 
(Figure 4.16, A, B and E respectively) while IQGAP was unchanged (Figure 4.16, D). 
Paradoxically, CGA appeared to decrease (p=0.3638, Figure 4.16, B).  




  <9 weeks <10weeks <11 weeks <12 weeks 
Sample #                                 
Gene 
Array 
Response 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
CAV2   -1.34 1.20 1.38 1.03 -1.16 -4.71 -1.24 1.15 1.03 -1.43 -1.06 1.50 1.03 -3.59 1.03 -1.04 1.33 -1.04 
SOD2   1.39 1.47 1.58 1.62 1.24 -1.40 -1.07 -1.29 1.62 1.07 -1.12 1.25 1.62 1.72 1.05 -1.04 1.20 -1.22 
PMP22   1.40 1.79 1.54 1.34 -1.90 -2.43 1.11  -1.04 -1.23 1.19 1.28 2.66 1.16 1.39 -0.96 1.33 -1.21 
TTF3   -1.09 1.11 1.56 -1.39 1.25 -1.92 -1.72 -1.36 -1.53 -1.70 -1.21 1.20 -1.04 -2.01 -1.20 -1.09 1.40 -1.30 
ACTR3   -1.42 1.04 1.10 1.47 -1.24 1.17 1.02 1.55 1.48 -1.11 -1.13 1.19 1.06 1.23 -1.25 1.10 1.09 -1.39 
IQGAP   -1.06 1.17 1.21 -2.30 -2.02 1.41 -1.14 1.56 0.99 -1.18 -1.18 1.19 -1.11 1.07 -1.04 -1.08 1.09 -1.30 
CGA   -1.48 -2.40 1.58 -3.34 -2.27 2.14 -6.16 -2.01 0.17 -1.12 3.61 -4.84 1.42 1.27 1.54 1.84 -1.25 2.44 
PTMA   -1.19 1.15 1.05 -1.10 -1.05 -1.03 1.00 1.47 1.35 -1.09 -1.20 1.11 1.51 -1.32 -1.09 1.02 1.19 -1.37 
ROCK   1.31 1.12 -1.16 -1.90 1.90 1.11 1.15 1.53 1.32 -1.29 -1.18 1.42 0.60 -1.44 -1.09 1.14 -1.05 -1.26 
 
 
Figure 4.13. Gene expression relative to control in E2 treated uNK. Candidate genes were assessed in 18 samples of isolated uNK cells form a range of 
gestations (8-12 weeks.) Fold regulation values are described and colour coded (see scale). Fold change values less than 1, i.e. down regulated expression, 
are expressed as the negative inverse e.g. Fold change of 0.5 is equivalent to fold regulation of -2. 
>-2 >-2<-1.1 >-1.1<1.1 >1.1<1.5 >1.5 





Sample #         
Gene 
Array Response 1 2 3 4 5 6 
CAV2   -1.16 -4.71 -1.24 1.15 1.03 -1.43 
SOD2   1.24 -1.40 -1.07 -1.29 1.62 1.07 
PMP22   -1.90 -2.43 1.11  -1.04 -1.23 
TTF3   1.25 -1.92 -1.72 -1.36 -1.53 -1.70 
ACTR3   -1.24 1.17 1.02 1.55 1.48 -1.11 
IQGAP   -2.02 1.41 -1.14 1.56 0.99 -1.18 
CGA   -2.27 2.14 -6.16 -2.01 0.17 -1.12 
PTMA   -1.05 -1.03 1.00 1.47 1.35 -1.09 
ROCK   1.90 1.11 1.15 1.53 1.32 -1.29 
 
 
Figure 4.14. Gene expression relative to control in E2 treated uNK. Candidate genes were 
assessed in 6 samples of isolated uNK cells form a gestational range of 9 to 10 weeks. Fold 
regulation values are described and colour coded (see scale). Fold change values less than 
1, i.e. down regulated expression, are expressed as the negative inverse e.g. Fold change of 
0.5 is equivalent to fold regulation of -2. Samples from this gestational range were more 
reproducible and responses were in greater agreement with expected values. 
>-2 >-2<-1.1 >-1.1<1.1 >1.1<1.5 >1.5 















































Figure 4.15. Putatively down-regulated genes showed most agreement with prior array data. 
The mRNA expression of CAV2 (A) was significantly decreased (P<0.01, n=6) which was in 
agreement with the -1.65 fold change observed in array data. TTF3 (D) was also significantly 
decreased (P<0.05, n=6) in agreement with the -1.52 fold change predicted by the array. 
SOD2 (B) mRNA expression appeared unchanged by E2 treatment, while PMP22 (C) 
tended to decreased by E2 treatment (p=0.0537, n=6). 
 
























































Figure 4.16. Putatively up-regulated genes showed less agreement with previous array 
findings and response to E2 was more variable. Expression of mRNAs encoding ACTR3 (A, 
p=0.2536), PTMA (C, p=0.3028) and ROCK (E, p=0.1035) showed a trend towards 
increased expression with oestrogen treatment while IQGAP (D) was unchanged and in 
contrast to predicted response CGA appeared to show a non-significant decrease (B, 
p=0.3638). 
 





4.4.8. The anti-oestrogen ICI 182,780 (ICI) had min imal impact on candidate 
gene expression in uNK cells. 
The expression of array candidate genes were further inv stigated in 4 additional samples of 
uNK cells (Figure 4.17) treated +/- ICI for 2 hours to ascertain whether E2 from serum or 
media could be masking any treatment effect. Interes ingly, the expression of PTMA 
significantly increased (Figure 4.17, A) however this would not be consistent with blocking 
of E2-mediated increase observed in the array data. IQGAP and SOD2 were unchanged in 
response to ICI treatment (Figure 4.17, B and C). ACTR3 had a slight non-significant 
increase following ICI treatment (Figure 4.17, D, p=0.1680) which is not consistent with 







































Figure 4.17. Expression of mRNAs encoding prothymosin alpha (PTMA) are increased in 
response to ICI treatment. The average response to ICI suggests increased PTMA mRNA 
expression following treatment (A, n=4, p=0.0397). Expression of mRNAs encoding IQGAP 
(B) and SOD2 (C) are unchanged in response to ICI treatment (n=4, p=0.0713 and p=0.7380 
respectively). The expression of mRNAs encoding ACTR3 (D) appear increased in response 
to ICI treatment (n=4, p=0.1680). 
 






The present investigation sought to determine the impact of oestrogen receptor-dependent 
signalling on gene expression in uNK cells purified from 1st trimester decidua. The studies 
presented herein describe novel regulation of transcription in uNK cells mediated by 
oestradiol. Our investigation has shown that E2 significantly decreases concentrations of 
mRNAs encoding CAV2 and TTF3 in uNK cells possibly via ERβ and Sp-1 mediated 
transcription. 
The presence of large numbers of uNK in decidua was confirmed by positive CD56 staining 
consistent with previous reports (25, 249). First trimester decidual samples ranging from 8 to 
12 weeks gestation contained CD56+ CD16- CD3- uNK cells, which could be isolated at high 
purity (> 94% CD56 positive cells in ungated cell population). The isolated population was 
viable (>94%) and remained viable following in vitro treatment for 2 hours, notably ~80% of 
cells remained viable after 24 hours culture. This wa  surprising as the cells were cultured in 
minimally supplemented media in order exclude non-treatment effects. uNK cells are often 
cultured with additional cytokines such IL-15 (414) to enhance viability however in our 
hands a highly viable population could be obtained that remained tenable for up to 24 hours 
without supplementation with cytokines. The uNK cells resident in decidual samples were 
ERβ+/ERα- and their oestrogen receptor phenotype was therefor  identical to uNK cells in 
non-pregnant endometrium (249) furthermore they retain d this phenotype when purified by 
MACS. To date, transcriptional analysis of uNK cells has been limited to array analysis of 
subtypes (27) and secretion of cytokines and expression of their receptors (39, 460). 
However the transcriptional effect of E2 treatment o  uNK cells has not been investigated. In 
the present study having identified and characterised a viable isolated population of uNK 
from decidua we sought to investigate the impact of oestradiol (E2) treatment on their 
function. As a starting point for these studies we utilised array analysis results from isolated 
uNK cells treated +/- E2 for 2 hours from a previous study within our group; Forty-six genes 
had been identified as being differentially regulated following E2 treatment (6 down-
regulated, 40 up-regulated), of which 28 were known ge es, from this list 9 candidate genes 
(4 down-regulated, 5 up-regulated) were selected for follow up validation.  
The impact of E2 treatment on expression of candidate genes across 18 samples of isolated 
uNK was found to be highly variable. However, in the present set of samples, the uNK cells 
had been isolated from decidua from a wider range of gestational ages (8-12 weeks) than the 
samples used for the original array analyses all of which were matched as being 8-9 weeks 
gestation. Interestingly, gross histological analysis suggested there was no difference in uNK 





number or distribution with gestation (up to 12 weeks.) However, Lash et al have postulated 
that uNK cells in decidua at 8-10 weeks and 12-14 weeks are functionally distinct with 
varied secretion of cytokines and growth factors (41, 3). Furthermore uNK cells may be 
responsible for mediating different responses at different gestational ages as evidenced by 
gestation-specific impacts on trophoblast invasion (58). Thus gestational age is likely to be 
an important factor in uNK responses and was therefore thought to contribute to the 
variability in oestrogen-dependent gene expression observed across the sample set. To 
control for this, samples from gestations between 9 and 10 weeks were clustered as this 
represented the highest number of samples within the narrowest gestational age range from 
the total sample set. When gene expression was re-analysed using these samples responses 
were found to be more consistent with those recorded from the array data.  
In uNK cells, exposure to E2 for 2 hours resulted in own-regulation of Caveolin-2 (CAV2) 
mRNA. Caveolins are scaffolding proteins which may be important in mediating non-
genomic response to oestrogen (498). CAV2 can regulate caveolin-1-dependent caveolae 
formation (499) and is associated with tumour progression in breast cancer (500). CAV-1 
and CAV-2 have previously been shown to be regulated by ERβ but in that case expression 
was upregulated in colon cancer cell lines (501). Thus the down-regulation of CAV-2 in 
uNK cells reported in the current chapter represents novel E2-mediated transcriptional 
regulation of CAV-2 that is distinct to this cell type. 
Tissue factor (TTF3, factor 3, TF) is a cell surface glycoprotein involved in blood 
coagulation cascades and known to be present in leukocytes. In decidualised endometrial 
stromal cells expression of tissue factor parallels that of prolactin (157) and it is thus also 
considered a decidualisation marker. Tissue factor expression is controlled by specificity 
protein (Sp)-1 which itself may interact with progesterone and/or oestrogen receptors (158). 
TTF3 expression may be modulated by oestrogen in moocytes (502) and plays a role in 
mediating cellular migration (503). Progestins increase TTF3 mRNA and protein 
concentration in human endometrial stromal cells which is synergistically enhanced by co-
stimulation with E2, however E2 alone does not increase TF transcription in this cell type 
(159). In the current investigation we found that TTF3 mRNA expression was significantly 
decreased following E2 treatment in uNK cells, which may result in modification of cellular 
migration capacity. This novel finding may be of particular relevance in uNK cells which do 
not express PR but do express ERβ and thus may be regulated by oestrogens in the 
endometrium. 





Peripheral myelin protein 22 (PMP22) is an integral membrane protein that is a major 
component of myelin. PMP22 mRNA expression tended to be decreased in uNK cells 
following treatment with E2. 
Actin related protein 3 (ACTR3) encodes a major constituent of the actin related protein 
(Arp) 2/3 complex. It is essential to cell shape and motility through lamellopodial actin 
assembly. The Arp2/3 complex initiates formation of actin filament networks in response to 
intracellular signals and Arp2/3 protein has been co-purified with ligand activated ERα in 
breast cancer cells suggesting a role for oestrogen in its regulation (504). Interestingly 
Arp2/3 is required for mediating NK cell cytotoxicity and Arp2/3 knock-down also reduced 
NK cell adhesion and slowed chemotaxis (505). In the current study E2 treatment tended to 
increase mRNA expression of ACTR3 in uNK cells. This may represent a mechanism by 
which oestrogen increases chemotaxis and adhesion of uNK cells and could therefore 
enhance recruitment to the uterus. However, if oestr gens increase expression of ACTR3 
this could also increase cytotoxicity of uNK which may be detrimental in the tissue 
environment. 
IQ motif containing GTPase activating-like protein 1 (IQGAP1) is a scaffold protein that 
integrates signals for localised actin polymerisation (506). It is important in regulating the 
cytoskeleton and promoting cell motility (507, 508). Our investigations demonstrated that 
while array bioinforntics analysis predicted IQGAP expression to be up-regulated by E2, the 
actual response to treatment in uNK cells was highly variable averaging out to no overall 
change in expression. IQGAP is known to interact with the Arp 2/3 complex (506) so 
modulated expression by oestrogen may be influenced by this factor and may explain in part 
the highly variable response to E2. 
Prothymosin alpha (PTMA) is associated with cell proliferation and chromatin remodelling 
and is known to enhance ER transcriptional activity by sequestering repressors of oestrogen 
activity and enabling coactivator association with ER. PTMA is itself regulated by 
oestrogen, the gene promoter contains two half-ERE sites where ER may bind (237). In a 
study by Martini et al expression of PTMA in ER-positive MCF-7 breast cancer cell line was 
increased following treatment with E2 (509). Of particular relevance to the current study was 
that the change in mRNA concentration reported by Martini et al was rapid and observed 
after only 1-2 hours of treatment, maximal at 4 hours and reduced thereafter (509). In the 
same study, up-regulation of PTMA was reported to be via ERα or ERβ but was not 
activated via PR or GR. In the results presented in this chapter, E2 treatment for 2 hours in 





uNK cells which are ERβ+ showed a trend towards increased PTMA mRNA expression 
although a significant difference between treatments could not be found. PTMA was 
predicted to be increased by the array study (FC 2.26) and mRNA concentrations appeared 
high with cDNA detected at low Ct values (average Ct 24.5, data not shown). Thus while 
increased mRNA expression mediated by E2 could not be confirmed, PTMA mRNA 
expression was detected and this protein could therefore play a role in influencing uNK cell 
function by modulating responses to E2 and promoting proliferation. The lack of activity 
with GR described by Martini et al, as well as the lack of ERα and PR expression in uNK 
also provides strong evidence for steroid hormone responsive transcriptional regulation of 
this gene by ERβ alone in this cell type. 
Rho-associated kinases (ROCKs) are important in many physiological functions of 
leukocytes including chemotaxis mediated by actin polymerization and cytoskeletal 
rearrangement (510, 511). Rho associated coiled-coil containing protein kinase 1 (ROCK1) 
synthesis is essential for macrophage chemotaxis and phagocytosis (512). There is little 
evidence for E2-regulated transcriptional regulation of ROCK1 although bioinformatics 
analysis suggests ERβ regulation via a tethered mechanism involving Sp1 could occur 
(reviewed in (188)). In the current study E2 treatment tended to increase ROCK1 mRNA 
expression in uNK cells in agreement with predicted array response. Thus regulation of 
ROCK1 by E2 may be a potential mechanism for mediating recruitment of uNK to decidua. 
Immunohistochemistry studies revealed expression of candidate genes in multiple cell types 
in decidua including the stromal cells. In a pilot study, E2 dependent expression of the 
candidate genes was examined in a cell line of immortalized human endometrial stromal 
cells (SHT 290, (465)). Although expression of mRNAs encoding; ACTR3, CAV2, CGA, 
IQGAP, PTMA, PMP22. TTF3, SOD2 and ROCK, could be detected, treatment of cells with 
E2 for 2 hours did not alter mRNA concentrations suggesting any stromal contamination of 
uNK samples would not have accounted for the observed changes in gene expression and 
highlighting the cell-specific nature of oestrogen-dependent changes in gene expression (data 
not shown).  
Previous studies have documented the influence of proliferative phase stromal cell derived 
factors (35, 36, 388) on uNK cell function. This, together with the failure to detect 
progesterone receptor expression in uNK cells had previously led to the assumption that 
steroid regulation of uNK must be indirect. However d tection of ERβ in this cell type (249) 
raised the possibility that E2-mediated transcriptional regulation is likely. The present study 





sought to elucidate such regulation. Seemingly robust array findings suggested a tight 
network of 46 transcripts which were differentially regulated in uNK cells. However follow-
up validation of the array proved to be inconsistent a d suggested gestational age might 
influence transcriptional responses. The genes investigated did yield some significant 
changes. CAV2 and TTF3 were significantly down regulated and PMP22 showed a strong 
trend towards decreased expression following E2 treatm nt. ACTR3, PTMA and ROCK all 
tended to be increased by E2 treatment while IQGAP appeared unchanged. Bioinformatic 
analysis of these genes suggested a strong association with genes related to actin 
cytoskeleton remodelling which may impact on cell motility. Differential expression of 
ROCK, ACTR3, IQGAP and TTF3 could all influence cell motility while PTMA may 
influence proliferation of uNK. The response to E2 itself could also be influenced by CAV2 
and PTMA consistent with informatics analysis.  
uNK cells represent an interesting cell type in which to investigate ER dependent changes in 
transcription as they only express the ERβ isoform. In the current study, bioinformatic 
analysis of transcriptional networks associated with candidate genes revealed the potential 
for ERβ regulation via classical EREs as well as non-classic l Sp1 regions. Consistent with 
this, Liu et al previously reported that chromatin immunoprecipitation (ChIP) analysis 
performed on MCF7 cells with induced expression of ERβ revealed ERβ-bound regions 
within the genome had a predominance of classical estrogen response elements (EREs) and 
GC-rich motifs (i.e. Sp1 regions) (513). Distinct ERβ binding regions in uNK cells may 
mediate physiological effects which are discrete from other cell types in the stromal 
compartment. The impact of classical oestrogen agonists, antagonists and selective oestrogen 
receptor modulators (SERMs) may therefore be unique n this cell population which may 
allow targeted modulation of uNK by ERβ specific agonists without the pleiotropic 
endometrial response to classical oestrogens. This may be particularly relevant to disorders 
of pregnancy such as recurrent pregnancy loss (RPL) where uNK cell numbers appear 
increased and are associated with greater prevalence of CD16+ NK cells (50, 51). 
Taken together these findings suggest a potential role for E2 modulation of uNK cells. 
However, the functional influence of E2 in vivo requires further investigation. Additional 
bioinformatics analysis of the array dataset (Dr. Elaine Marshall personal communication) 
suggested E2 impacts on uNK cells might result in alter tions in processes associated with 
cell migration (discussed in chapter 5). In addition t  cell migration, angiogenesis might be 
affected by E2 impacts on uNK cells in vivo. uNK cells are known to secrete angiogenic 
factors such as VEGF-C and angiopoietin-2 (44) and are also known to induce angiogenesis 





in human umbilical vein endothelial cells (39). Oestrogen is known to stimulate VEGF and 
thus may impact expression of angiogenic factors in uNK cells. Increased uNK cell numbers 
in the human endometrium is concomitant with decidualisation and local angiogenesis. Thus 
local oestrogen produced by decidualising stromal cells, reported in chapter 3, may influence 
increases in uNK cell number and angiogenesis during decidualisation. 
In summary, in the present study a viable uNK population was isolated from decidua that 
retained ERβ expression and uNK phenotype. The isolated uNKs were r sponsive to E2 
stimulation, and transcriptional responses suggest modulation of cell motility. The impact of 
oestrogen on uNK motility and the secretion of angiogenic factors is investigated in Chapter 
5.
Chapter 5. Modulation of uNK function and angiogenesis during decidualisation: 





5. Modulation of uNK function and angiogenesis duri ng 
decidualisation: Implications for local oestrogen i n cellular 
cross-talk. 
5.1. Introduction 
The human endometrium is a complex multicellular organ that undergoes cyclical 
remodelling in response to fluctuating levels of sex steroid hormones produced by the 
ovaries (1). The endometrium is bounded by a layer of pithelial cells on its luminal surface 
with a multicellular stroma containing fibroblasts, blood vessels (lined with endothelial 
cells), a dynamic immune cell population (including uNK cells and macrophages) as well as 
glands bounded by secretory epithelium  (2). Following menses the functional layer of the 
endometrium regenerates in response to rising levels of oestrogen produced by ovarian 
follicles. Oestrogen also induces expression of the progesterone receptor in during the 
proliferative phase (6-8). Following ovulation circulating levels of progesterone rise 
(secretory phase) and this, together with regulatory agents that enhance cyclic AMP (cAMP) 
levels, precipitate changes in endometrial architectur  including differentiation of stromal 
fibroblasts and remodelling of the vasculature, both of which are essential prerequisites for 
successful implantation of a conceptus and thereafter formation of a functional placenta (9). 
During the secretory phase there is a marked increase in the population of resident immune 
cells; leukocytes make up ~5% of uterine cells in the proliferative phase but rise to ~25% in 
the secretory phase (487). The most prominent population of uterine leukocytes are the 
uterine natural killer cells (uNK) the number of whic  further increases to account for 75% 
of total leukocytes in the decidua of early pregnancy (30). In the human, decidualisation and 
immune cell invasion occur during every cycle regardless of the presence of a conceptus, 
however, should implantation occur stromal transformation spreads beyond the perivascular 
regions and is prolonged. Formation of a mature matern l decidua is considered to play a 
pivotal role in limiting invasion of the embryonic trophoblast (14). 
5.1.1. Immune cell recruitment 
The presence of uNK cells in the uterus is essential for successful implantation (514, 515). 
However, before menarche and after the menopause uNK cell numbers are sparse suggesting 
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their recruitment and/or proliferation may be steroid regulated. In women who have 
undergone ovariectomy, administration of exogenous e trogen and progesterone are 
required for development of a receptive endometrium which is host to a population of uNK 
(516). uNK cells are present in small numbers in proliferative and early secretory 
endometrium but are increased in late secretory endometrium and decidua (25). uNK 
accumulate around spiral arterioles and are abundant in perivascular sites following 
decidualisation. The high numbers of uNK cells present in the uterus following 
decidualisation may be due to increased leukocyte recruitment. There is evidence to suggest 
this may be mediated by steroid hormones, and in particular oestradiol (E2) (74). For 
example, adhesion of CD56 positive cells to decidua basalis, mediated via α4 integrin and L-
selectin, can be induced in CD56 positive cells from male donors following treatment with 
E2 (515). There is an increase in α4 integrin in CD56bright pbNK cells at the LH surge a time 
when oestrogen levels are maximal (517). There are increased numbers of circulating 
CD56bright NK cells in women of reproductive age compared to males which is notable as this 
is the population believed to be homed to the uterus (26). Deloia et al. demonstrated that 
treatment of women with oral oestrogens increased total uterine leukocytes, the majority of 
which were uNK cells and macrophages while T cell numbers were unaffected (74). 
Following ovarian stimulation during IVF treatment, supraphysiological levels of sex 
steroids, including oestrogen, can be detected in the circulation and higher numbers of 
leukocytes have been detected in the uterus with a shift towards an increased ratio of 
CD56bright to CD56dim observed. This effect was specific to the uterus as there was no change 
in peripheral blood NK populations (488). Homing of NK cells to the uterus may be 
dysregulated in infertility and recurrent pregnancy loss with increased numbers of uNK cells 
reported in mid-secretory phase non-pregnant endometriu  of women with these conditions 
(50). Taken together, the available data suggest oetrogen may influence the homing of 
appropriate leukocytes to the uterus. 
uNK cells do not express progesterone receptor (PR)or oestrogen receptor (ER) α, but do 
express ERβ and glucocorticoid receptor (GR) (249) however both PR and ERα/ERβ are 
abundantly expressed in multiple cell types within t e endometrium. Thus regulation of uNK 
cells by steroid hormones may also be indirect as a result of changes within the uterine 
environment. Notably, interleukin-15 (IL-15) is one example of a cytokine which can 
regulate proliferation and activation of NK and T cells. IL-15 is produced by uterine stromal 
cells under the influence of progesterone and is known to induce proliferation and 
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recruitment of uNK cells (423). IL-15 can also increase CD56 expression in CD16- pbNK 
and induce a chemokine receptor repertoire similar to uNK (427).  
uNK cells express high levels of the cytokine receptors CXCR3 and CXCR4. Oestrogen 
induces CXCL10 and CXCL11 expression in the endometrium, with CXCL10 protein being 
increased in secretory phase endometrial explants treated with oestradiol, and both CXCL10 
and CXCL11 can interact with CXCR3. CXCR3 is expressed on uNK cells and may 
therefore be a further mechanism for uterine control of uNK cells which is stimulated by 
oestrogen. Indeed, stimulation of CXCR3 by CXL10 is reported to increase the migration of 
CD16- NK cells in vitro (460). CXCL12 (SDF-1) acts via CXCR4 and induces specific 
migration of CD16- NK cells (390). Oestrogen is know  to regulate the CXCL12-CXCR4 
pathway (391). 
5.1.2. Regulation of the endometrial vascular compa rtment 
Angiogenesis, the formation of new blood vessels from existing vessels, is a feature of 
pathologies including cancers (102). Functional angiogenesis is rare in normal tissues apart 
from those of the reproductive system where it is a feature of the dynamic remodelling of the 
corpus luteum of the ovary (103) and the endometrium  (104). In the human uterus 
endometrial arterioles arise from arcuate arteries in the myometrium which pass into 
arterioles in the basal endometrium that directly supply the functional layer. Proliferation of 
endometrial endothelial cells is at a peak in the mid to late proliferative phase and then again 
in the secretory phase (99). Endometrial arteries ar  tr nsformed during decidualisation. The 
thin walled straight arteries characteristic of theproliferative phase become increasingly 
tortuous with a thicker rim of actin-positive medial cells during the secretory phase, a 
phenotype which continues in early decidua until remodelling of the vasculature occurs in 
response to trophoblast invasion (9, 104). Unusually endometrial angiogenesis does not seem 
to involve vasculogenesis from progenitor cells or capillary sprouting but instead appears to 
involve elongation and enlargement of existing vessels while still retaining the integral 
structure of the artery (2).  
Many angiogenic factors have been identified in the endometrium which may mediate this 
process including; VEGFA, VEGFC, PlGF, Ang-1, Ang-2 as well as the receptors VEGF3 
and Tie-1 and Tie-2 (44, 104). Despite the presence of angiogenic factors in stroma and 
epithelium in the endometrium, there may also be a role for uNK cells in mediating this 
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process. It is notable that uNK cells form aggregats around spiral arteries and glands in the 
late secretory endometrium and decidua (25). Furthermore, cytokine secretion is an 
important feature of uNK function and secretion of angiogenic factors VEGFC, PLGF, and 
Ang-2 has been described (39, 44). In addition, an increased capacity for network formation 
by HUVEC (Human umbilical vein endothelial cells) i seen following co-culture with uNK 
but not pbNK cells (39) suggesting a specific role f the uNK cell subset in regulating 
angiogenesis in the uterus. The functional impact of uNK cells may also be maturation 
dependent, as VEGFC secretion by uNK cells decreases with gestational age during 
pregnancy (43). Characterisation of uNK cell cytokine secretion has largely been undertaken 
in isolated populations and it is interesting that contrary to reports suggesting VEGFC and 
Ang2 was expressed by uNK cels, laser capture microscopy dissection of uNK cells from 
sections of decidual tissue resulted in detection of mRNAs encoding VEGFA but not Ang2 
in uNK cells in situ (518) suggesting cytokine secretion by uNK cells may be modified by 
the tissue environment. This is further demonstrated by reduced angiogenic growth factor 
secretion in uNK cells in contact with trophoblast (42) suggesting that the pro-angiogenic 
function of uNK cells may be modified following implantation. Factors controlling this 
process are unknown, however, it is notable that uNK cell density is positively correlated 
with endometrial angiogenesis in women with recurrent r productive failure (51). Stromal 
derived factors which may influence uNK cell-mediated angiogenesis include IL-15, which 
increases VEGFC secretion in uNK cells (44); transcription of VEGFA mRNA can be 
mediated by oestrogen via either ERα or ERβ in many cell types (104). 
5.1.3. Summary 
In summary, there is evidence that a range of signall ng factors and cytokines produced 
within endometrial tissue can contribute to recruitment/differentiation of immune cell 
populations and formation and function of the vascular compartment. Studies detailed in 
Chapters 3 and 4 of this thesis have reported novel findings demonstrating biosynthesis of 
oestrogens by human endometrial stromal cells in response to decidualisation and suggested 
this may in turn provide a previously unrecognised timulus to alter gene expression in ERβ-
positive uNK cells. Experiments described in the current chapter expand on these findings 
and describe complementary studies on the interplay between oestrogen-dependent 
interactions between the stromal, immune and vasculr cell types that comprise the stromal 
compartment.  
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To extend studies reported in Chapter 4, where Ingenuity pathway analysis revealed that 
treatment of uNK cells with E2 altered expression of genes encoding proteins associated 
with actin cytoskeleton signalling and motility (Dr Elaine Marshall personal 
communication), impacts of E2 on migration and chemotaxis of uNK cells were 
investigated.   
5.2. Aims 
1. To investigate the impact of oestrogen on migration of uNK cells 
2. To investigate the impact of the stromal environment on chemotaxis of uNK cells 
3. Investigate the impact of oestrogen treatment on the secretion of angiogenic factors 
by uNK cells and their impact on human endometrial endothelial cells 
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5.3.1. Isolation of uNK cells 
Primary human uterine NK cells were isolated from human first trimester decidua as detailed 
in Chapter 4 (sections 4.3.1 to 4.3.4). Following their isolation, uNK cells were immune-
phenotyped using FACS and both purity and viability was confirmed (see 4.4.2). 
 Research # Tissue # Lab # Date GESTATION 
Sample 1¥§ 7762 554 CD1040D 10/05/11 <8 wks 
Sample 2 7644 385 CD774D 21/04/10 8 wks 1 day 
Sample 3 7633 380 CD763D 25/03/10 8 wks 4 days 
Sample 4§ 5721 703 CT1205D 12/09/11 8 wks 6 days 
Sample 5* 5696 446 CD480D 07/04/11 9 wks 
Sample 6* 7648 387 CD778D 22/04/10 9 wks 2 days 
Sample 7* 5650 417 CD722D 08/04/10 9 wks 5 days 
Sample 8* 7663 397 CD731D 14/06/10 9 wks 6 days 
Sample 9*¥§ 7721 545 CD999D 13/12/10 9 wks 6 days 
Sample 10* 7640 383 CD770D 08/04/10 10 wks 1 day 
Sample 11 6415 524 CD713D 04/03/10 10 wks 5 days 
Sample 12 6418 527 CD716D 08/03/10 10 wks 5 days 
Sample 13¥ 7688 537 CD966D 28/09/10 10 wks 5 days 
Sample 14 6413 523 CD798D 01/03/10 11 wks 2 days 
Sample 15 7647 386 CD777D 22/01/10 11 wks 2 days 
Sample 16 7642 384 CD772D 15/04/10 11 wks 2 days 
Sample 17 6417 526 CD715D 08/03/10 11 wks 5 days 
Sample 18 7652 390 CD782D 04/05/10 11 wks 5 days 
Table 5.1. Decidual samples from which uNK cells were isolated for treatment. Gestation in 
weeks (wks) and days based on ultrasound scan and date of last menstrual period. uNK cell 
samples that were pooled for experiment 5.4.3. are indicated by *. Samples that were used 
for RNA analysed on motility array (¥, n=3) and angiogenesis array (§, n=3) are also 
highlighted. 
 
5.3.2. Primary human endometrial stromal cells 
Primary human endometrial stromal cells (hESC) were isolated from biopsies of healthy 
endometrium as detailed in section 2.3.1. Cells were s eded in 6 well plates at a density of 
2x105 cells per well and treated as detailed in Chapter 3, Section 3.3.1. 
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5.3.3. RNA extraction and Taqman Q-RT PCR 
Extraction of RNA from cell extracts was performed using RNAeasy® mini kit (Qiagen, 
Crawley, UK) as previously described (full method see section 3.3.4). RNA samples were 
standardised to concentration of 100ng/µL prior to cDNA preparation. Reverse transcription 
of RNA to form a single strand of complementary DNA (cDNA) was carried out using the 
SuperScript VILO cDNA synthesis kit (InVitrogen) according to the manufacturer’s 
instructions (Section 3.3.6). 
5.3.4. RT2 PCR profiler arrays 
The RT2 profiler PCR arrays (SABiosciences, Frederick, MD, USA) are designed to analyse 
a panel of genes related to a specific biological function. This platform combines the 
performance of real time PCR with the multi gene profiling capabilities of a microarray. 
Each array contains a panel of 96 primer sets for a set of 84 functionally focussed genes, 
together with five housekeeping genes and three RNA and PCR quality controls. 
RNA samples from uNK cells treated +/- E2 were isolated as previously described (Section 
2.3.3) and retrotranscribed using RT2 single strand cDNA synthesis kit. Samples from 3 sets 
of treated uNK cells were analysed for differential gene expression following E2 treatment 
(Table 5.1). RNA samples were converted to first strand cDNA using the RT2 first strand kit 
(SABiosciences, Frederick, MD, USA). Briefly, 300ng/ml RNA was mixed with 1x genomic 
DNA elimination mixture and made up to final volume of 10 µL with nuclease-free H2O per 
sample. SYBR green dye binds with all types of double stranded DNA, therefore complete 
removal of genomic DNA is essential for accurate expr ssion data. The contents were mixed 
and briefly centrifuged before being incubated at 42oC for 5 minutes, then cooled on ice for 
at least 1 minute. The RT cocktail was prepared as follows for each reaction: 
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RT Cocktail x1 rxn x6 rxn 
BC3 (5x RT Buffer 3) 4 µL 24 µL 
P2 (Primer & External control Mix) 1 µL 6 µL 
RE3 (RT Enzyme Mix 3) 2 µL 12 µL 
H2O 3 µL 18 µL 
Final Volume 10 µL 60 µL 
Table 5.2. RT cocktail mixture for cDNA synthesis 
10 µL of RT cocktail was added to each treated RNA sample and mixed by pipette. The 
samples were then incubated for 15 minutes at 42oC and the reaction was then stopped by 
heating to 92oC for 5 minutes. 20 µL of cDNA synthesis mix was diluted by addition of 91
µL of H2O and samples held on ice or stored at -20
oC until RT PCR was performed. Frozen 
samples were thawed on ice immediately prior to use. Th  RT PCR reaction mixture was as 
follows: 
Reagent Volume 
2X SABiosciences RT2 qPCR Master Mix 1350 µL 
Diluted first strand cDNA synthesis reaction 102 µL 
H2O 1248 µL 
Total Volume 2700 µL 
Table 5.3. RT PCR reaction mixture for each 96 well array plate. 
25 µL of the experimental mixture was added to each well of the 96 well array plate using a 
multi-channel pipette to minimise intra-well variability. Following addition of samples, 
plates were sealed and held on ice until use. Prior to RT PCR plates were centrifuged for 1 
minute at room temperature at 1000 g to remove bubbles. Real time PCR amplification was 
performed using the Applied Biosystems® 7900HT Fast Real-Time PCR System PCR using 
RT2 Real-Timer SyBR Green/ROX PCR Mix kit according to manufacturer’s instructions. 
Using an ABI 7900HT the following two-step cycling program was set up: 
Cycles Duration Temperature 
1 10 minutes 95oC 
15 seconds 95oC 40 
1 minute 60oC 
Table 5.4. Thermal cycling program for PCR amplification. 
SABiosciences RT2 SYBR Green Master Mix utilises Hot-start Taq DNA polymerase, which 
prevents polymerase activity before heat activation and thereby reducing amplification of 
non-specific PCR products. SYBR green fluorescence was detected and recorded during the 
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annealing step in each cycle and the threshold Ct for each well was calculated. As an 
additional quality control, a melt curve program was run after every cycling program for 
each array plate. A first derivative dissociation curve for each well was recorded and 
checked for single peaks at temperatures greater than 80oC. Wells which did not meet these 
criteria were excluded from analysis. 
PCR array data analysis was performed using the SABiosciences web portal 
(http://www.SABiosciences.com/pcrarrayanalysis.php). Data analysis was performed using 
the ∆∆Ct method (Section 2.10.3). 
5.3.5. Human cell motility array 
The Human cell motility RT2 profiler PCR array (SABiosciences, Frederick, MD, USA) 
profiles the expression of 84 genes involved in modulating the movement of cells. The array 
includes growth factors and receptors important for chemotaxis, genes involved in Rho 
family signalling and adhesion, and genes encoding components of various cellular 
projections. The gene list is shown below (Table 5.5), responses for each functional grouping 
for all genes can be found in the appendix and relevant responses are detailed in the 
appropriate results section. 
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REF Symbol Description 
A01 ACTN1 Actinin, alpha 1 
A02 ACTN3 Actinin, alpha 3 
A03 ACTN4 Actinin, alpha 4 
A04 ACTR2 ARP2 actin-related protein 2 homolog (yeast) 
A05 ACTR3 ARP3 actin-related protein 3 homolog (yeast) 
A06 AKT1 V-akt murine thymoma viral oncogene homolog 1 
A07 ARF6 ADP-ribosylation factor 6 
A08 ARHGDIA Rho GDP dissociation inhibitor (GDI) alpha 
A09 ARHGEF7 Rho guanine nucleotide exchange factor (GEF) 7 
A10 BAIAP2 BAI1-associated protein 2 
A11 BCAR1 Breast cancer anti-estrogen resistance 1 
A12 CAPN1 Calpain 1, (mu/I) large subunit 
B01 CAPN2 Calpain 2, (m/II) large subunit 
B02 CAV1 Caveolin 1, caveolae protein, 22kDa 
B03 CDC42 Cell division cycle 42 (GTP binding protein, 25kDa) 
B04 CFL1 Cofilin 1 (non-muscle) 
B05 CRK V-crk sarcoma virus CT10 oncogene homolog (avian) 
B06 CSF1 Colony stimulating factor 1 (macrophage) 
B07 CTTN Cortactin 
B08 DIAPH1 Diaphanous homolog 1 (Drosophila) 
B09 DPP4 Dipeptidyl-peptidase 4 
B10 EGF Epidermal growth factor 
B11 EGFR Epidermal growth factor receptor 
B12 ENAH Enabled homolog (Drosophila) 
C01 EZR Ezrin 
C02 FAP Fibroblast activation protein, alpha 
C03 FGF2 Fibroblast growth factor 2 (basic) 
C04 HGF Hepatocyte growth factor (hepapoietin A; scatter factor) 
C05 IGF1 Insulin-like growth factor 1 (somatomedin C) 
C06 IGF1R Insulin-like growth factor 1 receptor 
C07 ILK Integrin-linked kinase 
C08 ITGA4 Integrin, alpha 4  
C09 ITGB1 Integrin, beta 1 (fibronectin receptor, beta polypeptide,) 
C10 ITGB2 Integrin, beta 2  
C11 ITGB3 Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 
C12 LIMK1 LIM domain kinase 1 
D01 MAPK1 Mitogen-activated protein kinase 1 
D02 MET Met proto-oncogene (hepatocyte growth factor receptor) 
D03 MMP14 Matrix metallopeptidase 14 (membrane-inserted) 
D04 MMP2 Matrix metallopeptidase 2  
D05 MMP9 Matrix metallopeptidase 9 
D06 MSN Moesin 
D07 MYH10 Myosin, heavy chain 10, non-muscle 
D08 MYH9 Myosin, heavy chain 9, non-muscle 
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D09 MYL9 Myosin, light chain 9, regulatory 
D10 MYLK Myosin light chain kinase 
D11 PAK1 P21 protein (Cdc42/Rac)-activated kinase 1 
D12 PAK4 P21 protein (Cdc42/Rac)-activated kinase 4 
E01 PFN1 Profilin 1 
E02 PIK3CA Phosphoinositide-3-kinase, catalytic, alph  polypeptide 
E03 PLAUR Plasminogen activator, urokinase receptor 
E04 PLCG1 Phospholipase C, gamma 1 
E05 PLD1 Phospholipase D1, phosphatidylcholine-specific 
E06 PRKCA Protein kinase C, alpha 
E07 PTEN Phosphatase and tensin homolog 
E08 PTK2 PTK2 protein tyrosine kinase 2 
E09 PTK2B PTK2B protein tyrosine kinase 2 beta 
E10 PTPN1 Protein tyrosine phosphatase, non-receptor type 1 
E11 PXN Paxillin 
E12 RAC1 Ras-related C3 botulinum toxin substrate 1  
F01 RAC2 Ras-related C3 botulinum toxin substrate 2  
F02 RASA1 RAS p21 protein activator (GTPase activating protein) 1 
F03 RDX Radixin 
F04 RHO Rhodopsin 
F05 RHOA Ras homolog gene family, member A 
F06 RHOB Ras homolog gene family, member B 
F07 RHOC Ras homolog gene family, member C 
F08 RND3 Rho family GTPase 3 
F09 ROCK1 Rho-associated, coiled-coil containing protein kinase 1 
F10 SH3PXD2A SH3 and PX domains 2A 
F11 SRC V-src sarcoma viral oncogene homolog (avian) 
F12 STAT3 Signal transducer and activator of transcription 3  
G01 SVIL Supervillin 
G02 TGFB1 Transforming growth factor, beta 1 
G03 TIMP2 TIMP metallopeptidase inhibitor 2 
G04 TLN1 Talin 1 
G05 VASP Vasodilator-stimulated phosphoprotein 
G06 VCL Vinculin 
G07 VEGFA Vascular endothelial growth factor A 
G08 VIM Vimentin 
G09 WASF1 WAS protein family, member 1 
G10 WASF2 WAS protein family, member 2 
G11 WASL Wiskott-Aldrich syndrome-like 
G12 WIPF1 WAS/WASL interacting protein family, member 1 
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Table 5.5. Table detailing the 84 genes which were investigated in the cell motility array. The 
position on the plate (REF) corresponds to reported intensities on the heat map. 
5.3.6. Human angiogenesis array 
The human angiogenesis RT2 profiler PCR array (SABiosciences, Frederick, MD, USA) 
profiles the expression of 84 genes involved in modulating angiogenesis. The array includes 
growth factors and their receptors, chemokines and cytokines, matrix and adhesion 
molecules, proteases and their inhibitors and transcription factors, all of which are involved 
in the development of new blood vessels. The gene list is shown below (Table 5.6), 
responses for each functional grouping for all genes can be found in the appendix and 
relevant responses are detailed in the appropriate results section.  
Chapter 5. Modulation of uNK function and angiogenesis during decidualisation: 





REF Symbol Description 
A01 AKT1 V-akt murine thymoma viral oncogene homolog 1 
A02 ANGPT1 Angiopoietin 1 
A03 ANGPT2 Angiopoietin 2 
A04 ANGPTL3 Angiopoietin-like 3 
A05 ANGPTL4 Angiopoietin-like 4 
A06 ANPEP Alanyl (membrane) aminopeptidase 
A07 BAI1 Brain-specific angiogenesis inhibitor 1 
A08 CCL11 Chemokine (C-C motif) ligand 11 
A09 CCL2 Chemokine (C-C motif) ligand 2 
A10 CDH5 Cadherin 5, type 2 (vascular endothelium) 
A11 COL18A1 Collagen, type XVIII, alpha 1 
A12 COL4A3 Collagen, type IV, alpha 3 (Goodpasture antigen) 
B01 CXCL1 Chemokine (C-X-C motif) ligand 1  
B02 CXCL10 Chemokine (C-X-C motif) ligand 10 
B03 CXCL3 Chemokine (C-X-C motif) ligand 3 
B04 CXCL5 Chemokine (C-X-C motif) ligand 5 
B05 CXCL6 Chemokine (C-X-C motif) ligand 6  
B06 CXCL9 Chemokine (C-X-C motif) ligand 9 
B07 TYMP Thymidine phosphorylase 
B08 S1PR1 Sphingosine-1-phosphate receptor 1 
B09 EFNA1 Ephrin-A1 
B10 EFNA3 Ephrin-A3 
B11 EFNB2 Ephrin-B2 
B12 EGF Epidermal growth factor 
C01 ENG Endoglin 
C02 EPHB4 EPH receptor B4 
C03 EREG Epiregulin 
C04 FGF1 Fibroblast growth factor 1 (acidic) 
C05 FGF2 Fibroblast growth factor 2 (basic) 
C06 FGFR3 Fibroblast growth factor receptor 3 
C07 FIGF C-fos induced growth factor (vascular endothelial growth factor D) 
C08 FLT1 
Fms-related tyrosine kinase 1 (vascular endothelial growth 
factor/vascular permeability factor receptor) 
C09 HAND2 Heart and neural crest derivatives expressed 2 
C10 HGF Hepatocyte growth factor (hepapoietin A; scatter factor) 
C11 HIF1A Hypoxia inducible factor 1, alpha subunit  
C12 HPSE Heparanase 
D01 ID1 Inhibitor of DNA binding 1 
D02 ID3 Inhibitor of DNA binding 3 
D03 IFNA1 Interferon, alpha 1 
D04 IFNB1 Interferon, beta 1, fibroblast 
D05 IFNG Interferon, gamma 
D06 IGF1 Insulin-like growth factor 1 (somatomedin C) 
D07 IL1B Interleukin 1, beta 
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D08 IL6 Interleukin 6 (interferon, beta 2) 
D09 IL8 Interleukin 8 
D10 ITGAV Integrin, alpha V 
D11 ITGB3 Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 
D12 JAG1 Jagged 1 
E01 KDR Kinase insert domain receptor  
E02 LAMA5 Laminin, alpha 5 
E03 LECT1 Leukocyte cell derived chemotaxin 1 
E04 LEP Leptin 
E05 MDK Midkine (neurite growth-promoting factor 2)
E06 MMP2 Matrix metallopeptidase 2  
E07 MMP9 Matrix metallopeptidase 9  
E08 NOTCH4 Notch 4 
E09 NRP1 Neuropilin 1 
E10 NRP2 Neuropilin 2 
E11 PDGFA Platelet-derived growth factor alpha polyeptide 
E12 PECAM1 Platelet/endothelial cell adhesion molecul  
F01 PF4 Platelet factor 4 
F02 PGF Placental growth factor 
F03 PLAU Plasminogen activator, urokinase 
F04 PLG Plasminogen 
F05 PLXDC1 Plexin domain containing 1 
F06 PROK2 Prokineticin 2 
F07 PTGS1 Prostaglandin-endoperoxide synthase 1  
F08 SERPINF1 Serpin peptidase inhibitor, clade F  
F09 SPHK1 Sphingosine kinase 1 
F10 STAB1 Stabilin 1 
F11 TEK TEK tyrosine kinase, endothelial 
F12 TGFA Transforming growth factor, alpha 
G01 TGFB1 Transforming growth factor, beta 1 
G02 TGFB2 Transforming growth factor, beta 2 
G03 TGFBR1 Transforming growth factor, beta receptor 1 
G04 THBS1 Thrombospondin 1 
G05 THBS2 Thrombospondin 2 
G06 TIMP1 TIMP metallopeptidase inhibitor 1 
G07 TIMP2 TIMP metallopeptidase inhibitor 2 
G08 TIMP3 TIMP metallopeptidase inhibitor 3 
G09 TNF Tumor necrosis factor 
G10 TNFAIP2 Tumor necrosis factor, alpha-induced protein 2 
G11 VEGFA Vascular endothelial growth factor A 
G12 VEGFC Vascular endothelial growth factor C 
Table 5.6. Table detailing the 84 genes which were investigated in the angiogenesis array. 
The position on the plate (REF) corresponds to reported intensities on the heat map. 
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5.3.7. Migration assay 
Migration of uNK cells was assessed using modified transwell migration assay. Isolated 
uNK cells were suspended in culture media; RPMI 1640 phenol red free media (Sigma) 
supplemented with 10% charcoal stripped foetal calf serum, 1% L-Glutamin and 1% 
Penicillin/Streptomycin, at a density of 1x106 cells/ml. Cells were treated with vehicle 
control, 10-8M E2, 10-6M ICI or combination of E2 and ICI for 1 hour prior to assay. 
Following treatment, cells were pelleted and resuspended in culture media prior to migration 
assay. A 1.6mg/ml collagen gel was prepared with 3mg/ml bovine collagen I 
(GIBCO/Invitrogen, A10644-01), 10x MEM (Sigma, M-0275) and 7.5% NaHCO3 (Sigma, 
S8761) and 200 µL of the gel was pipetted onto the bottom of the well in a 24 well plate and 
placed in the incubator (37oC, 5% CO2) for 30 minutes to allow for gelation of the collagen 
matrix. The collagen gel was considered a neutral surface that would allow adherence of 
uNK cells without acting as a chemoattractant and was prepared as described immediately 
prior to migration assay. 800µL of serum free RPMI 1640 phenol red free media wasadded 
to the well on top of the collagen matrix. Cell culture inserts with 5µm membrane pore 
(Costar/Corning, 3421, NY, USA) were then placed into the well into which 200µL of uNK 
suspension was added. Cells were treated in duplicate. Cells were left in the incubator to 
migrate for 1 hour. Following migration cell culture inserts were removed and cells in lower 
chamber were counted. Migrated cells were counted by imaging 8 random fields using 
Axiovert 200 Inverted Fluorescent Microscope (Zeiss) and mean number of migrated cells 
was calculated for each treatment.  
5.3.8. Chemotaxis assay 
The chemotaxis of uNK cells was assessed using Ibidi µ-Slide Chemotaxis3D chamber slides 
(Ibidi, 80326, supplied by Thistle Scientific Ltd, Uddingston, UK). Isolated uNK cells were 
suspended in a collagen matrix and the response to different chemotaxis stimuli was 
measured using time lapse microscopy and recorded using Axiovert 200 Inverted 
Fluorescent Microscope (Zeiss, see Figure 5.1.) 
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Figure 5.1. Schematic diagram of cells in 3D matrix subject to chemotaxis gradient (+/-). 
Cells can be viewed using inverted microscope. 
Isolated uNK cells were suspended in RPMI 1640 phenol red free media (R7509, Sigma, 
Dorset, UK) supplemented with 10% charcoal stripped foetal calf serum, 1% L-Glutamin 
and 1% Penicillin/Streptomycin at a density of 3x109 cells/ml. A 1.6mg/ml collagen gel was 
prepared with 5 mg/ml bovine collagen I (Gibco, A10644-01, supplied by Invitrogen, 
Paisley, UK), 10x MEM (M-0275, Sigma, Dorset, UK) and 7.5% NaHCO3 (S8761, Sigma, 
Dorset, UK) and mixed carefully with the uNK cell suspension avoiding air bubbles during 
mixing. The collagen gel cell suspension was then filled into the middle chamber of the µ-
Slide and placed in the incubator (37oC, 5% CO2) for 30 minutes to allow for gelation of the 
collagen matrix. Three chambers were seeded and two controls were set up; -/- containing 
chemoattractant free media in both reservoirs and +/+ containing chemoattractant media in 
both reservoirs to account for influence of random migration (chemokinesis.) Finally a 
chamber with chemoattractant free media in one reservoir and chemoattractant media in the 
other (+/-) was set up which formed a chemotaxis gradient across the chamber. 
Chemoattractant free media was conditioned media recovered from undecidualised 
endometrial stromal cells (stromal conditioned media). Chemoattractant media was media 
recovered from decidualised stromal cells (decidual conditioned media). 
Cells were imaged every 5 minutes for 4 hours using Axiovert 200 Inverted Fluorescent 
Microscope from Zeiss and image stacks analysed using ImageJ (NIH.gov) and the manual 
tracking plug-in (http://rsbweb.nih.gov/ij/plugins/track/track.html). Results were analysed 
using Ibidi Chemotaxis and Migration tool software. 
5.3.9. Angiogenesis assay 
Isolated uNK cells were cultured at a density of 1x106 cells per/ml for cell treatment in 
phenol red-free RPMI 1640 medium (Sigma, Cat. No. R7509) supplemented with 10% 
CSFCS, 1% Penicillin/Streptomycin (Sigma, Cat. No. P-4333), 1% L-glutamine (Sigma, Cat. 
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No. G-7513), and 0.5% fungizone (Invitrogen, Cat. No 15290-018). Cells were cultured for 
24 hours at 37oC under 5% CO2 in air. Cells were treated with 10
-8M E2, 10-6M ICI or 
combination of E2 and ICI for 24 hours. Following treatment, cells were pelleted and the 
supernatant, uNK conditioned media (uNK CM), was stored at -80oC until assay. uNK cell 
CM was thawed immediately prior to assay and warmed to 37oC. 
Telomerase immortalised human endometrial endothelial cells (HEEC, Gift from Dr. 
Graciela Krikun, Department of Obstetrics, Gynecology and Reproductive Science, Yale 
University, New Haven, CT, USA) (466) were plated at a density of 25,000 per transwell 
insert (inserted into 24 well plates) which had been coated with growth factor reduced 
matrigel (BD Biosciences, Oxford, UK) and allowed to solidify prior to cell plating. uNK 
cell CM was added to the bottom chambers and cells incubated overnight at 37ºC with 5% 
CO2.  Each treatment was set up in duplicate. After 16 hours incubation HEECs were fixed 
with ice cold methanol for 20 minutes and then stained with hematoxylin. The formation of 
networks was visualised using Axiovert 200 Inverted Fluorescent Microscope (Carl Zeiss, 
UK). Three fields of vision were captured at 5x magnification for each well. Network 
formation was quantified using ImageJ (NIH.gov) and verified by counting branch points. 
5.3.10. Statistical Analysis 
Statistical analysis was performed using GraphPad Prism (GraphPad Prism version 5.04 for 
Windows, GraphPad Software, La Jolla California USA, www.graphpad.com). The criterion 
for siginificance for all tests was set at p<0.05. 
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5.4.1. E2 treatment results in changes in expressio n of genes associated with 
cell motility. 
Results from studies detailed in chapter 4 suggested that treatment of uNK cells with E2 
altered expression of genes encoding proteins associ ted with actin cytoskeleton signalling 
and motility. Impacts of E2 on uNK expression of genes associated with cell motility were 
investigated using PCR arrays.   
The expression of 84 genes involved in modulating the movement of cells was investigated 
in response to E2 in uNK. The array includes growth factors and receptors important for 
chemotaxis, genes involved in Rho family signalling and adhesion, and genes encoding 
components of various cellular projections. 
E2 treatment appeared to result in down regulation of genes associated with cell motility. 
The expression of gene candidates was readily detected in uNK cells with >60% of genes 
having Ct<30. The overall expression response following E2 treatment of all array 
candidates is summarised in Figure 5.2 and 5.3. Of the 84 genes analysed, only one gene was 
found not to be expressed (ENAH; Figure 5.2, grey box) and only three genes appeared to be 
up regulated (Table 5.7; MYH10, ACTN3 and HGF). The sample set of 3 treated pairs of 
uNK cells that was analysed by the array was small and therefore it is not surprising that 
although trends were detected only two genes reached significance (Table 5.7; MSN, 
ITGB1). To provide further insight the data set was n rrowed to exclude results that were 
highly non-significant or exhibited low changes in expression in response to treatment. Fold 
change in response to E2 from this set is shown in Figure 5.3 and detailed in Table 5.7. 
Consistent with overall changes, the narrowed data set showed tendency for down-regulation 
of target genes in response to E2 with only a small number of up-regulated genes. Changes 
in fold regulation in response to E2 did not appear to be pronounced with only three genes 
with fold regulation greater than 2 or less than -2 (Table 5.7; EGFR, PIK3CA, HGF). When 
genes were grouped into functional gene groupings based on information supplied with the 
array product specification information (see Appendix), E2 appeared to regulate selected 
genes related to chemotaxis, growth factor receptor expression, Rho signalling, cell-cell 
adhesion, leukocyte adhesion and rolling, and cellular projections; filopodia and 
lamellipodia. However, E2 did not appear to have an impact on expression of genes 
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associated with stress fibers, membrane blebbing, invas ve projections, growth cones or cell 
polarity. Within gene groups of functional processes E2 regulated only selected genes while 
others appeared to be unchanged. For example, genesassociated with cell-cell adhesion were 
significantly down-regulated by E2 (ITGB1; p=0.04, MSN; p=0.015, n=3, Table 8.16) and 
non-significant trend suggesting decreased expression of EGFR as a result of E2 treatment (-
2.34 fold regulation). However, other genes associated with this process were unchanged; 
DPP4, EZR, ITGA4 and ITGB2. This was also true of genes associated with lamellipodia; 
EGFR1, PIK3CA, PLD1 and PXN showed no significant change in expression in response to 
E2 (despite negative fold change values), while DPP4, FAP, RDX, SVIL, and VCL were 
unchanged and ENAH was not detected. Interestingly, in contrast to previous findings from 
our group, actin related genes appeared unchanged by E2 (ACTN1, ACTN4, ACTR2 and 
ACTR3) with the exception of ACTN3 which was one of only three genes which to display 
positive fold change values in repsonse to E2 however the change in ACTN3 was not found 
to be significant.  
 
 
Figure 5.2. Heat map indicating gene expression of cell motility genes following E2 treatment 
of uNK. The expression of genes associated with cell motility was very high in uNK cells with 
>60% of genes having Ct<30 and there were low number of no calls. The impact of E2 
seemed to decrease expression of most genes in the array. 
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Figure 5.3. Fold change in gene expression of selected cell motility genes following E2 
treatment. Genes with low changes in expression or very high “P values” were excluded for 
simplicity. Most genes were down-regulated with treatment however HGF, MYH10 and 
ACTN3 were up-regulated. Control group is vehicle treated uNK cells and Group1 is E2 
treated uNK. 
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Symbol Fold Change 95% CI P value Fold Regulation 
EGFR 0.4266 ( 0.00001, 0.90 ) 0.213332 -2.3442 
PIK3CA 0.4694 ( 0.00001, 1.22 ) 0.382145 -2.1305 
BAIAP2 0.5305 ( 0.15, 0.91 ) 0.184226 -1.885 
ITGB3 0.5383 ( 0.08, 0.99 ) 0.173152 -1.8577 
PLD1 0.5736 ( 0.23, 0.91 ) 0.133215 -1.7435 
CAV1 0.6151 ( 0.00001, 1.52 ) 0.600257 -1.6257 
PLAUR 0.6339 ( 0.09, 1.18 ) 0.368307 -1.5776 
RND3 0.6377 ( 0.00001, 1.82 ) 0.533238 -1.5681 
PAK4 0.6552 ( 0.16, 1.15 ) 0.345822 -1.5262 
WASL 0.6639 ( 0.11, 1.22 ) 0.38761 -1.5063 
IGF1 0.6877 ( 0.01, 1.36 ) 0.554432 -1.454 
MMP2 0.7096 ( 0.15, 1.27 ) 0.40729 -1.4092 
PRKCA 0.7279 ( 0.31, 1.15 ) 0.380198 -1.3739 
VASP 0.7341 ( 0.18, 1.28 ) 0.431172 -1.3623 
SRC 0.7464 ( 0.17, 1.32 ) 0.514935 -1.3397 
PTK2 0.7481 ( 0.24, 1.26 ) 0.440942 -1.3366 
MSN 0.7708 ( 0.67, 0.87 ) 0.015217 -1.2974 
SH3PXD2A 0.7801 ( 0.50, 1.06 ) 0.276494 -1.282 
EGF 0.7889 ( 0.00001, 2.25 ) 0.366281 -1.2676 
PXN 0.8146 ( 0.53, 1.10 ) 0.341253 -1.2276 
TGFB1 0.8269 ( 0.01, 1.64 ) 0.686773 -1.2093 
ITGB1 0.8645 ( 0.78, 0.95 ) 0.042202 -1.1567 
MYH10 1.2596 ( 0.12, 2.40 ) 0.530781 1.2596 
ACTN3 1.3504 ( 0.20, 2.50 ) 0.379028 1.3504 
HGF 2.0782 ( 0.00001, 5.34 ) 0.462532 2.0782 
 
Table 5.7. Table detailing fold change in gene expression of selected cell motility genes 
following E2 treatment. Most genes were down-regulated with treatment however HGF, MY 
and ACTN3 were up-regulated. Values shown are differential responses following treatment. 
95% CI and P value are also shown. There was low significance in this small sample size. 
Chapter 5. Modulation of uNK function and angiogenesis during decidualisation: 





5.4.2. E2-treated uNK exhibit increased migration. 
Overall E2 appears to down regulate expression of genes associated with cell motility in 
uNK cells. In order to address whether the transcriptional changes observed could have a 
functional impact we investigated the impact of E2 on migration of uNK cells using a 
transwell migration assay. Interestingly, when uNK cells were treated with 10-8M E2 for 1 
hour an increase in cell migration was observed (Figure 5.5 A, n=4, p<0.001). This effect 
appears to be receptor mediated as incubation of cells with the ER antagonist ICI blocked the 
E2 effect (Figure 5.5 B n=2, p<0.05). 
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Figure 5.4. Isolated uNK cells pre-treated with E2 have increased migration. uNK cells were 
treated for 1 hour with 10-8M E2 and then subject to transwell migration assay for 1 hour. E2-
treated cells exhibit increased migration (A, n=4, p<0.001). This effect could be blocked by 
the oestrogen receptor antagonist ICI (B). 
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5.4.3. Impact of the stromal environment on chemota xis of uNK cells 
5.4.3.1. Primary uNK cells express factors associated with control of chemotaxis 
To investigate whether factors from the stromal enviro ment could influence motility of 
uNK cells and whether E2 could modulate such respones, expression of receptors to known 
chemotactic stimuli were investigated in uNK cells. Expression of mRNAs encoding 
receptors for SDF-1 (CXCR4) and IL-15 (IL-15RA) were investigated in uNK cells treated 
+/- E2 for 2 hours. CXCR4 was detected at low levels (average Ct≈35) in uNK cells however 
expression tended to be increased by E2 treatment (Figure 5.5 A). IL-15 receptor alpha (IL-
15RA) was readily detected (average Ct≈25) however expression was not affected by E2 
treatment (Figure 5.5 B). Immunohistochemistry revealed that CXCR4 is expressed in first 
trimester decidua (Figure 5.6; A, B) and is co-locaised to uNK cells confirming CXCR4 





















Figure 5.5. The expression of mRNAs encoding the IL-15 receptor α were unchanged (B) 
while E2 tended to increase mRNA expression of CXCR4 (A, p=0.1970) N=6. 
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Figure 5.6. CXCR4 is expressed throughout decidua and is colocalised to uNK cells. Positive 
immunoexpression of CXCR4 was detected in stromal and epithelial cells in fixed sections of 
first trimester decidua (A, B). Negative controls were conducted in the absence of primary 
antibody (C). Co-localisation of CXCR4 (D, green staining) with the surface marker CD56 (D, 
red staining) confirms CXCR4 expression in uNK cells. Scalebar equivalent to 50µm. 
 
5.4.3.2. Expression of factors associated with uNK chemotaxis is increased in decidualised 
ESC. 
Decidualisation is associated with an increase in the number of uNK cells with either 
migration or proliferation of existing uNK cell populations in the endometrium proposed as a 
mechanism to explain the increase. SDF-1 is a strong chemoattractant of lymphocytes 
including uNK cells and this factor may contribute to the recruitment and/or proliferation of 
uNK cells in the endometrium following decidualisaton. IL-15 is known to impact on the 
proliferation and differentiation of uNK cells and increased expression of IL-15 during 
decidualisation may also impact on uNK cell populations in the endometrium and contribute 
to the increased numbers in first trimester decidua. Following decidualisation there is a 
significant increase in both SDF-1 and IL-15 mRNAs in a time dependent manner (Figure 
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5.7). SDF-1 expression is increased early in decidualisation at 24 hours (Figure 5.7 A, n=4, 
p<0.05) and most notably at 2 days (Figure 5.7 A, n=4, P<0.001). In hESC treated to 
decidualise, the expression of mRNA encoding IL-15 is increased after 2 days (Figure 5.7 B, 
n=4, p<0.001) and to lesser extent is also increased fter 4 and 8 days compared to non-















































































Figure 5.7. Expression of mRNAs encoding SDF-1 (A) and IL-15 (B) are significantly 
increased in response to decidualisation. SDF-1 expression is increased early in 
decidualisation at 24 hours (n=4, p<0.05) and most notably at 2 days (n=4, P<0.001). In 
decidualised ESC IL-15 is greatly increased after 2 days (n=4, p<0.001), with 8 fold increase 
in expression. IL-15 is also increased after 4 and 8 days decidualisation (n=4, p<0.001 and 
p<0.05 respectively). 
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5.4.3.3. uNK cells show positive chemoattraction to decidualised conditioned media. 
As expression of SDF-1 and IL-15 by endometrial stromal cells is increased in response to a 
decidualisation stimulus and uNK cells expressed both receptors for IL15 and SDF-1 
(CXCR4) a chemotaxis assay was performed with media recovered from decidualised 
stromal cells which was used as a chemoattractant in chamber slide chemotaxis assay. Cells 
showed directed chemotaxis towards the decidualised con itioned media (DCM; Figure 5.8 
A) and but not to control media (stromal conditioned media; Figure 5.8 B). The centre of 
mass of uNK cells was (x, y; -33, -342) for DCM and (x, y; -8, 1) for control indicating 
directed chemotaxis towards DCM. uNK cells subject to +/- gradient travelled greater 
distance and at higher velocity than control cells and their movement was directed towards 
DCM (Figure 5.9). 
 
 
Figure 5.8. Chemotaxis of uNK cells is directed towards decidualised conditioned media 
(DCM) but not control (stromal conditioned) media over 4 hours at 37oC 95% CO2. A. 
Following tracking of cell movement of 34 cells; 30 marked left (DCM) and 4 tracked right 
(control media). B. No directed movement of uNK cells was detected in the absence of DCM. 
44 cells were counted of which 37 marked left and 7 marked right in the absence of DCM. 
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Figure 5.9. Representative values comparing measurements of cell movement in chemotaxis 
assay for control (-/-) and with a positive gradient to decidualised conditioned media (DCM; 
+/-). A. The average accumulated distance. B. The average Euclidean distance (direct 
distance between point of origin and end point). C.  The average velocity of uNK cells. D. 
The distance from origin of the average end point of cells (centre of mass). Each of the 
measured values for uNK cells under +/- gradient were higher than in control cells indicating 
uNK cells were directed towards DCM. (Control; n=44 cells, DCM; n=34 cells. *** p<0.001) 
5.4.4. Impact of the stromal environment on angioge nesis 
Decidualisation of the endometrium is associated with an increase in angiogenesis. 
Decidualisation of stromal cells begins in cells proximal to endometrial spiral arteries and 
thus factors released from stromal cells at this time may influence angiogenesis. Increased 
expression of angiogenic factors in the endometrium d ring decidualisation is important for 
vascular remodelling that takes in preparation for the establishment of pregnancy. Studies in 
this thesis have revealed that E2 is secreted by stromal cells during decidualisation which 
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may be important as E2 is known to stimulate VEGF expr ssion; however, it is unknown 
what effect locally produced E2 may have on angiogenesis. Furthermore, uNK cells 
accumulate in the endometrial stroma in perivascular sites around the time of decidualisation 
and are known to secrete angiogenic factors.  
To investigate the impact of the stromal environment o  angiogenesis, the expression of 
angiogenic factors in decidualised ESC was investigated and the impact of locally produced 
E2 as a modulator of uNK cell angiogenic function was assessed. 
5.4.4.1. Expression of angiogenic factors is increased in decidualised ESC. 
Following decidualisation there was an increase in xpression of mRNAs encoding VEGFA 
(Figure 5.10 A, n=4, p<0.001), ADM (Figure 5.10 B, n=4, p<0.001) and angiopoeitin 2 
(ANGPT2, also Ang-2) (Figure 5.10 C, n=4, p<0.05) compared to non-decidualised controls. 
Angiopoeitin 4 (ANGPT4, also Ang-4) was decreased following decidualisation (Figure 5.10 
D, n=4, p=0.001).  
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Figure 5.10. Expression of mRNAs encoding VEGF, ADM, ANGPT2 and ANGPT4 in 
response to decidualisation. VEGF (n=4, p<0.001), ADM (n=4, p<0.001) and ANGPT2 (n=4, 
p<0.05) are increased after 8 days decidualisation. ANGPT4 is decreased after 8 days 
decidualisation (n=4, p=0.001). 
5.4.4.2. E2 treatment in uNK cells results in changes in expression of genes associated with 
angiogenesis. 
To investigate whether locally produced E2 could impact on the expression of angiogenic 
factors in uNK cells, the differential response to 2 hours E2 treatment was assessed by PCR 
array. The expression of 84 genes involved in modulating angiogenesis was investigated.  
The array includes growth factors and their receptors, chemokines and cytokines, matrix and 
adhesion molecules, proteases and their inhibitors and transcription factors, all of which have 
the potential to be involved in the development of new blood vessels. In contrast to the cell 
motility array analysis (Section 5.4.1) expression of many targets in the angiogenesis array 
were not detected. Approximately 25% of genes were d t rmined as ‘no calls’ (Ct>35) and 
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only ~18% of genes were expressed at Ct<30. However, incubation of cells with E2 seemed 
to have a wide ranging impact on expression of the genes that were detected. The overall 
expression response of all array candidates is summarised in Figure 5.12. Of the 84 genes 
analysed, twenty not detected (Figure 5.11, grey boxes), 18 tended to be up-regulated (Figure 
5.11, red boxes), 40 tended to be down-regulated (Figure 5.11, green boxes) and 6 were 
unchanged (Figure 5.11, black boxes).  
 
Figure 5.11. Heat map indicating gene expression of angiogenesis genes following E2 
treatment of uNK. The expression of genes associated with angiogenesis was appears to be 
tightly regulated with expression of many targets not detected (grey boxes). The impact of 
E2 seemed to have wide ranging impact on the genes that were detected.  
Despite the small sample size significant decreases in expression following E2 treatment 
were observed for THBS1, AKT1, TGFB1 and IL1B mRNAs (Table 5.8). There was also a 
wide dynamic range in changes in expression following E2 treatment (Figure 5.12 and Table 
5.8) from -3.8 (THBS1) to 4.4 (IFNG) fold regulation. The data set was narrowed to exclude 
results from genes that had very high P values or low changes in expression and fold change 
in response to E2 from this set is shown in Figure 5.12 and detailed in Table 5.8. Incubation 
of cells with E2 tended to mostly decrease expression of candidate genes however there were 
several genes which appeared to be up-regulated.  
5.4.4.2.1. Gene expression responses in functional groups 
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When genes were arranged into functional gene groupings based on array product 
specification information (See Appendix section 8.1), E2 treatment tended to decrease the 
expression of angiogenic growth factors such as ANPEP, EREG, FIGF. Interestingly, PGF 
and VEGFC were not detected while VEGFA was unchanged following treatment. Other 
growth factors such as TGFB1 were significantly decreased (p=0.028122, n=3) while 
TFGBR1 and EFNA3 tended to be decreased with treatment. The functional group which 
showed greatest regulation by E2 was cytokines and chemokines associated with 
angiogenesis (Table 8.5). E2 significantly decreased th  expression of IL1B (p=0.037542, 
n=3) and tended to decrease expression of CXCL1, CXCL3, and IL6. However, E2 tended to 
increase expression of CCL2, CXCL10, CXCL9 and IFNG, while CCL11, CXCL6, IFNA1 
and IFNB1 were not detected. Adhesion molecules were largely undetected, but THBS1 was 
significantly down-regulated in response to E2 (p=0.02 214, n=3) while IL-8, ITGAV and 
S1PR1 also tended to be decreased with treatment. The expression of ANGPTL3, NAI3, 
COL4A3, LAMA5, STAB1, CCL11, CDH5 COL18A1, ITGB3, and THBS2 could not be 
detected. However, CCL2 tended to be increased by E2 and is also associated with adhesion 
(Table 8.7). The proteases MMP2 and MMP9 tended to be increased by E2 treatment and the 
expression of the metalloproteinase inhibitor TIMP1 also tended to be increased. LECT1, 
LEP, PLG, and TIMP3 could not be detected. The transcriptional modulator AKT1 was 
significantly decreased by E2, and ID3, HAND2 and SPHK1 tended to be decreased by 
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Figure 5.12. Fold change in gene expression of selected angiogenesis genes following E2 
treatment. Genes with low changes in expression or very high P values were excluded for 
simplicity. Differential expression following E2 treatment resulted wide range of responses in 
target genes. Control group is vehicle treated uNK and Group1 is E2 treated uNK. 
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 Fold Change 95% CI P value Fold Regulation 
THBS1 0.2646 ( 0.00001, 0.60 ) 0.020214 -3.7791 
EFNA3 0.2864 ( 0.00001, 0.78 ) 0.12797 -3.4912 
ANPEP 0.3043 ( 0.00001, 0.68 ) 0.122483 -3.2859 
CXCL1 0.3165 ( 0.00001, 0.76 ) 0.196089 -3.1599 
AKT1 0.3462 ( 0.21, 0.48 ) 0.001286 -2.8884 
IL8 0.3514 ( 0.07, 0.64 ) 0.05618 -2.8458 
TGFB1 0.4245 ( 0.21, 0.64 ) 0.028122 -2.3557 
FIGF 0.4555 ( 0.00001, 1.48 ) 0.792319 -2.1955 
TGFBR1 0.506 ( 0.07, 0.94 ) 0.212099 -1.9761 
IL6 0.5666 ( 0.08, 1.06 ) 0.270708 -1.7651 
SPHK1 0.5803 ( 0.22, 0.94 ) 0.10907 -1.7233 
IL1B 0.5987 ( 0.35, 0.84 ) 0.037542 -1.6704 
ID3 0.6329 ( 0.20, 1.07 ) 0.262278 -1.58 
TNFAIP2 0.6329 ( 0.34, 0.93 ) 0.110976 -1.58 
ANGPT2 0.8914 ( 0.42, 1.36 ) 0.722491 -1.1218 
VEGFA 1.007 ( 0.10, 1.92 ) 0.756185 1.007 
MMP9 1.4272 ( 0.85, 2.00 ) 0.150482 1.4272 
PECAM1 1.7144 ( 0.42, 3.01 ) 0.29493 1.7144 
MMP2 1.7916 ( 0.88, 2.71 ) 0.066499 1.7916 
CXCL10 1.9562 ( 0.00001, 4.04 ) 0.446108 1.9562 
TIMP1 2.6924 ( 0.29, 5.10 ) 0.105164 2.6924 
CCL2 2.8044 ( 0.00001, 5.69 ) 0.128538 2.8044 
IFNG 4.4089 ( 0.00001, 10.88 ) 0.108815 4.4089 
Table 5.8. Table detailing fold change in gene expression in selected angiogenesis genes 
following E2 treatment displayed in Figure 5.11. E2 elicited wide ranging changes in 
expression. Values shown are differential responses following treatment. 95% CI and P 
value are also shown. There was low statistical significance in this small sample size.
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5.4.4.3. Human endometrial endothelial cells show increased network formation following 
culture with E2-treated uNK conditioned media. 
Studies in previous sections have revealed that decidualisation of endometrial stromal cells is 
associated with production of E2 and increased expression of angiogenic factors such as 
VEGF, ANGPT2 and ADM (section 5.4.4.1). In order to test whether increased angiogenesis 
during decidualisation may be mediated by E2-dependent changes in uNK cell function. In 
uNK cells treated with E2 there are changes in gene expression associated with angiogenesis. 
The impact of conditioned media from E2 treated uNK cells on angiogenesis was measured 
using immortalised human endometrial endothelial cel s (HEEC) using an angiogenesis 
assay (see section 2.6. for details.) Conditioned mia recovered from uNK cells that had 
been treated with 10-8M E2 for 24 hours increased network formation in HEEC compared to 
vehicle treated controls (Figure 5.13, n=4, p<0.05),  but this effect did not seem to be 
























Figure 5.13. Human endometrial endothelial cells show increased angiogenesis following 
culture with E2-treated uNK conditioned media. n=4, *p<0.05. 
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The functional changes that occur in the endometrium during decidualisation such as 
angiogenesis and leukocyte recruitment are essential to implantation and establishment of 
pregnancy but their control is poorly understood. As an extension of studies in Chapters 3 
and 4, we investigated the importance of the interplay between E2 and uNK cells in these 
processes. 
The studies presented herein describe a novel mechanism by which oestrogen modulates 
uNK function. Our investigation has shown for the first time that E2 enhances migration of 
isolated uNK cells, and that factors secreted from decidualised stromal cells, which may 
include SDF-1, IL-15 and E1/E2, stimulate directed chemotaxis of uNK cells. We have also 
shown that E2 stimulates the secretion of soluble factors from uNK cells which enhance 
angiogenesis of endometrial endothelial cells (HEECs). Gene expression analysis suggests 
that this may involve VEGFA, CCL2, and PECAM1 but frther studies are required to 
validate these observations. To the best of our knowledge, this study is the first description 
of a functional impact of modulation of uNK by E2. Together with our previous findings 
highlighting local production of E2 in the uterus we suggest a novel mechanism for local 
control of functional processes during differentiation of the endometrium that is mediated by 
E2 and cellular cross-talk between uNK, stromal and e othelial cells. 
It has been reported that E2 increases homing of pbNK cells to the uterus (74) but the impact 
of E2 on migration of isolated populations of uNK has not previously been investigated. 
Notably, we report significantly increased numbers of uNK cells that migrated when they 
were pre-treated with E2 for 1 hour compared with those treated with control media. This 
effect was blocked by co-treatment with the ER antagonist ICI 182, 780, a finding that could 
be consistent with E2 having an impact on ERβ-mediated changes in cell function.  
In order to investigate which factors may be modulated by E2 to account for the observed 
increase in migration we analysed an array panel of cell motility genes to investigate 
differential expression following E2 treatment. These findings were limited by the small 
sample size (n=3) and previously described variability in gene expression following E2 
treatment in uNK (Chapter 4). Expression of mRNAs encoding genes associated with 
regulation of cell motility were readily detected in uNK. However, in this experiment, only 
two genes were identified as being significantly regulated by E2; Moesin (MSN) a protein 
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important in cell-cell recognition and for cell movement and integrin beta 1 (ITGB1) a 
protein important in mediating cell adhesion. Interestingly, expression of both of these genes 
was apparently down-regulated following E2 treatment. This small study suggested that 
expession of myosin heavy chain 10, non-muscle (MYH10) a factor important in 
cytokinesis, alpha-actin 3 (ACTN3) as well as hepatocyte growth factor (HGF) a paracrine 
factor important for growth and motility and is also potent angiogenic factor (519), increased 
in response to E2 although differences between samples meant this was non-significant. 
Interestingly, in contrast to previous findings from array studies in our group (Chapter 4 and 
Dr. Elaine Marshall, personal communication), actin related genes appeared unchanged by 
E2 (ACTN1, ACTN4, ACTR2 and ACTR3) however expression of ACTN3 appeared to 
show non-significant up-regulation by E2. 
PCR-array analysis of expression of cell motility genes following E2 treatment appeared to 
contradict the observed E2 impact on motility reported in section 5.4.2. Together these 
findings suggest an apparent paradox in that many ge es associated with cell motility were 
found to be down-regulated in response to E2, yet we described increased migration of uNK 
cells in response to E2. One possible explanation for this may be that we are not monitoring 
genes regulated by membrane bound ERs (mERs) expressed in uNK cells. An impact via 
mERs would be consistent with the rapid response to E2 (1 hour treatment) (520). 
Propagation of ligand response via membrane ERs could involve membrane-tethered ERβ 
(521) or G-protein coupled receptors (GPCR) such as GPR30. It has been reported that 
compounds such as ICI 182780 that act as pure antagonists on ERα and ERβ may have 
agonist activity for GPR30 (522) adding additional complexity to interpretation of studies. 
Thus the apparent block of E2-mediated migration by the ER antagonist ICI 182, 780 
reported in this chapter may not involve GPR30 interaction in the signalling cascade. Cell 
surface expression of ERα46 (an isoform of ERα) has been reported in lymphocytes (523) 
and a membrane impermeable form of E2 has been shown t  increase IFN secretion by 
CD56bright pbNK (523), providing strong evidence that uNK cells may be regulated via a 
mER. If this is the case a biphasic response to E2 may exist in uNK cells; an increase in cell 
migration dependent on membrane-ERs that increases homing of uNK to appropriate sites in 
the uterus in parallel with a transcription dependent down-regulation of cell motility genes in 
the presence of persistent E2. This may occur in parallel with cytokine dependent changes in 
cell function as we noted increased expression of CXCR4 mRNA in uNK cells in response to 
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E2 treatment (Section 5.4.3.1, Figure 5.5). Further experiments are required to investigate 
these mechanisms. 
In the present study, high levels of SDF-1 and IL-15 mRNA were detected in decidualised 
stromal cells which appeared to be time-dependent. IL-15 is known to be essential for uNK 
cell homing to implantation sites in mice (428) and is an established regulator of uNK cell 
functions including proliferation, differentiation and recruitment.  
The results presented demonstrate that expression of SDF-1 and IL-15, known to be 
chemoattractant to uNK cells (35, 57), is increased during decidualisation of endometrial 
stromal cells which in vivo is concomitant with uNK cell accumulation in the endometrium. 
Thus, decidual conditioned media (DCM), which may contain secreted IL-15 and SDF-1, 
was tested to determine whether it can act as a chemoattractant to uNK cells. Using a 
chamber slide chemotaxis assay we were able to report novel data demonstrating directed 
movement of uNK towards DCM but not control media. Previous studies have reported that 
co-culture of uNK cells with decidual stromal cells protects uNK cells from apoptosis (524) 
and conditioned media from ESC from secretory phase endometrium and early pregnancy 
decidua promotes uNK cell proliferation (38). However to the best of our knowledge this is 
the first data demonstrating an effect of conditioned media from decidualised ESC on 
chemotaxis of isolated uNK cells. SDF-1 and IL-15 secreted by decidual stromal cells may 
be acting as a chemoattractant, however an ELISA for IL-15 could not detect the protein in 
DCM (data not shown).  
The receptor-mediated increase in human uNK cell migration stimulated by E2 reported 
herein, is in agreement with previous reports that suggest E2 enhances homing of pbNK to 
the uterus (74). However, it is distinct in that it describes a local mechanism of control for 
uNK cells, which may augment pbNK cell homing. For example, while an increase in 
circulating E2 is correlated with pbNK cell homing to the uterus, results presented in 
Chapter3 of this thesis have demonstrated that oestrogen is produced by decidualising cells, 
and that E2 increases migration of tissue derived uNK cells which are distinct from pbNK 
cells (27). Thus, local E2 may mediate tissue migration of uNK cells within the uterus to 
decidualising cells and consequently to spiral arterioles. It is interesting that uNK cells may 
retain this migratory potential once homed to the ut rus and it is conceivable that active 
gradients of steroids and cytokines derived from the stromal environment may modulate and 
regulate uNK cells in situ. Furthermore, transcriptional down-regulation of cell motility 
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genes observed in response to E2 may enhance this effect as a reduction in migration in an 
E2-rich tissue environment would encourage retention of uNK cells in the tissue. Consistent 
with the proposed temporal E2 regulation of uNK cell r cruitment, expression of IL-15 and 
SDF-1 by endometrial stromal cells was transiently up-regulated early in decidualisation and 
decreased thereafter. The results described may represent a novel mechanism of uNK cell 
regulation during a brief window in which the cells within the decidualising stroma signal 
the recruitment of uNK cells.  
As an aside to the current investigations, it was noted that one uNK cell sample which was 
outwith the gestational range of this study (>12 weeks) did not respond to E2 treatment and 
had significantly reduced overall migration (data not shown). This may be anomalous; 
however, it is possible that the migratory response of uNK cells to E2 may diminish with 
gestational age, as has been described for other functions of uNK cells (43). Alternatively, as 
the uNK cells have been derived from a later gestation and thus have been resident in the 
tissue for longer, persistent signals from the local environment, such as E2, may have led to 
down-regulation of cell motility genes. The contribution of specific motility factors and their 
regulation by E2 in uNK cells requires further investigation however results presented herein 
have described novel evidence that E2 increases migration of uNK cells and that stromal 
derived factors in DCM, which may include oestrogen and cytokines such as SDF-1 and IL-
15, can directly influence uNK cell motility.  
Decidualisation is associated with an increase in angiogenesis of the spiral arteries of the 
endometrium (104). VEGF is a prime regulator of angiogenesis during decidualisation (525) 
and it has been reported that oestrogen stimulates VEGF expression in human endometrial 
stromal and epithelial cells (114) providing a link between our novel findings of local E1/E2 
biosynthesis in decidualised cells and angiogenesis, consistent with results reported in the 
mouse (128). Angiopoietins (Ang) act with VEGF to pr mote angiogenesis (111). 
In the current investigation an increase in expression of VEGFA, ADM and Ang-2 mRNAs 
was detected following decidualisation of endometrial stromal cells. This is consistent with 
previous reports that suggest VEGFA is up-regulated following decidualisation and in the 
secretory phase (112, 526) but is in contradiction o previous studies which suggest Ang-2 
mRNA expression is decreased in secretory phase endometrium (527). ADM expression has 
only previously been reported in human endometrial epithelial and endothelial cells (528, 
529) and these data therefore extend the range of end metrial cell types capable of producing 
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this factor. Ang-4 mRNA was decreased following deci ualisation, to our knowledge there is 
no previous evidence of Ang-4 regulation during deci ualisation in human endometrial 
stromal cells, however the aromatase inhibitor letrozole has been shown to decrease Ang-4 
expression during in vitro decidualisation of mice uterine stromal cells (128) suggesting a 
link with oestrogen biosynthesis. Data presented in the current chapter desrcibe increased 
expression of VEGFA, Ang-2 and ADM in decidualised stromal cells which would appear to 
be consistent with a role in stimulation of angiogenesis and may be important for vascular 
remodelling that takes place during modification of the implantation site. In addition to its 
stimulatory affect on VEGF, E2 itself is also reported to directly stimulate proliferation and 
migration of endothelial cells (530) and uterine angiogenesis is impaired in ERαKO mice 
(115). Thus local E2 acting in a paracrine manner i the uterus may be pro-angiogenic. Our 
new studies would be consistent with changes which correlate with increased angiogenesis 
being influenced by local oestrogen produced in decidualised stromal cells.  
In addition to decidualised stromal cells, increased numbers of uNK cells accumulate close 
to spiral arteries in the endometrium. uNK cells have been reported to secrete angiogenic 
factors such as VEGFC, PLGF, and Ang-2 (39, 44, 531). It was hypothesised that local 
oestrogen may also impact on the capacity of uNK cells to secrete angiogenic factors.  
The impact of uNK cell conditioned media (uNK CM) on HEECs was analysed using an 
angiogenesis assay. HEECs were chosen for the assays a  this endothelial cell is more 
representative of the endometrial vascular bed than t e commonly used HUVECs ((532) and 
Dr. Erin Greaves personal communication). Notably, supernatants from E2 treated uNK cells 
significantly increased network formation in HEECs compared to unconditioned media or 
media recovered from control uNKs suggesting E2 might enhance the ability of uNK cells to 
influence the stromal environment by increased secretion of angiogenic factors. The 
secretion of angiogenic factors by uNK cells has been shown to be gestation dependent (43) 
and for this reason only the response to uNK CM from gestations of <10 weeks were 
analysed in this study. It is notable that in uNK CM from one sample that was out with the 
gestational range of this study, E2 uNK CM did not i crease angiogenesis network formation 
in HEECs (data not shown) consistent with gestation dependent response described by Lash 
et al (43). Thus response to E2 as a modulator of angiogenic secretion by uNK cells may also 
be dependent on gestation. 
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To investigate what factors may be modulated by E2 the expression of an array panel of 
angiogenesis genes in uNK cells treated +/- E2 were inv stigated. The expression of genes 
associated with angiogenesis in uNK appeared to be ightly regulated, with several genes not 
detected. Despite the small sample size, expression of four genes were significantly down-
regulated by E2 treatment; Thrombspondin (THBS1), Rac-alpha serine/threonine-protein 
kinase (AKT1), Transforming growth factor 1 (TGFB1), and interleukin β1 (IL-1β).  
THBS1 is inhibitor of angiogenesis and suppresses th  expression of the angiogenic factor 
PECAM1 (533, 534). Thus decreased expression of THBS1 in uNK cell mediated by E2 
may be indirectly pro-angiogenic. AKT1 is serine/threonine protein kinase that is activated 
by a number of different growth factors and cytokines. AKT signalling is critical to vascular 
homeostasis and mediating VEGF signalling (535) and AKT1 -/- mice have impaired VEGF-
induced angiogenesis (536). Thus down-regulation of AKT1 by E2 in uNK may impair 
VEGF signalling. TGFB1 is an evolutionarily conservd cytokine which is involved in a 
variety of cellular functions (537). TGFB1 can be both a stimulator and inhibitor of 
angiogenesis depending on experimental conditions (538) and is reported to disrupt 
angiogenesis in microvascular cells in the bovine corpus luteum (539). As E2 treated uNK 
cell conditioned media was pro-angiogenic, decreased expression of TGFB1 in response to 
E2 may suggest TGFB1 is acting as an inhibitor of angiogenesis in this instance. Interleukin 
1β (IL-1β, also IL-1B) is a pleiotropic cytokine with effects in many cell types. While IL-1β 
is reported to be pro-angiogenic (540), IL-1β inhibits decidualisation (396, 397) and thus 
decreased secretion of IL1β by uNK cells as a result of E2 stimulation may be essential in 
maintaining the uterine environment during decidualisation. 
A further 11 genes exhibited large fold changes (greater than 2 or less than -2) in response to 
treatment (8 down, 3 up; Table 5.8) however due to the small sample size analysed, many of 
these responses were non-significant. Interestingly, mRNAs encoding expression of VEGF-
C and placental growth factor (PLGF) were not detect d and VEGFA expression was 
unaffected by E2 treatment a finding at odds with previous reports (43, 114). In the current 
experiment, expression of growth factors associated with angiogenesis such as ANGPT2, 
ANPEP and FIGF, showed a non-significant decrease in xpression as a result of E2 
treatment, while others were not detected (ANGPT1, FGF1 and PGF). These results suggest 
that any impact of uNK cells on angiogenesis may not be mediated by classical growth factor 
secretion.  
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Although some pro-angiogenic cytokines were expressed by uNK cells there was a non-
significant decrease in the expression of IL6 and CXCL1, and a significant decrease in IL1β 
as a result of E2 treatment. However, a non-significant trend in increased expression of 
CCL2 (2.8 fold up-regulation, p=0.13, Table 5.8) by E2 was detected. CCL2 is known to 
induce angiogenesis directly (541) and the gene expression studies reported in the current 
study suggests E2 may enhance its expression. Furthermore, CCL2 combined with E2 has 
been shown to increase VEGF in stromal cells (531). Thus, combined secretion of CCL2 and 
E2 by stromal cells and uNK cells respectively may increase VEGF in the stromal 
environment and influence angiogenesis. 
At the start of this study it was proposed that loca ly produced E2 might influence the ability 
of uNK cells to produce angiogenic factors. In the results presented herein novel findings are 
reported which demonstrate, using uNK cell conditioned media, that E2 stimulates the 
secretion of soluble factors from uNK cells which enhance angiogenesis of HEECs. To the 
best of our knowledge this is the first evidence of regulation of HEECs by uNK cells and of 
an oestrogen-mediated regulation of angiogenic cytokine secretion by uNK cells. 
Transcriptional analysis of genes which may be regulated by E2 revealed that many of the 
classical growth factors did not appear to be expressed in our samples. In addition, a mixture 
of changes in expression of mRNAs encoding both pro- and anti-angiogenic factors was 
detected in cells treated with E2 including; AKT1, reported to be a modulator of VEGF 
signalling and was significantly down regulated by E2, and inhibitors of angiogenesis such 
as THBS1 and TGFB1 which were also significantly down-regulated by E2. However, 
CCL2 and PECAM1, which may be pro-angiogenic, appeared to be increased in response to 
E2. The changes in expression of individual genes do not point to a single factor being 
responsible for the observed impacts on angiogenesis but rather it is likely that the sum of 
these changes results in a ‘cocktail’ of factors that have an impact on endothelial cells when 
they are exposed to uNK cell conditioned media for several hours. 
5.5.1. Summary 
In summary, the findings described in the current chapter contribute further evidence to 
support a role for intra-uterine biosynthesis of oestrogen in mediating the functional changes 
occurring in the stromal compartment during decidualisation of the endometrium. Novel 
evidence is reported that suggests oestrogen enhances the motility of uNK cells that may 
‘home’ uNK cells to decidualising cells and spiral arteries in the endometrium in vivo. 
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Furthermore, we have shown for the first time that E2 increases the angiogenic capacity of 
uNK cells and that uNK secreted factors have a direct, positive impact on network formation 
of cells derived from the endometrial vascular bed. The precise factors involved and the 
transcriptional impact of E2 on uNK cell migration a d uNK cell-mediated angiogenesis 
remain to be fully elucidated. However, these findings are consistent with a functional 
interplay between uNK cells, endothelial cells and decidualised stromal cells that is mediated 
by oestrogen, which may promote an appropriate enviro ment for establishment and 
maintenance of pregnancy. 




6. Final discussion 
6.1. Introduction 
The human endometrium is a complex multi-cellular tissue that occupies the luminal 
compartment of the uterus. The luminal surface is defined by a layer of epithelial cells 
supported on a multi-cellular stroma containing fibroblasts, glands (lined by a secretory 
epithelium), blood vessels (lined with endothelial ce ls) and several populations of immune 
cells; the latter includes a unique population of natural killer cells (uNK). In women of 
reproductive age, the endometrium undergoes dynamic remodelling in response to 
fluctuating levels of sex steroids secreted by ovarian cells: phases of endometrial function 
include an oestrogen-dominated proliferative phase, a progesterone-dominated secretory 
phase and menses (endometrial shedding precipitated by falling levels of progesterone). A 
key feature of the secretory phase is differentiation (decidualisation) of stromal fibroblasts 
(ESC) an event characterized by transformation of cell shape, secretion of growth 
factors/cytokines, accompanied by angiogenesis/vascul r remodelling and an increase in the 
numbers of resident immune cells by migration/proliferation. Decidualisation ensures an 
appropriate nutritional and hormonal environment exists during the establishment of 
pregnancy. Although mice do not menstruate, regulation of uterine function essentially 
mirrors that in woman with cell proliferation during an oestrogen dominated phase 
(proestrous) and functional maturation during a progesterone-dominated phase leading to 
development of a “window of uterine receptivity” stimulated by the action of oestrogen on 
the progesterone primed uterus (169, 174). Notably, studies in mice treated with an 
aromatase inhibitor suggest that de novo biosynthesis of oestrogen within the uterus may 
play an essential role in regulation of decidualisation but no data exist for human. Studies 
from this laboratory have previously reported that uman endometrial endothelial and uNK 
cells both express oestrogen receptor beta (248, 249) but the impact of oestrogens on their 
function had not been explored prior to the studies escribed in this thesis.  
6.2. Key findings 
In the current study three questions were addressed:  
1. Is oestrogen biosynthesis a feature of endometrial stromal cell decidualisation in 
women?  
2. What is the impact of oestrogen on uNK cell function?  
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3. What role (if any) does oestrogen play in the interplay between decidual, immune 
and vascular cells within the endometrial stroma? 
It was hypothesized that, consistent with evidence from studies in mice, decidualisation of 
human endometrial stromal cells results in alterations in biosynthesis of oestrogens and that 
the local (intra-uterine) biosynthesis of oestrogens could have a functional impact on cell 
populations in the endometrial stroma, including those that are ERβ positive such as the 
abundant uterine natural killer cells, and endothelial cells of the endometrial vasculature. 
During the secretory phase of the cycle decidualising endometrial stromal cells and uNK 
cells are in close proximity to the endometrial spiral arteries which are lined by endothelial 
cells. It was postulated that oestrogen produced by cells within the stromal compartment 
alter cell function in either a paracrine or an autocrine manner and thus impact on the 
functional interplay between cells within the endometrial stroma. 
6.2.1. Human endometrial stromal cells demonstrate the capacity for de novo 
oestrogen biosynthesis 
In Chapter 3 results are presented that confirm our primary hypothesis that decidualisation of 
human ESC results in alterations in their capacity for biosynthesis of oestrogens. Notably, it 
was found that in vitro decidualisation of primary cells was associated with expression of 
aromatase protein and time-dependent changes in expression of genes encoding proteins 
important in steroid biosynthesis including transiet up-regulation of StAR and CYP11A1. A 
change in enzyme activity in decidualised cells wasalso detected characterized by increased 
aromatase activity and an apparent reduction in 17βHSD2 activity. Secretion of both E1 and 
E2 by primary ESC was confirmed using ELISA, with increasing production of E2 
associated with progressive decidualisation of cells. Secretion of E1 and E2 was partially 
ameliorated by inhibitors of aromatase and STS. There was evidence to suggest that 
treatment of cells with STX64 (an STS inhibitor) resulted in reduced biosynthesis of E1 as 
well as expression of the decidualisation marker protein IGFBP1, which may indicate that 
E1 reinforces the process of decidualisation in women. The production of E1 exceeded that 
of E2. Consistent with this, incubation with the aromatase inhibitor anastrozole had a greater 
impact on concentrations of E1 than E2 in culture the media suggesting aromatase-mediated 
conversion from androstenedione (A4) to E1 is the more active reaction in decidualised ESC.  
The results obtained provide the first evidence of de novo biosynthesis of oestrogens during 
decidualisation of human ESC. Aromatase is essential i  the biosynthesis of all oestrogens. 
Aromatase activity in human ESC has previously been r ported (345), however, a 
subsequent study failed to detect either aromatase enzyme activity or mRNA expression in 
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normal ESC (311). In the studies reported in Chapter 3 of this thesis, both aromatase protein 
expression and increased aromatase activity were reported and although aromatase mRNA 
concentrations were low, an increase in aromatase mRNA concentrations was detected 
following decidualisation of hESC in vitro for 8 days. In support of induction of aromatase 
expression and activity during decidualisation, concentrations of E1 and E2 were reduced by 
addition of an aromatase inhibitor.  
In humans, expression of the aromatase gene is regulat d by tissue-specific promoters (327, 
542).  For example, in ovarian endometriosis, gene xpression is stimulated by cAMP and 
PGE2 acting via promoter II (378). Bulkulmez et al h ve reported that in proliferative phase 
endometrial explants aromatase mRNA transcripts containi g exon IIa at their 5’ ends were 
increased in response to stimulation with A4 (349). The authors reported that the ER 
antagonist ICI 182,780 (Faslodex®, AstraZeneca), and the aromatase inhibitor fadrozole 
(543) suppressed A4-mediated induction of aromatase mRNA suggesting the impact of A4 
was in fact a reflection of its conversion to oestrogens. Consistent with this, they also 
reported that the non-aromatisable androgen dihydrotest sterone did not induce aromatase 
mRNA expression. It is likely that E1, as the direct aromatized product of A4, may be of key 
importance in mediating increases in aromatase expression both in the studies reported by 
Bulkulmez and those reported in this thesis during decidualisation of ESC.  
High levels of E1 were reported in response to decidual sation which may therefore impact 
on induction of aromatase expression. We speculate that an intracrine/autocrine positive 
feedback loop may also contribute to the increased romatase expression observed as a result 
of persistent high levels of E1 detected in culture media from decidualised ESC in our study. 
Aromatase may also be regulated by progesterone. A study by Tseng et al. reported that 
aromatase activity in ESC was increased by progestins but not androgens or glucocorticoids 
(346). The authors reported that oestrogen alone had no impact on aromatase activity but 
potentiated progestin-mediated increases. In the current study aromatase gene expression 
appeared to be increased when ESC were exposed to a s eroid environment of high 
progesterone and high secreted oestrogens, conditions which have been shown by Tseng et al 
to induce aromatase expression in ESC (345, 346).  
Previous studies from our laboratory group have revealed an important role for the orphan 
nuclear receptor, oestrogen-related receptor α (ERRα) in decidualisation of human ESC. 
ERRα is reported to be increased in decidualisation andinhibition of ERRα reduces 
expression of IGFBP1 in ESC (305) a result that mirrors our findings following inhibition of 
STS. Miao et al reported that in prostatic stromal cells, ERRα up-regulates the expression of 
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aromatase via the I.3/II promoter region and that prostaglandin E2 (PGE2) enhanced ERRα 
recruitment to the same promoter (544). Interestingly, Miao et al also reported that 
stimulation of the PKA pathway by PGE2, which increas s intracellular cAMP, also 
increased ERRα expression in prostatic stromal cells (544). During decidualisation of ESC, 
the increased expression of ERRα may therefore also act to up-regulate aromatase expression 
via a similar mechanism to that reported in prostatic s romal cells. Further studies are 
required to confirm which promoter element is the most important in regulation of the 
CYP19A1 gene in endometrial stromal cells. 
The effects of ERRα are potentiated by the ERRα co-activator peroxisome proliferator-
activated receptor gamma co-activator-1 alpha (PGC-1α). Interestingly, PGC-1α together 
with ERRα increases the expression of the steroidogenic enzymes, CYP11A1 and CYP17A1 
in hepatic cells (545). Furthermore, in the same study, the authors identified ERR response 
elements (ERRE) in the promoters of both CYP11A1 and CYP17A1 genes and ERRα was 
reported to bind these elements by chromatin immunoprecipitation (ChIP) analysis. An 
increase in CYP11A1 mRNA expression was detected in decidualised ESC which may also 
be influenced by ERRα-mediated transcriptional regulation. In addition, it has been reported 
that ERRs have the capacity for transcriptional cross-talk with ER regulated genes such as 
osteopontin (reviewed in (298)) which may have additional impacts on the transcriptional 
response to oestrogens produced during decidualisation. Taken together these studies suggest 
that ERRα may act as a transcriptional regulator during deciualisation which may account 
for some of the changes in expression in steroidogenic enzymes reported in this thesis. 
Aghajanova et al compared the regulation of steroid metabolizing enzymes in response to 
cAMP treatment in normal endometrial stromal cells and stromal cells isolated from eutopic 
endometrium from women with endometriosis (313). The authors reported increased 
immunoexpression of 17βHSD2 protein in ESC treated with cAMP for 96 hours that was 
absent in ESC isolated from women with endometriosis. Furthermore, there was no impact 
on expression of 17βHSD1 regardless of whether the women had endometriosis or not. The 
main focus of the study by Aghajanova et al was a comparison of steroidogenic enzymes in 
women with or without endometriosis and their treatment regime differed from the studies 
presented in chapter 3 as their cells were treated with cAMP or P4 alone and results only 
presented for a single time point (96 hours.) In cotrast, the impact of cAMP alone or in 
combination with P4, over multiple time points was investigated in the current study. 
Additionally, in the study by Aghajanova et al enzyme expression was expressed as fold 
change to ‘no endometriosis’ controls so only limited information can be extrapolated for 
comparison to the results presented in chapter 3. In addition, the findings that expression of 
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mRNA encoding 17βHSD2 is up-regulated whilst 17βHSD1 is unchanged in response to 
decidualising stimuli are in agreement with the results reported by Aghajanova et al (313). 
However, novel time-dependent increases in expression of mRNAs encoding StAR, 
CYP11A1, SRD5A1 and STS in response to cAMP and P4 treatment were also reported in 
the present study. Additionally, the results presented herein demonstrated decreased 
17βHSD2 activity was detected, as measured by TLC, a result apparently at odds with 
observed changes in mRNA concentrations emphasizing the need to expand studies beyond 
that of measurement of mRNA alone. Taken together tse results suggest a novel 
description of the regulation of steroidogenic enzymes and metabolism during 
decidualisation and shed new light on regulation of fertility in women. 
6.2.2. A role for oestrone? 
In addition to secreted E2, significantly high levels of E1 secreted by decidualised hESC 
were detected across all time points investigated. The level of E1 was consistently high from 
the earliest time point. In contrast, levels of E2 increased with progression of decidualisation 
leading to a near equivalent ratio of E1/E2 by 8 days decidualisation. This may in part 
account for the decrease in 17βHSD2 activity (decreased conversion of E2 to E1) detect d in 
decidualised stromal cells as the comparative excess of E1 compared to E2 during 
decidualisation may impact on the dynamics of their r spective metabolism. This may also 
impact on the capacity to detect the conversion of E1 to E2 by TLC.  
High concentrations of E1 may also have an impact on ER mediated transcription. 
Classically E1 is considered to be the ‘weaker’ oestr gen compared to that of E2. This 
perception has been based on affinity studies for the oestrogen receptor. Oestrogens are 
lipophilic and thus are able to diffuse in and out f cells. Oestrogens are retained within cells 
with high affinity following intranuclear binding to the ER protein and subsequently are able 
to modulate gene expression (546). The dissociation rate of an oestrogen from the activated 
ER gives an indication of the effectiveness of an oestrogenic ligand in maintaining the 
receptor in an activated state (547). In 1980, Weichmann et al (548) reported that in calf 
uterus, E2-ER complexes had greater retention than E1-ER complexes; this publication 
predates the identification of ERβ. The authors suggested that the greater interaction and 
retention of E2 with ER may make possible long term uterine growth responses to E2 (548). 
However, in a more recent paper E1 has been reported to induce uterine growth in the rat 
(549). Kuiper et al (550) investigated saturation bi ding of in vitro synthesised human ERα 
and rat ERβ protein. The authors reported relative binding affinity (RBA) of a range of 
oestrogenic ligands, expressing them as a proportion of E2 binding, and found that E1 had 
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60% RBA for the human ERα protein and 37% RBA for the ERβ protein (rat) (550). While 
the reported affinity of E1 was lower than that of E2 for both receptor isoforms, in this study 
E1 had greater affinity than tamoxifen, genistein and bisphenol A for both ERs (550). The 
capacity for E1 to induce expression of an ERE-report r construct in T47D human breast 
cancer cells was investigated by Legler et al (551). Legler et al reported that E2 was ten 
times more potent than E1 at inducing ERE luciferas ctivity for either human ERα or ERβ 
protein demonstrated by the concentration of oestrogen required to elicit EC50 (nominal 
concentration at which 50% maximum response is reached) which was around ten times 
higher for E1 than E2 (551). In Chapter three it was reported that the ratio of E1/E2 in hESC 
following two days decidualisation was approximately 4:1. An excess in the relative 
concentrations of E1 compared to E2 could favour E1 stimulation of ER-mediated 
transcription and if higher concentrations of E1 than E2 are present then this may 
compensate for the lower affinity of E1 for ERα and ERβ proteins. Selective oestrogen 
receptor modulators (SERMs) are reported to have tissue-specific agonist and antagonist 
actions which are influenced by the expression of co-a tivators and co-repressors and the 
relative expression of different ER isoforms in a given tissue context (552). The specific 
capacity for E1-ER complexes to recruit cofactors and the influence of different ER isoforms 
on the impact of E1-mediated transcription requires further investigation to fully appreciate 
the impact, if any, E1 could have on transcription in the context of different tissue 
environments. The impact of E1 on non-classical ER signalling such as via indirect tethering 
to transcription factors (Sp1, AP-1) or via membrane localised ERs is also poorly 
understood. The molecular response to E1 in the stromal environment may result in tissue-
specific agonist profiles that are distinct from E2, however this requires further investigation. 
In this regard, temporal changes in the E1 to E2 ratio during decidualisation may account for 
some of the temporal changes in mRNA expression report d in Chapter 3. 
Baird et al (553) reported that plasma concentrations f E1 were highest in women during 
the proliferative phase but that E1 was proportionally lower than E2 in the secretory phase. 
In contrast, it is reported in the current study that during decidualisation the ratio of locally 
produced oestrogens favours E1 initially but is equivalent by 8 days decidualisation. Baird et 
al also reported that in postmenopausal women the plasma E1 to E2 ratio was approximately 
7 to 1 (553). In postmenopausal women the majority of circulating oestrogen is produced 
from peripheral conversion which is influenced by oesity (554); conversion of A4 to E1 has 
been reported in human female fat tissue (555) and adipose is thought to be the major source 
of oestrogens in postmenopausal women (556). Furthermor , Hemsell et al (557) have 
reported that with advancing age there is a progressiv  increase in the efficiency with which 
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A4 is converted to E1 in plasma. Despite the reported high circulating levels of E1 in 
postmenopausal women this does not appear to impact on uterine growth as postmenopausal 
uteri are atrophic. However, ERs from postmenopausal teri may be less active than those 
pre-menopause as Strathy et al (558) reported that ER from postmenopausal uteri have 
minimal capacity to bind nuclear acceptor sites in a cell-free assay. The efficacy of ERs in 
the postmenopausal uterus may also be influenced by the relative abundance/availability of 
co-regulatory proteins. The expression/activity of steroid metabolising enzymes in 
postmenopausal uteri may give an indication of the potential for high circulating E1 to be 
converted locally in target cells. As E1 is reported o have lower affinity than E2 for ER, E1 
may require conversion to the more potent E2 in order to elicit effects at ERs in the 
postmenopausal uterus. 
The presence of high concentrations of local oestrogen may also influence receptor turnover. 
E2 is known to promote down-regulation of ERα concomitant with the receptor’s 
transcriptional activation (559) while SERMs such as t moxifen and raloxifene are reported 
to increase steady state levels of ERα (560, 561). Degradation of ERα is mediated by the 
ubiquitin-proteasome degradation system and is promoted by E2-mediated recruitment of co-
regulatory proteins. When bound to the receptor complex, these proteins contribute to 
receptor down-regulation, as mutations in co-activator binding residues in ERα are reported 
to stabilise the receptor and abolishes E2-mediated receptor degradation (559).  
In Chapter 3, it was reported that the expression of mRNAs encoding ERα and ERβ were 
decreased and increased respectively following decidualisation for 8 days. The observed 
decrease in ERα mRNA may parallel degradation of the ERα protein although this was not 
measured in the current study. If this is the case, the local biosynthesis of E2 by hESC during 
decidualisation may mediate ERα turnover in the endometrial stroma which could be 
critically important as down-regulation of ERα is essential to implantation (479, 562). 
Interestingly, Tateishi et al (563) reported that there is an ubiquitin-proteasome pathway for 
ERβ that is not coupled to transcription. The authors indentified two regions within ERβ that 
are essential for ubiquitination and degradation; a N-terminal region essential for 
recruitment of ubiquitin ligase and a C terminal F domain which protects ligand unbound 
ERβ from degradation, however the conformation of the F domain was proposed to change 
following oestrogen binding which would permit recruitment of the 26 proteasome and 
degradation of the receptor (563). Whether E1 influences receptor turnover is not known but 
high levels of E1 and/ or E2 may differentially affect ERβ protein expression/turnover as in 
contrast to ERα, increased concentrations of ERβ mRNA were detected in response to 
decidualisation in the current study. 
Chapter 6. Final Discussion. 
223 
 
6.2.3. Oestrogen alters gene expression in uNK cell s 
Studies presented in Chapter 4 demonstrated that a vi ble uNK population could be isolated 
from first trimester decidua that retained ERβ expression and had a phenotype apparently 
identical to uNK from non-pregnant endometrium (249). The isolated uNKs were responsive 
to E2 stimulation, and bioinformatic analysis of transcriptional responses suggested steroid 
exposure could modulate cell motility. Although these results provided preliminary evidence 
that E2 can modulate the function of uNK it was notable that stratification of results 
according to the gestational age of the decidua from which the cells were recovered 
suggested that functional responses may be subject to ‘conditioning’ by the local 
environment. It has been reported that tissue-resident uNK cells have a phenotype that is 
distinct from those of peripheral blood NK subsets (27).  
The current study utilized human first trimester deci ua as an abundant source of primary 
uNK cells (75). Descriptions of uNK from non-pregnant endometrium are limited but they 
are reported to be phenotypically similar to those from decidua being CD56+, CD16-, with a 
granular appearance and lacking cytotoxicity. However, uNK from non-pregnant 
endometrium have recently been shown by Manaster et al to differ from decidual uNK 
because of lack of NKp30 expression (also natural cytotoxicity receptor, NCR3, an NK cell 
activating receptor (564)) and fail to secrete a full range of cytokines (565). Interestingly, in 
the same study, treatment of uNK with IL-15 restored NKp30 expression and increased their 
ability to secrete cytokines resulting in a shift to a phenotype more closely resembling that of 
decidua-derived uNK (565) which suggests reported differences in phenotype of uNK from 
non-pregnant endometrium may be a reflection of an ‘inactivated’ state. IL-15 expression is 
high in the secretory phase endometrium (36) and this cytokine may therefore activate uNK 
at this time.  
A recent transcriptional analysis by Kopcow et al hs suggested that uNK cells derived from 
first trimester decidua are distinct from those in the cycling endometrium (566) however in 
our hands decidua-derived uNK appear phenotypically similar to uNK being both ERβ+ and 
CD56bright. In the study by Kopcow et al (566), several differences in methodological 
practices could account for the transcriptional differences observed between uNK from 
decidua and non-pregnant endometrium. Firstly, the isolation methods utilized to recover the 
two populations were different; endometrial NK cells were isolated based on a selection of 
CD45+, CD56+ CD3- phenotype while decidual NK cells were isolated as a selected CD56+ 
CD16- CD3- phenotype. Thus, the cells isolated from the endometrium may contain both 
CD56+ CD16+ and CD56+ CD16- populations of NK cells; notably, while the latter is 
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considered to be a mature uNK cell phenotype, the former may represent an undifferentiated 
precursor of uNK, that is homologous to the pbNK CD56bright population and could thus be 
functionally different from ‘mature’ uNK. This makes it likely that whilst a homogenous 
uNK population was derived from decidua, a heterolog us NK population was derived from 
the non-pregnant endometrium. In addition, uNK derived from decidua in the study by 
Kopcow were from a wide range of gestational ages (6-12 weeks) and as revealed by the 
studies presented in Chapter 4 it is likely that those cells may vary significantly in their 
transcriptional responses dependent upon the gestation nd age of the source tissue. As 
reported in Chapter 4 and by others (43, 58), the present study has described gestational 
impacts on uNK function and further studies on deciual uNK from early gestations and 
those recovered at greater than 12 weeks gestation are required to explore whether they have 
functionally distinct transcriptional networks in response to E2 stimulation.  
It seems likely that uNK from non-pregnant endometrium and decidua may have different 
functional properties as a result of variations in their tissue micro-environment. This would 
be consistent with the large body of data showing that he levels of hormones and cytokines 
change throughout the menstrual cycle and that the decidua of early pregnancy also has a 
distinct steroid/cytokine profile. To determine whet r a distinct ‘subpopulation’ of uNK 
really exists transcriptional responses to ligands such as IL-15 could be compared. 
Interestingly, NK cells in secondary lymphoid tissue  such as spleen, lymph nodes and 
tonsils, all express different phenotypes. For example, splenic NK are CD56dim CD16+ and 
express perforin, natural cytotoxicity receptors (NCRs) and Killer-cell immunoglobulin-like 
receptors (KIRs), whereas NK cells in lymph nodes and tonsils are CD56+ CD16-, lack 
perforin and NCR expression (567). However, stimulation of lymph and tonsil NK cells with 
IL-2 activates cytolytic activity, increases perforin and expression of CD16 and KIRS (567). 
IL-15 is structurally similar to IL-2 and they share common binding properties (568).  
Crucial to these studies is the fact that ERβ mRNA and protein are both expressed in tissue-
resident uNK in both non-pregnant endometrium and decidua. The studies presented 
complement and extend existing information which suggests that uNK are a functionally 
dynamic population (43, 58), furthermore ERβ-dependent transcriptional targets have been 
identified which may further modulate uNK function i  oestrogen-rich tissues. In light of 
these novel findings, we suggest E2 (or E1) may regulate functional processes of uNK 
particularly in late-secretory endometrium (following stromal cell decidualisation) and in 
first trimester decidua, at which point uNK cell populations are likely to have reached a 
similar ‘mature’/‘activated’ phenotype due to the increased expression IL-15 reported at 
these times in the endometrium. 
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6.2.4. Oestrogens enhance the functional interplay between endometrial 
stromal cells (uNK, stromal fibroblasts and endothe lial cells)  
Our investigations have shown for the first time that exposure to E2 enhances migration of 
uNK cells; these results complement those suggesting that factors secreted from decidualised 
stromal cells, which may include SDF-1 and IL-15 stimulate directed chemotaxis of uNK 
cells (see Figure 6.1). Notably, expression of SDF-1 by human ESC is reported to be 
increased by E2 (386) and increased expression of SDF-1 and IL-15 occurs during stromal 
cell decidualisation with both factors able to stimulate NK recruitment to the uterus (57, 390, 
425). It has been reported that treatment of premenopausal women with E2 increases the 
number of uNK cells and macrophages found in the uterus an effect postulated to include 
homing of pbNK (74). A direct impact of E2 on migration of purified populations of uNK 
has not previously been studied. In the current study, sing an in vitro assay, we detected a 
significant increase in uNK cell migration as a result of treatment with E2, an effect that was 
blocked by co-treatment with the ER antagonist ICI. As uNK cells are ERβ+/ERα- this 
provides the first evidence that E2 can increase migration in an ERβ dependent manner. 
Changes in expression of known cell motility genes in response to E2 did not reveal 
alterations in the expression of any factors which might account for the observed increase in 
migration in response to E2. However, we speculate stimulation of membrane bound ERs 
might account for the rapid response to E2 (1 hour treatment) (520) and that a biphasic 
response to E2 may exist in uNK; an increase in cell migration dependent on membrane-ERs 
that increases homing of uNK to appropriate sites in the uterus, which is augmented by a 
transcription-dependent down-regulation of cell motility genes in the presence of persistent 
E2. Further experiments are required to investigate these mechanisms and to determine the 
balance between the direct impact of E2 on uNK cells and the indirect impacts mediated by 
stromal cell derived factors (Figure 6.1).  




Figure 6.1. Summary diagram depicting the proposed role of oestrogen and stromal-derived 
factors in regulating uNK cell functions during decidualisation. A. NK recruitment to the 
uterus. Decidualisation results in the increased expression of SDF-1 and IL-15 in 
decidualised ESC, factors which are known to enhance recruitment of NK cells to the uterus. 
In addition, local production of E2 enhances migration of uNK cells which may home uNK 
cells to peri-vascular sites during decidualisation. White circle; CXCR4 (SDF-1 receptor), 
orange circle; IL-15Rα (IL-15 receptor.) B. Angiogenesis during decidualisation. 
Decidualisation results in increased expression of the pro-angiogenic factors VEGFA and 
ANG2 in decidualised ESC. Locally produced E2 enhances the secretion of factors by uNK 
cells which increase ‘network formation’ in endometrial endothelial cells consistent with a 
role for local E2 in enhancing the angiogenic capacity of uNK cells. In addition, uNK cells are 
reported to induce angiogenesis by secretion of VEGFC and Ang-2. 
Our results have also revealed for the first time that incubation of uNK with E2 stimulates 
the secretion of soluble factors which enhance ‘network formation’ (an in vitro angiogenesis 
assay) of endometrial endothelial cells (HEECs) which s indicative of an increase in 
angiogenesis. Previous studies have reported that uNK cells induce ‘network formation’ of 
HUVECs (human umbilical vein endothelial cells) (39, 43) however the data reported in 
Chapter 5 represent the first evidence of modulation of HEECs by uNK and a role for E2 in 
this process. This is particularly pertinent to ourstudies elaborating on the interplay between 
endometrial cell populations as studies in our own (Dr Erin Greaves, personal 
communication) and other laboratories (532) suggest that HEECs provide more 
representative model of the vascular bed in the endometrium than do HUVECs. To gain 
insight into those factors responsible for this E2-mediated cell to cell dialogue we used 
targeted gene array expression analysis. Preliminary results suggested that this may involve 
E2-dependent suppression of the angiogenesis inhibitor THBS1 and modulation of AKT1 
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signalling. In addition, expression of the pro-angiogenic factors VEGFA, CCL2, and 
PECAM1 by uNK cells may also be increased by exposure to E2 but further studies are 
required to validate this. To the best of our knowledge, this study is the first description of a 
functional impact of modulation of uNK by E2 on a different cell type.  
Studies in mice using an aromatase inhibitor have revealed uterine biosynthesis of 
oestrogens play a critical role in neovascularisation during decidualisation (128). The current 
studies that have detected oestrogen secretion by decidualised ESC would be consistent with 
direct and indirect impacts on angiogenesis due to locally increased concentrations of 
oestrogens as well as factors released by decidualised stromal cells or uNK cells in response 
to E1 or E2 (see Figure 6.1). For example, an increase in production of angiogenic factors 
such as VEGFA, Ang-2 and ADM by decidualised ESC would be consistent with the 
development of a pro-angiogenic environment during decidualisation. While individual 
factors from the different cellular compartments may all contribute to increased angiogenesis 
in the endometrium their production could be orchestrated by local oestrogen biosynthesis 
which might augment the cross-talk between stromal, uNK and vascular cells. This might 
also involve the secretion of cytokines by tissue-resident uNK cells, for example, we have 
demonstrated that E2 can stimulate increased CCL2 expression by uNK cells. This factor has 
been shown by others to combine with E2 to increase stromal VEGF expression (531) which 
in turn may further stimulate angiogenesis. Our results also suggest that E2 may increase 
secretion of interferon γ (IFNγ) by uNK cells; this factor is reported to induce production of 
IL-15 expression by stromal cells. IL-15 also plays  key role in regulation of uNK function, 
survival and recruitment consistent with a dynamic interplay between the stromal and 
immune compartments in the endometrium.  
A number of studies have previously shown functional i teractions between ESC and uNK 
some of which may also be modulated by local oestrogen biosynthesis although this 
possibility was not considered in the original papers. For example, co-culture of uNK cells 
with decidual stromal cells protects uNK cells from apoptosis (524) and conditioned media 
from ESC from secretory phase endometrium and early pregnancy decidua promotes uNK 
cell proliferation (38). In addition, it has been reported that conditioned media from uterine 
leukocytes (which were predominantly uNK) substantially altered ESC gene expression 
(414); increased expression of cytokines IL-8, CCL8, and CXCL1 and also increased stromal 
expression of IL-15 and IL-15Rα was reported. Interestingly, IL-8 is expressed in 
perivascular cells in late-secretory phase endometrium (410) and mRNA expression is 
reported to be highest in late-secretory and mid-prolife ative phase in total endometrial 
extracts (411). Additionally, IL-8 secretion by uNK cells is reported to increase the 
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invasiveness of extra-villous trophoblast cells (59). Our studies presented in Chapter 5 
suggested that E2 may decrease expression of IL-8 mRNA in uNK cells and thus expression 
of IL-8 may be another example of a factor that is regulated by local E2 and participates in 
stromal-uNK cell cross-talk.  
If local production of E2 by decidual cells also persists in pregnancy, E2 may further 
potentiate the role of uNK cells in spiral artery remodelling and trophoblast invasion through 
stimulation of factors such as IFNγ. There is evidence to suggest uNK cells have a functio al 
role in tissue vascular remodelling and placental development and that dysregulation of uNK 
may be a component of the aetiology of pre-eclampsia (9). In pregnancy, transformation of 
spiral arteries is generally complete by 10-12 weeks gestation (45) and expression of 
angiogenic growth factors by uNK is reported to be increased at 8-10 weeks gestation 
compared with 12-14 weeks gestation (43) suggesting uNK may specifically influence 
vascular remodeling at the earliest stages of gestation. Notably, uNK cells are reported to 
accumulate within the vascular wall of first trimester placental-decidual co-cultures and this 
appears to be associated with loss of vascular smooth muscle cells and widening of the 
vessel lumens (569).  Evidence from animal models also suggests uNK cells could be 
essential to vascular remodelling during pregnancy. In NK-deficient mice spiral artery 
remodelling is impaired; however administration of IFNγ rescues this phenotype (570). 
Thus, IFNγ from decidual uNK cells may be essential in spiral artery remodelling in mice. In 
addition, IFNγ has also been shown to control migration of cytotrophoblast cells in human 
co-cultures (446). In the preliminary studies presented in Chapter 5, we report that E2-treated 
uNK exhibit a non-significant increase in the expression of IFNγ mRNA as a result of E2 
treatment. IL-8 and CXCL10 have also been shown to regulate trophoblast invasion (39, 
571), factors which were both differentially regulated by E2 in uNK cells in this study. 
Regulation of cytokine secretion from uNK cells by E2 in the local uterine environment in 
early pregnancy may therefore also regulate vascular remodelling and trophoblast invasion in 
vivo.  
Taken together these data suggest that E2 may modulate many of the factors which are key 
to functional roles of uNK, firstly by modulating angiogenesis during decidualisation and 
then in pregnancy influencing trophoblast invasion and spiral artery remodelling. This would 
be consistent with dynamic functions of uNK in response to changing tissue environments. 
Whether local oestrogen production persists in decidua and whether responsiveness of uNK 
to E2 is retained as pregnancy progresses requires f ther investigation, however we have 
reported novel data that support the capacity for E2 to modulate uNK function. 
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6.3. Clinical implications 
Oestrogen action is an essential requisite for implantation. In mice, although oestrogens are a 
critical determinant of the window of receptivity, their concentration/action needs to be 
tightly regulated as excessive concentrations of oestr gens are associated with aberrant 
expression of genes normally conducive to implantation, while suboptimal levels do not 
promote progression from the pre-receptive state (174). Several oestrogen-regulated factors, 
such as leukemia inhibitory factor (LIF), are locally modulated within different cellular 
compartments of the endometrium allowing the transition to a receptive state which is 
permissive to implantation. Dysregulation of local steroid metabolism in the endometrial 
stroma may contribute to production of factors which result in an ‘out of phase’ 
endometrium precipitating implantation failure.  
Furthermore, supraphysiological levels of sex steroids as a result of controlled ovarian 
hyperstimulation (COH) during in vitro fertilization (IVF) treatment regimes can imbalance 
local steroid metabolism and this might also affect uterine receptivity. Indeed it has been 
reported that ‘high responders’ to COH i.e. women with significantly elevated serum E2 and 
P4, have low implantation rates which may be as a result of an altered steroid milieu (572).  
We have also shown that oestrogens can alter the function of uNK cells and therefore any 
imbalances in local hormone levels could further impact on reproductive function. These 
findings may be relevant to subfertility associated with obesity as oestrogen biosynthesis 
takes place in adipose tissue and also in disorders associated with alterations in the 
androgen:oestrogen balance such as polycystic ovarian syndrome (PCOS). PCOS is an 
endocrine disorder affecting women of reproductive ag  and is associated with menstrual 
cycle disturbances, hyperandrogenism and infertility (362). Disruptions in local steroid 
metabolism in the endometrium as a result of hyperandrogenism in PCOS may account for 
some of the associated infertility due to altered gene expression in ER positive cells 
including the uNK cells. Disorders of pregnancy such as recurrent pregnancy loss (RPL) 
have been associated with dysregulation of uNK cells but the mechanism is unclear (50). 
uNK numbers appear increased in RPL and are associated with greater prevalence of CD16+ 
NK cells (50, 51). This may also be as a result of disturbances in inter-cellular dialogue 
within the stromal compartment resulting in inappropriate homing of uNK cells to the uterus, 
dysregulation of uNK function by an altered steroid environment, or dysregulation of 
oestrogen mediated cross-talk with the vasculature. Factors which could be involved include 
IL-15, which is responsible for modulating the functional phenotype of uNK cells, but also 
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oestrogens which we have suggested may be important in regulating angiogenesis, spiral 
artery remodelling and trophoblast invasion associated with the regulation of uNK cell 
function. Impaired decidualisation associated with decreased prolactin production is also 
associated with RPL and dysregulation of local steroid metabolism may impact on this 
process (484). The proposed roles for uNK in regulating vascular function may also be 
important in heavy menstrual bleeding (HMB). For example, oestrogens may enhance 
vascular stability through stimulating VEGF production from cells within the stromal 
environment, however, whether impaired local oestrogen biosynthesis is associated with 
HMB is unknown and merits further investigation. 
Endometriosis is classified as an oestrogen-dependent inflammatory disease that is 
associated with pain and the formation of lesions within the peritoneal cavity (373). The 
novel findings reported in this thesis which describe a capacity for normal endometrial 
stromal cells to differentiate into cells capable of oestrogen biosynthesis may help in part to 
explain one of the paradoxes of Sampson’s theory of endometriosis (573). Sampson 
proposed that retrograde menstruation of endometrial material into the peritoneal cavity was 
responsible for lesion formation in various ectopic sites. However retrograde menstruation 
occurs in 90% of women, yet the incidence of endometriosis is much lower (373). It is 
conceivable that the efflux of endometrial stromal ce ls with the capacity for oestrogen 
biosynthesis (decidualised ESC) may increase the prevalence of lesion formation as 
endometriosis is an oestrogen-dependent disease and these cells may be more likely than 
non-oestrogen producing cells to flourish outside the uterine cavity as a result of  stimulation 
of proliferation or neoangiogenesis. If this is thecase, the state of differentiation of stromal 
cells during menses may be important and thus duration of menses may influence whether 
lesions become established. Menses is triggered by cessation of ovarian steroid support 
following demise of the corpus luteum and progesteron  withdrawal. In our study 
progesterone was required for oestrogen biosynthesis in ESC in vitro. As a result of 
progesterone withdrawal during menses, oestrogen biosynthesis may cease in ESC in vivo, in 
parallel with processes that occur during normal menstrual breakdown. If this is the case, the 
time it takes for oestrogen biosynthesis to cease following progesterone withdrawal may 
affect the likelihood of lesion formation. Shorter menstrual cycles are associated with 
increased risk of endometriosis (574) and perhaps efflux of stromal cells that are still capable 
of oestrogen biosynthesis during menses may play a previously unrecognised role in the 
aetiology of this condition, however further studies are required. 
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Another interesting distinction between the decidualised stromal cells described in this study, 
and eutopic stromal cells from women with endometriosis, is the differential expression of 
17βHSD1 and 17βHSD2. Following decidualisation we reported an increase in expression of 
17βHSD2 mRNAs and no change in expression of 17βHSD1. It is reported that 
decidualisation of ESC from eutopic endometrium from women with endometriosis by 
cAMP promoted an expression profile of increased 17βHSD1 and decreased 17βHSD2 
indicative of altered gene regulation in response to decidualising stimuli (313). This could be 
a consequence of epigenetic modification of 17βHSD1 or 17βHSD2 in the eutopic 
endometrium of women with endometriosis. An increase in the survival of extra-uterine 
endometrial tissue could be linked to prior modificat on of gene expression or dysregulation 
as a result of an aberrant decidualisation response. Thus, an increased understanding of the 
precise temporal expression of steroid metabolizing e zymes in the healthy endometrium, 
throughout the menstrual cycle and during decidualisation may lead to the discovery of 
factors which may indicate an increased risk of endometriosis in advance of lesion 
formation. Such an approach may be particularly beneficial in this condition as early 
diagnosis is difficult, and there is often a delay of several years between onset of symptoms 
and a definitive diagnosis (575). 
6.4. Future Studies 
Future studies should focus on elaborating the steroid metabolome of normal cycling 
endometrium, and aim to investigate not only the expr ssion of mRNAs encoding steroid 
metabolising enzymes, but also the capacity for metabolism of steroids within the different 
cellular compartments of the endometrium.  
The function of uNK cells appears to be dynamic and characterisation of functional 
responses to hormones/cytokines by uNK cells isolated from different phases of the normal 
cycle as well as decidua derived from different gestational ages will be essential in order to 
unravel the complex role of this cell type in regulating endometrial function.  
Thus, understanding the hormonal milieu that is preent in the stromal micro-environment of 
the endometrium across dynamic changes in cycling endometrium and decidua of pregnancy, 
would allow better understanding of cellular cross-talk mediated by steroid hormones and 
the control of functional processes in reproductive function in health and disease. 
6.5. Conclusion 
The data presented in this thesis provide evidence that local biosynthesis of oestrogens 
within the endometrial stroma may play a previously unrecognised role in regulating the 
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function of uNK cells and endometrial endothelial cells in women. These results have 
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The RT2 profiler PCR arrays (SABiosciences, Frederick, MD, USA) are designed to analyse 
a panel of genes related to a specific biological function. Each array contains a panel of 96 
primer sets for a set of 84 functionally focussed genes, together with five housekeeping 
genes and three RNA and PCR quality controls. 
The responses for each functional grouping for functio al genes in the angiogenesis and cell 
motility array can be found in the following appendix. Differential gene expression in 
response to treatment with E2 in uNK cells is shown. Gene tables are grouped according to 
broad functional groupings as denoted in the product specification literature provided by the 
manufacturer (SABiosciences, Frederick, MD, USA). There is a degree of overlap between 






8.1. Angiogenesis array 
8.1.1.1. Angiogenic factors 
 Symbol FC 95% CI P value Fold Regulation 
A02 ANGPT1 0.5585 ( 0.00001, 1.74 ) 0.913699 -1.7905 
A03 ANGPT2 0.8914 ( 0.42, 1.36 ) 0.722491 -1.1218 
A06 ANPEP 0.3043 ( 0.00001, 0.68 ) 0.122483 -3.2859 
B07 TYMP 0.8425 ( 0.25, 1.43 ) 0.797764 -1.1869 
C03 EREG 0.6153 ( 0.18, 1.05 ) 0.236852 -1.6252 
C04 FGF1 0.5585 ( 0.00001, 1.74 ) 0.913699 -1.7905 
C05 FGF2 0.6766 ( 0.00001, 1.49 ) 0.723398 -1.4781 
C07 FIGF 0.4555 ( 0.00001, 1.48 ) 0.792319 -2.1955 
C08 FLT1 0.5585 ( 0.00001, 1.74 ) 0.913699 -1.7905 
D12 JAG1 1.2803 ( 0.06, 2.50 ) 0.916332 1.2803 
E01 KDR 0.5585 ( 0.00001, 1.74 ) 0.913699 -1.7905 
E02 LAMA5 0.7457 ( 0.00001, 1.96 ) 0.947289 -1.341 
E09 NRP1 0.8631 ( 0.00001, 1.88 ) 0.861361 -1.1586 
E10 NRP2 1.1008 ( 0.03, 2.18 ) 0.941099 1.1008 
F02 PGF 0.5585 ( 0.00001, 1.74 ) 0.913699 -1.7905 
F05 PLXDC1 0.5585 ( 0.00001, 1.74 ) 0.913699 -1.7905 
F10 STAB1 1.5326 ( 0.16, 2.90 ) 0.491607 1.5326 
G11 VEGFA 1.007 ( 0.10, 1.92 ) 0.756185 1.007 
G12 VEGFC 0.7192 ( 0.00001, 1.93 ) 0.941156 -1.3904 
 





 Symbol FC 95% CI P value Fold Regulation 
A04 ANGPTL3 0.7508 ( 0.00001, 1.96 ) 0.948514 -1.332 
A07 BAI1 0.8878 ( 0.00001, 2.08 ) 0.990181 -1.1264 
A12 COL4A3 0.5585 ( 0.00001, 1.74 ) 0.913699 -1.7905 
D09 IL8 0.3514 ( 0.07, 0.64 ) 0.05618 -2.8458 
E02 LAMA5 0.7457 ( 0.00001, 1.96 ) 0.947289 -1.341 
E09 NRP1 0.8631 ( 0.00001, 1.88 ) 0.861361 -1.1586 
E10 NRP2 1.1008 ( 0.03, 2.18 ) 0.941099 1.1008 
F10 STAB1 1.5326 ( 0.16, 2.90 ) 0.491607 1.5326 
Table 8.2. adhesion molecules 
 Symbol FC 95% CI P value Fold Regulation 
A05 ANGPTL4 1.0018 ( 0.00001, 2.19 ) 0.953736 1.0018 
E12 PECAM1 1.7144 ( 0.42, 3.01 ) 0.29493 1.7144 
F01 PF4 0.5585 ( 0.00001, 1.74 ) 0.913699 -1.7905 
F06 PROK2 0.5585 ( 0.00001, 1.74 ) 0.913699 -1.7905 
F08 SERPINF1 1.3725 ( 0.44, 2.30 ) 0.341365 1.3725 
G10 TNFAIP2 0.6329 ( 0.34, 0.93 ) 0.110976 -1.58 
Table 8.3. Proteases, inhibitors other matrix proteins 
 
 Symbol FC 95% CI P value Fold Regulation 
C09 HAND2 0.6335 ( 0.00001, 1.56 ) 0.768935 -1.5786 
F09 SPHK1 0.5803 ( 0.22, 0.94 ) 0.10907 -1.7233 





8.1.1.2. Other factors involved in angiogenesis 
 Symbol FC 95% CI P value Fold Regulation 
A08 CCL11 0.5585 ( 0.00001, 1.74 ) 0.913699 -1.7905 
A09 CCL2 2.8044 ( 0.00001, 5.69 ) 0.128538 2.8044 
B01 CXCL1 0.3165 ( 0.00001, 0.76 ) 0.196089 -3.1599 
B02 CXCL10 1.9562 ( 0.00001, 4.04 ) 0.446108 1.9562 
B03 CXCL3 0.6848 ( 0.00001, 1.47 ) 0.482861 -1.4602 
B04 CXCL5 0.8119 ( 0.00001, 2.22 ) 0.840271 -1.2317 
B05 CXCL6 0.5585 ( 0.00001, 1.74 ) 0.913699 -1.7905 
B06 CXCL9 1.6734 ( 0.00001, 6.99 ) 0.816324 1.6734 
D03 IFNA1 0.5585 ( 0.00001, 1.74 ) 0.913699 -1.7905 
D04 IFNB1 0.6191 ( 0.00001, 1.82 ) 0.922284 -1.6152 
D05 IFNG 4.4089 ( 0.00001, 10.88 ) 0.108815 4.4089 
D07 IL1B 0.5987 ( 0.35, 0.84 ) 0.037542 -1.6704 
D08 IL6 0.5666 ( 0.08, 1.06 ) 0.270708 -1.7651 
E05 MDK 0.7609 ( 0.13, 1.39 ) 0.688258 -1.3142 
Table 8.5. Cytokines and chemokines. 
 Symbol FC 95% CI P value Fold Regulation 
B08 S1PR1 0.68 ( 0.00001, 1.75 ) 0.406441 -1.4706 
B09 EFNA1 0.7325 ( 0.00001, 1.70 ) 0.751892 -1.3652 
B10 EFNA3 0.2864 ( 0.00001, 0.78 ) 0.12797 -3.4912 
B11 EFNB2 1.0701 ( 0.00001, 2.24 ) 0.922248 1.0701 
B12 EGF 0.5841 ( 0.00001, 1.67 ) 0.871683 -1.7119 
C02 EPHB4 0.5702 ( 0.00001, 1.76 ) 0.915206 -1.7538 
C06 FGFR3 0.6379 ( 0.00001, 1.84 ) 0.925341 -1.5678 
C10 HGF 0.6714 ( 0.00001, 1.88 ) 0.931332 -1.4895 
D06 IGF1 0.6174 ( 0.00001, 2.00 ) 0.827903 -1.6197 
D11 ITGB3 0.5585 ( 0.00001, 1.74 ) 0.913699 -1.7905 
E11 PDGFA 0.5585 ( 0.00001, 1.74 ) 0.913699 -1.7905 
F11 TEK 0.5585 ( 0.00001, 1.74 ) 0.913699 -1.7905 
F12 TGFA 0.6012 ( 0.00001, 1.71 ) 0.84366 -1.6634 
G01 TGFB1 0.4245 ( 0.21, 0.64 ) 0.028122 -2.3557 
G02 TGFB2 0.6986 ( 0.00001, 1.91 ) 0.935521 -1.4315 
G03 TGFBR1 0.506 ( 0.07, 0.94 ) 0.212099 -1.9761 





 Symbol FC 95% CI P value Fold Regulation 
A08 CCL11 0.5585 ( 0.00001, 1.74 ) 0.913699 -1.7905 
A09 CCL2 2.8044 ( 0.00001, 5.69 ) 0.128538 2.8044 
A10 CDH5 0.5585 ( 0.00001, 1.74 ) 0.913699 -1.7905 
A11 COL18A1 0.7338 ( 0.00001, 1.94 ) 0.944465 -1.3628 
B08 S1PR1 0.68 ( 0.00001, 1.75 ) 0.406441 -1.4706 
C01 ENG 1.2795 ( 0.33, 2.23 ) 0.621572 1.2795 
D10 ITGAV 0.7992 ( 0.10, 1.50 ) 0.485518 -1.2512 
D11 ITGB3 0.5585 ( 0.00001, 1.74 ) 0.913699 -1.7905 
G04 THBS1 0.2646 ( 0.00001, 0.60 ) 0.020214 -3.7791 
G05 THBS2 0.961 ( 0.00001, 2.14 ) 0.979739 -1.0405 
Table 8.7. adhesion 
 Symbol FC 95% CI P value Fold Regulation 
E03 LECT1 0.5585 ( 0.00001, 1.74 ) 0.913699 -1.7905 
E04 LEP 0.5585 ( 0.00001, 1.74 ) 0.913699 -1.7905 
E06 MMP2 1.7916 ( 0.88, 2.71 ) 0.066499 1.7916 
E07 MMP9 1.4272 ( 0.85, 2.00 ) 0.150482 1.4272 
F03 PLAU 1.229 ( 0.69, 1.77 ) 0.382705 1.229 
F04 PLG 0.5585 ( 0.00001, 1.74 ) 0.913699 -1.7905 
G06 TIMP1 2.6924 ( 0.29, 5.10 ) 0.105164 2.6924 
G07 TIMP2 1.0518 ( 0.00001, 2.26 ) 0.973573 1.0518 
G08 TIMP3 0.5585 ( 0.00001, 1.74 ) 0.913699 -1.7905 
Table 8.8. Proteases, inhibitors and other matrix proteins 
 Symbol FC 95% CI P value Fold Regulation 
A01 AKT1 0.3462 ( 0.21, 0.48 ) 0.001286 -2.8884 
C11 HIF1A 1.1817 ( 0.45, 1.92 ) 0.774817 1.1817 
C12 HPSE 1.0042 ( 0.00001, 2.18 ) 0.958967 1.0042 
D01 ID1 1.3007 ( 0.00001, 3.03 ) 0.570529 1.3007 
D02 ID3 0.6329 ( 0.20, 1.07 ) 0.262278 -1.58 
E08 NOTCH4 1.1638 ( 0.00001, 2.33 ) 0.858575 1.1638 
F07 PTGS1 0.5689 ( 0.00001, 1.76 ) 0.915036 -1.7578 




8.1.2. Cell motility array 
8.1.2.1. Chemotaxis 
 Symbol FC 95% CI P value Fold Regulation 
C03 FGF2 0.8883 ( 0.15, 1.63 ) 0.722328 -1.1258 
C10 ITGB2 0.9545 ( 0.00001, 2.33 ) 0.93106 -1.0477 
D01 MAPK1 0.9179 ( 0.78, 1.05 ) 0.327079 -1.0894 
D07 MYH10 1.2596 ( 0.12, 2.40 ) 0.530781 1.2596 
D08 MYH9 0.8587 ( 0.45, 1.26 ) 0.535791 -1.1646 
E03 PLAUR 0.6339 ( 0.09, 1.18 ) 0.368307 -1.5776 
E05 PLD1 0.5736 ( 0.23, 0.91 ) 0.133215 -1.7435 
E06 PRKCA 0.7279 ( 0.31, 1.15 ) 0.380198 -1.3739 
F01 RAC2 0.9649 ( 0.83, 1.10 ) 0.688026 -1.0363 
G02 TGFB1 0.8269 ( 0.01, 1.64 ) 0.686773 -1.2093 
G07 VEGFA 0.881 ( 0.33, 1.43 ) 0.627208 -1.135 
G10 WASF2 0.8361 ( 0.69, 0.99 ) 0.113536 -1.1961 
G12 WIPF1 0.8624 ( 0.55, 1.17 ) 0.515482 -1.1596 
Table 8.10. Chemotaxis 
8.1.2.2. Receptors 
 Symbol FC 95% CI P value Fold Regulation 
B11 EGFR 0.4266 ( 0.00001, 0.90 ) 0.213332 -2.3442 
C06 IGF1R 0.9245 ( 0.57, 1.28 ) 0.777562 -1.0817 
C08 ITGA4 0.9985 ( 0.53, 1.46 ) 0.907358 -1.0015 
C09 ITGB1 0.8645 ( 0.78, 0.95 ) 0.042202 -1.1567 
C10 ITGB2 0.9545 ( 0.00001, 2.33 ) 0.93106 -1.0477 
C11 ITGB3 0.5383 ( 0.08, 0.99 ) 0.173152 -1.8577 
D02 MET 0.6275 ( 0.00001, 1.64 ) 0.766728 -1.5936 
E03 PLAUR 0.6339 ( 0.09, 1.18 ) 0.368307 -1.5776 
F04 RHO 0.9448 ( 0.70, 1.19 ) 0.735465 -1.0584 




8.1.2.3. Growth factors 
 Symbol FC 95% CI P value Fold Regulation 
B06 CSF1 0.9664 ( 0.41, 1.52 ) 0.826921 -1.0348 
B10 EGF 0.7889 ( 0.00001, 2.25 ) 0.366281 -1.2676 
C03 FGF2 0.8883 ( 0.15, 1.63 ) 0.722328 -1.1258 
C04 HGF 2.0782 ( 0.00001, 5.34 ) 0.462532 2.0782 
C05 IGF1 0.6877 ( 0.01, 1.36 ) 0.554432 -1.454 
G02 TGFB1 0.8269 ( 0.01, 1.64 ) 0.686773 -1.2093 
G07 VEGFA 0.881 ( 0.33, 1.43 ) 0.627208 -1.135 
Table 8.12. Growth factors 
8.1.2.4. Rho family GTPases 
 Symbol FC 95% CI P value Fold Regulation 
A04 ACTR2 0.9592 ( 0.70, 1.22 ) 0.74566 -1.0425 
A05 ACTR3 0.9183 ( 0.79, 1.05 ) 0.307675 -1.089 
A08 ARHGDIA 0.5423 ( 0.00001, 1.15 ) 0.338822 -1.844 
C12 LIMK1 0.8705 ( 0.70, 1.04 ) 0.227567 -1.1488 
D06 MSN 0.7708 ( 0.67, 0.87 ) 0.015217 -1.2974 
D09 MYL9 1.0166 ( 0.35, 1.68 ) 0.925491 1.0166 
E04 PLCG1 1.1095 ( 0.00001, 3.12 ) 0.91189 1.1095 
E05 PLD1 0.5736 ( 0.23, 0.91 ) 0.133215 -1.7435 
E06 PRKCA 0.7279 ( 0.31, 1.15 ) 0.380198 -1.3739 
E07 PTEN 0.9432 ( 0.73, 1.16 ) 0.700471 -1.0602 
E10 PTPN1 0.9102 ( 0.71, 1.11 ) 0.438296 -1.0987 
F04 RHO 0.9448 ( 0.70, 1.19 ) 0.735465 -1.0584 
F05 RHOA 1.0739 ( 0.91, 1.24 ) 0.407981 1.0739 
F06 RHOB 0.9768 ( 0.50, 1.45 ) 0.877817 -1.0238 
F07 RHOC 0.9184 ( 0.66, 1.17 ) 0.649835 -1.0888 
F08 RND3 0.6377 ( 0.00001, 1.82 ) 0.533238 -1.5681 
F09 ROCK1 0.8819 ( 0.31, 1.46 ) 0.662993 -1.1339 
G08 VIM 1.0401 ( 0.24, 1.84 ) 0.90575 1.0401 





 Symbol FC 95% CI P value Fold Regulation 
A04 ACTR2 0.9592 ( 0.70, 1.22 ) 0.74566 -1.0425 
A05 ACTR3 0.9183 ( 0.79, 1.05 ) 0.307675 -1.089 
A10 BAIAP2 0.5305 ( 0.15, 0.91 ) 0.184226 -1.885 
B04 CFL1 1.0366 ( 0.81, 1.27 ) 0.762844 1.0366 
B05 CRK 0.9844 ( 0.74, 1.23 ) 0.886593 -1.0159 
D11 PAK1 1.0309 ( 0.04, 2.02 ) 0.832824 1.0309 
D12 PAK4 0.6552 ( 0.16, 1.15 ) 0.345822 -1.5262 
E05 PLD1 0.5736 ( 0.23, 0.91 ) 0.133215 -1.7435 
E06 PRKCA 0.7279 ( 0.31, 1.15 ) 0.380198 -1.3739 
E12 RAC1 0.8847 ( 0.58, 1.19 ) 0.551169 -1.1303 
F01 RAC2 0.9649 ( 0.83, 1.10 ) 0.688026 -1.0363 
F12 STAT3 0.881 ( 0.19, 1.57 ) 0.779725 -1.1351 
G09 WASF1 0.8235 ( 0.32, 1.32 ) 0.774144 -1.2143 
G10 WASF2 0.8361 ( 0.69, 0.99 ) 0.113536 -1.1961 
G11 WASL 0.6639 ( 0.11, 1.22 ) 0.38761 -1.5063 
Table 8.14. Rac signalling 
 Symbol FC 95% CI P value Fold Regulation 
A04 ACTR2 0.9592 ( 0.70, 1.22 ) 0.74566 -1.0425 
A05 ACTR3 0.9183 ( 0.79, 1.05 ) 0.307675 -1.089 
B03 CDC42 1.0976 ( 0.82, 1.37 ) 0.558195 1.0976 
E01 PFN1 0.9556 ( 0.77, 1.14 ) 0.65679 -1.0465 
G09 WASF1 0.8235 ( 0.32, 1.32 ) 0.774144 -1.2143 
G10 WASF2 0.8361 ( 0.69, 0.99 ) 0.113536 -1.1961 
G11 WASL 0.6639 ( 0.11, 1.22 ) 0.38761 -1.5063 





 Symbol FC 95% CI P value Fold Regulation 
B09 DPP4 1.0593 ( 0.00001, 2.43 ) 0.924135 1.0593 
B11 EGFR 0.4266 ( 0.00001, 0.90 ) 0.213332 -2.3442 
C01 EZR 1.0373 ( 0.02, 2.06 ) 0.998311 1.0373 
C08 ITGA4 0.9985 ( 0.53, 1.46 ) 0.907358 -1.0015 
C09 ITGB1 0.8645 ( 0.78, 0.95 ) 0.042202 -1.1567 
C10 ITGB2 0.9545 ( 0.00001, 2.33 ) 0.93106 -1.0477 
D06 MSN 0.7708 ( 0.67, 0.87 ) 0.015217 -1.2974 
D08 MYH9 0.8587 ( 0.45, 1.26 ) 0.535791 -1.1646 
F09 ROCK1 0.8819 ( 0.31, 1.46 ) 0.662993 -1.1339 
G02 TGFB1 0.8269 ( 0.01, 1.64 ) 0.686773 -1.2093 
Table 8.16. cell-cell adhesion 
 Symbol FC 95% CI P value Fold Regulation 
A01 ACTN1 0.8957 ( 0.52, 1.27 ) 0.536094 -1.1165 
A02 ACTN3 1.3504 ( 0.20, 2.50 ) 0.379028 1.3504 
B06 CSF1 0.9664 ( 0.41, 1.52 ) 0.826921 -1.0348 
C07 ILK 1.0427 ( 0.83, 1.26 ) 0.738315 1.0427 
C09 ITGB1 0.8645 ( 0.78, 0.95 ) 0.042202 -1.1567 
C10 ITGB2 0.9545 ( 0.00001, 2.33 ) 0.93106 -1.0477 
C11 ITGB3 0.5383 ( 0.08, 0.99 ) 0.173152 -1.8577 
D03 MMP14 0.9089 ( 0.00001, 2.38 ) 0.820498 -1.1003 
E07 PTEN 0.9432 ( 0.73, 1.16 ) 0.700471 -1.0602 
E09 PTK2B 1.1644 ( 0.24, 2.09 ) 0.724516 1.1644 
E11 PXN 0.8146 ( 0.53, 1.10 ) 0.341253 -1.2276 
F02 RASA1 0.9695 ( 0.70, 1.24 ) 0.838768 -1.0315 
F05 RHOA 1.0739 ( 0.91, 1.24 ) 0.407981 1.0739 





 Symbol FC 95% CI P value Fold Regulation 
A01 ACTN1 0.8957 ( 0.52, 1.27 ) 0.536094 -1.1165 
A02 ACTN3 1.3504 ( 0.20, 2.50 ) 0.379028 1.3504 
A09 ARHGEF7 0.9903 ( 0.33, 1.65 ) 0.93552 -1.0098 
A11 BCAR1 0.9217 ( 0.00001, 1.93 ) 0.846037 -1.0849 
A12 CAPN1 1.0813 ( 0.17, 2.00 ) 0.555978 1.0813 
B01 CAPN2 0.8394 ( 0.38, 1.30 ) 0.526571 -1.1913 
B02 CAV1 0.6151 ( 0.00001, 1.52 ) 0.600257 -1.6257 
B12 ENAH 1.0781 ( 0.92, 1.23 ) 0.369607 1.0781 
C07 ILK 1.0427 ( 0.83, 1.26 ) 0.738315 1.0427 
C09 ITGB1 0.8645 ( 0.78, 0.95 ) 0.042202 -1.1567 
D09 MYL9 1.0166 ( 0.35, 1.68 ) 0.925491 1.0166 
E08 PTK2 0.7481 ( 0.24, 1.26 ) 0.440942 -1.3366 
E09 PTK2B 1.1644 ( 0.24, 2.09 ) 0.724516 1.1644 
E11 PXN 0.8146 ( 0.53, 1.10 ) 0.341253 -1.2276 
G04 TLN1 1.0593 ( 0.34, 1.78 ) 0.954997 1.0593 
G05 VASP 0.7341 ( 0.18, 1.28 ) 0.431172 -1.3623 
G06 VCL 0.9932 ( 0.51, 1.48 ) 0.986411 -1.0068 
Table 8.18. focal adhesion 
 Symbol FC 95% CI P value Fold Regulation 
C01 EZR 1.0373 ( 0.02, 2.06 ) 0.998311 1.0373 
C08 ITGA4 0.9985 ( 0.53, 1.46 ) 0.907358 -1.0015 
C09 ITGB1 0.8645 ( 0.78, 0.95 ) 0.042202 -1.1567 
C10 ITGB2 0.9545 ( 0.00001, 2.33 ) 0.93106 -1.0477 
D06 MSN 0.7708 ( 0.67, 0.87 ) 0.015217 -1.2974 
F09 ROCK1 0.8819 ( 0.31, 1.46 ) 0.662993 -1.1339 




8.1.2.6. Integrin mediated signalling 
 Symbol FC 95% CI P value Fold Regulation 
A11 BCAR1 0.9217 ( 0.00001, 1.93 ) 0.846037 -1.0849 
C07 ILK 1.0427 ( 0.83, 1.26 ) 0.738315 1.0427 
C08 ITGA4 0.9985 ( 0.53, 1.46 ) 0.907358 -1.0015 
C09 ITGB1 0.8645 ( 0.78, 0.95 ) 0.042202 -1.1567 
C10 ITGB2 0.9545 ( 0.00001, 2.33 ) 0.93106 -1.0477 
C11 ITGB3 0.5383 ( 0.08, 0.99 ) 0.173152 -1.8577 
D08 MYH9 0.8587 ( 0.45, 1.26 ) 0.535791 -1.1646 
E08 PTK2 0.7481 ( 0.24, 1.26 ) 0.440942 -1.3366 
Table 8.20. Integrin mediated signalling 
8.1.2.7. Cellular Projections 
 Symbol FC 95% CI P value Fold Regulation 
A10 BAIAP2 0.5305 ( 0.15, 0.91 ) 0.184226 -1.885 
B03 CDC42 1.0976 ( 0.82, 1.37 ) 0.558195 1.0976 
B08 DIAPH1 0.9094 ( 0.52, 1.30 ) 0.645942 -1.0996 
B11 EGFR 0.4266 ( 0.00001, 0.90 ) 0.213332 -2.3442 
B12 ENAH 1.0781 ( 0.92, 1.23 ) 0.369607 1.0781 
C01 EZR 1.0373 ( 0.02, 2.06 ) 0.998311 1.0373 
D06 MSN 0.7708 ( 0.67, 0.87 ) 0.015217 -1.2974 
F03 RDX 0.9253 ( 0.80, 1.05 ) 0.320237 -1.0808 
G01 SVIL 1.1654 ( 0.33, 2.01 ) 0.904226 1.1654 
G05 VASP 0.7341 ( 0.18, 1.28 ) 0.431172 -1.3623 





 Symbol FC 95% CI P value Fold Regulation 
B07 CTTN 0.8164 ( 0.17, 1.47 ) 0.873956 -1.2249 
B09 DPP4 1.0593 ( 0.00001, 2.43 ) 0.924135 1.0593 
B11 EGFR 0.4266 ( 0.00001, 0.90 ) 0.213332 -2.3442 
B12 ENAH 1.0781 ( 0.92, 1.23 ) 0.369607 1.0781 
C02 FAP 0.956 ( 0.24, 1.67 ) 0.802964 -1.046 
E02 PIK3CA 0.4694 ( 0.00001, 1.22 ) 0.382145 -2.1305 
E05 PLD1 0.5736 ( 0.23, 0.91 ) 0.133215 -1.7435 
E08 PTK2 0.7481 ( 0.24, 1.26 ) 0.440942 -1.3366 
E11 PXN 0.8146 ( 0.53, 1.10 ) 0.341253 -1.2276 
F03 RDX 0.9253 ( 0.80, 1.05 ) 0.320237 -1.0808 
G01 SVIL 1.1654 ( 0.33, 2.01 ) 0.904226 1.1654 
G05 VASP 0.7341 ( 0.18, 1.28 ) 0.431172 -1.3623 
G06 VCL 0.9932 ( 0.51, 1.48 ) 0.986411 -1.0068 
Table 8.22. lamellipodia 
 Symbol FC 95% CI P value Fold Regulation 
A03 ACTN4 0.8693 ( 0.51, 1.23 ) 0.565807 -1.1504 
B08 DIAPH1 0.9094 ( 0.52, 1.30 ) 0.645942 -1.0996 
D07 MYH10 1.2596 ( 0.12, 2.40 ) 0.530781 1.2596 
D08 MYH9 0.8587 ( 0.45, 1.26 ) 0.535791 -1.1646 
D10 MYLK 0.8879 ( 0.38, 1.39 ) 0.675214 -1.1263 
F05 RHOA 1.0739 ( 0.91, 1.24 ) 0.407981 1.0739 
F06 RHOB 0.9768 ( 0.50, 1.45 ) 0.877817 -1.0238 
F07 RHOC 0.9184 ( 0.66, 1.17 ) 0.649835 -1.0888 
Table 8.23. stress fibers 
 Symbol FC 95% CI P value Fold Regulation 
A01 ACTN1 0.8957 ( 0.52, 1.27 ) 0.536094 -1.1165 
A02 ACTN3 1.3504 ( 0.20, 2.50 ) 0.379028 1.3504 
A03 ACTN4 0.8693 ( 0.51, 1.23 ) 0.565807 -1.1504 
C01 EZR 1.0373 ( 0.02, 2.06 ) 0.998311 1.0373 
D07 MYH10 1.2596 ( 0.12, 2.40 ) 0.530781 1.2596 
D08 MYH9 0.8587 ( 0.45, 1.26 ) 0.535791 -1.1646 
D10 MYLK 0.8879 ( 0.38, 1.39 ) 0.675214 -1.1263 
F08 RND3 0.6377 ( 0.00001, 1.82 ) 0.533238 -1.5681 
F09 ROCK1 0.8819 ( 0.31, 1.46 ) 0.662993 -1.1339 





 Symbol FC 95% CI P value Fold Regulation 
A04 ACTR2 0.9592 ( 0.70, 1.22 ) 0.74566 -1.0425 
A05 ACTR3 0.9183 ( 0.79, 1.05 ) 0.307675 -1.089 
A07 ARF6 0.92 ( 0.51, 1.33 ) 0.707735 -1.087 
B03 CDC42 1.0976 ( 0.82, 1.37 ) 0.558195 1.0976 
B04 CFL1 1.0366 ( 0.81, 1.27 ) 0.762844 1.0366 
B07 CTTN 0.8164 ( 0.17, 1.47 ) 0.873956 -1.2249 
B09 DPP4 1.0593 ( 0.00001, 2.43 ) 0.924135 1.0593 
B10 EGF 0.7889 ( 0.00001, 2.25 ) 0.366281 -1.2676 
C01 EZR 1.0373 ( 0.02, 2.06 ) 0.998311 1.0373 
C02 FAP 0.956 ( 0.24, 1.67 ) 0.802964 -1.046 
D03 MMP14 0.9089 ( 0.00001, 2.38 ) 0.820498 -1.1003 
D04 MMP2 0.7096 ( 0.15, 1.27 ) 0.40729 -1.4092 
D05 MMP9 0.8688 ( 0.00001, 1.89 ) 0.870163 -1.151 
D06 MSN 0.7708 ( 0.67, 0.87 ) 0.015217 -1.2974 
D08 MYH9 0.8587 ( 0.45, 1.26 ) 0.535791 -1.1646 
E03 PLAUR 0.6339 ( 0.09, 1.18 ) 0.368307 -1.5776 
F01 RAC2 0.9649 ( 0.83, 1.10 ) 0.688026 -1.0363 
F10 SH3PXD2A 0.7801 ( 0.50, 1.06 ) 0.276494 -1.282 
F11 SRC 0.7464 ( 0.17, 1.32 ) 0.514935 -1.3397 
G01 SVIL 1.1654 ( 0.33, 2.01 ) 0.904226 1.1654 
G02 TGFB1 0.8269 ( 0.01, 1.64 ) 0.686773 -1.2093 
G07 VEGFA 0.881 ( 0.33, 1.43 ) 0.627208 -1.135 
G11 WASL 0.6639 ( 0.11, 1.22 ) 0.38761 -1.5063 
G12 WIPF1 0.8624 ( 0.55, 1.17 ) 0.515482 -1.1596 
Table 8.25. invasive projections 
 Symbol FC 95% CI P value Fold Regulation 
A09 ARHGEF7 0.9903 ( 0.33, 1.65 ) 0.93552 -1.0098 
B03 CDC42 1.0976 ( 0.82, 1.37 ) 0.558195 1.0976 
B04 CFL1 1.0366 ( 0.81, 1.27 ) 0.762844 1.0366 
E09 PTK2B 1.1644 ( 0.24, 2.09 ) 0.724516 1.1644 





 Symbol FC 95% CI P value Fold Regulation 
A04 ACTR2 0.9592 ( 0.70, 1.22 ) 0.74566 -1.0425 
A05 ACTR3 0.9183 ( 0.79, 1.05 ) 0.307675 -1.089 
A07 ARF6 0.92 ( 0.51, 1.33 ) 0.707735 -1.087 
A10 BAIAP2 0.5305 ( 0.15, 0.91 ) 0.184226 -1.885 
A11 BCAR1 0.9217 ( 0.00001, 1.93 ) 0.846037 -1.0849 
B07 CTTN 0.8164 ( 0.17, 1.47 ) 0.873956 -1.2249 
B08 DIAPH1 0.9094 ( 0.52, 1.30 ) 0.645942 -1.0996 
C01 EZR 1.0373 ( 0.02, 2.06 ) 0.998311 1.0373 
C09 ITGB1 0.8645 ( 0.78, 0.95 ) 0.042202 -1.1567 
D08 MYH9 0.8587 ( 0.45, 1.26 ) 0.535791 -1.1646 
E12 RAC1 0.8847 ( 0.58, 1.19 ) 0.551169 -1.1303 
F01 RAC2 0.9649 ( 0.83, 1.10 ) 0.688026 -1.0363 
F02 RASA1 0.9695 ( 0.70, 1.24 ) 0.838768 -1.0315 
F03 RDX 0.9253 ( 0.80, 1.05 ) 0.320237 -1.0808 
F05 RHOA 1.0739 ( 0.91, 1.24 ) 0.407981 1.0739 
G04 TLN1 1.0593 ( 0.34, 1.78 ) 0.954997 1.0593 
G10 WASF2 0.8361 ( 0.69, 0.99 ) 0.113536 -1.1961 
Table 8.27. membrane ruffles 
8.1.2.8. Cell polarity 
 Symbol FC 95% CI P value Fold Regulation 
B03 CDC42 1.0976 ( 0.82, 1.37 ) 0.558195 1.0976 
B04 CFL1 1.0366 ( 0.81, 1.27 ) 0.762844 1.0366 
C01 EZR 1.0373 ( 0.02, 2.06 ) 0.998311 1.0373 
C06 IGF1R 0.9245 ( 0.57, 1.28 ) 0.777562 -1.0817 
C07 ILK 1.0427 ( 0.83, 1.26 ) 0.738315 1.0427 
D08 MYH9 0.8587 ( 0.45, 1.26 ) 0.535791 -1.1646 





 Symbol FC 95% CI P value Fold Regulation 
A06 AKT1 0.8816 ( 0.51, 1.25 ) 0.591216 -1.1343 
A12 CAPN1 1.0813 ( 0.17, 2.00 ) 0.555978 1.0813 
B01 CAPN2 0.8394 ( 0.38, 1.30 ) 0.526571 -1.1913 
B09 DPP4 1.0593 ( 0.00001, 2.43 ) 0.924135 1.0593 
C02 FAP 0.956 ( 0.24, 1.67 ) 0.802964 -1.046 
C04 HGF 2.0782 ( 0.00001, 5.34 ) 0.462532 2.0782 
D03 MMP14 0.9089 ( 0.00001, 2.38 ) 0.820498 -1.1003 
D04 MMP2 0.7096 ( 0.15, 1.27 ) 0.40729 -1.4092 
D05 MMP9 0.8688 ( 0.00001, 1.89 ) 0.870163 -1.151 
D08 MYH9 0.8587 ( 0.45, 1.26 ) 0.535791 -1.1646 
E03 PLAUR 0.6339 ( 0.09, 1.18 ) 0.368307 -1.5776 
G03 TIMP2 0.9211 ( 0.13, 1.71 ) 0.871882 -1.0857 
Table 8.29. Proteolysis 
 
